data_2ed0_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ed0 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.418 ' HG2' ' CB ' ' A' ' 12' ' ' ALA . 53.0 Cg_endo . . . . . 0 C--O 1.232 0.21 0 CA-C-O 121.59 0.579 . . . . 0.0 112.286 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 -31.02 20.97 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.712 2.275 . . . . 0.0 112.304 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 51.2 p-90 -76.57 -11.73 59.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.418 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -89.01 144.25 32.48 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.487 0.661 . . . . 0.0 111.197 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.84 132.55 23.44 Favored 'Trans proline' 0 C--O 1.231 0.132 0 C-N-CA 122.62 2.214 . . . . 0.0 112.322 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 34.6 mtm180 -57.07 -40.17 76.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -120.55 148.86 43.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.868 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -165.46 166.24 18.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -70.05 -61.91 1.59 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -150.96 -177.62 6.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.842 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.1 ttmm -118.23 144.78 45.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.9 m -142.44 152.93 17.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.198 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 p -127.71 115.73 40.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.057 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -52.05 138.53 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.0 pt -113.62 -25.13 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -126.11 159.37 33.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 -75.78 127.53 33.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CE1' ' HG3' ' A' ' 65' ' ' PRO . 89.2 t80 -131.62 109.81 10.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.97 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.5 m -93.41 110.49 22.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.188 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.421 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 1.6 pptp? -58.69 157.56 9.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -101.66 -45.83 5.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 pttt -128.43 155.96 43.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -44.11 -32.37 1.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.92 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.41 -42.49 70.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -81.05 178.66 8.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.405 HD21 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -123.6 140.86 52.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.421 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 99.5 p -110.82 128.1 55.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.518 ' CD2' HD12 ' A' ' 42' ' ' ILE . 4.2 p90 -149.96 168.03 24.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -121.09 158.28 28.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -51.62 96.84 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.83 34.11 0.49 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.424 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.55 124.41 45.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.796 0.332 . . . . 0.0 111.043 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.457 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 2.0 mp -82.39 101.41 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.518 HD12 ' CD2' ' A' ' 36' ' ' PHE . 23.0 mt -95.64 122.28 46.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.075 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -83.96 97.29 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.21 133.03 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.169 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.448 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.0 pt -127.25 -29.0 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -135.25 148.92 49.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.531 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 5.7 mtmp? -135.74 105.39 6.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -66.76 170.52 6.37 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -50.54 -54.58 21.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.815 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 52' ' ' TRP . 16.2 m-20 -84.37 174.71 9.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.828 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.44 76.16 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.504 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.482 ' N ' ' O ' ' A' ' 50' ' ' ASP . 93.2 m95 -156.23 108.89 2.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.801 0.334 . . . . 0.0 110.916 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.531 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.4 OUTLIER -113.58 149.38 34.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.448 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 6.2 tt0 -100.13 128.57 46.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.912 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.41 167.68 29.1 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.448 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.6 t -104.72 133.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 0.0 111.2 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.21 125.01 22.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 58' ' ' ASN . 12.5 t30 50.41 30.7 4.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.09 -27.06 8.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.6 t -88.46 128.71 40.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.942 0.401 . . . . 0.0 111.143 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.72 151.48 21.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.108 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -179.95 153.05 11.46 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.446 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.96 133.68 36.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 110.869 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.474 ' CE1' HG22 ' A' ' 42' ' ' ILE . 47.5 p90 -132.85 150.53 75.94 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.651 0.738 . . . . 0.0 110.866 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.43 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.8 131.54 21.39 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.753 2.302 . . . . 0.0 112.421 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.02 51.17 3.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -130.42 -37.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.776 0.322 . . . . 0.0 110.915 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -84.25 10.52 10.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.957 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -123.1 161.55 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.201 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -136.8 126.69 25.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.5 m -69.65 127.51 33.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.841 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 3.4 pt . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.207 179.929 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.534 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.163 0 CA-C-O 121.566 0.569 . . . . 0.0 112.379 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 -41.63 4.21 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.36 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.534 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 54.8 p-90 -57.15 -18.79 16.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.75 61.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.544 0.687 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 133.24 25.19 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.627 2.218 . . . . 0.0 112.355 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 52.9 mtm180 -72.57 -33.55 66.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.5 t -112.94 118.1 33.93 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.815 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 22.3 p90 -160.98 142.43 11.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.969 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -56.8 -60.53 3.43 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -161.07 -178.12 6.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 ptpp? -114.84 168.51 9.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.923 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.404 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.4 m -146.93 156.88 10.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.178 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.427 HG12 ' CG2' ' A' ' 72' ' ' ILE . 14.8 p -113.34 142.16 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.124 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.88 106.87 15.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.096 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.476 HG13 ' CD2' ' A' ' 24' ' ' TYR . 28.2 pt -80.84 -15.76 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.476 ' CD2' HG13 ' A' ' 23' ' ' ILE . 58.5 m-85 -138.81 158.72 43.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.84 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 98.66 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.797 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.428 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 61.3 t80 -91.93 133.98 35.2 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.998 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 38.9 m -112.29 120.21 40.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.68 135.45 52.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.915 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -103.2 -33.33 9.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -113.81 159.28 19.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -62.67 -22.15 66.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -90.94 38.54 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.931 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -140.14 174.92 10.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.449 HD21 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -124.88 135.69 53.11 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.449 ' N ' HD21 ' A' ' 34' ' ' LEU . 84.8 p -104.41 137.87 41.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.845 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.428 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 13.8 p90 -161.57 159.77 28.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.827 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -109.16 173.46 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -66.01 110.35 2.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.85 39.4 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.437 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.41 149.89 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.791 0.329 . . . . 0.0 111.097 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 45.6 mm -102.78 123.47 56.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.449 HG22 ' CZ ' ' A' ' 64' ' ' PHE . 49.4 mt -126.9 125.54 66.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.103 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -84.18 120.07 25.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.4 t -82.45 114.83 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 pt -110.56 -14.54 10.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.172 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.42 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 32.1 tttp -146.19 144.49 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.908 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.559 ' HE2' ' CE1' ' A' ' 53' ' ' TYR . 13.2 mtpt -136.51 110.65 8.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.889 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -82.41 161.42 22.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -55.63 -36.82 67.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -84.57 175.65 9.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.892 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -72.15 67.62 1.15 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.392 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.496 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 65.5 m95 -158.8 121.35 3.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.731 0.3 . . . . 0.0 110.999 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.559 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 6.4 m-85 -118.65 154.9 31.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.936 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.42 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 16.7 tt0 -104.19 123.55 47.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.24 167.91 26.3 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.64 133.27 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.115 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -139.23 116.52 11.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.8 t30 55.7 39.11 30.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.31 -36.61 2.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.446 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 88.2 t -76.31 123.91 33.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.983 0.42 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.3 m -107.62 146.38 32.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.114 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.59 169.0 41.41 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.544 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.429 ' CD2' ' N ' ' A' ' 63' ' ' LEU . 2.2 mm? -88.52 127.16 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.881 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.449 ' CZ ' HG22 ' A' ' 42' ' ' ILE . 49.1 p90 -136.63 144.75 48.39 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.666 0.746 . . . . 0.0 110.892 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 143.11 49.71 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.707 2.272 . . . . 0.0 112.337 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.467 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -83.98 7.26 71.42 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.427 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.0 m-20 -90.24 -35.24 15.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.871 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -80.1 3.25 21.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.62 172.75 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.163 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -142.26 137.03 30.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 49.1 m -69.42 130.59 42.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.849 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.449 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.156 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 53.7 Cg_endo . . . . . 0 N--CA 1.465 -0.187 0 CA-C-O 121.599 0.583 . . . . 0.0 112.335 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -29.56 23.5 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.301 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.495 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 62.5 p-90 -77.8 -25.94 49.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.853 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.42 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -65.58 151.68 94.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.59 0.709 . . . . 0.0 111.172 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 175.92 7.44 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.666 2.244 . . . . 0.0 112.297 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 10.7 tpp180 -88.29 -51.26 5.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.87 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.2 t -123.53 155.26 37.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.895 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 13.5 p90 -164.84 161.22 20.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 82.5 mt -66.72 -59.9 3.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -156.96 167.67 29.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -102.22 128.73 48.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 10.7 m -119.68 164.69 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.144 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.42 HG12 ' CG2' ' A' ' 72' ' ' ILE . 9.7 p -133.63 140.54 46.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.255 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.88 118.64 21.83 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.075 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.2 pt -91.39 -14.75 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.09 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -136.74 161.36 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -86.23 132.66 33.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.887 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -130.91 144.89 51.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.9 m -118.34 95.44 4.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.241 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.422 ' C ' ' HD3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -40.49 135.45 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.866 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -108.77 -54.64 2.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.916 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -79.91 162.47 24.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -69.84 -25.05 63.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -95.94 54.38 1.48 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -149.66 178.29 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 tt -131.32 142.43 50.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.926 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.7 p -108.19 143.36 37.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.874 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -166.91 167.99 14.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.774 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -120.34 164.81 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.979 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -55.74 117.97 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 105.25 43.88 1.55 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.95 138.52 52.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.78 0.324 . . . . 0.0 111.12 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 47.9 mm -89.76 129.72 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.164 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.23 145.5 34.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.165 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -106.96 114.17 28.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 43.6 t -77.76 118.03 23.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 2.9 pt -117.06 -8.88 12.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.45 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.5 ttmm -136.36 140.85 43.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.981 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 36.9 mttp -134.89 103.02 5.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' A' ' 50' ' ' ASP . 32.7 m-20 -83.55 38.81 0.64 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.891 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 48' ' ' ASN . 2.4 m-20 36.67 32.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.932 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.463 ' O ' ' CE1' ' A' ' 53' ' ' TYR . 31.0 m-20 -151.89 -175.04 5.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.816 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -76.27 52.99 3.07 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.419 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 96.4 m95 -162.87 106.97 1.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.766 0.317 . . . . 0.0 110.927 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.463 ' CE1' ' O ' ' A' ' 50' ' ' ASP . 4.7 m-85 -120.32 154.82 34.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.94 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.488 ' OE1' ' N ' ' A' ' 55' ' ' GLY . 0.1 OUTLIER -98.25 141.14 31.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.88 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' A' ' 54' ' ' GLU . . . -161.85 165.45 35.77 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.413 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 56.1 t -107.43 146.13 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.858 0.361 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.3 ttp -155.22 108.18 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.2 t30 68.14 32.96 4.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.65 -23.77 7.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.502 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.1 t -88.29 122.75 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.91 0.386 . . . . 0.0 111.107 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.3 m -106.33 148.43 28.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -176.77 163.29 32.18 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.489 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -84.58 125.85 32.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.368 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -127.19 152.11 75.49 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.683 0.754 . . . . 0.0 110.886 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 143.41 51.08 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.715 2.277 . . . . 0.0 112.289 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -86.56 24.79 7.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.494 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -111.33 -28.81 8.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -87.72 5.08 41.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -127.82 173.27 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.127 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.82 135.6 18.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.904 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.8 p -65.77 131.47 46.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.42 ' CG2' HG12 ' A' ' 21' ' ' VAL . 43.1 pt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.551 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 121.662 0.609 . . . . 0.0 112.278 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.67 -13.68 35.24 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.675 2.25 . . . . 0.0 112.398 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.551 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.9 p-90 -93.93 -34.65 13.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.488 ' N ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.31 145.78 13.14 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.521 0.677 . . . . 0.0 111.096 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.536 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.7 Cg_endo -69.8 133.68 26.08 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.727 2.285 . . . . 0.0 112.36 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 43.4 mtt180 -59.93 -33.43 71.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.98 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -140.42 137.92 34.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.403 ' CB ' HG23 ' A' ' 45' ' ' ILE . 38.7 p90 -153.74 161.54 42.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.97 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mt -57.14 -71.68 0.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.912 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -151.49 165.74 33.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.4 ' HG2' ' CD1' ' A' ' 72' ' ' ILE . 15.5 ttpt -100.83 134.39 43.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.02 159.72 26.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -119.02 132.97 67.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.18 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -77.76 100.59 6.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.3 pt -75.86 -14.9 15.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -134.1 173.7 11.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -100.3 107.91 19.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.849 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.541 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 70.5 t80 -107.07 134.05 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 28' ' ' LYS . 30.1 m -110.23 111.94 23.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.101 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 27' ' ' THR . 0.0 OUTLIER -36.15 128.99 0.71 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 179.898 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -100.88 -41.07 6.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -104.3 165.01 11.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -67.37 -27.01 66.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 9.6 p-10 -94.21 16.61 14.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.826 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.486 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -106.13 166.12 10.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.943 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -118.37 141.57 48.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.4 t -107.68 140.33 40.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -158.31 150.6 21.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -102.56 160.78 14.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -46.42 152.35 0.45 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 63.78 36.26 93.08 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.53 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -106.74 166.49 10.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.764 0.316 . . . . 0.0 111.087 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.7 mm -120.2 129.5 75.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.211 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.411 HG23 ' CE1' ' A' ' 64' ' ' PHE . 20.4 mt -129.54 141.14 47.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.536 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 53.6 m-85 -105.28 92.13 4.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 86.1 t -58.27 113.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.075 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.403 HG23 ' CB ' ' A' ' 16' ' ' TYR . 7.7 pt -110.84 -15.15 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.107 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.42 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.2 ttmt -140.76 147.46 39.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttt -135.85 147.76 48.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.968 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -125.53 151.09 46.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -39.15 -49.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.867 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -76.56 -176.0 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.21 64.73 4.11 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -148.75 114.79 5.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -121.23 146.78 46.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.895 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.42 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 4.1 tt0 -96.44 126.63 41.77 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.882 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -140.18 167.45 25.44 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.448 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 t -105.1 143.52 16.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.831 0.348 . . . . 0.0 111.082 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.5 tmm? -152.66 112.36 3.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.28 39.71 22.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.956 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.86 -34.68 2.55 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 86.8 t -75.58 126.78 36.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.95 0.405 . . . . 0.0 111.131 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.5 m -104.27 141.38 36.39 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.33 153.89 17.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.517 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.3 mt -75.63 156.23 35.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.411 ' CE1' HG23 ' A' ' 42' ' ' ILE . 35.2 p90 -155.79 148.16 17.66 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 130.26 19.13 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.738 2.292 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.13 -2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.52 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -86.22 -33.73 20.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.838 0.352 . . . . 0.0 110.911 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.541 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 9.5 m-85 -69.83 -23.59 63.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -115.33 175.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.167 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -136.36 162.72 32.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 m -88.22 113.71 24.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.791 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.4 ' CD1' ' HG2' ' A' ' 19' ' ' LYS . 47.7 pt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.179 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo . . . . . 0 N--CA 1.464 -0.228 0 CA-C-O 121.614 0.589 . . . . 0.0 112.377 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -19.69 35.77 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.731 2.287 . . . . 0.0 112.316 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 42.0 p-90 -90.47 -20.25 22.93 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.942 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.93 148.47 94.59 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.614 0.721 . . . . 0.0 111.151 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 133.45 25.67 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 67.6 mtt85 -43.06 -46.25 5.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.824 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.6 p -145.8 144.16 30.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.3 p90 -134.66 174.6 10.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -76.68 -56.36 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.95 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -154.46 168.94 25.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttt -110.12 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.798 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.7 148.28 22.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.177 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -112.86 131.79 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.32 99.68 2.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.082 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.556 ' CD1' ' CE2' ' A' ' 24' ' ' TYR . 16.3 pt -73.13 -14.65 16.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.556 ' CE2' ' CD1' ' A' ' 23' ' ' ILE . 28.9 m-85 -143.56 156.13 44.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.92 162.96 28.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 2.9 t80 -168.84 131.5 1.32 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.946 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 17.4 m -109.84 131.99 54.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.093 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.67 164.27 10.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.954 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -129.07 -5.74 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.849 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ptpp? -146.6 143.13 28.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -47.11 -23.9 0.57 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -93.45 47.35 1.24 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.818 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -145.26 -179.74 6.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.453 ' CD1' ' O ' ' A' ' 55' ' ' GLY . 2.2 tt -126.48 151.16 48.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.924 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.445 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.9 p -121.22 123.99 43.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.417 ' CD2' HD12 ' A' ' 42' ' ' ILE . 29.3 p90 -140.95 152.59 45.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -110.26 165.02 12.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.961 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -52.64 108.29 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 104.96 39.66 2.27 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.88 21.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.74 0.305 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.8 mm -107.4 111.14 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.201 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.417 HD12 ' CD2' ' A' ' 36' ' ' PHE . 81.3 mt -117.06 141.36 35.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.164 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -105.09 108.85 20.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.971 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -67.11 115.36 4.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.181 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.1 pt -118.17 -18.44 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.14 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.437 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 4.1 tmtm? -138.94 146.45 41.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.437 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 17.1 mtpp -136.2 112.36 9.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -74.9 173.76 10.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -51.61 -17.52 0.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -112.75 -175.84 2.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.586 ' O ' ' CE2' ' A' ' 53' ' ' TYR . . . -63.31 -10.19 33.93 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.448 ' CH2' ' HD3' ' A' ' 65' ' ' PRO . 59.4 m95 -61.96 122.53 15.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.705 0.288 . . . . 0.0 110.9 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.586 ' CE2' ' O ' ' A' ' 51' ' ' GLY . 19.5 m-85 -123.84 135.55 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.435 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 9.3 tt0 -87.39 121.9 30.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.453 ' O ' ' CD1' ' A' ' 34' ' ' LEU . . . -134.57 158.23 23.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.2 t -101.43 129.8 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.476 ' O ' ' ND2' ' A' ' 58' ' ' ASN . 2.2 tmm? -138.43 138.08 37.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.813 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.476 ' ND2' ' O ' ' A' ' 57' ' ' MET . 1.9 p30 39.97 38.07 0.44 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.909 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.61 -38.08 2.79 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -75.95 117.71 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 17.1 m -100.62 145.64 28.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.158 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -171.75 177.13 44.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.622 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.1 mt -94.47 155.31 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.784 0.326 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.53 ' CE1' ' O ' ' A' ' 53' ' ' TYR . 51.2 p90 -158.54 151.55 18.5 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.612 0.72 . . . . 0.0 110.927 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.448 ' HD3' ' CH2' ' A' ' 52' ' ' TRP . 53.6 Cg_endo -69.74 129.91 18.44 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.755 2.304 . . . . 0.0 112.371 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -61.47 -17.66 53.86 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.463 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 69' ' ' VAL . 32.0 t30 -68.97 -65.89 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -38.52 -31.71 0.06 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.871 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.404 ' N ' ' O ' ' A' ' 67' ' ' ASN . 3.3 m -107.18 173.66 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -143.59 168.72 19.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 28.9 t -96.05 118.41 32.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 21.5 pt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.091 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo . . . . . 0 C--O 1.23 0.116 0 CA-C-O 121.661 0.609 . . . . 0.0 112.282 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -44.59 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.326 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 33.8 p-90 -56.25 -16.72 5.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.974 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 144.19 89.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.656 0.741 . . . . 0.0 111.103 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.31 14.42 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -55.64 -39.92 71.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 7.3 t -117.49 129.93 56.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.789 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.455 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 9.6 p90 -156.32 140.52 16.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.936 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mp -49.93 -68.12 0.2 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -146.37 175.66 10.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 43' ' ' TYR . 0.6 OUTLIER -116.46 126.82 53.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.903 179.952 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.26 159.51 23.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.086 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.2 p -119.68 143.46 31.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.112 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.441 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . . . -79.16 114.67 18.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.088 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.555 HG13 ' CD2' ' A' ' 24' ' ' TYR . 33.6 pt -92.97 -9.34 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.555 ' CD2' HG13 ' A' ' 23' ' ' ILE . 55.1 m-85 -147.88 158.23 43.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -82.12 128.71 34.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -135.22 129.84 34.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.918 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 28' ' ' LYS . 91.0 m -107.17 104.43 14.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 27' ' ' THR . 14.8 pttm -36.84 122.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -81.59 -8.68 59.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.789 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.9 mmtm -135.27 -175.08 3.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.91 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.26 -16.74 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.943 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -88.69 -22.42 23.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.821 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.43 166.4 22.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.422 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -120.0 134.77 55.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.422 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.4 t -99.73 145.4 27.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 22.4 p90 -164.9 161.26 20.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -106.85 172.83 6.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -66.3 112.04 3.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 122.8 -17.26 8.22 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.448 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.03 146.92 52.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.752 0.311 . . . . 0.0 111.123 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.8 mm -104.47 141.45 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.182 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.406 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 16.8 mt -135.58 142.85 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.088 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.504 ' CE1' ' HE3' ' A' ' 19' ' ' LYS . 93.1 m-85 -105.67 104.76 14.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.873 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.5 t -61.24 121.92 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.105 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.2 pt -123.93 -14.91 5.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.171 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.466 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 35.3 tttm -137.29 148.79 46.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.468 ' HD3' ' CD1' ' A' ' 53' ' ' TYR . 38.2 mmtt -119.76 161.66 20.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.422 ' CB ' ' HB2' ' A' ' 52' ' ' TRP . 2.4 m-80 -133.12 -174.95 3.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.943 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -109.72 -28.07 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.593 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 54.9 m-20 -99.45 40.39 1.22 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.837 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 60.79 79.8 0.11 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.543 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.593 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 94.1 m95 -162.67 137.37 6.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.76 0.314 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.468 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 11.9 m-85 -132.87 136.46 46.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.861 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.466 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.7 tt0 -95.86 115.37 27.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.959 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.406 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -125.68 173.26 17.61 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.472 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.3 t -113.01 139.1 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.157 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.469 ' O ' ' N ' ' A' ' 60' ' ' VAL . 5.3 tmm? -149.36 143.8 26.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.424 ' C ' ' O ' ' A' ' 57' ' ' MET . 11.6 p-10 35.78 37.79 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.0 2.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' MET . 89.1 t -76.05 138.94 19.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.0 111.165 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.447 HG22 ' N ' ' A' ' 62' ' ' GLY . 15.8 m -114.64 146.72 40.53 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.447 ' N ' HG22 ' A' ' 61' ' ' THR . . . -171.86 177.9 44.38 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.376 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.0 mp -105.05 134.12 48.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.825 0.345 . . . . 0.0 110.951 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -125.92 153.1 73.62 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.677 0.751 . . . . 0.0 110.846 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.42 50.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.281 . . . . 0.0 112.297 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.31 36.8 2.4 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.477 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -127.87 -29.69 2.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -91.25 16.29 10.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.6 m -146.59 162.5 9.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.098 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 33.0 mm-40 -139.76 150.97 45.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 91.7 p -85.74 109.57 18.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.8 pt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.084 -179.995 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo . . . . . 0 C--O 1.232 0.196 0 CA-C-O 121.65 0.604 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.87 -34.84 13.42 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -71.43 -30.48 66.11 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -55.13 148.8 28.11 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.51 0.671 . . . . 0.0 111.118 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.87 145.53 56.77 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.647 2.232 . . . . 0.0 112.35 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -51.39 -36.56 44.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.3 m -160.45 156.41 25.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.708 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 19.3 p90 -150.19 -180.0 7.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.3 mt -84.09 -64.6 1.13 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -139.99 176.24 8.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.8 130.65 54.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 15.8 m -123.85 160.4 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.177 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.88 147.77 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.13 22.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.061 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.425 HG13 ' CD2' ' A' ' 24' ' ' TYR . 31.3 pt -92.74 -7.61 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.425 ' CD2' HG13 ' A' ' 23' ' ' ILE . 59.8 m-85 -146.84 163.37 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.944 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.76 121.81 28.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.872 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -135.19 114.26 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.42 ' O ' ' C ' ' A' ' 28' ' ' LYS . 24.6 m -98.21 106.01 18.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' A' ' 27' ' ' THR . 5.2 pttm -35.57 133.18 0.4 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.933 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -90.55 -27.71 18.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -128.94 163.64 24.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.828 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -53.77 -39.95 65.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.947 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -76.2 49.1 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.805 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -157.11 167.08 31.46 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.425 ' HB2' ' CA ' ' A' ' 62' ' ' GLY . 2.5 tt -122.63 146.42 47.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.937 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.5 p -109.46 145.46 36.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.85 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.3 p90 -169.88 148.04 3.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -103.76 153.15 21.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.97 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -39.62 110.57 0.15 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.19 44.88 0.97 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.487 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -126.25 130.46 50.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.772 0.32 . . . . 0.0 111.103 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.3 mm -87.97 136.19 23.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.6 148.97 22.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.118 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.708 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 77.0 m-85 -104.31 115.02 29.64 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.9 t -74.66 121.74 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.184 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.9 pt -122.72 -7.0 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.435 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 0.1 OUTLIER -136.67 144.8 44.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -122.16 103.23 8.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.862 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -74.73 -175.01 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.942 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -99.4 -10.47 22.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.42 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -120.38 40.42 3.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.595 ' O ' ' CE1' ' A' ' 53' ' ' TYR . . . 79.84 -44.29 2.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.43 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.474 ' O ' ' CD1' ' A' ' 53' ' ' TYR . 25.9 m95 -34.46 137.96 0.11 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.808 0.337 . . . . 0.0 110.926 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.595 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 22.0 m-85 -136.84 137.9 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.926 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.8 tt0 -94.15 116.67 29.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.89 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.4 163.34 25.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.547 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.6 t -98.73 146.12 8.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.143 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -151.45 118.65 5.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.902 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.9 t30 49.67 43.76 24.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.931 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 80.4 -40.67 2.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 95.2 t -75.83 120.56 25.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 m -100.96 141.47 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.168 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.425 ' CA ' ' HB2' ' A' ' 34' ' ' LEU . . . -165.87 154.37 24.95 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.498 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -80.54 147.87 30.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.902 0.382 . . . . 0.0 110.902 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -147.99 148.43 29.79 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.676 0.751 . . . . 0.0 110.884 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.5 40.27 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.463 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -73.22 -3.93 62.46 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.527 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -82.22 -28.45 31.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -90.48 8.36 34.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.463 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 8.6 m -135.7 169.06 21.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -140.63 150.18 43.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.4 t -85.03 113.63 21.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.877 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.3 pt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.139 179.895 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.556 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 N--CA 1.467 -0.086 0 CA-C-O 121.585 0.577 . . . . 0.0 112.339 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -33.36 17.04 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.585 2.19 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 22.4 p-90 -63.6 -23.18 67.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.438 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -65.23 148.26 98.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 121.493 0.663 . . . . 0.0 111.087 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 149.15 66.19 Favored 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.662 2.242 . . . . 0.0 112.37 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -54.94 -44.18 74.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.897 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.5 t -145.79 165.66 28.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -159.6 -179.14 7.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 22.9 mt -84.58 -57.31 3.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -152.96 -179.88 8.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HG2' ' N ' ' A' ' 20' ' ' VAL . 13.3 tttp -113.75 154.38 27.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.403 ' N ' ' HG2' ' A' ' 19' ' ' LYS . 29.1 m -152.18 147.15 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -117.09 139.4 44.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.206 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.27 135.42 36.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.109 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.494 HG13 ' CD2' ' A' ' 24' ' ' TYR . 16.1 pt -115.07 -15.17 10.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.179 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.494 ' CD2' HG13 ' A' ' 23' ' ' ILE . 62.9 m-85 -128.53 164.51 22.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.895 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -87.22 123.98 32.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.919 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' A' ' 27' ' ' THR . 86.0 t80 -117.31 160.27 21.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.949 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.41 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 6.7 m -133.53 132.08 40.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.22 136.34 36.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.914 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -99.56 -32.02 11.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.978 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -110.12 163.42 13.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.13 4.71 13.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -108.55 -26.75 10.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.408 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -70.4 -177.99 1.61 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -124.41 139.57 53.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.7 p -115.88 124.91 51.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.828 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -148.04 156.54 42.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -114.86 169.88 8.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -45.64 137.42 5.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.871 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.45 46.51 9.88 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.548 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.9 136.28 52.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.341 . . . . 0.0 111.037 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 21.8 mm -88.72 135.7 25.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.461 HG23 ' CE1' ' A' ' 64' ' ' PHE . 65.9 mt -141.99 143.46 26.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -110.28 109.67 20.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.96 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.8 t -69.25 110.07 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 26.2 pt -107.79 -14.12 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.193 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 46.9 tttt -144.52 138.45 27.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.886 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.565 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 6.6 mtmp? -135.05 102.99 5.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -75.97 175.51 8.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -76.38 48.36 0.53 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -163.36 -176.92 5.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.481 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -82.7 49.62 4.22 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.472 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.535 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 46.1 m95 -148.71 121.39 8.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.565 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 2.9 m-85 -119.06 149.26 41.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.65 123.13 37.91 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.8 177.02 19.6 Favored Glycine 0 N--CA 1.454 -0.157 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.449 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.465 HG12 ' N ' ' A' ' 57' ' ' MET . 45.8 t -117.86 144.22 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.73 0.3 . . . . 0.0 111.196 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.465 ' N ' HG12 ' A' ' 56' ' ' VAL . 6.5 tmm? -157.02 129.99 7.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.816 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.43 ' O ' ' CG ' ' A' ' 58' ' ' ASN . 30.7 t30 47.55 38.47 8.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.01 -35.14 2.55 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.499 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 97.9 t -76.02 126.04 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 2.9 m -106.97 150.87 26.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 33' ' ' GLU . . . 173.91 162.2 25.29 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.526 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.22 163.96 22.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.461 ' CE1' HG23 ' A' ' 42' ' ' ILE . 29.8 p90 -160.68 152.47 16.52 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.525 0.679 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.535 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.78 137.27 35.03 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.679 2.253 . . . . 0.0 112.321 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 68' ' ' TYR . . . -67.27 -56.11 13.28 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.429 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.9 m-20 -40.95 -24.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 13.4 m-85 -76.77 -42.73 39.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 18.8 m -108.24 142.64 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.231 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -102.94 165.64 10.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.802 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.4 t -105.66 105.23 15.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 37.3 pt . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.172 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.567 ' CG ' ' CE2' ' A' ' 11' ' ' TRP . 53.8 Cg_endo . . . . . 0 C--O 1.23 0.115 0 CA-C-O 121.662 0.609 . . . . 0.0 112.329 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.8 -33.35 16.62 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.603 2.202 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.567 ' CE2' ' CG ' ' A' ' 9' ' ' PRO . 22.2 p-90 -65.56 -27.82 68.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.545 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -58.32 147.41 67.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.59 0.71 . . . . 0.0 111.126 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.6 10.72 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.668 2.245 . . . . 0.0 112.294 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.4 mtt180 -85.0 -43.94 13.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.8 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 39.0 t -136.66 152.79 50.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.812 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.53 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 7.1 p90 -159.77 157.21 28.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.904 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 44' ' ' VAL . 19.8 mt -61.35 -66.95 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -144.14 -175.65 4.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.858 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -120.19 133.05 55.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.4 m -128.15 161.23 36.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.195 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 22' ' ' ALA . 11.3 p -126.14 141.08 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.193 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.456 ' N ' HG22 ' A' ' 21' ' ' VAL . . . -71.9 118.4 14.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.102 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.4 pt -99.04 -35.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -129.77 135.11 48.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -56.69 122.58 12.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.894 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 87.9 t80 -121.1 127.71 51.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -97.04 123.51 40.79 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.074 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.418 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -76.15 131.29 39.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.887 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -94.08 -47.9 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -105.14 146.8 28.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -45.22 -32.29 1.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.33 -44.77 96.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.922 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -65.68 165.33 12.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.958 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 tt -121.63 140.09 52.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.418 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 52.8 p -99.2 130.99 45.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -151.6 167.91 26.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.965 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -127.6 159.74 33.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.81 109.07 0.37 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.897 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.59 43.47 0.75 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.445 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.96 131.7 47.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.788 0.328 . . . . 0.0 111.068 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.78 100.4 11.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.431 HG21 ' N ' ' A' ' 43' ' ' TYR . 30.4 mt -104.8 137.55 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.1 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.53 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 80.7 m-85 -91.18 121.79 33.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.966 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 17' ' ' LEU . 48.0 t -80.92 104.5 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.066 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.33 -33.58 4.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.4 tptm -129.31 144.22 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 10.9 mtpt -136.45 124.46 22.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -101.4 151.25 22.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -39.34 -49.66 1.99 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.921 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.74 177.22 7.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.951 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.6 66.9 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.516 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -151.68 113.07 4.34 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.733 0.301 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.48 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 1.3 m-85 -122.95 154.23 38.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -104.45 134.59 47.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.879 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.17 157.07 27.05 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.488 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.3 t -95.48 136.43 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.926 0.394 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.41 ' O ' ' N ' ' A' ' 60' ' ' VAL . 21.8 ttp -141.18 119.67 12.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.824 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 43.93 42.76 4.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.79 -26.64 4.65 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.493 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.41 ' N ' ' O ' ' A' ' 57' ' ' MET . 93.0 t -81.1 127.76 39.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.881 0.372 . . . . 0.0 111.162 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.7 m -112.19 147.86 35.27 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 178.04 162.84 28.63 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.533 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.9 mt -88.44 128.79 35.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -120.38 147.33 44.95 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.716 0.77 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 122.83 9.5 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.667 2.245 . . . . 0.0 112.35 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.457 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -58.53 -10.8 8.46 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -76.61 -32.16 57.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.732 0.301 . . . . 0.0 110.787 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.424 ' O ' ' CG1' ' A' ' 69' ' ' VAL . 11.7 m-85 -97.83 35.32 1.72 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.906 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.457 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 9.9 m -161.32 153.81 3.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.441 ' CG ' HG11 ' A' ' 21' ' ' VAL . 5.6 pt-20 -130.06 144.14 51.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 37.9 m -84.66 120.33 26.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 24.9 pt . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.181 179.862 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.56 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 121.624 0.593 . . . . 0.0 112.33 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.81 -33.95 15.4 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.681 2.254 . . . . 0.0 112.318 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.56 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 54.8 p-90 -73.55 -29.7 62.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.406 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -52.71 151.53 7.99 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.604 0.716 . . . . 0.0 111.089 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.63 133.25 25.33 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 56.5 mtm180 -48.68 -45.48 39.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.865 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.5 p -136.64 163.39 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.942 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -166.27 171.21 12.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.005 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.03 -52.29 9.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.447 ' C ' ' OE1' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -160.44 172.84 16.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.967 179.898 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.05 145.92 42.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.4 m -135.64 163.28 35.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.109 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.29 140.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.05 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.19 102.93 12.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.072 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.551 HD12 ' CE2' ' A' ' 24' ' ' TYR . 8.5 pt -84.25 -7.22 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.551 ' CE2' HD12 ' A' ' 23' ' ' ILE . 46.7 m-85 -145.43 136.6 24.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.912 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -65.69 136.02 55.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.872 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -137.97 128.1 25.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.883 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.3 m -97.32 151.33 20.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.209 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 7.8 ptmt -93.03 132.58 37.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.844 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.02 -18.26 22.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.816 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -138.16 167.73 21.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.92 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -83.33 36.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.902 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -127.39 -28.94 2.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.937 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -88.98 -174.97 4.68 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.969 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -129.21 140.4 51.5 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.1 p -108.38 140.32 41.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -153.75 166.58 32.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.933 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -114.41 170.27 8.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -61.8 102.02 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 115.23 42.5 0.76 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.584 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.38 140.96 48.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 111.146 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.2 mm -92.85 122.44 44.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.151 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.482 HG23 ' CE2' ' A' ' 64' ' ' PHE . 70.4 mt -127.47 136.21 61.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -101.35 107.68 19.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.962 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.5 t -69.17 113.49 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.091 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.435 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.0 pt -113.93 -2.37 10.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.164 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.0 tptm -156.2 137.08 13.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 ptpt -136.51 116.65 13.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 58.7 m-20 -90.1 155.91 18.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -43.15 -37.33 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -85.11 -175.27 5.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.526 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -82.56 81.37 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.526 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 91.9 m95 -162.02 120.66 2.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 33.6 m-85 -118.52 135.36 54.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.927 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.454 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 7.8 tt0 -91.0 111.11 22.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -125.96 169.89 17.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.487 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.3 t -115.52 129.83 71.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 111.097 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.8 tmm? -137.34 125.36 22.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 45.8 t30 51.02 37.98 19.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.28 -31.49 2.9 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.6 132.36 31.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.914 0.388 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.436 HG22 ' N ' ' A' ' 62' ' ' GLY . 18.9 m -114.27 145.14 42.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.436 ' N ' HG22 ' A' ' 61' ' ' THR . . . -168.76 145.12 9.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -67.95 123.85 21.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.482 ' CE2' HG23 ' A' ' 42' ' ' ILE . 42.3 p90 -123.82 152.67 66.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 138.91 38.88 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.646 2.231 . . . . 0.0 112.324 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.19 29.24 3.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -116.78 -35.02 4.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.848 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -78.21 2.36 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.938 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.96 178.41 2.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.082 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -142.68 124.17 14.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 72.2 m -71.7 103.69 3.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.9 pt . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.973 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.148 0 CA-C-O 121.558 0.566 . . . . 0.0 112.297 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 2.87 3.13 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.692 2.262 . . . . 0.0 112.366 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 32.0 p-90 -120.42 18.01 12.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.91 144.51 64.05 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.611 0.72 . . . . 0.0 111.057 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 155.89 64.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.386 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -50.98 -53.72 30.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.867 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.3 t -145.13 165.45 28.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -158.67 155.39 28.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.905 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -64.56 -46.94 80.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.912 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -165.97 179.35 5.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.564 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 24.2 ttmt -119.43 132.76 55.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.823 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.467 HG21 ' CG2' ' A' ' 44' ' ' VAL . 35.0 m -120.44 168.53 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.115 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.409 HG13 ' CG2' ' A' ' 72' ' ' ILE . 7.7 p -124.83 137.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.997 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.06 92.53 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.114 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.442 HD13 ' CE2' ' A' ' 24' ' ' TYR . 35.7 pt -69.38 -34.71 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.192 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.442 ' CE2' HD13 ' A' ' 23' ' ' ILE . 77.6 m-85 -128.82 151.81 49.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.869 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.81 102.02 11.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.891 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -103.49 130.55 50.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.9 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -96.04 108.97 21.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.4 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 12.7 pttm -45.24 142.18 2.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.928 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -95.34 -48.93 5.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -101.26 175.84 5.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.902 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -67.85 -38.65 83.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.68 -40.52 95.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.829 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.4 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 32.5 mt-10 -57.09 162.41 2.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -118.59 141.2 48.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 p -108.4 133.22 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -155.84 152.6 28.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.912 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -106.4 160.01 15.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.423 ' OE1' ' C ' ' A' ' 38' ' ' GLU . 1.0 OUTLIER -45.37 137.72 4.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.865 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.3 48.03 5.83 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.83 142.51 50.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 111.145 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.418 ' C ' HG13 ' A' ' 42' ' ' ILE . 28.7 mm -94.84 139.51 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.137 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.524 HG23 ' CE2' ' A' ' 64' ' ' PHE . 20.8 mt -141.88 143.19 27.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.181 179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.564 ' CE1' ' HE2' ' A' ' 19' ' ' LYS . 97.9 m-85 -103.05 98.81 8.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.897 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.467 ' CG2' HG21 ' A' ' 20' ' ' VAL . 25.6 t -64.25 95.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.207 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.414 HG13 ' N ' ' A' ' 46' ' ' LYS . 48.1 pt -88.12 -34.48 7.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.414 ' N ' HG13 ' A' ' 45' ' ' ILE . 1.4 tppp? -126.04 148.04 49.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.916 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.542 ' HE2' ' CD1' ' A' ' 53' ' ' TYR . 13.9 mtpt -136.58 112.75 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -87.64 150.73 23.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -41.89 -49.38 4.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.36 175.4 6.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.907 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.17 61.65 2.21 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.53 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -151.39 110.66 3.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.715 0.293 . . . . 0.0 110.939 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.542 ' CD1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -112.8 151.71 30.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.41 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.4 tt0 -99.78 126.91 45.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.958 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.15 27.9 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.41 HG13 ' N ' ' A' ' 57' ' ' MET . 98.0 t -97.22 139.85 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 111.092 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.41 ' N ' HG13 ' A' ' 56' ' ' VAL . 5.7 ttp -153.4 111.11 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.1 t30 62.24 39.3 12.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.35 -35.26 2.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.26 130.46 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 0.0 111.06 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.2 m -116.86 131.42 56.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.14 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.37 163.42 32.94 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.451 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.2 mt -80.09 123.38 27.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.524 ' CE2' HG23 ' A' ' 42' ' ' ILE . 21.3 p90 -115.6 151.25 45.94 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 110.906 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 118.01 5.42 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.724 2.283 . . . . 0.0 112.307 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -55.03 -13.04 4.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.416 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -75.67 -34.12 60.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.842 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.405 ' O ' ' CG1' ' A' ' 69' ' ' VAL . 13.2 m-85 -94.59 32.6 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.455 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 26.9 m -158.34 139.24 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.6 mm-40 -120.55 158.16 27.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.826 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.7 p -90.15 127.03 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.409 ' CG2' HG13 ' A' ' 21' ' ' VAL . 43.5 pt . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.147 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.516 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.4 Cg_endo . . . . . 0 C--O 1.231 0.134 0 CA-C-O 121.587 0.578 . . . . 0.0 112.376 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -29.32 24.18 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.619 2.212 . . . . 0.0 112.389 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.516 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 48.4 p-90 -73.47 -14.21 61.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.934 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.469 ' HB2' ' CE2' ' A' ' 43' ' ' TYR . . . -76.67 143.68 72.08 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.684 0.754 . . . . 0.0 111.025 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 123.24 9.89 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.2 mmt85 -41.9 -47.48 4.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.4 t -121.57 153.24 38.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.453 ' CB ' HG22 ' A' ' 45' ' ' ILE . 25.9 p90 -164.8 163.95 21.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.936 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 51.4 mt -65.85 -61.98 1.76 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.019 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -156.86 178.58 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.001 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -114.92 147.95 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.461 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 22.1 m -146.55 158.95 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.463 HG13 ' CG2' ' A' ' 72' ' ' ILE . 13.0 p -124.81 132.62 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.221 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.16 117.9 12.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.518 HG13 ' CD2' ' A' ' 24' ' ' TYR . 41.7 pt -98.89 -14.47 7.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CD2' HG13 ' A' ' 23' ' ' ILE . 47.5 m-85 -136.38 151.63 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.931 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -78.33 115.07 17.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -113.88 148.61 36.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.4 m -120.16 112.03 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.179 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 15.0 pttm -57.82 136.75 57.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.931 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.32 -24.43 42.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 pttt -155.06 179.02 9.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.12 -43.01 77.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.939 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -47.23 -36.4 8.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.976 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -87.4 176.99 7.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.433 HD11 ' N ' ' A' ' 62' ' ' GLY . 1.7 tt -128.0 152.44 47.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.932 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.0 p -108.54 139.31 43.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.843 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -165.43 153.86 11.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.936 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -112.59 166.06 11.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.949 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -51.83 106.23 0.14 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.966 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 116.83 46.43 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.425 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -141.38 117.83 10.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.809 0.338 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.468 HD13 ' N ' ' A' ' 41' ' ' ILE . 3.7 mp -80.82 147.53 6.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.9 mt -142.89 133.42 22.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 12' ' ' ALA . 77.0 m-85 -86.74 109.89 19.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.884 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 80.2 t -76.29 124.05 33.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.453 HG22 ' CB ' ' A' ' 16' ' ' TYR . 10.6 pt -120.7 -23.87 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.127 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 9.5 tmtt? -128.75 145.95 51.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.457 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 19.1 mtpt -123.38 160.65 26.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.914 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 52' ' ' TRP . 2.7 m-80 -129.79 -174.89 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -104.45 -26.73 12.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.814 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.597 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 34.6 t70 -100.04 39.85 1.3 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.528 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 59.06 78.17 0.14 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.497 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.597 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 97.5 m95 -162.33 115.16 1.72 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.805 0.336 . . . . 0.0 110.853 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.32 137.65 51.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.92 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -91.1 126.24 36.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.863 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.98 167.13 25.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.523 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 84.7 t -112.64 126.75 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.778 0.323 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.3 ttp -133.24 107.18 7.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.905 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 59.27 41.73 19.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.982 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.73 -34.15 3.19 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 92.7 t -76.21 125.02 35.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.938 0.399 . . . . 0.0 111.067 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.7 m -107.58 146.79 31.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.133 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.433 ' N ' HD11 ' A' ' 34' ' ' LEU . . . 179.49 139.69 3.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.2 mp -69.13 161.42 29.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.369 . . . . 0.0 110.877 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -163.11 154.51 14.78 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.587 0.708 . . . . 0.0 110.9 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.48 ' HG2' ' CD1' ' A' ' 68' ' ' TYR . 53.7 Cg_endo -69.68 122.74 9.44 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.391 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.413 ' O ' ' CG2' ' A' ' 69' ' ' VAL . . . -51.29 -52.0 34.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 68' ' ' TYR . 19.0 m120 -40.71 -65.05 0.46 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.817 0.341 . . . . 0.0 110.818 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.48 ' CD1' ' HG2' ' A' ' 65' ' ' PRO . 23.7 m-85 -36.37 -33.99 0.05 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.423 ' N ' ' O ' ' A' ' 67' ' ' ASN . 30.9 m -108.67 164.54 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.129 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.475 ' CD ' ' N ' ' A' ' 71' ' ' SER . 2.8 tm-20 -122.03 137.49 54.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.475 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 14.9 m -80.7 77.86 7.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.834 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.463 ' CG2' HG13 ' A' ' 21' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 C--O 1.23 0.123 0 CA-C-O 121.62 0.591 . . . . 0.0 112.321 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -25.65 28.4 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.64 2.227 . . . . 0.0 112.341 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.502 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 47.0 p-90 -79.33 -18.78 51.85 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -75.08 148.34 84.19 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.73 . . . . 0.0 111.087 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.8 Cg_endo -69.79 132.61 23.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.634 2.223 . . . . 0.0 112.399 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.449 ' C ' ' O ' ' A' ' 13' ' ' PRO . 3.6 ptt180 -34.37 -46.81 0.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.833 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 24.2 m -144.5 169.51 17.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -160.65 166.88 28.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.969 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -65.86 -56.67 10.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -152.57 -175.76 5.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -126.11 121.82 33.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.95 167.28 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.175 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 p -133.95 136.87 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.61 119.06 15.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.42 HG13 ' CD2' ' A' ' 24' ' ' TYR . 24.4 pt -97.79 -8.55 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.151 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.42 ' CD2' HG13 ' A' ' 23' ' ' ILE . 41.1 m-85 -142.58 165.79 26.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -88.35 114.28 24.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.836 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.416 ' HB3' ' CZ ' ' A' ' 36' ' ' PHE . 90.8 t80 -114.47 111.49 21.48 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.97 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 22.2 m -92.57 94.69 9.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.417 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 0.7 OUTLIER -43.67 157.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.904 179.925 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -118.53 -20.85 8.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' GLU . 12.6 mmmm -124.69 137.3 54.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -41.93 -30.53 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.19 -41.94 85.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.953 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.424 ' N ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -64.22 169.22 4.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -121.1 138.96 53.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.962 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.7 p -101.15 153.28 19.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.902 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.416 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 24.9 p90 -174.24 165.91 4.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.973 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.426 ' O ' ' C ' ' A' ' 38' ' ' GLU . 15.0 pt20 -130.5 151.35 51.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 37' ' ' GLN . 16.6 tt0 -36.69 104.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 117.94 38.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.481 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -123.54 130.09 52.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.717 0.294 . . . . 0.0 111.108 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.4 mm -87.11 133.01 31.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.416 HG21 ' N ' ' A' ' 43' ' ' TYR . 78.5 mt -131.18 140.93 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.118 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.416 ' N ' HG21 ' A' ' 42' ' ' ILE . 44.8 m-85 -105.88 97.9 7.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.36 114.03 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.164 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.5 pt -110.91 -20.1 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.172 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 37.4 mttp -144.46 154.92 43.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -136.5 159.71 40.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -129.45 149.03 51.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -38.34 -39.28 0.43 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 52' ' ' TRP . 1.5 m-20 -96.03 174.21 7.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.969 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -63.62 77.19 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.489 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.536 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 85.0 m95 -160.16 120.33 2.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.877 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -131.73 151.89 51.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -91.47 142.54 27.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.81 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -156.86 158.61 28.94 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.463 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.5 t -104.65 131.04 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 111.133 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.1 tmm? -136.26 112.2 9.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.3 t30 59.35 38.1 23.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.42 -38.17 3.17 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.446 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 87.3 t -77.42 126.79 38.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 111.201 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.411 HG21 ' N ' ' A' ' 62' ' ' GLY . 33.2 m -107.57 142.92 36.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' N ' HG21 ' A' ' 61' ' ' THR . . . -163.09 173.52 39.29 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.483 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.4 mt -95.77 128.07 42.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.839 0.352 . . . . 0.0 110.922 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -130.34 148.98 72.06 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.715 0.769 . . . . 0.0 110.897 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -70.03 142.75 47.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.594 2.196 . . . . 0.0 112.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.82 11.83 45.22 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.443 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -99.38 -12.91 19.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.796 0.331 . . . . 0.0 110.893 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -108.17 17.6 22.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.7 m -139.17 173.55 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 -145.74 167.05 24.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.857 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 96.7 p -102.12 112.83 25.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.0 pt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.138 179.958 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.529 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 121.639 0.6 . . . . 0.0 112.331 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.73 -31.63 20.28 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.684 2.256 . . . . 0.0 112.373 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.529 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 38.0 p-90 -68.99 -22.95 64.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.871 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.42 145.07 87.37 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.0 Cg_endo -69.77 136.93 34.2 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.753 2.302 . . . . 0.0 112.362 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.451 ' C ' ' O ' ' A' ' 13' ' ' PRO . 5.2 ptt85 -34.31 -48.2 0.33 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -148.44 174.19 12.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 23.5 p90 -169.14 151.39 4.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.936 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -49.67 -68.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -151.24 -179.67 7.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.29 144.07 44.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.0 m -127.87 170.36 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.129 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.7 p -136.69 127.37 41.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.15 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.08 112.35 9.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.129 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.519 HD13 ' CE2' ' A' ' 24' ' ' TYR . 12.2 pt -92.84 -7.54 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.519 ' CE2' HD13 ' A' ' 23' ' ' ILE . 30.8 m-85 -136.94 166.12 24.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.951 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -85.23 141.7 29.94 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.827 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.403 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 83.6 t80 -151.96 118.25 5.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.916 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 91.3 m -104.83 111.98 24.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.128 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -43.94 150.28 0.28 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.997 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -115.91 -47.01 2.8 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.877 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.47 149.64 24.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 64.6 mm-40 -48.47 -28.35 3.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.873 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -89.21 43.23 1.13 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -143.27 159.53 42.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -116.87 130.74 56.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.906 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 22.5 t -97.41 144.21 27.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.515 ' CD2' HD12 ' A' ' 42' ' ' ILE . 9.6 p90 -164.83 150.3 9.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 18.5 mt-30 -105.46 153.54 21.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -45.52 110.11 0.22 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.96 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.53 36.87 1.25 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.6 141.8 48.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.719 0.295 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -92.18 112.86 26.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.087 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.527 HG22 ' CE2' ' A' ' 64' ' ' PHE . 45.5 mt -115.89 125.25 72.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -89.22 106.03 18.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.9 t -68.05 120.62 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.106 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 12.8 pt -121.45 -14.97 7.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.172 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.4 ttmt -132.78 122.2 24.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.462 ' HD3' ' CD1' ' A' ' 53' ' ' TYR . 18.7 mmtt -114.55 102.72 10.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -90.59 143.44 26.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -40.07 -48.2 2.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 -71.88 -178.1 2.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.27 62.71 4.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -152.28 118.97 5.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.462 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 4.4 m-85 -120.99 160.6 23.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -112.28 123.46 50.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.937 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.27 166.46 24.11 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.463 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 65.1 t -107.9 124.42 64.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.9 0.381 . . . . 0.0 111.157 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.8 tmm? -129.79 106.29 8.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.798 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 4.5 t30 61.24 39.8 15.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.72 -30.01 3.96 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.482 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.9 t -82.59 115.98 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.92 0.39 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.4 m -109.77 143.43 39.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -172.16 163.72 36.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.422 HD22 ' N ' ' A' ' 63' ' ' LEU . 2.1 mm? -68.56 150.15 48.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.878 0.37 . . . . 0.0 110.922 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.527 ' CE2' HG22 ' A' ' 42' ' ' ILE . 5.3 p90 -162.17 151.42 13.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.676 0.75 . . . . 0.0 110.872 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 136.79 33.87 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.708 2.272 . . . . 0.0 112.308 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -75.44 -42.29 27.94 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.477 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -51.06 -29.32 12.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.895 0.378 . . . . 0.0 110.917 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.403 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 10.5 m-85 -71.62 -30.06 65.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.9 m -110.0 137.15 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.12 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 71' ' ' SER . 0.4 OUTLIER -101.52 131.39 47.7 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.404 ' N ' ' OE2' ' A' ' 70' ' ' GLU . 19.2 m -74.6 103.3 4.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.7 pt . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.548 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.139 0 CA-C-O 121.537 0.557 . . . . 0.0 112.402 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -39.32 6.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.244 . . . . 0.0 112.361 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.566 ' CE3' ' HA ' ' A' ' 12' ' ' ALA . 41.9 p-90 -58.13 -38.25 76.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.566 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.53 143.15 20.56 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.51 0.672 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 135.43 30.62 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.2 mtm180 -87.06 36.05 0.72 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.3 t -171.51 105.99 0.22 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.827 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 19.9 p90 -157.7 171.21 20.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.7 mt -85.8 -47.15 9.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.451 ' OE2' ' C ' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -168.84 174.26 6.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.9 pttm -116.98 161.21 19.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.454 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 33.9 m -148.67 160.97 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.11 139.68 40.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.184 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.19 95.59 6.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.101 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.536 HG13 ' CD2' ' A' ' 24' ' ' TYR . 38.7 pt -69.67 -23.89 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.137 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' CD2' HG13 ' A' ' 23' ' ' ILE . 64.3 m-85 -124.23 160.41 28.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.927 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.65 100.62 13.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.444 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 89.4 t80 -109.74 130.19 55.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.418 ' O ' ' CE2' ' A' ' 26' ' ' TYR . 15.4 t -93.43 -175.16 3.72 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.081 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' HD3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -114.52 130.52 56.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.941 179.938 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -102.48 -52.2 3.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.884 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -96.86 145.32 25.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -49.43 -24.01 1.79 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.03 47.86 1.23 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -146.37 172.16 13.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.852 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.411 HD11 ' N ' ' A' ' 62' ' ' GLY . 1.5 tt -129.3 133.43 47.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.857 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.6 t -100.24 141.33 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.825 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . 0.444 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 11.3 p90 -155.32 174.81 14.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.934 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -127.36 165.32 19.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.933 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -57.97 109.55 0.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.89 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.56 45.75 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -145.13 119.25 9.44 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.652 0.263 . . . . 0.0 111.205 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.462 HD13 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -80.7 139.07 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.126 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.521 HG22 ' CE2' ' A' ' 64' ' ' PHE . 20.3 mt -129.77 117.98 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.489 ' CE2' ' HB2' ' A' ' 12' ' ' ALA . 16.4 m-85 -72.21 107.17 4.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.68 105.79 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.4 pt -93.65 -15.31 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.043 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.41 ' CB ' ' HB3' ' A' ' 54' ' ' GLU . 9.8 tptt -141.72 143.8 33.72 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.834 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -134.58 116.33 14.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -97.16 152.1 19.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.841 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.01 -43.42 29.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -75.75 176.04 8.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -76.2 70.17 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.481 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.0 m95 -163.34 119.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 110.891 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -120.55 155.11 34.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.41 ' HB3' ' CB ' ' A' ' 46' ' ' LYS . 19.8 tt0 -103.77 118.3 36.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.35 160.53 25.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.408 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 85.4 t -101.27 139.73 21.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.764 0.316 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.1 ttp -140.02 111.78 7.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.879 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.8 t30 49.24 38.65 13.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.03 -29.97 6.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 94.6 t -79.81 118.92 28.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.927 0.394 . . . . 0.0 111.196 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.4 m -108.98 139.64 43.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' N ' HD11 ' A' ' 34' ' ' LEU . . . -171.37 163.23 36.0 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.526 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -81.19 135.45 35.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.726 0.298 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.521 ' CE2' HG22 ' A' ' 42' ' ' ILE . 45.5 p90 -136.34 152.96 76.01 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.689 0.756 . . . . 0.0 110.842 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 132.4 23.26 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.627 2.218 . . . . 0.0 112.392 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.39 -1.13 41.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.554 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -86.85 -33.71 19.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -87.11 29.53 0.83 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.977 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 20.4 m -157.38 142.28 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.105 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -118.49 164.87 14.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.965 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 p -92.89 132.63 36.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.872 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.454 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.121 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo . . . . . 0 N--CA 1.465 -0.158 0 CA-C-O 121.517 0.549 . . . . 0.0 112.343 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.26 4.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.602 2.201 . . . . 0.0 112.367 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.521 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 64.4 p-90 -60.46 -40.21 90.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.012 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.551 ' HB3' ' CE2' ' A' ' 43' ' ' TYR . . . -40.21 144.17 0.58 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.627 0.727 . . . . 0.0 111.018 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.9 140.26 41.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.618 2.212 . . . . 0.0 112.294 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -65.39 -45.06 85.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 73.2 m -115.22 150.97 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.8 p90 -169.41 147.44 3.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.837 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -56.11 -52.94 62.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.931 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -165.0 170.83 14.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -103.6 155.9 18.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.5 m -149.06 138.98 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.159 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.4 p -110.87 127.36 68.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.17 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.83 123.38 24.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.122 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.51 HD11 ' CE2' ' A' ' 24' ' ' TYR . 36.8 pt -97.68 -34.56 4.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.06 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.51 ' CE2' HD11 ' A' ' 23' ' ' ILE . 31.9 m-85 -108.0 178.12 4.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -95.54 126.39 40.8 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -126.0 134.48 51.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.906 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.6 m -116.75 111.96 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.135 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.08 127.07 9.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -90.17 -57.2 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -94.72 -177.36 4.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -78.26 -28.8 47.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.447 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 8.7 m-20 -85.62 23.95 1.3 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . 0.447 ' OE1' ' C ' ' A' ' 32' ' ' ASP . 1.5 mp0 -114.69 177.89 4.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.934 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 tt -132.16 134.2 45.11 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.915 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 87.6 p -97.67 127.71 43.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -150.51 170.4 19.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.907 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -139.1 162.23 35.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -43.86 109.35 0.14 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 106.61 44.22 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -121.35 125.4 46.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.336 . . . . 0.0 111.115 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.9 mm -82.75 100.1 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.015 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.548 HG23 ' CE1' ' A' ' 64' ' ' PHE . 32.6 mt -105.95 131.16 56.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.146 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.551 ' CE2' ' HB3' ' A' ' 12' ' ' ALA . 79.4 m-85 -99.34 104.11 15.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.931 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.54 124.43 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.179 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.455 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 8.9 pt -124.77 -25.37 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.131 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.38 152.99 42.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 6.0 mtmp? -128.56 151.05 49.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.855 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.473 ' ND2' ' HB2' ' A' ' 52' ' ' TRP . 2.6 m-20 -126.47 -174.69 3.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.871 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -94.22 -31.54 14.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.607 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -95.34 39.29 1.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.55 63.14 5.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.531 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.607 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 95.0 m95 -134.75 96.97 3.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -91.63 137.63 32.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.455 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.4 tt0 -96.67 111.63 23.71 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.842 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -124.65 171.71 16.81 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.412 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.8 t -110.42 134.66 51.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.891 0.377 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -140.61 111.31 6.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.87 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.1 t30 59.29 39.8 22.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.847 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.62 -38.17 2.93 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.441 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 98.7 t -75.62 127.43 37.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.999 0.428 . . . . 0.0 111.086 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.429 HG23 ' N ' ' A' ' 62' ' ' GLY . 38.3 m -106.46 153.91 21.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.16 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.429 ' N ' HG23 ' A' ' 61' ' ' THR . . . -177.1 170.03 42.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 13.6 mt -98.89 141.25 31.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.818 0.342 . . . . 0.0 110.912 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.548 ' CE1' HG23 ' A' ' 42' ' ' ILE . 20.7 p90 -139.58 154.39 71.29 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.744 0.783 . . . . 0.0 110.838 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.46 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 53.9 Cg_endo -69.83 140.69 43.05 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.584 2.189 . . . . 0.0 112.349 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -80.59 41.17 2.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 -126.37 -43.53 1.76 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.901 0.382 . . . . 0.0 110.898 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -69.02 -23.65 64.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.963 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.8 m -113.66 148.83 16.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.156 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -108.55 155.52 20.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.973 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 44.6 p -99.56 100.67 11.71 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.79 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.6 pt . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.102 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.56 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo . . . . . 0 N--CA 1.466 -0.118 0 CA-C-O 121.619 0.591 . . . . 0.0 112.25 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -47.86 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.596 2.197 . . . . 0.0 112.378 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.56 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 34.0 p-90 -57.07 -20.83 27.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.874 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.84 144.06 98.36 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.503 0.668 . . . . 0.0 111.124 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 14' ' ' ARG . 54.0 Cg_endo -69.77 105.8 1.55 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.622 2.215 . . . . 0.0 112.434 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.452 ' C ' ' O ' ' A' ' 13' ' ' PRO . 4.4 ptt85 -34.41 -46.54 0.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 t -120.23 149.75 41.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 38.4 p90 -169.01 163.12 11.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.922 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mt -60.96 -66.96 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.401 ' O ' ' CD1' ' A' ' 16' ' ' TYR . 11.2 pt-20 -146.8 -176.41 5.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.945 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.427 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 16.3 ttmt -127.91 127.34 43.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.839 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.03 158.97 25.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.166 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.77 124.12 64.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -54.72 138.36 42.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.077 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.8 pt -121.0 -13.51 8.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.154 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -132.64 147.65 52.34 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.04 105.65 3.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -113.56 141.81 46.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.954 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 50.9 m -122.73 110.98 16.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 24.7 pttt -48.68 151.05 1.24 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.953 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -97.33 -45.23 6.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.877 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.63 171.71 8.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -66.63 -7.02 17.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.892 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -87.4 -23.83 24.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.929 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -90.55 -178.35 5.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -129.42 150.76 50.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.8 t -116.53 139.32 50.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -156.34 152.27 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.904 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -113.32 153.27 28.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.956 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -43.08 99.19 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.86 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 123.6 28.22 1.33 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.479 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.05 138.34 46.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.719 0.295 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.1 mm -95.81 127.61 47.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.169 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.418 HG21 ' CE2' ' A' ' 64' ' ' PHE . 64.5 mt -127.65 133.98 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.196 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 72.5 m-85 -95.44 98.54 10.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.9 t -63.65 117.85 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.5 pt -116.58 -25.14 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.459 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 28.6 ttmt -128.42 142.8 50.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.567 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 21.3 mtpp -130.21 120.62 24.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.848 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -94.77 152.67 18.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -39.13 -47.12 1.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -81.98 -179.42 7.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.769 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.435 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -75.21 70.52 1.84 Allowed Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.472 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 58.3 m95 -149.74 122.77 8.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 111.043 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.567 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 7.0 m-85 -120.29 151.43 39.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.91 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.459 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 2.8 tt0 -104.02 113.58 27.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -131.48 154.43 20.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.553 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 93.0 t -96.64 112.36 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.326 . . . . 0.0 111.176 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -118.11 112.0 19.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 22.5 t30 65.5 35.81 7.04 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.06 -31.57 3.1 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 76.7 t -83.69 129.98 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.826 0.345 . . . . 0.0 111.158 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.8 m -109.51 143.33 39.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.8 148.61 12.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.521 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.408 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.8 mm? -66.28 135.19 54.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.418 ' CE2' HG21 ' A' ' 42' ' ' ILE . 48.1 p90 -140.35 148.48 54.09 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.612 0.72 . . . . 0.0 110.91 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 132.47 23.22 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.4 -10.29 69.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -79.72 -28.35 40.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.881 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -89.21 20.9 3.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.8 m -138.06 178.43 4.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.126 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 71' ' ' SER . 6.3 tm-20 -143.69 160.07 41.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.828 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.472 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 9.7 m -104.11 113.64 27.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.886 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.5 pt . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 -179.992 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 52.7 Cg_endo . . . . . 0 C--O 1.23 0.116 0 CA-C-O 121.62 0.591 . . . . 0.0 112.293 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.73 2.287 . . . . 0.0 112.373 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.445 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 50.3 p-90 -54.85 -29.79 56.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.954 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.06 156.07 51.02 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.497 0.665 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 151.14 68.67 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.707 2.271 . . . . 0.0 112.26 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 68.2 mtt180 -72.51 -48.87 37.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.841 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.2 t -129.22 98.61 4.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.836 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -105.32 143.35 33.62 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.93 -67.31 0.27 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.933 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -143.31 178.9 7.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.888 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -123.12 141.98 51.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.467 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.0 m -137.54 174.05 11.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.045 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 p -134.13 150.6 31.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.12 96.92 10.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.036 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.473 HG13 ' CD2' ' A' ' 24' ' ' TYR . 32.1 pt -73.24 -12.27 15.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.473 ' CD2' HG13 ' A' ' 23' ' ' ILE . 60.5 m-85 -131.53 172.25 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.93 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.24 96.49 6.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 29.5 t80 -98.96 155.35 17.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -123.81 131.59 53.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.434 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -78.31 125.95 30.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -96.68 -53.27 3.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.807 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.431 ' NZ ' ' HA ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -96.21 164.47 12.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.959 179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.08 -28.43 67.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -86.76 42.97 1.05 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.966 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -148.01 152.95 38.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.894 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.417 HD23 ' N ' ' A' ' 35' ' ' SER . 1.8 tt -112.17 130.67 55.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.792 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.434 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 55.7 p -96.16 134.03 39.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -154.96 169.18 24.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.909 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -126.25 161.19 28.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -50.47 108.01 0.2 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.892 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.48 32.96 2.59 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.476 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.61 145.67 34.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.71 0.291 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 22.0 mm -102.37 126.55 56.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.129 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.402 HG21 ' CE2' ' A' ' 64' ' ' PHE . 19.5 mt -134.76 141.99 41.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.112 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -104.16 124.02 48.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.899 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.6 t -77.62 117.44 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.042 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.3 pt -116.99 -12.2 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.44 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 17.7 tttm -153.95 151.32 29.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -134.16 111.45 10.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.921 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -75.26 164.88 25.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -40.72 -46.61 2.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.34 -179.83 7.28 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.803 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.449 ' O ' ' CZ ' ' A' ' 53' ' ' TYR . . . -60.82 -7.66 8.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.476 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -69.88 128.28 35.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.852 0.358 . . . . 0.0 110.93 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.449 ' CZ ' ' O ' ' A' ' 51' ' ' GLY . 3.8 m-85 -126.68 148.72 49.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.951 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.44 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.2 tt0 -90.88 130.3 36.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -146.24 167.19 27.96 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.437 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.7 t -108.82 136.1 45.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.864 0.364 . . . . 0.0 111.146 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.419 ' HE1' ' ND2' ' A' ' 58' ' ' ASN . 8.6 ttp -143.48 122.62 12.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.882 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.419 ' ND2' ' HE1' ' A' ' 57' ' ' MET . 8.6 p30 43.81 39.76 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.93 -30.74 3.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.06 117.01 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 111.084 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 10.3 m -99.38 135.18 41.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -164.5 163.15 36.0 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.459 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.7 mt -89.88 124.61 34.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.81 0.338 . . . . 0.0 110.917 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.402 ' CE2' HG21 ' A' ' 42' ' ' ILE . 35.8 p90 -119.83 144.65 37.74 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.619 0.724 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 138.63 38.17 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.667 2.244 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.08 3.69 56.85 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.521 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -89.89 -24.58 21.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.925 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -98.12 26.0 5.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.926 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.2 m -144.27 179.97 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.086 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.423 ' CG ' HD11 ' A' ' 23' ' ' ILE . 2.2 mm-40 -150.69 125.91 10.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 31.3 p -64.35 82.35 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.126 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.199 0 CA-C-O 121.617 0.59 . . . . 0.0 112.327 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -47.6 0.9 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 49.6 p-90 -55.24 -40.73 71.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.844 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -47.39 153.1 1.02 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.558 0.694 . . . . 0.0 111.147 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.63 146.92 62.47 Favored 'Trans proline' 0 C--O 1.23 0.121 0 C-N-CA 122.744 2.296 . . . . 0.0 112.33 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.9 ptt180 -49.14 -57.89 5.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.844 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 36.1 t -133.85 149.88 51.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.1 p90 -149.2 159.72 44.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.9 mt -66.79 -61.06 2.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.873 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.11 175.72 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.416 ' HG2' ' N ' ' A' ' 20' ' ' VAL . 31.1 tttt -121.46 151.72 39.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.971 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.462 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 29.1 m -145.36 177.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.177 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.458 ' CG1' ' HG3' ' A' ' 70' ' ' GLU . 8.3 p -137.1 139.18 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.432 ' N ' HG22 ' A' ' 21' ' ' VAL . . . -79.29 87.99 4.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.114 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.554 HD12 ' CE2' ' A' ' 24' ' ' TYR . 30.2 pt -64.52 -28.02 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.135 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.554 ' CE2' HD12 ' A' ' 23' ' ' ILE . 55.3 m-85 -128.97 156.31 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -81.34 120.71 25.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.918 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.56 ' CE1' ' O ' ' A' ' 27' ' ' THR . 5.4 t80 -129.28 124.09 33.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.56 ' O ' ' CE1' ' A' ' 26' ' ' TYR . 5.7 t -84.85 172.63 11.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.125 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 17.2 pttm -107.97 124.24 49.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -80.19 -29.68 38.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.1 mttp -126.66 150.29 49.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.864 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -51.72 -28.02 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.916 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -70.92 -38.43 72.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.892 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -66.52 171.18 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.457 HD11 ' N ' ' A' ' 62' ' ' GLY . 1.4 tt -122.68 137.96 54.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.976 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -108.21 138.49 44.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -151.84 172.29 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -127.73 154.39 45.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -38.22 123.79 1.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.07 52.85 2.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.449 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.75 128.58 42.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.723 0.297 . . . . 0.0 111.115 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 31.9 mm -84.19 125.63 40.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.076 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.0 mt -134.22 131.18 55.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.172 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -96.51 114.15 25.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.5 t -72.4 123.29 26.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 16.2 pt -120.78 -28.02 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.127 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 30.5 tptt -123.1 140.36 53.1 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -130.71 105.32 7.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.404 ' ND2' HD22 ' A' ' 63' ' ' LEU . 91.9 m-20 -86.64 154.06 21.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.915 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -44.98 -56.81 4.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.96 176.75 3.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.884 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -74.33 73.71 1.32 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 95.7 m95 -158.56 112.22 2.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.797 0.332 . . . . 0.0 110.993 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -112.6 154.6 25.77 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -108.8 120.65 43.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.872 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -136.0 173.36 21.92 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -105.18 132.8 51.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.814 0.34 . . . . 0.0 111.156 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.11 109.71 7.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 t30 55.15 39.79 31.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.58 -31.23 3.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.446 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.7 t -79.12 121.16 31.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 111.141 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.408 ' C ' HD11 ' A' ' 34' ' ' LEU . 24.0 m -99.47 150.07 22.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.457 ' N ' HD11 ' A' ' 34' ' ' LEU . . . -178.5 169.58 41.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.485 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.404 HD22 ' ND2' ' A' ' 48' ' ' ASN . 5.4 mt -94.47 138.32 32.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.843 0.354 . . . . 0.0 110.992 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -139.85 150.85 64.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.592 0.71 . . . . 0.0 110.959 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.537 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.5 Cg_endo -69.76 139.73 40.94 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.711 2.274 . . . . 0.0 112.355 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.73 6.28 47.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.509 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -92.58 -30.83 15.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.776 0.322 . . . . 0.0 110.79 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -90.35 25.06 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.957 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 21.0 m -148.34 142.73 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.113 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . 0.458 ' HG3' ' CG1' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -112.37 141.51 46.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.888 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.428 ' C ' ' OE1' ' A' ' 70' ' ' GLU . 74.7 m -78.25 79.69 4.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.462 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.109 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.464 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.9 Cg_endo . . . . . 0 C--O 1.233 0.246 0 CA-C-O 121.597 0.582 . . . . 0.0 112.302 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.63 21.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.312 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' TRP . . . . . 0.464 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 21.9 p-90 -100.46 -31.31 11.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.878 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.46 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -72.55 149.02 90.76 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.626 0.727 . . . . 0.0 111.109 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.451 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 54.2 Cg_endo -69.66 168.19 22.14 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.66 2.24 . . . . 0.0 112.412 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 -83.97 -49.67 8.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.1 t -128.79 141.33 51.34 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.859 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -150.66 160.09 44.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.947 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.8 mt -59.83 -62.1 2.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -150.15 175.4 11.78 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.882 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.433 ' HG2' ' CD1' ' A' ' 72' ' ' ILE . 6.4 ttpm? -120.91 140.42 51.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.776 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.25 158.21 43.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.102 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.432 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 11.6 p -122.16 116.7 49.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.173 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -57.69 148.39 24.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.091 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.2 pt -124.71 -33.01 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.183 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -117.92 165.97 13.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -86.59 139.72 30.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.868 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -140.26 128.71 22.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.917 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 35.3 m -111.11 111.22 22.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -53.63 138.32 34.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.95 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -92.38 -28.58 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 mmtp -112.77 -177.04 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.931 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -99.58 34.37 2.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -128.69 -38.82 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -68.85 -175.02 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.447 HD13 ' N ' ' A' ' 62' ' ' GLY . 1.8 tt -126.12 146.4 49.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.927 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.406 ' N ' HD23 ' A' ' 34' ' ' LEU . 3.8 m -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.917 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -147.1 159.66 43.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.804 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -113.03 166.64 11.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.96 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -51.97 124.7 13.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 92.61 36.79 6.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.473 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.72 116.12 21.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.668 0.27 . . . . 0.0 111.134 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.463 ' N ' HD11 ' A' ' 41' ' ' ILE . 3.6 mp -82.37 143.55 11.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.118 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.466 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 21.3 mt -135.37 132.61 52.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.076 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 76.7 m-85 -85.71 100.87 12.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.972 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 86.4 t -69.74 111.25 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.199 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 pt -101.73 -19.93 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.044 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -139.81 138.63 35.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.5 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 58.3 mttt -130.67 110.02 11.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 49' ' ' ASP . 65.8 m-80 -83.0 151.06 25.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 48' ' ' ASN . 34.1 m-20 -36.0 -59.64 0.59 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -72.79 179.8 3.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.37 74.94 0.68 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.532 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -156.76 110.94 2.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.935 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.5 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.5 OUTLIER -123.47 148.83 45.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.881 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -93.52 128.66 39.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.906 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.466 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -143.94 152.14 23.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.444 HG12 ' N ' ' A' ' 57' ' ' MET . 98.5 t -96.43 143.06 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.931 0.396 . . . . 0.0 111.093 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.444 ' N ' HG12 ' A' ' 56' ' ' VAL . 4.8 tmm? -145.15 127.01 15.38 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 57' ' ' MET . 22.0 t30 38.24 46.12 0.85 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.973 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.91 -40.97 3.01 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.476 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.4 t -75.84 124.12 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.0 0.429 . . . . 0.0 111.126 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.433 HG21 ' N ' ' A' ' 62' ' ' GLY . 31.8 m -107.55 150.16 27.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.172 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . 0.447 ' N ' HD13 ' A' ' 34' ' ' LEU . . . 179.47 152.97 11.16 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.477 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.1 mp -72.71 151.96 41.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.864 0.364 . . . . 0.0 110.993 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -151.46 147.51 20.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.595 0.712 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.86 133.04 24.44 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.654 2.236 . . . . 0.0 112.365 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.06 49.02 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.484 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -121.55 -29.86 4.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -94.3 3.4 55.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.994 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.09 160.86 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.113 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -135.35 124.65 24.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 66.2 m -58.05 113.33 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.433 ' CD1' ' HG2' ' A' ' 19' ' ' LYS . 44.3 pt . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.131 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.554 -0.218 . . . . 0.0 112.554 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 m -63.69 176.93 0.79 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.839 0.352 . . . . 0.0 110.869 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.9 m -112.27 114.95 28.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.834 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 152.74 -136.28 5.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 m -85.25 124.5 31.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.835 0.35 . . . . 0.0 110.826 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 27.6 p -110.45 82.32 1.58 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.857 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -122.1 91.58 0.47 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -131.56 144.2 52.37 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.508 0.67 . . . . 0.0 110.886 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.418 ' HG2' ' CB ' ' A' ' 12' ' ' ALA . 53.0 Cg_endo -69.85 164.56 34.18 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.654 2.236 . . . . 0.0 112.286 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 -31.02 20.97 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.712 2.275 . . . . 0.0 112.304 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 51.2 p-90 -76.57 -11.73 59.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.418 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -89.01 144.25 32.48 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.487 0.661 . . . . 0.0 111.197 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.84 132.55 23.44 Favored 'Trans proline' 0 C--O 1.231 0.132 0 C-N-CA 122.62 2.214 . . . . 0.0 112.322 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 34.6 mtm180 -57.07 -40.17 76.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -120.55 148.86 43.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.868 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -165.46 166.24 18.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -70.05 -61.91 1.59 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -150.96 -177.62 6.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.842 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.1 ttmm -118.23 144.78 45.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.9 m -142.44 152.93 17.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.198 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.6 p -127.71 115.73 40.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.057 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -52.05 138.53 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.0 pt -113.62 -25.13 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -126.11 159.37 33.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 -75.78 127.53 33.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CE1' ' HG3' ' A' ' 65' ' ' PRO . 89.2 t80 -131.62 109.81 10.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.97 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.5 m -93.41 110.49 22.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.188 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.421 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 1.6 pptp? -58.69 157.56 9.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -101.66 -45.83 5.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 pttt -128.43 155.96 43.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -44.11 -32.37 1.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.92 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.41 -42.49 70.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -81.05 178.66 8.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.405 HD21 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -123.6 140.86 52.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.421 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 99.5 p -110.82 128.1 55.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.518 ' CD2' HD12 ' A' ' 42' ' ' ILE . 4.2 p90 -149.96 168.03 24.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -121.09 158.28 28.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -51.62 96.84 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.83 34.11 0.49 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.424 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.55 124.41 45.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.796 0.332 . . . . 0.0 111.043 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.457 ' N ' ' CD1' ' A' ' 41' ' ' ILE . 2.0 mp -82.39 101.41 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.518 HD12 ' CD2' ' A' ' 36' ' ' PHE . 23.0 mt -95.64 122.28 46.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.075 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -83.96 97.29 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.21 133.03 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.169 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.448 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.0 pt -127.25 -29.0 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -135.25 148.92 49.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.531 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 5.7 mtmp? -135.74 105.39 6.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -66.76 170.52 6.37 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -50.54 -54.58 21.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.815 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 52' ' ' TRP . 16.2 m-20 -84.37 174.71 9.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.828 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.44 76.16 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.504 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.482 ' N ' ' O ' ' A' ' 50' ' ' ASP . 93.2 m95 -156.23 108.89 2.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.801 0.334 . . . . 0.0 110.916 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.531 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.4 OUTLIER -113.58 149.38 34.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.448 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 6.2 tt0 -100.13 128.57 46.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.912 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.41 167.68 29.1 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.448 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.6 t -104.72 133.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 0.0 111.2 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.21 125.01 22.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 58' ' ' ASN . 12.5 t30 50.41 30.7 4.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.09 -27.06 8.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.6 t -88.46 128.71 40.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.942 0.401 . . . . 0.0 111.143 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.72 151.48 21.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.108 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -179.95 153.05 11.46 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.446 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.96 133.68 36.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 110.869 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.474 ' CE1' HG22 ' A' ' 42' ' ' ILE . 47.5 p90 -132.85 150.53 75.94 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.651 0.738 . . . . 0.0 110.866 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.43 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.8 131.54 21.39 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.753 2.302 . . . . 0.0 112.421 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.02 51.17 3.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -130.42 -37.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.776 0.322 . . . . 0.0 110.915 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -84.25 10.52 10.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.957 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -123.1 161.55 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.201 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -136.8 126.69 25.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.5 m -69.65 127.51 33.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.841 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 3.4 pt -116.5 -10.64 12.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.9 t -134.61 116.22 14.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 163.51 -167.99 37.95 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.463 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -8.89 24.76 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 64.8 p -88.54 122.06 31.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.928 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 t -74.51 105.97 5.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.788 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.435 179.988 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.3 p -105.72 154.32 20.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.407 . . . . 0.0 110.781 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.8 m -95.53 132.91 40.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.82 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.04 117.71 0.32 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.47 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.4 t -118.02 -46.23 2.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.79 0.329 . . . . 0.0 110.85 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.9 m -90.89 103.89 16.54 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.86 159.36 49.41 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -48.27 154.22 1.12 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.551 0.691 . . . . 0.0 110.899 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.534 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.6 Cg_endo -69.85 169.55 18.76 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.641 2.227 . . . . 0.0 112.379 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 -41.63 4.21 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.36 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.534 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 54.8 p-90 -57.15 -18.79 16.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.75 61.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.544 0.687 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 133.24 25.19 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.627 2.218 . . . . 0.0 112.355 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 52.9 mtm180 -72.57 -33.55 66.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.5 t -112.94 118.1 33.93 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.815 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 22.3 p90 -160.98 142.43 11.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.969 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -56.8 -60.53 3.43 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -161.07 -178.12 6.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 ptpp? -114.84 168.51 9.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.923 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.404 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.4 m -146.93 156.88 10.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.178 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.427 HG12 ' CG2' ' A' ' 72' ' ' ILE . 14.8 p -113.34 142.16 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.124 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.88 106.87 15.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.096 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.476 HG13 ' CD2' ' A' ' 24' ' ' TYR . 28.2 pt -80.84 -15.76 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.476 ' CD2' HG13 ' A' ' 23' ' ' ILE . 58.5 m-85 -138.81 158.72 43.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.84 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 98.66 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.797 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.428 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 61.3 t80 -91.93 133.98 35.2 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.998 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 38.9 m -112.29 120.21 40.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.68 135.45 52.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.915 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -103.2 -33.33 9.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -113.81 159.28 19.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -62.67 -22.15 66.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -90.94 38.54 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.931 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -140.14 174.92 10.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.449 HD21 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -124.88 135.69 53.11 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.449 ' N ' HD21 ' A' ' 34' ' ' LEU . 84.8 p -104.41 137.87 41.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.845 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.428 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 13.8 p90 -161.57 159.77 28.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.827 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -109.16 173.46 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -66.01 110.35 2.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.85 39.4 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.437 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.41 149.89 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.791 0.329 . . . . 0.0 111.097 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 45.6 mm -102.78 123.47 56.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.449 HG22 ' CZ ' ' A' ' 64' ' ' PHE . 49.4 mt -126.9 125.54 66.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.103 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -84.18 120.07 25.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.4 t -82.45 114.83 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 pt -110.56 -14.54 10.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.172 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.42 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 32.1 tttp -146.19 144.49 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.908 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.559 ' HE2' ' CE1' ' A' ' 53' ' ' TYR . 13.2 mtpt -136.51 110.65 8.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.889 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -82.41 161.42 22.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -55.63 -36.82 67.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -84.57 175.65 9.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.892 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -72.15 67.62 1.15 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.392 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.496 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 65.5 m95 -158.8 121.35 3.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.731 0.3 . . . . 0.0 110.999 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.559 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 6.4 m-85 -118.65 154.9 31.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.936 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.42 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 16.7 tt0 -104.19 123.55 47.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -143.24 167.91 26.3 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.64 133.27 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.115 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -139.23 116.52 11.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.8 t30 55.7 39.11 30.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.31 -36.61 2.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.446 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 88.2 t -76.31 123.91 33.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.983 0.42 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.3 m -107.62 146.38 32.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.114 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.59 169.0 41.41 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.544 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.429 ' CD2' ' N ' ' A' ' 63' ' ' LEU . 2.2 mm? -88.52 127.16 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.881 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.449 ' CZ ' HG22 ' A' ' 42' ' ' ILE . 49.1 p90 -136.63 144.75 48.39 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.666 0.746 . . . . 0.0 110.892 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 143.11 49.71 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.707 2.272 . . . . 0.0 112.337 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.467 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -83.98 7.26 71.42 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.427 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.0 m-20 -90.24 -35.24 15.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.871 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -80.1 3.25 21.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.62 172.75 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.163 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -142.26 137.03 30.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 49.1 m -69.42 130.59 42.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.849 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.449 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -122.48 -14.23 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.156 180.0 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 51.4 p -63.77 -52.25 61.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.28 177.24 18.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.542 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 111.08 2.72 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.5 m -102.66 156.94 17.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 96.2 p -86.81 121.23 29.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.88 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.496 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.386 0 N-CA-C 112.459 -0.256 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 75.7 p -56.02 127.07 28.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.85 0.357 . . . . 0.0 110.817 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.6 m -61.74 118.19 6.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.828 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.74 -131.56 3.79 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 m -157.19 125.67 5.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.923 0.392 . . . . 0.0 110.804 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -93.65 129.01 40.09 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.92 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.58 110.66 0.43 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.457 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -138.52 144.06 40.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.841 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 53.7 Cg_endo -69.81 167.21 25.15 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.716 2.277 . . . . 0.0 112.335 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -29.56 23.5 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.301 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.495 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 62.5 p-90 -77.8 -25.94 49.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.853 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.42 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -65.58 151.68 94.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.59 0.709 . . . . 0.0 111.172 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 175.92 7.44 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.666 2.244 . . . . 0.0 112.297 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 10.7 tpp180 -88.29 -51.26 5.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.87 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.2 t -123.53 155.26 37.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.895 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 13.5 p90 -164.84 161.22 20.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 82.5 mt -66.72 -59.9 3.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -156.96 167.67 29.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -102.22 128.73 48.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 10.7 m -119.68 164.69 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.144 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.42 HG12 ' CG2' ' A' ' 72' ' ' ILE . 9.7 p -133.63 140.54 46.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.255 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.88 118.64 21.83 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.075 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.2 pt -91.39 -14.75 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.09 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -136.74 161.36 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -86.23 132.66 33.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.887 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -130.91 144.89 51.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.9 m -118.34 95.44 4.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.241 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.422 ' C ' ' HD3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -40.49 135.45 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.866 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -108.77 -54.64 2.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.916 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -79.91 162.47 24.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -69.84 -25.05 63.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -95.94 54.38 1.48 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -149.66 178.29 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 tt -131.32 142.43 50.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.926 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.7 p -108.19 143.36 37.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.874 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -166.91 167.99 14.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.774 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -120.34 164.81 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.979 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -55.74 117.97 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 105.25 43.88 1.55 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.95 138.52 52.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.78 0.324 . . . . 0.0 111.12 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 47.9 mm -89.76 129.72 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.164 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.23 145.5 34.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.165 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -106.96 114.17 28.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 43.6 t -77.76 118.03 23.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.149 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 2.9 pt -117.06 -8.88 12.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.45 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.5 ttmm -136.36 140.85 43.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.981 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 36.9 mttp -134.89 103.02 5.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' A' ' 50' ' ' ASP . 32.7 m-20 -83.55 38.81 0.64 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.891 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 48' ' ' ASN . 2.4 m-20 36.67 32.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.932 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.463 ' O ' ' CE1' ' A' ' 53' ' ' TYR . 31.0 m-20 -151.89 -175.04 5.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.816 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -76.27 52.99 3.07 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.419 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 96.4 m95 -162.87 106.97 1.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.766 0.317 . . . . 0.0 110.927 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.463 ' CE1' ' O ' ' A' ' 50' ' ' ASP . 4.7 m-85 -120.32 154.82 34.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.94 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.488 ' OE1' ' N ' ' A' ' 55' ' ' GLY . 0.1 OUTLIER -98.25 141.14 31.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.88 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' A' ' 54' ' ' GLU . . . -161.85 165.45 35.77 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.413 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 56.1 t -107.43 146.13 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.858 0.361 . . . . 0.0 111.081 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.3 ttp -155.22 108.18 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.2 t30 68.14 32.96 4.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.65 -23.77 7.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.502 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.1 t -88.29 122.75 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.91 0.386 . . . . 0.0 111.107 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.3 m -106.33 148.43 28.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -176.77 163.29 32.18 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.489 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -84.58 125.85 32.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.368 . . . . 0.0 110.909 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -127.19 152.11 75.49 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.683 0.754 . . . . 0.0 110.886 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 143.41 51.08 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.715 2.277 . . . . 0.0 112.289 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -86.56 24.79 7.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.494 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -111.33 -28.81 8.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -87.72 5.08 41.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -127.82 173.27 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.127 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.82 135.6 18.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.904 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.8 p -65.77 131.47 46.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.42 ' CG2' HG12 ' A' ' 21' ' ' VAL . 43.1 pt -113.95 -30.37 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -87.21 89.15 7.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.803 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 59.8 164.06 0.14 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.509 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 1.58 4.34 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.65 2.233 . . . . 0.0 112.34 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 77' ' ' SER . 77.7 p -168.52 162.04 11.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 76' ' ' SER . 98.9 p -37.04 116.16 0.43 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.761 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.483 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.5 m -41.4 141.19 0.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.913 0.387 . . . . 0.0 110.828 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -101.9 118.75 37.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.819 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.75 -78.21 0.53 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.449 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.8 p -54.68 138.76 40.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.882 0.372 . . . . 0.0 110.897 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.0 p -116.3 171.92 7.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.912 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.97 -71.14 1.3 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.492 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -40.45 143.83 0.63 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.633 0.73 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.551 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.8 Cg_endo -69.81 164.16 35.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.79 2.327 . . . . 0.0 112.278 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.67 -13.68 35.24 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.675 2.25 . . . . 0.0 112.398 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.551 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.9 p-90 -93.93 -34.65 13.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.488 ' N ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.31 145.78 13.14 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.521 0.677 . . . . 0.0 111.096 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.536 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.7 Cg_endo -69.8 133.68 26.08 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.727 2.285 . . . . 0.0 112.36 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 43.4 mtt180 -59.93 -33.43 71.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.98 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -140.42 137.92 34.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.403 ' CB ' HG23 ' A' ' 45' ' ' ILE . 38.7 p90 -153.74 161.54 42.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.97 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mt -57.14 -71.68 0.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.912 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -151.49 165.74 33.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.4 ' HG2' ' CD1' ' A' ' 72' ' ' ILE . 15.5 ttpt -100.83 134.39 43.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.02 159.72 26.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -119.02 132.97 67.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.18 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -77.76 100.59 6.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.3 pt -75.86 -14.9 15.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -134.1 173.7 11.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -100.3 107.91 19.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.849 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.541 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 70.5 t80 -107.07 134.05 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 28' ' ' LYS . 30.1 m -110.23 111.94 23.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.101 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 27' ' ' THR . 0.0 OUTLIER -36.15 128.99 0.71 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 179.898 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -100.88 -41.07 6.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -104.3 165.01 11.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -67.37 -27.01 66.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 9.6 p-10 -94.21 16.61 14.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.826 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.486 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -106.13 166.12 10.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.943 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -118.37 141.57 48.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.4 t -107.68 140.33 40.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -158.31 150.6 21.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -102.56 160.78 14.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -46.42 152.35 0.45 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 63.78 36.26 93.08 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.53 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -106.74 166.49 10.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.764 0.316 . . . . 0.0 111.087 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.7 mm -120.2 129.5 75.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.211 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.411 HG23 ' CE1' ' A' ' 64' ' ' PHE . 20.4 mt -129.54 141.14 47.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.536 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 53.6 m-85 -105.28 92.13 4.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 86.1 t -58.27 113.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.075 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.403 HG23 ' CB ' ' A' ' 16' ' ' TYR . 7.7 pt -110.84 -15.15 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.107 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.42 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.2 ttmt -140.76 147.46 39.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 64.0 mttt -135.85 147.76 48.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.968 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -125.53 151.09 46.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -39.15 -49.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.867 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -76.56 -176.0 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.21 64.73 4.11 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -148.75 114.79 5.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -121.23 146.78 46.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.895 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.42 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 4.1 tt0 -96.44 126.63 41.77 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.882 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -140.18 167.45 25.44 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.448 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 t -105.1 143.52 16.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.831 0.348 . . . . 0.0 111.082 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.5 tmm? -152.66 112.36 3.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.28 39.71 22.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.956 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.86 -34.68 2.55 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 86.8 t -75.58 126.78 36.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.95 0.405 . . . . 0.0 111.131 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.5 m -104.27 141.38 36.39 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -174.33 153.89 17.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.517 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.3 mt -75.63 156.23 35.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.411 ' CE1' HG23 ' A' ' 42' ' ' ILE . 35.2 p90 -155.79 148.16 17.66 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 130.26 19.13 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.738 2.292 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.13 -2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.52 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -86.22 -33.73 20.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.838 0.352 . . . . 0.0 110.911 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.541 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 9.5 m-85 -69.83 -23.59 63.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -115.33 175.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.167 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -136.36 162.72 32.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 m -88.22 113.71 24.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.791 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.4 ' CD1' ' HG2' ' A' ' 19' ' ' LYS . 47.7 pt -84.1 -19.69 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.179 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.2 t -112.71 121.55 45.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 95.77 -158.32 21.96 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.455 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 140.24 42.03 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.698 2.266 . . . . 0.0 112.344 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 93.6 p -64.01 -45.25 89.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.86 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 67.8 p -163.1 173.66 13.22 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.964 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.2 p -113.57 168.15 10.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.899 0.38 . . . . 0.0 110.853 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.3 p -45.67 -65.35 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.887 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.09 60.79 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.541 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.2 m -88.49 152.71 21.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.967 0.413 . . . . 0.0 110.728 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.8 p -138.62 117.56 12.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.879 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.91 -39.77 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.427 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -87.66 145.65 37.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.589 0.709 . . . . 0.0 110.88 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 169.33 19.1 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.824 2.35 . . . . 0.0 112.377 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -19.69 35.77 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.731 2.287 . . . . 0.0 112.316 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 42.0 p-90 -90.47 -20.25 22.93 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.942 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -70.93 148.47 94.59 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.614 0.721 . . . . 0.0 111.151 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 133.45 25.67 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 67.6 mtt85 -43.06 -46.25 5.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.824 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.6 p -145.8 144.16 30.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.3 p90 -134.66 174.6 10.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -76.68 -56.36 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.95 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -154.46 168.94 25.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttt -110.12 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.798 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.7 148.28 22.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.177 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -112.86 131.79 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.32 99.68 2.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.082 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.556 ' CD1' ' CE2' ' A' ' 24' ' ' TYR . 16.3 pt -73.13 -14.65 16.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.556 ' CE2' ' CD1' ' A' ' 23' ' ' ILE . 28.9 m-85 -143.56 156.13 44.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.92 162.96 28.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 2.9 t80 -168.84 131.5 1.32 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.946 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 17.4 m -109.84 131.99 54.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.093 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.67 164.27 10.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.954 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -129.07 -5.74 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.849 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ptpp? -146.6 143.13 28.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -47.11 -23.9 0.57 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -93.45 47.35 1.24 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.818 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -145.26 -179.74 6.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.453 ' CD1' ' O ' ' A' ' 55' ' ' GLY . 2.2 tt -126.48 151.16 48.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.924 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.445 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.9 p -121.22 123.99 43.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.417 ' CD2' HD12 ' A' ' 42' ' ' ILE . 29.3 p90 -140.95 152.59 45.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -110.26 165.02 12.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.961 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -52.64 108.29 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 104.96 39.66 2.27 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.88 21.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.74 0.305 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.8 mm -107.4 111.14 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.201 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.417 HD12 ' CD2' ' A' ' 36' ' ' PHE . 81.3 mt -117.06 141.36 35.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.164 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -105.09 108.85 20.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.971 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -67.11 115.36 4.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.181 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.1 pt -118.17 -18.44 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.14 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.437 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 4.1 tmtm? -138.94 146.45 41.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.437 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 17.1 mtpp -136.2 112.36 9.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -74.9 173.76 10.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -51.61 -17.52 0.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -112.75 -175.84 2.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.586 ' O ' ' CE2' ' A' ' 53' ' ' TYR . . . -63.31 -10.19 33.93 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.448 ' CH2' ' HD3' ' A' ' 65' ' ' PRO . 59.4 m95 -61.96 122.53 15.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.705 0.288 . . . . 0.0 110.9 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.586 ' CE2' ' O ' ' A' ' 51' ' ' GLY . 19.5 m-85 -123.84 135.55 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.435 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 9.3 tt0 -87.39 121.9 30.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.453 ' O ' ' CD1' ' A' ' 34' ' ' LEU . . . -134.57 158.23 23.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 59.2 t -101.43 129.8 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.476 ' O ' ' ND2' ' A' ' 58' ' ' ASN . 2.2 tmm? -138.43 138.08 37.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.813 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.476 ' ND2' ' O ' ' A' ' 57' ' ' MET . 1.9 p30 39.97 38.07 0.44 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.909 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.61 -38.08 2.79 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -75.95 117.71 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 17.1 m -100.62 145.64 28.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.158 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -171.75 177.13 44.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.622 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.1 mt -94.47 155.31 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.784 0.326 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.53 ' CE1' ' O ' ' A' ' 53' ' ' TYR . 51.2 p90 -158.54 151.55 18.5 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.612 0.72 . . . . 0.0 110.927 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.448 ' HD3' ' CH2' ' A' ' 52' ' ' TRP . 53.6 Cg_endo -69.74 129.91 18.44 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.755 2.304 . . . . 0.0 112.371 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -61.47 -17.66 53.86 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.463 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 69' ' ' VAL . 32.0 t30 -68.97 -65.89 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -38.52 -31.71 0.06 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.871 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.404 ' N ' ' O ' ' A' ' 67' ' ' ASN . 3.3 m -107.18 173.66 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -143.59 168.72 19.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 28.9 t -96.05 118.41 32.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 21.5 pt -104.59 -22.09 5.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.091 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.0 m -126.14 158.62 35.06 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.823 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 169.35 -167.81 40.78 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.516 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -13.29 34.48 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.652 2.235 . . . . 0.0 112.316 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 88.7 p -56.2 125.03 19.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.811 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 45.7 t -87.42 103.33 15.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.833 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.23 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.425 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.558 -0.217 . . . . 0.0 112.558 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.1 t -170.63 175.82 4.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.861 0.362 . . . . 0.0 110.844 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.4 t -66.56 172.58 4.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.874 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.38 -66.46 0.43 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.486 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 m -164.59 173.71 11.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.899 0.38 . . . . 0.0 110.841 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.2 m -130.17 -44.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.827 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.92 85.4 0.61 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.464 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 0.4 OUTLIER -152.77 149.8 23.07 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.656 0.741 . . . . 0.0 110.842 -179.99 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.71 167.56 24.01 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.694 2.263 . . . . 0.0 112.282 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -44.59 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.326 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 33.8 p-90 -56.25 -16.72 5.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.974 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 144.19 89.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.656 0.741 . . . . 0.0 111.103 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.31 14.42 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -55.64 -39.92 71.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 7.3 t -117.49 129.93 56.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.789 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.455 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 9.6 p90 -156.32 140.52 16.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.936 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 3.9 mp -49.93 -68.12 0.2 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -146.37 175.66 10.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 43' ' ' TYR . 0.6 OUTLIER -116.46 126.82 53.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.903 179.952 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.26 159.51 23.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.086 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.2 p -119.68 143.46 31.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.112 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.441 ' HB3' ' CD1' ' A' ' 36' ' ' PHE . . . -79.16 114.67 18.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.088 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.555 HG13 ' CD2' ' A' ' 24' ' ' TYR . 33.6 pt -92.97 -9.34 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.555 ' CD2' HG13 ' A' ' 23' ' ' ILE . 55.1 m-85 -147.88 158.23 43.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -82.12 128.71 34.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -135.22 129.84 34.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.918 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 28' ' ' LYS . 91.0 m -107.17 104.43 14.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 27' ' ' THR . 14.8 pttm -36.84 122.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -81.59 -8.68 59.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.789 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.9 mmtm -135.27 -175.08 3.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.91 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.26 -16.74 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.943 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -88.69 -22.42 23.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.821 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.43 166.4 22.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.422 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -120.0 134.77 55.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.422 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.4 t -99.73 145.4 27.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' A' ' 22' ' ' ALA . 22.4 p90 -164.9 161.26 20.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -106.85 172.83 6.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -66.3 112.04 3.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 122.8 -17.26 8.22 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.448 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.03 146.92 52.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.752 0.311 . . . . 0.0 111.123 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.8 mm -104.47 141.45 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.182 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.406 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 16.8 mt -135.58 142.85 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.088 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.504 ' CE1' ' HE3' ' A' ' 19' ' ' LYS . 93.1 m-85 -105.67 104.76 14.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.873 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.5 t -61.24 121.92 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.105 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.2 pt -123.93 -14.91 5.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.171 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.466 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 35.3 tttm -137.29 148.79 46.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.468 ' HD3' ' CD1' ' A' ' 53' ' ' TYR . 38.2 mmtt -119.76 161.66 20.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.422 ' CB ' ' HB2' ' A' ' 52' ' ' TRP . 2.4 m-80 -133.12 -174.95 3.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.943 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -109.72 -28.07 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.593 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 54.9 m-20 -99.45 40.39 1.22 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.837 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 60.79 79.8 0.11 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.543 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.593 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 94.1 m95 -162.67 137.37 6.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.76 0.314 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.468 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 11.9 m-85 -132.87 136.46 46.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.861 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.466 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.7 tt0 -95.86 115.37 27.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.959 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.406 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -125.68 173.26 17.61 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.472 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.3 t -113.01 139.1 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.157 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.469 ' O ' ' N ' ' A' ' 60' ' ' VAL . 5.3 tmm? -149.36 143.8 26.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.424 ' C ' ' O ' ' A' ' 57' ' ' MET . 11.6 p-10 35.78 37.79 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.0 2.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' MET . 89.1 t -76.05 138.94 19.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.0 111.165 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.447 HG22 ' N ' ' A' ' 62' ' ' GLY . 15.8 m -114.64 146.72 40.53 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.447 ' N ' HG22 ' A' ' 61' ' ' THR . . . -171.86 177.9 44.38 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.376 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.0 mp -105.05 134.12 48.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.825 0.345 . . . . 0.0 110.951 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -125.92 153.1 73.62 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.677 0.751 . . . . 0.0 110.846 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.42 50.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.281 . . . . 0.0 112.297 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.31 36.8 2.4 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.477 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -127.87 -29.69 2.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -91.25 16.29 10.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.6 m -146.59 162.5 9.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.098 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 33.0 mm-40 -139.76 150.97 45.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 91.7 p -85.74 109.57 18.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.8 pt -95.18 -26.21 4.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.084 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.2 t -74.1 -62.81 1.38 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.838 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -125.97 -161.42 10.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.568 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 177.95 5.06 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.629 2.22 . . . . 0.0 112.316 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.5 t -107.02 116.5 32.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 32.7 p -81.25 138.25 35.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.466 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 m -116.9 94.88 4.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.843 0.354 . . . . 0.0 110.829 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -144.73 156.17 43.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.958 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 5' ' ' SER . . . 113.27 104.25 2.64 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.449 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 4' ' ' GLY . 5.1 t -35.06 104.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.861 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.5 m -113.04 129.5 56.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.834 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 126.26 -48.8 0.95 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.449 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -51.85 153.0 4.7 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.642 0.734 . . . . 0.0 110.804 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 169.28 19.27 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.692 2.261 . . . . 0.0 112.34 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.87 -34.84 13.42 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 52.2 p-90 -71.43 -30.48 66.11 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -55.13 148.8 28.11 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.51 0.671 . . . . 0.0 111.118 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.87 145.53 56.77 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.647 2.232 . . . . 0.0 112.35 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -51.39 -36.56 44.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.3 m -160.45 156.41 25.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.708 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 19.3 p90 -150.19 -180.0 7.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.3 mt -84.09 -64.6 1.13 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -139.99 176.24 8.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.8 130.65 54.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 15.8 m -123.85 160.4 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.177 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.88 147.77 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.13 22.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.061 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.425 HG13 ' CD2' ' A' ' 24' ' ' TYR . 31.3 pt -92.74 -7.61 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.425 ' CD2' HG13 ' A' ' 23' ' ' ILE . 59.8 m-85 -146.84 163.37 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.944 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.76 121.81 28.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.872 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -135.19 114.26 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.42 ' O ' ' C ' ' A' ' 28' ' ' LYS . 24.6 m -98.21 106.01 18.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' A' ' 27' ' ' THR . 5.2 pttm -35.57 133.18 0.4 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.933 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -90.55 -27.71 18.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -128.94 163.64 24.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.828 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -53.77 -39.95 65.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.947 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -76.2 49.1 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.805 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -157.11 167.08 31.46 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.425 ' HB2' ' CA ' ' A' ' 62' ' ' GLY . 2.5 tt -122.63 146.42 47.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.937 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.5 p -109.46 145.46 36.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.85 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.3 p90 -169.88 148.04 3.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -103.76 153.15 21.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.97 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -39.62 110.57 0.15 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.19 44.88 0.97 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.487 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -126.25 130.46 50.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.772 0.32 . . . . 0.0 111.103 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.3 mm -87.97 136.19 23.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.6 148.97 22.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.118 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.708 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 77.0 m-85 -104.31 115.02 29.64 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.9 t -74.66 121.74 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.184 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.9 pt -122.72 -7.0 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.435 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 0.1 OUTLIER -136.67 144.8 44.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -122.16 103.23 8.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.862 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -74.73 -175.01 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.942 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -99.4 -10.47 22.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.42 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -120.38 40.42 3.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.595 ' O ' ' CE1' ' A' ' 53' ' ' TYR . . . 79.84 -44.29 2.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.43 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.474 ' O ' ' CD1' ' A' ' 53' ' ' TYR . 25.9 m95 -34.46 137.96 0.11 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.808 0.337 . . . . 0.0 110.926 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.595 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 22.0 m-85 -136.84 137.9 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.926 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.8 tt0 -94.15 116.67 29.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.89 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.4 163.34 25.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.547 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.6 t -98.73 146.12 8.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.143 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -151.45 118.65 5.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.902 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.9 t30 49.67 43.76 24.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.931 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 80.4 -40.67 2.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 95.2 t -75.83 120.56 25.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 m -100.96 141.47 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.168 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.425 ' CA ' ' HB2' ' A' ' 34' ' ' LEU . . . -165.87 154.37 24.95 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.498 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -80.54 147.87 30.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.902 0.382 . . . . 0.0 110.902 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -147.99 148.43 29.79 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.676 0.751 . . . . 0.0 110.884 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.5 40.27 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.463 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -73.22 -3.93 62.46 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.527 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -82.22 -28.45 31.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -90.48 8.36 34.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.463 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 8.6 m -135.7 169.06 21.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -140.63 150.18 43.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.4 t -85.03 113.63 21.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.877 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.3 pt -104.48 -32.62 2.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.139 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.7 t -74.95 -53.63 8.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -59.15 168.64 6.56 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.556 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.87 176.36 6.96 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.704 2.27 . . . . 0.0 112.246 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 85.2 p -150.76 148.22 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.837 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 93.5 p -111.38 -47.37 3.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.858 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.248 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.434 179.961 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.9 m -72.79 127.26 32.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.836 0.351 . . . . 0.0 110.903 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.0 t -166.33 163.41 17.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.896 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.13 -102.76 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.463 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.4 m -95.77 81.89 3.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.823 0.344 . . . . 0.0 110.883 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 70.6 m 57.79 48.49 13.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.865 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.93 127.38 8.97 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.449 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -45.31 148.81 1.06 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.657 0.741 . . . . 0.0 110.792 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.556 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.79 163.55 37.88 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.612 2.208 . . . . 0.0 112.339 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -33.36 17.04 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.585 2.19 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 22.4 p-90 -63.6 -23.18 67.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.438 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -65.23 148.26 98.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 121.493 0.663 . . . . 0.0 111.087 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 149.15 66.19 Favored 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.662 2.242 . . . . 0.0 112.37 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -54.94 -44.18 74.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.897 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.5 t -145.79 165.66 28.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -159.6 -179.14 7.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 22.9 mt -84.58 -57.31 3.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -152.96 -179.88 8.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HG2' ' N ' ' A' ' 20' ' ' VAL . 13.3 tttp -113.75 154.38 27.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.403 ' N ' ' HG2' ' A' ' 19' ' ' LYS . 29.1 m -152.18 147.15 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -117.09 139.4 44.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.206 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.27 135.42 36.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.109 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.494 HG13 ' CD2' ' A' ' 24' ' ' TYR . 16.1 pt -115.07 -15.17 10.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.179 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.494 ' CD2' HG13 ' A' ' 23' ' ' ILE . 62.9 m-85 -128.53 164.51 22.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.895 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -87.22 123.98 32.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.919 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' A' ' 27' ' ' THR . 86.0 t80 -117.31 160.27 21.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.949 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.41 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 6.7 m -133.53 132.08 40.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.22 136.34 36.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.914 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -99.56 -32.02 11.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.978 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -110.12 163.42 13.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.13 4.71 13.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -108.55 -26.75 10.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.408 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -70.4 -177.99 1.61 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -124.41 139.57 53.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.7 p -115.88 124.91 51.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.828 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -148.04 156.54 42.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.849 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -114.86 169.88 8.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -45.64 137.42 5.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.871 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.45 46.51 9.88 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.548 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.9 136.28 52.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.341 . . . . 0.0 111.037 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 21.8 mm -88.72 135.7 25.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.461 HG23 ' CE1' ' A' ' 64' ' ' PHE . 65.9 mt -141.99 143.46 26.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -110.28 109.67 20.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.96 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.8 t -69.25 110.07 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.137 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 26.2 pt -107.79 -14.12 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.193 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 46.9 tttt -144.52 138.45 27.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.886 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.565 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 6.6 mtmp? -135.05 102.99 5.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -75.97 175.51 8.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -76.38 48.36 0.53 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -163.36 -176.92 5.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.481 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -82.7 49.62 4.22 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.472 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.535 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 46.1 m95 -148.71 121.39 8.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.565 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 2.9 m-85 -119.06 149.26 41.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.65 123.13 37.91 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.8 177.02 19.6 Favored Glycine 0 N--CA 1.454 -0.157 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.449 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.465 HG12 ' N ' ' A' ' 57' ' ' MET . 45.8 t -117.86 144.22 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.73 0.3 . . . . 0.0 111.196 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.465 ' N ' HG12 ' A' ' 56' ' ' VAL . 6.5 tmm? -157.02 129.99 7.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.816 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.43 ' O ' ' CG ' ' A' ' 58' ' ' ASN . 30.7 t30 47.55 38.47 8.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.01 -35.14 2.55 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.499 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 97.9 t -76.02 126.04 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 2.9 m -106.97 150.87 26.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.159 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.4 ' HA3' ' C ' ' A' ' 33' ' ' GLU . . . 173.91 162.2 25.29 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.526 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.22 163.96 22.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.461 ' CE1' HG23 ' A' ' 42' ' ' ILE . 29.8 p90 -160.68 152.47 16.52 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.525 0.679 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.535 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.78 137.27 35.03 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.679 2.253 . . . . 0.0 112.321 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 68' ' ' TYR . . . -67.27 -56.11 13.28 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.429 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.9 m-20 -40.95 -24.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 13.4 m-85 -76.77 -42.73 39.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 18.8 m -108.24 142.64 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.231 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -102.94 165.64 10.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.802 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.4 t -105.66 105.23 15.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.33 -16.27 9.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.172 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 11.1 t -74.59 159.29 32.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 88.33 -169.38 37.74 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.474 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 161.46 45.86 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.657 2.238 . . . . 0.0 112.309 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 84.1 p -77.8 160.27 28.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.868 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.0 m -94.29 118.34 31.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.833 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.376 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.474 -179.969 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.9 m -101.06 128.76 46.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.833 0.349 . . . . 0.0 110.843 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 86.6 p -158.32 157.47 32.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 129.38 -167.96 21.14 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.2 m -70.1 -58.01 4.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.857 0.36 . . . . 0.0 110.864 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 77.5 p -106.61 -50.39 3.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.58 -93.5 0.16 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.516 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -115.41 156.28 46.04 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.729 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.567 ' CG ' ' CE2' ' A' ' 11' ' ' TRP . 53.8 Cg_endo -69.8 166.81 26.4 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.645 2.23 . . . . 0.0 112.329 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.8 -33.35 16.62 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.603 2.202 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.567 ' CE2' ' CG ' ' A' ' 9' ' ' PRO . 22.2 p-90 -65.56 -27.82 68.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.545 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -58.32 147.41 67.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.59 0.71 . . . . 0.0 111.126 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.6 10.72 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.668 2.245 . . . . 0.0 112.294 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.4 mtt180 -85.0 -43.94 13.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.8 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 39.0 t -136.66 152.79 50.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.812 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.53 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 7.1 p90 -159.77 157.21 28.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.904 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 44' ' ' VAL . 19.8 mt -61.35 -66.95 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -144.14 -175.65 4.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.858 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -120.19 133.05 55.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.4 m -128.15 161.23 36.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.195 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 22' ' ' ALA . 11.3 p -126.14 141.08 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.193 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.456 ' N ' HG22 ' A' ' 21' ' ' VAL . . . -71.9 118.4 14.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.102 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.4 pt -99.04 -35.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -129.77 135.11 48.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -56.69 122.58 12.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.894 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 87.9 t80 -121.1 127.71 51.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -97.04 123.51 40.79 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.074 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.418 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -76.15 131.29 39.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.887 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -94.08 -47.9 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -105.14 146.8 28.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -45.22 -32.29 1.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.33 -44.77 96.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.922 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -65.68 165.33 12.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.958 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 3.7 tt -121.63 140.09 52.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.418 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 52.8 p -99.2 130.99 45.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -151.6 167.91 26.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.965 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -127.6 159.74 33.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.81 109.07 0.37 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.897 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.59 43.47 0.75 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.445 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.96 131.7 47.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.788 0.328 . . . . 0.0 111.068 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.78 100.4 11.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.431 HG21 ' N ' ' A' ' 43' ' ' TYR . 30.4 mt -104.8 137.55 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.1 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.53 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 80.7 m-85 -91.18 121.79 33.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.966 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 17' ' ' LEU . 48.0 t -80.92 104.5 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.066 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.33 -33.58 4.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.4 tptm -129.31 144.22 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 10.9 mtpt -136.45 124.46 22.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -101.4 151.25 22.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -39.34 -49.66 1.99 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.921 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.74 177.22 7.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.951 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.6 66.9 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.516 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -151.68 113.07 4.34 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.733 0.301 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.48 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 1.3 m-85 -122.95 154.23 38.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.4 tt0 -104.45 134.59 47.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.879 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.17 157.07 27.05 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.488 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.3 t -95.48 136.43 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.926 0.394 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.41 ' O ' ' N ' ' A' ' 60' ' ' VAL . 21.8 ttp -141.18 119.67 12.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.824 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 43.93 42.76 4.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.79 -26.64 4.65 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.493 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.41 ' N ' ' O ' ' A' ' 57' ' ' MET . 93.0 t -81.1 127.76 39.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.881 0.372 . . . . 0.0 111.162 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.7 m -112.19 147.86 35.27 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 178.04 162.84 28.63 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.533 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.9 mt -88.44 128.79 35.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -120.38 147.33 44.95 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.716 0.77 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 122.83 9.5 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.667 2.245 . . . . 0.0 112.35 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.457 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -58.53 -10.8 8.46 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -76.61 -32.16 57.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.732 0.301 . . . . 0.0 110.787 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.424 ' O ' ' CG1' ' A' ' 69' ' ' VAL . 11.7 m-85 -97.83 35.32 1.72 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.906 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.457 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 9.9 m -161.32 153.81 3.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.441 ' CG ' HG11 ' A' ' 21' ' ' VAL . 5.6 pt-20 -130.06 144.14 51.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 37.9 m -84.66 120.33 26.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 24.9 pt -99.33 -32.76 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.181 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 28.0 t -62.54 155.5 25.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 161.44 164.46 16.38 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.57 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 120.53 7.32 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.735 2.29 . . . . 0.0 112.296 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.2 t 53.37 43.05 31.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.915 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 51.5 m -126.9 139.13 53.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.52 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.53 -0.228 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.4 m -89.56 -57.65 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 110.857 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.5 t -88.55 154.06 20.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.836 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.22 117.65 0.58 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.538 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.0 t -79.77 -46.75 16.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.832 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.8 t -75.33 -57.55 3.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 114.88 45.68 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -81.57 157.0 70.45 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-O 121.606 0.717 . . . . 0.0 110.821 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.56 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 53.6 Cg_endo -69.72 166.24 28.2 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.602 2.201 . . . . 0.0 112.33 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.81 -33.95 15.4 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.681 2.254 . . . . 0.0 112.318 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.56 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 54.8 p-90 -73.55 -29.7 62.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.406 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -52.71 151.53 7.99 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.604 0.716 . . . . 0.0 111.089 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.63 133.25 25.33 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 56.5 mtm180 -48.68 -45.48 39.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.865 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.5 p -136.64 163.39 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.942 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -166.27 171.21 12.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.005 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 19.4 mt -77.03 -52.29 9.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.882 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.447 ' C ' ' OE1' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -160.44 172.84 16.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.967 179.898 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.05 145.92 42.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.4 m -135.64 163.28 35.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.109 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.29 140.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.05 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.19 102.93 12.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.072 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.551 HD12 ' CE2' ' A' ' 24' ' ' TYR . 8.5 pt -84.25 -7.22 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.551 ' CE2' HD12 ' A' ' 23' ' ' ILE . 46.7 m-85 -145.43 136.6 24.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.912 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -65.69 136.02 55.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.872 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -137.97 128.1 25.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.883 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.3 m -97.32 151.33 20.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.209 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 7.8 ptmt -93.03 132.58 37.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.844 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.02 -18.26 22.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.816 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -138.16 167.73 21.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.92 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -83.33 36.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.902 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -127.39 -28.94 2.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.937 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -88.98 -174.97 4.68 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.969 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -129.21 140.4 51.5 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.1 p -108.38 140.32 41.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -153.75 166.58 32.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.933 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -114.41 170.27 8.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -61.8 102.02 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 115.23 42.5 0.76 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.584 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.38 140.96 48.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 111.146 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.2 mm -92.85 122.44 44.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.151 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.482 HG23 ' CE2' ' A' ' 64' ' ' PHE . 70.4 mt -127.47 136.21 61.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -101.35 107.68 19.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.962 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.5 t -69.17 113.49 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.091 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.435 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.0 pt -113.93 -2.37 10.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.164 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.0 tptm -156.2 137.08 13.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 ptpt -136.51 116.65 13.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 58.7 m-20 -90.1 155.91 18.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -43.15 -37.33 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -85.11 -175.27 5.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.526 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -82.56 81.37 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.526 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 91.9 m95 -162.02 120.66 2.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 33.6 m-85 -118.52 135.36 54.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.927 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.454 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 7.8 tt0 -91.0 111.11 22.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -125.96 169.89 17.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.487 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.3 t -115.52 129.83 71.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 111.097 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.8 tmm? -137.34 125.36 22.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 45.8 t30 51.02 37.98 19.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.28 -31.49 2.9 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.6 132.36 31.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.914 0.388 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.436 HG22 ' N ' ' A' ' 62' ' ' GLY . 18.9 m -114.27 145.14 42.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.436 ' N ' HG22 ' A' ' 61' ' ' THR . . . -168.76 145.12 9.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -67.95 123.85 21.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.482 ' CE2' HG23 ' A' ' 42' ' ' ILE . 42.3 p90 -123.82 152.67 66.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 138.91 38.88 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.646 2.231 . . . . 0.0 112.324 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.19 29.24 3.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -116.78 -35.02 4.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.848 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -78.21 2.36 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.938 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.96 178.41 2.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.082 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -142.68 124.17 14.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 72.2 m -71.7 103.69 3.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.9 pt -91.29 -29.32 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 28.9 t -48.41 130.65 16.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -55.12 164.23 3.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.467 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 172.74 12.04 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.731 2.287 . . . . 0.0 112.387 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 68.7 m -108.25 -54.65 2.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 33.9 p -55.18 100.68 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.405 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.519 -179.965 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.3 t -89.55 42.43 1.09 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.887 0.375 . . . . 0.0 110.844 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.2 m -88.83 155.68 19.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.73 -133.48 0.24 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.528 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.8 p -51.84 177.2 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.906 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -129.81 97.74 4.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.44 88.4 0.18 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -154.41 152.4 26.09 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.637 0.732 . . . . 0.0 110.832 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 158.11 58.01 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.653 2.235 . . . . 0.0 112.297 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 2.87 3.13 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.692 2.262 . . . . 0.0 112.366 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 32.0 p-90 -120.42 18.01 12.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.91 144.51 64.05 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.611 0.72 . . . . 0.0 111.057 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 155.89 64.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.386 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -50.98 -53.72 30.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.867 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.3 t -145.13 165.45 28.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -158.67 155.39 28.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.905 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -64.56 -46.94 80.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.912 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -165.97 179.35 5.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.564 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 24.2 ttmt -119.43 132.76 55.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.823 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.467 HG21 ' CG2' ' A' ' 44' ' ' VAL . 35.0 m -120.44 168.53 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.115 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.409 HG13 ' CG2' ' A' ' 72' ' ' ILE . 7.7 p -124.83 137.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.997 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.06 92.53 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.114 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.442 HD13 ' CE2' ' A' ' 24' ' ' TYR . 35.7 pt -69.38 -34.71 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.192 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.442 ' CE2' HD13 ' A' ' 23' ' ' ILE . 77.6 m-85 -128.82 151.81 49.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.869 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.81 102.02 11.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.891 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -103.49 130.55 50.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.9 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -96.04 108.97 21.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.4 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 12.7 pttm -45.24 142.18 2.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.928 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -95.34 -48.93 5.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -101.26 175.84 5.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.902 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -67.85 -38.65 83.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.68 -40.52 95.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.829 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.4 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 32.5 mt-10 -57.09 162.41 2.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -118.59 141.2 48.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.902 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.6 p -108.4 133.22 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -155.84 152.6 28.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.912 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -106.4 160.01 15.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.423 ' OE1' ' C ' ' A' ' 38' ' ' GLU . 1.0 OUTLIER -45.37 137.72 4.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.865 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.3 48.03 5.83 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.83 142.51 50.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 111.145 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.418 ' C ' HG13 ' A' ' 42' ' ' ILE . 28.7 mm -94.84 139.51 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.137 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.524 HG23 ' CE2' ' A' ' 64' ' ' PHE . 20.8 mt -141.88 143.19 27.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.181 179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.564 ' CE1' ' HE2' ' A' ' 19' ' ' LYS . 97.9 m-85 -103.05 98.81 8.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.897 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.467 ' CG2' HG21 ' A' ' 20' ' ' VAL . 25.6 t -64.25 95.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.207 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.414 HG13 ' N ' ' A' ' 46' ' ' LYS . 48.1 pt -88.12 -34.48 7.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.414 ' N ' HG13 ' A' ' 45' ' ' ILE . 1.4 tppp? -126.04 148.04 49.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.916 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.542 ' HE2' ' CD1' ' A' ' 53' ' ' TYR . 13.9 mtpt -136.58 112.75 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -87.64 150.73 23.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -41.89 -49.38 4.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.36 175.4 6.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.907 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.17 61.65 2.21 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.53 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -151.39 110.66 3.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.715 0.293 . . . . 0.0 110.939 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.542 ' CD1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -112.8 151.71 30.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.41 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.4 tt0 -99.78 126.91 45.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.958 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.15 27.9 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.41 HG13 ' N ' ' A' ' 57' ' ' MET . 98.0 t -97.22 139.85 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 111.092 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.41 ' N ' HG13 ' A' ' 56' ' ' VAL . 5.7 ttp -153.4 111.11 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.1 t30 62.24 39.3 12.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.35 -35.26 2.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.26 130.46 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 0.0 111.06 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.2 m -116.86 131.42 56.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.14 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -158.37 163.42 32.94 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.451 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.2 mt -80.09 123.38 27.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.524 ' CE2' HG23 ' A' ' 42' ' ' ILE . 21.3 p90 -115.6 151.25 45.94 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 110.906 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 118.01 5.42 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.724 2.283 . . . . 0.0 112.307 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -55.03 -13.04 4.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.416 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -75.67 -34.12 60.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.842 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.405 ' O ' ' CG1' ' A' ' 69' ' ' VAL . 13.2 m-85 -94.59 32.6 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.455 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 26.9 m -158.34 139.24 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.6 mm-40 -120.55 158.16 27.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.826 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.7 p -90.15 127.03 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 73' ' ' SER . 43.5 pt -111.98 -37.2 2.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.147 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.457 ' N ' HG13 ' A' ' 72' ' ' ILE . 58.7 m -106.19 101.0 10.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.94 -175.05 47.28 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.467 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 1.21 4.57 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.77 2.313 . . . . 0.0 112.344 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.1 t -113.06 82.25 1.63 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.893 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.7 t -69.22 87.5 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.83 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.456 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.0 p -132.75 153.89 50.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.838 0.352 . . . . 0.0 110.879 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.6 m -58.72 128.14 35.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.819 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.06 78.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.447 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.7 m -104.29 168.72 8.91 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.868 0.366 . . . . 0.0 110.907 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.1 m -47.66 165.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.854 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.01 -44.55 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.442 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -90.43 151.59 44.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.64 0.733 . . . . 0.0 110.865 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.516 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.4 Cg_endo -69.73 160.67 48.84 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.651 2.234 . . . . 0.0 112.376 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -29.32 24.18 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.619 2.212 . . . . 0.0 112.389 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.516 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 48.4 p-90 -73.47 -14.21 61.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.934 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.469 ' HB2' ' CE2' ' A' ' 43' ' ' TYR . . . -76.67 143.68 72.08 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.684 0.754 . . . . 0.0 111.025 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 123.24 9.89 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.2 mmt85 -41.9 -47.48 4.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.4 t -121.57 153.24 38.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.453 ' CB ' HG22 ' A' ' 45' ' ' ILE . 25.9 p90 -164.8 163.95 21.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.936 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 51.4 mt -65.85 -61.98 1.76 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.019 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -156.86 178.58 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.001 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -114.92 147.95 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.461 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 22.1 m -146.55 158.95 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.463 HG13 ' CG2' ' A' ' 72' ' ' ILE . 13.0 p -124.81 132.62 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.221 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.16 117.9 12.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.518 HG13 ' CD2' ' A' ' 24' ' ' TYR . 41.7 pt -98.89 -14.47 7.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.518 ' CD2' HG13 ' A' ' 23' ' ' ILE . 47.5 m-85 -136.38 151.63 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.931 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -78.33 115.07 17.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -113.88 148.61 36.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.4 m -120.16 112.03 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.179 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 15.0 pttm -57.82 136.75 57.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.931 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.32 -24.43 42.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 pttt -155.06 179.02 9.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.12 -43.01 77.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.939 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -47.23 -36.4 8.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.976 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -87.4 176.99 7.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.433 HD11 ' N ' ' A' ' 62' ' ' GLY . 1.7 tt -128.0 152.44 47.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.932 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.0 p -108.54 139.31 43.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.843 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -165.43 153.86 11.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.936 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -112.59 166.06 11.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.949 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -51.83 106.23 0.14 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.966 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 116.83 46.43 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.425 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -141.38 117.83 10.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.809 0.338 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.468 HD13 ' N ' ' A' ' 41' ' ' ILE . 3.7 mp -80.82 147.53 6.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.9 mt -142.89 133.42 22.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 12' ' ' ALA . 77.0 m-85 -86.74 109.89 19.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.884 -179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 80.2 t -76.29 124.05 33.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.453 HG22 ' CB ' ' A' ' 16' ' ' TYR . 10.6 pt -120.7 -23.87 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.127 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 9.5 tmtt? -128.75 145.95 51.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.457 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 19.1 mtpt -123.38 160.65 26.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.914 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 52' ' ' TRP . 2.7 m-80 -129.79 -174.89 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -104.45 -26.73 12.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.814 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.597 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 34.6 t70 -100.04 39.85 1.3 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.528 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 59.06 78.17 0.14 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.497 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.597 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 97.5 m95 -162.33 115.16 1.72 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.805 0.336 . . . . 0.0 110.853 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -116.32 137.65 51.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.92 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -91.1 126.24 36.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.863 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.98 167.13 25.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.523 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 84.7 t -112.64 126.75 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.778 0.323 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.3 ttp -133.24 107.18 7.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.905 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 59.27 41.73 19.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.982 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.73 -34.15 3.19 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 92.7 t -76.21 125.02 35.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.938 0.399 . . . . 0.0 111.067 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.7 m -107.58 146.79 31.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.133 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.433 ' N ' HD11 ' A' ' 34' ' ' LEU . . . 179.49 139.69 3.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.2 mp -69.13 161.42 29.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.369 . . . . 0.0 110.877 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -163.11 154.51 14.78 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.587 0.708 . . . . 0.0 110.9 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.48 ' HG2' ' CD1' ' A' ' 68' ' ' TYR . 53.7 Cg_endo -69.68 122.74 9.44 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.391 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.413 ' O ' ' CG2' ' A' ' 69' ' ' VAL . . . -51.29 -52.0 34.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 68' ' ' TYR . 19.0 m120 -40.71 -65.05 0.46 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.817 0.341 . . . . 0.0 110.818 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.48 ' CD1' ' HG2' ' A' ' 65' ' ' PRO . 23.7 m-85 -36.37 -33.99 0.05 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.423 ' N ' ' O ' ' A' ' 67' ' ' ASN . 30.9 m -108.67 164.54 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.129 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.475 ' CD ' ' N ' ' A' ' 71' ' ' SER . 2.8 tm-20 -122.03 137.49 54.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.475 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 14.9 m -80.7 77.86 7.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.834 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.463 ' CG2' HG13 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -42.32 -26.87 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.7 t -73.35 159.51 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -173.96 -173.13 39.85 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.386 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 147.4 62.86 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.409 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.2 m -99.51 117.21 33.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.847 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.1 t 46.53 43.82 12.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.863 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.227 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.433 -179.921 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.567 -0.213 . . . . 0.0 112.567 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 84.1 p -117.01 162.23 18.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.862 0.363 . . . . 0.0 110.886 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.1 m -130.61 157.16 43.5 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.817 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -162.15 -77.23 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.551 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.9 m -131.72 -51.9 0.99 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.901 0.381 . . . . 0.0 110.868 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 p -129.33 166.08 20.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.818 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 131.46 -147.4 18.56 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.429 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 0.2 OUTLIER -127.83 150.06 72.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.582 0.706 . . . . 0.0 110.942 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.73 163.56 37.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.718 2.279 . . . . 0.0 112.321 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -25.65 28.4 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.64 2.227 . . . . 0.0 112.341 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.502 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 47.0 p-90 -79.33 -18.78 51.85 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -75.08 148.34 84.19 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.73 . . . . 0.0 111.087 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.8 Cg_endo -69.79 132.61 23.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.634 2.223 . . . . 0.0 112.399 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.449 ' C ' ' O ' ' A' ' 13' ' ' PRO . 3.6 ptt180 -34.37 -46.81 0.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.833 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 24.2 m -144.5 169.51 17.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -160.65 166.88 28.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.969 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -65.86 -56.67 10.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -152.57 -175.76 5.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -126.11 121.82 33.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.95 167.28 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.175 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 p -133.95 136.87 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.61 119.06 15.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.42 HG13 ' CD2' ' A' ' 24' ' ' TYR . 24.4 pt -97.79 -8.55 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.151 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.42 ' CD2' HG13 ' A' ' 23' ' ' ILE . 41.1 m-85 -142.58 165.79 26.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -88.35 114.28 24.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.836 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.416 ' HB3' ' CZ ' ' A' ' 36' ' ' PHE . 90.8 t80 -114.47 111.49 21.48 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.97 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 22.2 m -92.57 94.69 9.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.417 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 0.7 OUTLIER -43.67 157.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.904 179.925 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -118.53 -20.85 8.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' GLU . 12.6 mmmm -124.69 137.3 54.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -41.93 -30.53 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.19 -41.94 85.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.953 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.424 ' N ' ' O ' ' A' ' 30' ' ' LYS . 0.7 OUTLIER -64.22 169.22 4.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -121.1 138.96 53.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.962 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 4.7 p -101.15 153.28 19.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.902 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.416 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 24.9 p90 -174.24 165.91 4.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.973 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.426 ' O ' ' C ' ' A' ' 38' ' ' GLU . 15.0 pt20 -130.5 151.35 51.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 37' ' ' GLN . 16.6 tt0 -36.69 104.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 117.94 38.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.481 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -123.54 130.09 52.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.717 0.294 . . . . 0.0 111.108 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.4 mm -87.11 133.01 31.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.416 HG21 ' N ' ' A' ' 43' ' ' TYR . 78.5 mt -131.18 140.93 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.118 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.416 ' N ' HG21 ' A' ' 42' ' ' ILE . 44.8 m-85 -105.88 97.9 7.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.4 t -60.36 114.03 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.164 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.5 pt -110.91 -20.1 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.172 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 37.4 mttp -144.46 154.92 43.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -136.5 159.71 40.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -129.45 149.03 51.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -38.34 -39.28 0.43 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 52' ' ' TRP . 1.5 m-20 -96.03 174.21 7.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.969 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -63.62 77.19 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.489 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.536 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 85.0 m95 -160.16 120.33 2.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.877 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -131.73 151.89 51.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -91.47 142.54 27.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.81 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -156.86 158.61 28.94 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.463 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.5 t -104.65 131.04 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 111.133 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.1 tmm? -136.26 112.2 9.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.3 t30 59.35 38.1 23.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.42 -38.17 3.17 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.446 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 87.3 t -77.42 126.79 38.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 111.201 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.411 HG21 ' N ' ' A' ' 62' ' ' GLY . 33.2 m -107.57 142.92 36.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' N ' HG21 ' A' ' 61' ' ' THR . . . -163.09 173.52 39.29 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.483 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.4 mt -95.77 128.07 42.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.839 0.352 . . . . 0.0 110.922 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -130.34 148.98 72.06 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.715 0.769 . . . . 0.0 110.897 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -70.03 142.75 47.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.594 2.196 . . . . 0.0 112.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.82 11.83 45.22 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.443 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -99.38 -12.91 19.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.796 0.331 . . . . 0.0 110.893 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -108.17 17.6 22.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 4.7 m -139.17 173.55 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 -145.74 167.05 24.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.857 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 96.7 p -102.12 112.83 25.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.402 HG13 ' N ' ' A' ' 73' ' ' SER . 32.0 pt -104.22 -33.84 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.138 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.402 ' N ' HG13 ' A' ' 72' ' ' ILE . 29.5 t -124.32 106.77 10.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.815 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 153.23 -158.24 27.84 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.475 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 129.87 18.39 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.303 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 58.8 m -103.94 155.4 18.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 39.1 t -77.53 -57.26 3.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.483 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.9 t 53.8 41.84 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.0 110.8 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.2 m -63.81 176.12 1.0 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.805 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -130.88 -131.3 3.28 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.51 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m -104.6 85.2 2.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.838 0.351 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.0 m -129.48 167.93 17.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.802 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -143.35 51.36 0.66 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.477 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -54.14 145.88 32.85 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.599 0.714 . . . . 0.0 110.839 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.529 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.5 Cg_endo -69.74 165.47 30.85 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.657 2.238 . . . . 0.0 112.331 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.73 -31.63 20.28 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.684 2.256 . . . . 0.0 112.373 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.529 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 38.0 p-90 -68.99 -22.95 64.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.871 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.42 145.07 87.37 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.0 Cg_endo -69.77 136.93 34.2 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.753 2.302 . . . . 0.0 112.362 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.451 ' C ' ' O ' ' A' ' 13' ' ' PRO . 5.2 ptt85 -34.31 -48.2 0.33 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -148.44 174.19 12.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 23.5 p90 -169.14 151.39 4.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.936 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -49.67 -68.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -151.24 -179.67 7.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.29 144.07 44.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.0 m -127.87 170.36 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.129 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 6.7 p -136.69 127.37 41.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.15 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.08 112.35 9.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.129 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.519 HD13 ' CE2' ' A' ' 24' ' ' TYR . 12.2 pt -92.84 -7.54 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.519 ' CE2' HD13 ' A' ' 23' ' ' ILE . 30.8 m-85 -136.94 166.12 24.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.951 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -85.23 141.7 29.94 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.827 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.403 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 83.6 t80 -151.96 118.25 5.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.916 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 91.3 m -104.83 111.98 24.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.128 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -43.94 150.28 0.28 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.997 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -115.91 -47.01 2.8 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.877 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.47 149.64 24.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 64.6 mm-40 -48.47 -28.35 3.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.873 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -89.21 43.23 1.13 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -143.27 159.53 42.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -116.87 130.74 56.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.906 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 22.5 t -97.41 144.21 27.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.905 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.515 ' CD2' HD12 ' A' ' 42' ' ' ILE . 9.6 p90 -164.83 150.3 9.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 18.5 mt-30 -105.46 153.54 21.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -45.52 110.11 0.22 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.96 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.53 36.87 1.25 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.6 141.8 48.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.719 0.295 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -92.18 112.86 26.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.087 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.527 HG22 ' CE2' ' A' ' 64' ' ' PHE . 45.5 mt -115.89 125.25 72.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -89.22 106.03 18.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.9 t -68.05 120.62 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.106 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 12.8 pt -121.45 -14.97 7.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.172 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.4 ttmt -132.78 122.2 24.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.462 ' HD3' ' CD1' ' A' ' 53' ' ' TYR . 18.7 mmtt -114.55 102.72 10.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -90.59 143.44 26.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -40.07 -48.2 2.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 -71.88 -178.1 2.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.27 62.71 4.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -152.28 118.97 5.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.462 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 4.4 m-85 -120.99 160.6 23.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -112.28 123.46 50.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.937 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.27 166.46 24.11 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.463 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 65.1 t -107.9 124.42 64.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.9 0.381 . . . . 0.0 111.157 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.8 tmm? -129.79 106.29 8.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.798 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 4.5 t30 61.24 39.8 15.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.72 -30.01 3.96 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.482 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.9 t -82.59 115.98 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.92 0.39 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.4 m -109.77 143.43 39.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -172.16 163.72 36.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.422 HD22 ' N ' ' A' ' 63' ' ' LEU . 2.1 mm? -68.56 150.15 48.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.878 0.37 . . . . 0.0 110.922 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.527 ' CE2' HG22 ' A' ' 42' ' ' ILE . 5.3 p90 -162.17 151.42 13.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.676 0.75 . . . . 0.0 110.872 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 136.79 33.87 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.708 2.272 . . . . 0.0 112.308 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -75.44 -42.29 27.94 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.477 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -51.06 -29.32 12.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.895 0.378 . . . . 0.0 110.917 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.403 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 10.5 m-85 -71.62 -30.06 65.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.9 m -110.0 137.15 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.12 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 71' ' ' SER . 0.4 OUTLIER -101.52 131.39 47.7 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.404 ' N ' ' OE2' ' A' ' 70' ' ' GLU . 19.2 m -74.6 103.3 4.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.7 pt -92.12 -11.69 9.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 m -99.64 143.52 29.78 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.924 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 87.14 -162.77 33.99 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.54 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 99.14 0.72 Allowed 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.703 2.268 . . . . 0.0 112.34 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.3 t -102.28 129.76 48.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 97.8 p -71.65 153.54 42.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.816 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.505 179.92 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.237 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.1 t -154.56 111.44 3.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.349 . . . . 0.0 110.945 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 52.6 p -58.0 169.42 0.78 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 114.51 -165.68 12.09 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.483 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.5 m -138.79 170.53 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.377 . . . . 0.0 110.87 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.1 m -57.85 155.45 10.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.836 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.5 -50.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.71 150.78 88.86 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.605 0.717 . . . . 0.0 110.839 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.548 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.69 167.6 23.88 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -39.32 6.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.244 . . . . 0.0 112.361 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.566 ' CE3' ' HA ' ' A' ' 12' ' ' ALA . 41.9 p-90 -58.13 -38.25 76.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.566 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.53 143.15 20.56 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.51 0.672 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 135.43 30.62 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.2 mtm180 -87.06 36.05 0.72 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.3 t -171.51 105.99 0.22 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.827 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 19.9 p90 -157.7 171.21 20.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.7 mt -85.8 -47.15 9.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.451 ' OE2' ' C ' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -168.84 174.26 6.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.9 pttm -116.98 161.21 19.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.454 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 33.9 m -148.67 160.97 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.11 139.68 40.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.184 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.19 95.59 6.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.101 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.536 HG13 ' CD2' ' A' ' 24' ' ' TYR . 38.7 pt -69.67 -23.89 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.137 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' CD2' HG13 ' A' ' 23' ' ' ILE . 64.3 m-85 -124.23 160.41 28.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.927 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.65 100.62 13.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.444 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 89.4 t80 -109.74 130.19 55.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.418 ' O ' ' CE2' ' A' ' 26' ' ' TYR . 15.4 t -93.43 -175.16 3.72 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.081 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' HD3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -114.52 130.52 56.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.941 179.938 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -102.48 -52.2 3.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.884 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -96.86 145.32 25.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -49.43 -24.01 1.79 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.03 47.86 1.23 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -146.37 172.16 13.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.852 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.411 HD11 ' N ' ' A' ' 62' ' ' GLY . 1.5 tt -129.3 133.43 47.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.857 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.6 t -100.24 141.33 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.825 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . 0.444 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 11.3 p90 -155.32 174.81 14.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.934 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -127.36 165.32 19.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.933 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -57.97 109.55 0.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.89 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.56 45.75 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -145.13 119.25 9.44 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.652 0.263 . . . . 0.0 111.205 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.462 HD13 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -80.7 139.07 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.126 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.521 HG22 ' CE2' ' A' ' 64' ' ' PHE . 20.3 mt -129.77 117.98 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.489 ' CE2' ' HB2' ' A' ' 12' ' ' ALA . 16.4 m-85 -72.21 107.17 4.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.68 105.79 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.4 pt -93.65 -15.31 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.043 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.41 ' CB ' ' HB3' ' A' ' 54' ' ' GLU . 9.8 tptt -141.72 143.8 33.72 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.834 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -134.58 116.33 14.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -97.16 152.1 19.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.841 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.01 -43.42 29.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -75.75 176.04 8.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -76.2 70.17 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.481 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.0 m95 -163.34 119.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 110.891 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -120.55 155.11 34.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.41 ' HB3' ' CB ' ' A' ' 46' ' ' LYS . 19.8 tt0 -103.77 118.3 36.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.35 160.53 25.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.408 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 85.4 t -101.27 139.73 21.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.764 0.316 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.1 ttp -140.02 111.78 7.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.879 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.8 t30 49.24 38.65 13.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.03 -29.97 6.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 94.6 t -79.81 118.92 28.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.927 0.394 . . . . 0.0 111.196 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.4 m -108.98 139.64 43.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' N ' HD11 ' A' ' 34' ' ' LEU . . . -171.37 163.23 36.0 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.526 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -81.19 135.45 35.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.726 0.298 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.521 ' CE2' HG22 ' A' ' 42' ' ' ILE . 45.5 p90 -136.34 152.96 76.01 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.689 0.756 . . . . 0.0 110.842 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 132.4 23.26 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.627 2.218 . . . . 0.0 112.392 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.39 -1.13 41.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.554 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -86.85 -33.71 19.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -87.11 29.53 0.83 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.977 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 20.4 m -157.38 142.28 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.105 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -118.49 164.87 14.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.965 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 p -92.89 132.63 36.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.872 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.454 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -121.4 -28.37 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.121 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 36.4 t -85.0 156.13 21.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 170.94 -168.14 41.29 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.66 -20.91 34.67 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.691 2.261 . . . . 0.0 112.325 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 62.3 m -69.83 -48.59 58.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.933 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.8 m 57.11 42.36 25.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.829 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.528 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.0 p -165.59 110.57 0.87 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.848 0.356 . . . . 0.0 110.804 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.8 t -71.27 89.92 0.9 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.823 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 50.51 -148.41 7.25 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.523 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.5 m 48.5 47.22 20.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.914 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.2 m -137.64 141.37 41.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.961 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -121.08 65.69 0.46 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.459 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.44 144.0 29.28 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.573 0.702 . . . . 0.0 110.94 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo -69.69 168.28 21.93 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.26 4.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.602 2.201 . . . . 0.0 112.367 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.521 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 64.4 p-90 -60.46 -40.21 90.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.012 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.551 ' HB3' ' CE2' ' A' ' 43' ' ' TYR . . . -40.21 144.17 0.58 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.627 0.727 . . . . 0.0 111.018 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.9 140.26 41.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.618 2.212 . . . . 0.0 112.294 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -65.39 -45.06 85.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 73.2 m -115.22 150.97 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.8 p90 -169.41 147.44 3.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.837 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -56.11 -52.94 62.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.931 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -165.0 170.83 14.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -103.6 155.9 18.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.5 m -149.06 138.98 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.159 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.4 p -110.87 127.36 68.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.17 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.83 123.38 24.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.122 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.51 HD11 ' CE2' ' A' ' 24' ' ' TYR . 36.8 pt -97.68 -34.56 4.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.06 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.51 ' CE2' HD11 ' A' ' 23' ' ' ILE . 31.9 m-85 -108.0 178.12 4.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -95.54 126.39 40.8 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -126.0 134.48 51.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.906 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.6 m -116.75 111.96 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.135 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.08 127.07 9.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -90.17 -57.2 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -94.72 -177.36 4.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -78.26 -28.8 47.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.447 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 8.7 m-20 -85.62 23.95 1.3 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . 0.447 ' OE1' ' C ' ' A' ' 32' ' ' ASP . 1.5 mp0 -114.69 177.89 4.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.934 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 tt -132.16 134.2 45.11 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.915 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 87.6 p -97.67 127.71 43.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -150.51 170.4 19.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.907 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -139.1 162.23 35.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -43.86 109.35 0.14 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 106.61 44.22 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -121.35 125.4 46.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.336 . . . . 0.0 111.115 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.9 mm -82.75 100.1 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.015 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.548 HG23 ' CE1' ' A' ' 64' ' ' PHE . 32.6 mt -105.95 131.16 56.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.146 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.551 ' CE2' ' HB3' ' A' ' 12' ' ' ALA . 79.4 m-85 -99.34 104.11 15.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.931 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.54 124.43 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.179 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.455 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 8.9 pt -124.77 -25.37 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.131 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.38 152.99 42.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 6.0 mtmp? -128.56 151.05 49.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.855 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.473 ' ND2' ' HB2' ' A' ' 52' ' ' TRP . 2.6 m-20 -126.47 -174.69 3.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.871 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -94.22 -31.54 14.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.607 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -95.34 39.29 1.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.55 63.14 5.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.531 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.607 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 95.0 m95 -134.75 96.97 3.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -91.63 137.63 32.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.455 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.4 tt0 -96.67 111.63 23.71 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.842 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -124.65 171.71 16.81 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.412 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.8 t -110.42 134.66 51.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.891 0.377 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -140.61 111.31 6.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.87 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.1 t30 59.29 39.8 22.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.847 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.62 -38.17 2.93 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.441 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 98.7 t -75.62 127.43 37.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.999 0.428 . . . . 0.0 111.086 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.429 HG23 ' N ' ' A' ' 62' ' ' GLY . 38.3 m -106.46 153.91 21.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.16 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.429 ' N ' HG23 ' A' ' 61' ' ' THR . . . -177.1 170.03 42.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 13.6 mt -98.89 141.25 31.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.818 0.342 . . . . 0.0 110.912 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.548 ' CE1' HG23 ' A' ' 42' ' ' ILE . 20.7 p90 -139.58 154.39 71.29 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.744 0.783 . . . . 0.0 110.838 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.46 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 53.9 Cg_endo -69.83 140.69 43.05 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.584 2.189 . . . . 0.0 112.349 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -80.59 41.17 2.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 -126.37 -43.53 1.76 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.901 0.382 . . . . 0.0 110.898 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -69.02 -23.65 64.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.963 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.8 m -113.66 148.83 16.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.156 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -108.55 155.52 20.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.973 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 44.6 p -99.56 100.67 11.71 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.79 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.6 pt -80.07 -29.79 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.102 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 18.2 t -46.38 131.79 10.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -64.07 -158.34 0.25 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.69 -42.22 3.67 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.687 2.258 . . . . 0.0 112.363 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 47.1 m 60.33 40.15 17.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.823 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 17.0 t -96.39 -55.41 2.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.798 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.459 -179.996 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.385 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.7 t -105.83 116.35 31.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m -151.82 134.24 15.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.08 -69.82 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.517 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.9 t -135.39 144.84 46.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 0.0 110.879 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.3 m -85.74 96.86 9.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.39 -125.15 0.75 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.522 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 1.2 m-20 -40.91 149.04 0.35 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.609 0.719 . . . . 0.0 110.832 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.56 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo -69.82 163.88 36.68 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.705 2.27 . . . . 0.0 112.25 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -47.86 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.596 2.197 . . . . 0.0 112.378 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.56 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 34.0 p-90 -57.07 -20.83 27.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.874 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -66.84 144.06 98.36 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.503 0.668 . . . . 0.0 111.124 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 14' ' ' ARG . 54.0 Cg_endo -69.77 105.8 1.55 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.622 2.215 . . . . 0.0 112.434 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.452 ' C ' ' O ' ' A' ' 13' ' ' PRO . 4.4 ptt85 -34.41 -46.54 0.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 t -120.23 149.75 41.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 38.4 p90 -169.01 163.12 11.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.922 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mt -60.96 -66.96 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.401 ' O ' ' CD1' ' A' ' 16' ' ' TYR . 11.2 pt-20 -146.8 -176.41 5.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.945 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.427 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 16.3 ttmt -127.91 127.34 43.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.839 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.03 158.97 25.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.166 179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.77 124.12 64.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -54.72 138.36 42.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.077 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.8 pt -121.0 -13.51 8.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.154 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -132.64 147.65 52.34 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.04 105.65 3.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -113.56 141.81 46.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.954 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 50.9 m -122.73 110.98 16.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 24.7 pttt -48.68 151.05 1.24 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.953 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -97.33 -45.23 6.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.877 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.63 171.71 8.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -66.63 -7.02 17.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.892 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -87.4 -23.83 24.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.929 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -90.55 -178.35 5.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -129.42 150.76 50.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.8 t -116.53 139.32 50.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -156.34 152.27 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.904 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -113.32 153.27 28.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.956 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -43.08 99.19 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.86 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 123.6 28.22 1.33 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.479 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.05 138.34 46.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.719 0.295 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.1 mm -95.81 127.61 47.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.169 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.418 HG21 ' CE2' ' A' ' 64' ' ' PHE . 64.5 mt -127.65 133.98 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.196 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 72.5 m-85 -95.44 98.54 10.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 96.9 t -63.65 117.85 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.5 pt -116.58 -25.14 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.459 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 28.6 ttmt -128.42 142.8 50.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.567 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 21.3 mtpp -130.21 120.62 24.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.848 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -94.77 152.67 18.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -39.13 -47.12 1.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -81.98 -179.42 7.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.769 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.435 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -75.21 70.52 1.84 Allowed Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.472 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 58.3 m95 -149.74 122.77 8.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 111.043 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.567 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 7.0 m-85 -120.29 151.43 39.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.91 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.459 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 2.8 tt0 -104.02 113.58 27.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -131.48 154.43 20.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.553 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 93.0 t -96.64 112.36 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.326 . . . . 0.0 111.176 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -118.11 112.0 19.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 22.5 t30 65.5 35.81 7.04 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.06 -31.57 3.1 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 76.7 t -83.69 129.98 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.826 0.345 . . . . 0.0 111.158 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.8 m -109.51 143.33 39.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.8 148.61 12.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.521 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.408 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.8 mm? -66.28 135.19 54.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.418 ' CE2' HG21 ' A' ' 42' ' ' ILE . 48.1 p90 -140.35 148.48 54.09 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.612 0.72 . . . . 0.0 110.91 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 132.47 23.22 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.4 -10.29 69.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -79.72 -28.35 40.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.881 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -89.21 20.9 3.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.8 m -138.06 178.43 4.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.126 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 71' ' ' SER . 6.3 tm-20 -143.69 160.07 41.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.828 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.472 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 9.7 m -104.11 113.64 27.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.886 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.5 pt -109.5 -30.87 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.1 t -100.27 105.98 17.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.8 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 145.06 -164.72 27.87 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.508 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.67 -3.48 12.04 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.668 2.245 . . . . 0.0 112.386 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.1 t -43.76 113.45 0.51 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.843 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.1 t -40.03 -43.37 1.56 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.843 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.479 179.969 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.369 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.1 p 41.72 42.89 2.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.837 0.351 . . . . 0.0 110.862 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.3 m -106.08 149.33 26.83 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.844 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 173.26 -110.88 0.35 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.43 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.7 p -70.6 156.86 38.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.87 0.367 . . . . 0.0 110.868 -179.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.2 t -55.46 -48.45 74.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.6 125.83 1.42 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.46 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -88.81 148.3 41.16 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.623 0.725 . . . . 0.0 110.822 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 52.7 Cg_endo -69.77 163.67 37.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.706 2.271 . . . . 0.0 112.293 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.73 2.287 . . . . 0.0 112.373 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.445 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 50.3 p-90 -54.85 -29.79 56.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.954 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -61.06 156.07 51.02 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.497 0.665 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 151.14 68.67 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.707 2.271 . . . . 0.0 112.26 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 68.2 mtt180 -72.51 -48.87 37.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.841 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.2 t -129.22 98.61 4.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.836 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -105.32 143.35 33.62 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.93 -67.31 0.27 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.933 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -143.31 178.9 7.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.888 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.9 tttt -123.12 141.98 51.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.467 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.0 m -137.54 174.05 11.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.045 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.6 p -134.13 150.6 31.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.12 96.92 10.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.036 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.473 HG13 ' CD2' ' A' ' 24' ' ' TYR . 32.1 pt -73.24 -12.27 15.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.473 ' CD2' HG13 ' A' ' 23' ' ' ILE . 60.5 m-85 -131.53 172.25 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.93 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.24 96.49 6.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 29.5 t80 -98.96 155.35 17.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -123.81 131.59 53.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.434 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -78.31 125.95 30.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -96.68 -53.27 3.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.807 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.431 ' NZ ' ' HA ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -96.21 164.47 12.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.959 179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.08 -28.43 67.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -86.76 42.97 1.05 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.966 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -148.01 152.95 38.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.894 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.417 HD23 ' N ' ' A' ' 35' ' ' SER . 1.8 tt -112.17 130.67 55.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.792 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.434 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 55.7 p -96.16 134.03 39.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -154.96 169.18 24.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.909 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -126.25 161.19 28.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -50.47 108.01 0.2 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.892 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.48 32.96 2.59 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.476 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.61 145.67 34.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.71 0.291 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 22.0 mm -102.37 126.55 56.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.129 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.402 HG21 ' CE2' ' A' ' 64' ' ' PHE . 19.5 mt -134.76 141.99 41.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.112 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -104.16 124.02 48.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.899 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.6 t -77.62 117.44 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.042 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.3 pt -116.99 -12.2 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.44 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 17.7 tttm -153.95 151.32 29.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -134.16 111.45 10.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.921 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -75.26 164.88 25.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -40.72 -46.61 2.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.34 -179.83 7.28 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.803 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.449 ' O ' ' CZ ' ' A' ' 53' ' ' TYR . . . -60.82 -7.66 8.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.476 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -69.88 128.28 35.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.852 0.358 . . . . 0.0 110.93 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.449 ' CZ ' ' O ' ' A' ' 51' ' ' GLY . 3.8 m-85 -126.68 148.72 49.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.951 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.44 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.2 tt0 -90.88 130.3 36.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -146.24 167.19 27.96 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.437 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.7 t -108.82 136.1 45.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.864 0.364 . . . . 0.0 111.146 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.419 ' HE1' ' ND2' ' A' ' 58' ' ' ASN . 8.6 ttp -143.48 122.62 12.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.882 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.419 ' ND2' ' HE1' ' A' ' 57' ' ' MET . 8.6 p30 43.81 39.76 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.93 -30.74 3.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.06 117.01 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 111.084 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 10.3 m -99.38 135.18 41.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -164.5 163.15 36.0 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.459 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.7 mt -89.88 124.61 34.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.81 0.338 . . . . 0.0 110.917 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.402 ' CE2' HG21 ' A' ' 42' ' ' ILE . 35.8 p90 -119.83 144.65 37.74 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.619 0.724 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 138.63 38.17 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.667 2.244 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.08 3.69 56.85 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.521 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -89.89 -24.58 21.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.925 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -98.12 26.0 5.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.926 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.2 m -144.27 179.97 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.086 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.423 ' CG ' HD11 ' A' ' 23' ' ' ILE . 2.2 mm-40 -150.69 125.91 10.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 31.3 p -64.35 82.35 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -51.56 -32.36 13.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.126 179.935 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 45.0 m -107.25 152.59 23.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 105.85 -167.03 14.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.443 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 85.4 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.661 2.241 . . . . 0.0 112.351 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.7 p -115.76 151.45 35.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 60.4 p -152.23 137.38 17.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.917 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.481 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.418 -0.273 . . . . 0.0 112.418 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.4 p -174.99 171.23 3.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.5 p -169.06 155.15 6.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.821 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -134.85 92.22 0.24 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.555 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.7 m -79.61 144.12 34.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.899 0.38 . . . . 0.0 110.858 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.8 m -115.73 105.3 12.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.828 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.96 41.23 1.47 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.462 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -127.61 152.19 76.35 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.602 0.715 . . . . 0.0 110.869 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 167.77 23.44 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.754 2.302 . . . . 0.0 112.327 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -47.6 0.9 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 49.6 p-90 -55.24 -40.73 71.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.844 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -47.39 153.1 1.02 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.558 0.694 . . . . 0.0 111.147 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.63 146.92 62.47 Favored 'Trans proline' 0 C--O 1.23 0.121 0 C-N-CA 122.744 2.296 . . . . 0.0 112.33 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.9 ptt180 -49.14 -57.89 5.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.844 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 36.1 t -133.85 149.88 51.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.1 p90 -149.2 159.72 44.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.9 mt -66.79 -61.06 2.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.873 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.11 175.72 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.416 ' HG2' ' N ' ' A' ' 20' ' ' VAL . 31.1 tttt -121.46 151.72 39.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.971 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.462 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 29.1 m -145.36 177.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.177 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.458 ' CG1' ' HG3' ' A' ' 70' ' ' GLU . 8.3 p -137.1 139.18 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.432 ' N ' HG22 ' A' ' 21' ' ' VAL . . . -79.29 87.99 4.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.114 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.554 HD12 ' CE2' ' A' ' 24' ' ' TYR . 30.2 pt -64.52 -28.02 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.135 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.554 ' CE2' HD12 ' A' ' 23' ' ' ILE . 55.3 m-85 -128.97 156.31 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -81.34 120.71 25.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.918 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.56 ' CE1' ' O ' ' A' ' 27' ' ' THR . 5.4 t80 -129.28 124.09 33.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.56 ' O ' ' CE1' ' A' ' 26' ' ' TYR . 5.7 t -84.85 172.63 11.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.125 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 17.2 pttm -107.97 124.24 49.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -80.19 -29.68 38.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.1 mttp -126.66 150.29 49.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.864 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -51.72 -28.02 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.916 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -70.92 -38.43 72.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.892 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -66.52 171.18 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.457 HD11 ' N ' ' A' ' 62' ' ' GLY . 1.4 tt -122.68 137.96 54.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.976 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -108.21 138.49 44.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -151.84 172.29 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -127.73 154.39 45.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -38.22 123.79 1.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.07 52.85 2.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.449 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.75 128.58 42.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.723 0.297 . . . . 0.0 111.115 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 31.9 mm -84.19 125.63 40.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.076 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.0 mt -134.22 131.18 55.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.172 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -96.51 114.15 25.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.5 t -72.4 123.29 26.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 16.2 pt -120.78 -28.02 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.127 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 30.5 tptt -123.1 140.36 53.1 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -130.71 105.32 7.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.404 ' ND2' HD22 ' A' ' 63' ' ' LEU . 91.9 m-20 -86.64 154.06 21.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.915 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -44.98 -56.81 4.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.96 176.75 3.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.884 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -74.33 73.71 1.32 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 95.7 m95 -158.56 112.22 2.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.797 0.332 . . . . 0.0 110.993 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -112.6 154.6 25.77 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -108.8 120.65 43.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.872 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -136.0 173.36 21.92 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -105.18 132.8 51.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.814 0.34 . . . . 0.0 111.156 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.11 109.71 7.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 t30 55.15 39.79 31.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.58 -31.23 3.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.446 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.7 t -79.12 121.16 31.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 111.141 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.408 ' C ' HD11 ' A' ' 34' ' ' LEU . 24.0 m -99.47 150.07 22.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.457 ' N ' HD11 ' A' ' 34' ' ' LEU . . . -178.5 169.58 41.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.485 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.404 HD22 ' ND2' ' A' ' 48' ' ' ASN . 5.4 mt -94.47 138.32 32.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.843 0.354 . . . . 0.0 110.992 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -139.85 150.85 64.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.592 0.71 . . . . 0.0 110.959 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.537 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.5 Cg_endo -69.76 139.73 40.94 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.711 2.274 . . . . 0.0 112.355 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.73 6.28 47.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.509 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -92.58 -30.83 15.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.776 0.322 . . . . 0.0 110.79 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -90.35 25.06 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.957 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 21.0 m -148.34 142.73 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.113 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.458 ' HG3' ' CG1' ' A' ' 21' ' ' VAL . 0.3 OUTLIER -112.37 141.51 46.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.888 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.428 ' C ' ' OE1' ' A' ' 70' ' ' GLU . 74.7 m -78.25 79.69 4.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.462 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -46.91 -33.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.109 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -105.73 149.45 26.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.844 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -169.25 -158.43 13.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.453 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 -24.7 28.98 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.662 2.241 . . . . 0.0 112.264 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.0 m 37.91 43.09 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.791 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 89.6 p -82.17 165.5 20.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.796 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.46 -179.93 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.559 -0.216 . . . . 0.0 112.559 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m 63.76 42.83 5.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.864 0.364 . . . . 0.0 110.787 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.3 t -52.75 124.78 14.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.839 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.48 -100.75 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.1 m -87.26 109.51 19.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.821 0.343 . . . . 0.0 110.868 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 p -136.48 127.05 26.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.3 92.39 0.39 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.526 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -122.75 144.01 41.61 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.669 0.747 . . . . 0.0 110.834 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.464 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.9 Cg_endo -69.75 163.74 37.15 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.709 2.273 . . . . 0.0 112.302 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.63 21.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.312 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' TRP . . . . . 0.464 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 21.9 p-90 -100.46 -31.31 11.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.878 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.46 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -72.55 149.02 90.76 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.626 0.727 . . . . 0.0 111.109 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.451 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 54.2 Cg_endo -69.66 168.19 22.14 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.66 2.24 . . . . 0.0 112.412 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 -83.97 -49.67 8.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.1 t -128.79 141.33 51.34 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.859 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -150.66 160.09 44.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.947 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.8 mt -59.83 -62.1 2.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -150.15 175.4 11.78 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.882 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.433 ' HG2' ' CD1' ' A' ' 72' ' ' ILE . 6.4 ttpm? -120.91 140.42 51.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.776 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.25 158.21 43.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.102 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.432 ' CG1' ' CG2' ' A' ' 72' ' ' ILE . 11.6 p -122.16 116.7 49.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.173 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -57.69 148.39 24.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.091 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.2 pt -124.71 -33.01 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.183 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -117.92 165.97 13.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -86.59 139.72 30.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.868 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -140.26 128.71 22.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.917 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 35.3 m -111.11 111.22 22.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -53.63 138.32 34.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.95 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -92.38 -28.58 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 mmtp -112.77 -177.04 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.931 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -99.58 34.37 2.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -128.69 -38.82 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -68.85 -175.02 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.447 HD13 ' N ' ' A' ' 62' ' ' GLY . 1.8 tt -126.12 146.4 49.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.927 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.406 ' N ' HD23 ' A' ' 34' ' ' LEU . 3.8 m -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.917 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -147.1 159.66 43.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.804 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -113.03 166.64 11.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.96 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -51.97 124.7 13.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 92.61 36.79 6.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.473 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.72 116.12 21.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.668 0.27 . . . . 0.0 111.134 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.463 ' N ' HD11 ' A' ' 41' ' ' ILE . 3.6 mp -82.37 143.55 11.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.118 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.466 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 21.3 mt -135.37 132.61 52.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.076 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 76.7 m-85 -85.71 100.87 12.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.972 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 86.4 t -69.74 111.25 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.199 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 pt -101.73 -19.93 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.044 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -139.81 138.63 35.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.5 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 58.3 mttt -130.67 110.02 11.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 49' ' ' ASP . 65.8 m-80 -83.0 151.06 25.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 48' ' ' ASN . 34.1 m-20 -36.0 -59.64 0.59 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -72.79 179.8 3.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.37 74.94 0.68 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.532 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -156.76 110.94 2.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.935 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.5 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.5 OUTLIER -123.47 148.83 45.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.881 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -93.52 128.66 39.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.906 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.466 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -143.94 152.14 23.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.444 HG12 ' N ' ' A' ' 57' ' ' MET . 98.5 t -96.43 143.06 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.931 0.396 . . . . 0.0 111.093 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.444 ' N ' HG12 ' A' ' 56' ' ' VAL . 4.8 tmm? -145.15 127.01 15.38 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 57' ' ' MET . 22.0 t30 38.24 46.12 0.85 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.973 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.91 -40.97 3.01 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.476 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.4 t -75.84 124.12 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.0 0.429 . . . . 0.0 111.126 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.433 HG21 ' N ' ' A' ' 62' ' ' GLY . 31.8 m -107.55 150.16 27.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.172 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . 0.447 ' N ' HD13 ' A' ' 34' ' ' LEU . . . 179.47 152.97 11.16 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.477 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.1 mp -72.71 151.96 41.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.864 0.364 . . . . 0.0 110.993 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -151.46 147.51 20.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.595 0.712 . . . . 0.0 110.925 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.86 133.04 24.44 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.654 2.236 . . . . 0.0 112.365 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.06 49.02 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.484 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -121.55 -29.86 4.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -94.3 3.4 55.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.994 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 19.3 m -112.09 160.86 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.113 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -135.35 124.65 24.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 66.2 m -58.05 113.33 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 73' ' ' SER . 44.3 pt -80.52 -38.36 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.457 ' N ' HG13 ' A' ' 72' ' ' ILE . 30.8 t -73.09 147.41 44.97 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 92.79 162.41 36.88 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.511 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 138.0 36.75 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.672 2.248 . . . . 0.0 112.334 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -107.38 -46.37 3.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.837 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.7 m -94.42 119.38 33.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.884 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 -179.961 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.602 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.0 Cg_endo . . . . . 0 C--O 1.232 0.21 0 CA-C-O 121.59 0.579 . . . . 0.0 112.286 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 -31.02 20.97 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.712 2.275 . . . . 0.0 112.304 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 51.2 p-90 -76.57 -11.73 59.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.602 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -89.01 144.25 32.48 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.487 0.661 . . . . 0.0 111.197 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.84 132.55 23.44 Favored 'Trans proline' 0 C--O 1.231 0.132 0 C-N-CA 122.62 2.214 . . . . 0.0 112.322 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 34.6 mtm180 -57.07 -40.17 76.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -120.55 148.86 43.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.868 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -165.46 166.24 18.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -70.05 -61.91 1.59 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -150.96 -177.62 6.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.842 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.1 ttmm -118.23 144.78 45.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.649 HG22 ' O ' ' A' ' 42' ' ' ILE . 27.9 m -142.44 152.93 17.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.198 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 21' ' ' VAL . 3.6 p -127.71 115.73 40.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.057 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -52.05 138.53 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.0 pt -113.62 -25.13 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -126.11 159.37 33.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 -75.78 127.53 33.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CE1' ' HG3' ' A' ' 65' ' ' PRO . 89.2 t80 -131.62 109.81 10.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.97 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.5 m -93.41 110.49 22.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.188 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.422 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 1.6 pptp? -58.69 157.56 9.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -101.66 -45.83 5.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 pttt -128.43 155.96 43.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -44.11 -32.37 1.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.92 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.41 -42.49 70.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -81.05 178.66 8.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.738 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -123.6 140.86 52.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.738 ' N ' HD23 ' A' ' 34' ' ' LEU . 99.5 p -110.82 128.1 55.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 4.2 p90 -149.96 168.03 24.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -121.09 158.28 28.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -51.62 96.84 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.83 34.11 0.49 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.424 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.55 124.41 45.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.796 0.332 . . . . 0.0 111.043 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.688 ' N ' HD12 ' A' ' 41' ' ' ILE . 2.0 mp -82.39 101.41 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.649 ' O ' HG22 ' A' ' 20' ' ' VAL . 23.0 mt -95.64 122.28 46.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.075 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -83.96 97.29 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.21 133.03 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.169 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.448 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.0 pt -127.25 -29.0 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -135.25 148.92 49.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.519 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 5.7 mtmp? -135.74 105.39 6.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -66.76 170.52 6.37 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -50.54 -54.58 21.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.815 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' A' ' 52' ' ' TRP . 16.2 m-20 -84.37 174.71 9.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.828 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.44 76.16 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.504 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.484 ' N ' ' O ' ' A' ' 50' ' ' ASP . 93.2 m95 -156.23 108.89 2.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.801 0.334 . . . . 0.0 110.916 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.519 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.4 OUTLIER -113.58 149.38 34.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.448 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 6.2 tt0 -100.13 128.57 46.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.912 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.41 167.68 29.1 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.448 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.6 t -104.72 133.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 0.0 111.2 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.21 125.01 22.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 50.41 30.7 4.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.908 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.09 -27.06 8.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.6 t -88.46 128.71 40.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.942 0.401 . . . . 0.0 111.143 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.72 151.48 21.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.108 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -179.95 153.05 11.46 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.446 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.96 133.68 36.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 110.869 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.536 ' CE1' HG21 ' A' ' 42' ' ' ILE . 47.5 p90 -132.85 150.53 75.94 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.651 0.738 . . . . 0.0 110.866 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.435 ' HG3' ' CE1' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.8 131.54 21.39 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.753 2.302 . . . . 0.0 112.421 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.02 51.17 3.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -130.42 -37.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.776 0.322 . . . . 0.0 110.915 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -84.25 10.52 10.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.957 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -123.1 161.55 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.201 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -136.8 126.69 25.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.5 m -69.65 127.51 33.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.841 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 3.4 pt . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.207 179.929 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.556 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.163 0 CA-C-O 121.566 0.569 . . . . 0.0 112.379 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 -41.63 4.21 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.36 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 54.8 p-90 -57.15 -18.79 16.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.75 61.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.544 0.687 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 133.24 25.19 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.627 2.218 . . . . 0.0 112.355 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 52.9 mtm180 -72.57 -33.55 66.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.5 t -112.94 118.1 33.93 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.815 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.474 ' HB3' HG22 ' A' ' 45' ' ' ILE . 22.3 p90 -160.98 142.43 11.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.969 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -56.8 -60.53 3.43 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -161.07 -178.12 6.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 ptpp? -114.84 168.51 9.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.923 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.44 ' HA ' HD13 ' A' ' 72' ' ' ILE . 27.4 m -146.93 156.88 10.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.178 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 70' ' ' GLU . 14.8 p -113.34 142.16 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.124 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.88 106.87 15.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.096 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.473 HD12 ' CE2' ' A' ' 24' ' ' TYR . 28.2 pt -80.84 -15.76 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.473 ' CE2' HD12 ' A' ' 23' ' ' ILE . 58.5 m-85 -138.81 158.72 43.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.84 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 98.66 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.797 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.449 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 61.3 t80 -91.93 133.98 35.2 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.998 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 38.9 m -112.29 120.21 40.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.68 135.45 52.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.915 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -103.2 -33.33 9.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -113.81 159.28 19.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -62.67 -22.15 66.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -90.94 38.54 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.931 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -140.14 174.92 10.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -124.88 135.69 53.11 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.457 ' N ' HD23 ' A' ' 34' ' ' LEU . 84.8 p -104.41 137.87 41.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.845 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 13.8 p90 -161.57 159.77 28.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.827 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -109.16 173.46 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -66.01 110.35 2.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.85 39.4 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.437 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.41 149.89 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.791 0.329 . . . . 0.0 111.097 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 45.6 mm -102.78 123.47 56.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.411 HG21 ' CE1' ' A' ' 64' ' ' PHE . 49.4 mt -126.9 125.54 66.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.103 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -84.18 120.07 25.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.4 t -82.45 114.83 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.474 HG22 ' HB3' ' A' ' 16' ' ' TYR . 31.6 pt -110.56 -14.54 10.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.172 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.44 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 32.1 tttp -146.19 144.49 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.908 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.581 ' HE2' ' CE1' ' A' ' 53' ' ' TYR . 13.2 mtpt -136.51 110.65 8.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.889 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -82.41 161.42 22.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -55.63 -36.82 67.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -84.57 175.65 9.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.892 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -72.15 67.62 1.15 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.392 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.496 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 65.5 m95 -158.8 121.35 3.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.731 0.3 . . . . 0.0 110.999 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.581 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 6.4 m-85 -118.65 154.9 31.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.936 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.44 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 16.7 tt0 -104.19 123.55 47.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 61' ' ' THR . . . -143.24 167.91 26.3 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.64 133.27 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.115 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -139.23 116.52 11.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.8 t30 55.7 39.11 30.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.31 -36.61 2.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.446 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 88.2 t -76.31 123.91 33.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.983 0.42 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.49 HG23 ' O ' ' A' ' 55' ' ' GLY . 5.3 m -107.62 146.38 32.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.114 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.59 169.0 41.41 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.544 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.459 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.2 mm? -88.52 127.16 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.881 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.411 ' CE1' HG21 ' A' ' 42' ' ' ILE . 49.1 p90 -136.63 144.75 48.39 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.666 0.746 . . . . 0.0 110.892 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 143.11 49.71 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.707 2.272 . . . . 0.0 112.337 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.484 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -83.98 7.26 71.42 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.427 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.0 m-20 -90.24 -35.24 15.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.871 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -80.1 3.25 21.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.62 172.75 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.163 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.487 ' O ' HG12 ' A' ' 21' ' ' VAL . 13.7 tt0 -142.26 137.03 30.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 49.1 m -69.42 130.59 42.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.849 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.496 HD13 ' H ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.156 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.685 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.7 Cg_endo . . . . . 0 N--CA 1.465 -0.187 0 CA-C-O 121.599 0.583 . . . . 0.0 112.335 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -29.56 23.5 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.301 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.521 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 62.5 p-90 -77.8 -25.94 49.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.853 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.685 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -65.58 151.68 94.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.59 0.709 . . . . 0.0 111.172 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 175.92 7.44 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.666 2.244 . . . . 0.0 112.297 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 10.7 tpp180 -88.29 -51.26 5.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.87 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.2 t -123.53 155.26 37.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.895 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 13.5 p90 -164.84 161.22 20.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 82.5 mt -66.72 -59.9 3.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -156.96 167.67 29.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -102.22 128.73 48.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 44' ' ' VAL . 10.7 m -119.68 164.69 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.144 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.7 p -133.63 140.54 46.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.255 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.439 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -79.88 118.64 21.83 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.075 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.2 pt -91.39 -14.75 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.09 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -136.74 161.36 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -86.23 132.66 33.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.887 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -130.91 144.89 51.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.9 m -118.34 95.44 4.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.241 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.423 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -40.49 135.45 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.866 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -108.77 -54.64 2.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.916 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -79.91 162.47 24.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -69.84 -25.05 63.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -95.94 54.38 1.48 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -149.66 178.29 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.71 HD23 ' N ' ' A' ' 35' ' ' SER . 2.6 tt -131.32 142.43 50.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.926 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.71 ' N ' HD23 ' A' ' 34' ' ' LEU . 59.7 p -108.19 143.36 37.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -166.91 167.99 14.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.774 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -120.34 164.81 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.979 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -55.74 117.97 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 105.25 43.88 1.55 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.95 138.52 52.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.78 0.324 . . . . 0.0 111.12 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 47.9 mm -89.76 129.72 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.164 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.23 145.5 34.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.165 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -106.96 114.17 28.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.442 HG13 ' HB3' ' A' ' 53' ' ' TYR . 43.6 t -77.76 118.03 23.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.149 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.61 HD11 ' OE1' ' A' ' 54' ' ' GLU . 2.9 pt -117.06 -8.88 12.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.5 ttmm -136.36 140.85 43.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.981 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 36.9 mttp -134.89 103.02 5.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' A' ' 50' ' ' ASP . 32.7 m-20 -83.55 38.81 0.64 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.891 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 48' ' ' ASN . 2.4 m-20 36.67 32.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.932 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.463 ' O ' ' CE1' ' A' ' 53' ' ' TYR . 31.0 m-20 -151.89 -175.04 5.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.816 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -76.27 52.99 3.07 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.419 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 96.4 m95 -162.87 106.97 1.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.766 0.317 . . . . 0.0 110.927 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.463 ' CE1' ' O ' ' A' ' 50' ' ' ASP . 4.7 m-85 -120.32 154.82 34.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.94 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.61 ' OE1' HD11 ' A' ' 45' ' ' ILE . 0.1 OUTLIER -98.25 141.14 31.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.88 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' A' ' 54' ' ' GLU . . . -161.85 165.45 35.77 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.413 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.578 HG22 ' OG1' ' A' ' 61' ' ' THR . 56.1 t -107.43 146.13 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.858 0.361 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.3 ttp -155.22 108.18 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.2 t30 68.14 32.96 4.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.65 -23.77 7.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.502 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.1 t -88.29 122.75 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.91 0.386 . . . . 0.0 111.107 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.578 ' OG1' HG22 ' A' ' 56' ' ' VAL . 7.3 m -106.33 148.43 28.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -176.77 163.29 32.18 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.489 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.451 HD22 ' N ' ' A' ' 63' ' ' LEU . 3.0 mm? -84.58 125.85 32.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.368 . . . . 0.0 110.909 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -127.19 152.11 75.49 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.683 0.754 . . . . 0.0 110.886 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 143.41 51.08 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.715 2.277 . . . . 0.0 112.289 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -86.56 24.79 7.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.494 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -111.33 -28.81 8.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -87.72 5.08 41.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.439 HG12 ' HA ' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -127.82 173.27 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.127 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.82 135.6 18.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.904 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.8 p -65.77 131.47 46.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.1 pt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.976 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.653 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 121.662 0.609 . . . . 0.0 112.278 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.67 -13.68 35.24 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.675 2.25 . . . . 0.0 112.398 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.576 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.9 p-90 -93.93 -34.65 13.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.653 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -51.31 145.78 13.14 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.521 0.677 . . . . 0.0 111.096 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.554 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.7 Cg_endo -69.8 133.68 26.08 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.727 2.285 . . . . 0.0 112.36 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 43.4 mtt180 -59.93 -33.43 71.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.98 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -140.42 137.92 34.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -153.74 161.54 42.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.97 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.598 HD13 ' HG3' ' A' ' 47' ' ' LYS . 5.1 mt -57.14 -71.68 0.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.912 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -151.49 165.74 33.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.634 ' HG2' HD11 ' A' ' 72' ' ' ILE . 15.5 ttpt -100.83 134.39 43.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.02 159.72 26.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.497 HG12 HG23 ' A' ' 72' ' ' ILE . 8.1 p -119.02 132.97 67.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.18 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.639 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -77.76 100.59 6.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.3 pt -75.86 -14.9 15.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -134.1 173.7 11.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -100.3 107.91 19.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.849 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.55 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 70.5 t80 -107.07 134.05 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 28' ' ' LYS . 30.1 m -110.23 111.94 23.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.101 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 27' ' ' THR . 0.0 OUTLIER -36.15 128.99 0.71 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 179.898 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -100.88 -41.07 6.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -104.3 165.01 11.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -67.37 -27.01 66.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 9.6 p-10 -94.21 16.61 14.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.826 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.486 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -106.13 166.12 10.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.943 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -118.37 141.57 48.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.623 ' N ' HD23 ' A' ' 34' ' ' LEU . 2.4 t -107.68 140.33 40.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -158.31 150.6 21.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -102.56 160.78 14.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -46.42 152.35 0.45 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 63.78 36.26 93.08 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.53 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -106.74 166.49 10.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.764 0.316 . . . . 0.0 111.087 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.7 mm -120.2 129.5 75.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.211 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.4 mt -129.54 141.14 47.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.554 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 53.6 m-85 -105.28 92.13 4.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.5 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 86.1 t -58.27 113.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.075 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.7 pt -110.84 -15.15 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.441 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.2 ttmt -140.76 147.46 39.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.598 ' HG3' HD13 ' A' ' 17' ' ' LEU . 64.0 mttt -135.85 147.76 48.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.968 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -125.53 151.09 46.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -39.15 -49.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.867 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -76.56 -176.0 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.21 64.73 4.11 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -148.75 114.79 5.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.478 ' C ' HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -121.23 146.78 46.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.895 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.441 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 4.1 tt0 -96.44 126.63 41.77 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.882 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -140.18 167.45 25.44 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.448 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 t -105.1 143.52 16.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.831 0.348 . . . . 0.0 111.082 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.574 ' HB3' HD21 ' A' ' 34' ' ' LEU . 7.5 tmm? -152.66 112.36 3.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.28 39.71 22.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.956 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.86 -34.68 2.55 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 86.8 t -75.58 126.78 36.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.95 0.405 . . . . 0.0 111.131 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.5 m -104.27 141.38 36.39 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.454 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -174.33 153.89 17.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.517 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 53' ' ' TYR . 5.3 mt -75.63 156.23 35.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.5 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 35.2 p90 -155.79 148.16 17.66 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 130.26 19.13 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.738 2.292 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -71.13 -2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.52 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -86.22 -33.73 20.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.838 0.352 . . . . 0.0 110.911 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.55 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 9.5 m-85 -69.83 -23.59 63.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 22' ' ' ALA . 12.3 m -115.33 175.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.167 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -136.36 162.72 32.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 m -88.22 113.71 24.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.791 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.634 HD11 ' HG2' ' A' ' 19' ' ' LYS . 47.7 pt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.179 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.615 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.3 Cg_endo . . . . . 0 N--CA 1.464 -0.228 0 CA-C-O 121.614 0.589 . . . . 0.0 112.377 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -19.69 35.77 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.731 2.287 . . . . 0.0 112.316 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 42.0 p-90 -90.47 -20.25 22.93 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.942 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.615 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -70.93 148.47 94.59 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.614 0.721 . . . . 0.0 111.151 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 133.45 25.67 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 67.6 mtt85 -43.06 -46.25 5.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.824 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.6 p -145.8 144.16 30.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.3 p90 -134.66 174.6 10.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -76.68 -56.36 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.95 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -154.46 168.94 25.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttt -110.12 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.798 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.7 148.28 22.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.177 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -112.86 131.79 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.32 99.68 2.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.082 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.749 HD12 ' CE2' ' A' ' 24' ' ' TYR . 16.3 pt -73.13 -14.65 16.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.749 ' CE2' HD12 ' A' ' 23' ' ' ILE . 28.9 m-85 -143.56 156.13 44.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.92 162.96 28.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 2.9 t80 -168.84 131.5 1.32 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.946 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 17.4 m -109.84 131.99 54.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.093 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' HZ3' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -63.67 164.27 10.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.954 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -129.07 -5.74 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.849 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ptpp? -146.6 143.13 28.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -47.11 -23.9 0.57 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -93.45 47.35 1.24 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.818 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -145.26 -179.74 6.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.587 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -126.48 151.16 48.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.924 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.587 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.9 p -121.22 123.99 43.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -140.95 152.59 45.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -110.26 165.02 12.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.961 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -52.64 108.29 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 104.96 39.66 2.27 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.88 21.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.74 0.305 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.8 mm -107.4 111.14 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.201 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.534 HG21 ' CE1' ' A' ' 64' ' ' PHE . 81.3 mt -117.06 141.36 35.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.164 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -105.09 108.85 20.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.971 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -67.11 115.36 4.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.181 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.1 pt -118.17 -18.44 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.14 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 4.1 tmtm? -138.94 146.45 41.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 17.1 mtpp -136.2 112.36 9.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -74.9 173.76 10.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -51.61 -17.52 0.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -112.75 -175.84 2.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.586 ' O ' ' CE2' ' A' ' 53' ' ' TYR . . . -63.31 -10.19 33.93 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.443 ' CH2' ' HD3' ' A' ' 65' ' ' PRO . 59.4 m95 -61.96 122.53 15.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.705 0.288 . . . . 0.0 110.9 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.586 ' CE2' ' O ' ' A' ' 51' ' ' GLY . 19.5 m-85 -123.84 135.55 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.454 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 9.3 tt0 -87.39 121.9 30.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.453 ' O ' ' CD1' ' A' ' 34' ' ' LEU . . . -134.57 158.23 23.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.454 HG22 ' OG1' ' A' ' 61' ' ' THR . 59.2 t -101.43 129.8 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.476 ' O ' ' ND2' ' A' ' 58' ' ' ASN . 2.2 tmm? -138.43 138.08 37.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.813 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.476 ' ND2' ' O ' ' A' ' 57' ' ' MET . 1.9 p30 39.97 38.07 0.44 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.909 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.61 -38.08 2.79 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -75.95 117.71 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.454 ' OG1' HG22 ' A' ' 56' ' ' VAL . 17.1 m -100.62 145.64 28.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.158 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.75 177.13 44.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.622 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.1 mt -94.47 155.31 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.784 0.326 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.534 ' CE1' HG21 ' A' ' 42' ' ' ILE . 51.2 p90 -158.54 151.55 18.5 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.612 0.72 . . . . 0.0 110.927 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.443 ' HD3' ' CH2' ' A' ' 52' ' ' TRP . 53.6 Cg_endo -69.74 129.91 18.44 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.755 2.304 . . . . 0.0 112.371 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -61.47 -17.66 53.86 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.463 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 69' ' ' VAL . 32.0 t30 -68.97 -65.89 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -38.52 -31.71 0.06 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.871 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.404 ' N ' ' O ' ' A' ' 67' ' ' ASN . 3.3 m -107.18 173.66 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -143.59 168.72 19.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 28.9 t -96.05 118.41 32.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 21.5 pt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.091 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.5 Cg_endo . . . . . 0 C--O 1.23 0.116 0 CA-C-O 121.661 0.609 . . . . 0.0 112.282 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -44.59 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.326 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.403 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 33.8 p-90 -56.25 -16.72 5.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 144.19 89.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.656 0.741 . . . . 0.0 111.103 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.31 14.42 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -55.64 -39.92 71.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 7.3 t -117.49 129.93 56.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.789 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.455 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 9.6 p90 -156.32 140.52 16.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.936 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.59 HD22 ' HE2' ' A' ' 47' ' ' LYS . 3.9 mp -49.93 -68.12 0.2 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.93 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -146.37 175.66 10.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 43' ' ' TYR . 0.6 OUTLIER -116.46 126.82 53.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.903 179.952 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.26 159.51 23.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.086 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.44 HG23 HD13 ' A' ' 41' ' ' ILE . 9.2 p -119.68 143.46 31.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.112 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.16 114.67 18.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.088 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.549 HG13 ' CD2' ' A' ' 24' ' ' TYR . 33.6 pt -92.97 -9.34 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.549 ' CD2' HG13 ' A' ' 23' ' ' ILE . 55.1 m-85 -147.88 158.23 43.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -82.12 128.71 34.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -135.22 129.84 34.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.918 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 28' ' ' LYS . 91.0 m -107.17 104.43 14.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 27' ' ' THR . 14.8 pttm -36.84 122.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -81.59 -8.68 59.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.789 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.9 mmtm -135.27 -175.08 3.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.91 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.26 -16.74 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.943 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -88.69 -22.42 23.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.821 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.43 166.4 22.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.553 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -120.0 134.77 55.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.553 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.4 t -99.73 145.4 27.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -164.9 161.26 20.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -106.85 172.83 6.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -66.3 112.04 3.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 122.8 -17.26 8.22 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.448 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.03 146.92 52.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.752 0.311 . . . . 0.0 111.123 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.44 HD13 HG23 ' A' ' 21' ' ' VAL . 10.8 mm -104.47 141.45 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.182 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.699 HG21 ' CE2' ' A' ' 64' ' ' PHE . 16.8 mt -135.58 142.85 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.088 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.504 ' CE1' ' HE3' ' A' ' 19' ' ' LYS . 93.1 m-85 -105.67 104.76 14.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.873 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.5 t -61.24 121.92 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.105 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.2 pt -123.93 -14.91 5.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.171 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.486 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 35.3 tttm -137.29 148.79 46.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.59 ' HE2' HD22 ' A' ' 17' ' ' LEU . 38.2 mmtt -119.76 161.66 20.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.432 ' CB ' ' HB2' ' A' ' 52' ' ' TRP . 5.9 m120 -133.12 -174.95 3.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.943 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -109.72 -28.07 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.593 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 54.9 m-20 -99.45 40.39 1.22 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.837 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 60.79 79.8 0.11 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.543 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.593 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 94.1 m95 -162.67 137.37 6.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.76 0.314 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.485 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 11.9 m-85 -132.87 136.46 46.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.861 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.486 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.7 tt0 -95.86 115.37 27.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.959 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.41 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -125.68 173.26 17.61 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.472 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.3 t -113.01 139.1 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.157 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.469 ' O ' ' N ' ' A' ' 60' ' ' VAL . 5.3 tmm? -149.36 143.8 26.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.424 ' C ' ' O ' ' A' ' 57' ' ' MET . 11.6 p-10 35.78 37.79 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.0 2.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' MET . 89.1 t -76.05 138.94 19.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.0 111.165 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 15.8 m -114.64 146.72 40.53 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.402 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.86 177.9 44.38 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.376 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.0 mp -105.05 134.12 48.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.825 0.345 . . . . 0.0 110.951 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 42' ' ' ILE . 29.4 p90 -125.92 153.1 73.62 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.677 0.751 . . . . 0.0 110.846 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.42 50.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.281 . . . . 0.0 112.297 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.31 36.8 2.4 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.477 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -127.87 -29.69 2.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -91.25 16.29 10.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.6 m -146.59 162.5 9.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.098 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 33.0 mm-40 -139.76 150.97 45.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 91.7 p -85.74 109.57 18.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.8 pt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.084 -179.995 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.642 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.2 Cg_endo . . . . . 0 C--O 1.232 0.196 0 CA-C-O 121.65 0.604 . . . . 0.0 112.34 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.87 -34.84 13.42 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.404 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 52.2 p-90 -71.43 -30.48 66.11 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.642 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -55.13 148.8 28.11 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.51 0.671 . . . . 0.0 111.118 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.87 145.53 56.77 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.647 2.232 . . . . 0.0 112.35 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -51.39 -36.56 44.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.3 m -160.45 156.41 25.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.708 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 19.3 p90 -150.19 -180.0 7.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.3 mt -84.09 -64.6 1.13 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -139.99 176.24 8.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.8 130.65 54.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 44' ' ' VAL . 15.8 m -123.85 160.4 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.177 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.88 147.77 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.13 22.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.061 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.417 HG13 ' CD2' ' A' ' 24' ' ' TYR . 31.3 pt -92.74 -7.61 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.417 ' CD2' HG13 ' A' ' 23' ' ' ILE . 59.8 m-85 -146.84 163.37 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.944 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.76 121.81 28.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.872 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -135.19 114.26 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.42 ' O ' ' C ' ' A' ' 28' ' ' LYS . 24.6 m -98.21 106.01 18.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' A' ' 27' ' ' THR . 5.2 pttm -35.57 133.18 0.4 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.933 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -90.55 -27.71 18.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -128.94 163.64 24.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.828 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -53.77 -39.95 65.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.947 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -76.2 49.1 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.805 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -157.11 167.08 31.46 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.803 HD23 ' N ' ' A' ' 35' ' ' SER . 2.5 tt -122.63 146.42 47.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.937 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.803 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.5 p -109.46 145.46 36.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.85 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.3 p90 -169.88 148.04 3.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -103.76 153.15 21.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.97 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -39.62 110.57 0.15 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.19 44.88 0.97 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.487 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -126.25 130.46 50.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.772 0.32 . . . . 0.0 111.103 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.3 mm -87.97 136.19 23.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.6 148.97 22.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.118 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.708 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 77.0 m-85 -104.31 115.02 29.64 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 20' ' ' VAL . 22.9 t -74.66 121.74 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.184 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.9 pt -122.72 -7.0 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.455 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 0.1 OUTLIER -136.67 144.8 44.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -122.16 103.23 8.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.862 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -74.73 -175.01 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.942 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -99.4 -10.47 22.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.42 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -120.38 40.42 3.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.595 ' O ' ' CE1' ' A' ' 53' ' ' TYR . . . 79.84 -44.29 2.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.43 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.474 ' O ' ' CD1' ' A' ' 53' ' ' TYR . 25.9 m95 -34.46 137.96 0.11 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.808 0.337 . . . . 0.0 110.926 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.595 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 22.0 m-85 -136.84 137.9 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.926 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.455 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 23.8 tt0 -94.15 116.67 29.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.89 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.4 163.34 25.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.547 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.6 t -98.73 146.12 8.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.143 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -151.45 118.65 5.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.902 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.9 t30 49.67 43.76 24.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.931 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 80.4 -40.67 2.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 95.2 t -75.83 120.56 25.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 m -100.96 141.47 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.168 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.428 ' C ' ' HB2' ' A' ' 34' ' ' LEU . . . -165.87 154.37 24.95 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.498 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -80.54 147.87 30.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.902 0.382 . . . . 0.0 110.902 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -147.99 148.43 29.79 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.676 0.751 . . . . 0.0 110.884 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.5 40.27 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.464 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -73.22 -3.93 62.46 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.527 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -82.22 -28.45 31.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -90.48 8.36 34.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.464 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 8.6 m -135.7 169.06 21.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -140.63 150.18 43.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.4 t -85.03 113.63 21.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.877 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.3 pt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.139 179.895 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.585 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 N--CA 1.467 -0.086 0 CA-C-O 121.585 0.577 . . . . 0.0 112.339 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -33.36 17.04 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.585 2.19 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 22.4 p-90 -63.6 -23.18 67.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.434 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -65.23 148.26 98.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 121.493 0.663 . . . . 0.0 111.087 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 149.15 66.19 Favored 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.662 2.242 . . . . 0.0 112.37 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -54.94 -44.18 74.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.897 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.5 t -145.79 165.66 28.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -159.6 -179.14 7.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 22.9 mt -84.58 -57.31 3.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -152.96 -179.88 8.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.582 ' HE3' HG23 ' A' ' 41' ' ' ILE . 13.3 tttp -113.75 154.38 27.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.41 ' N ' ' HG2' ' A' ' 19' ' ' LYS . 29.1 m -152.18 147.15 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -117.09 139.4 44.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.206 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.27 135.42 36.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.109 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.492 HG13 ' CD2' ' A' ' 24' ' ' TYR . 16.1 pt -115.07 -15.17 10.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.179 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CD2' HG13 ' A' ' 23' ' ' ILE . 62.9 m-85 -128.53 164.51 22.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.895 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -87.22 123.98 32.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.919 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' A' ' 27' ' ' THR . 86.0 t80 -117.31 160.27 21.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.949 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.41 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 6.7 m -133.53 132.08 40.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.22 136.34 36.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.914 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -99.56 -32.02 11.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.978 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -110.12 163.42 13.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.13 4.71 13.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -108.55 -26.75 10.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.411 ' C ' ' HA3' ' A' ' 62' ' ' GLY . 0.1 OUTLIER -70.4 -177.99 1.61 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -124.41 139.57 53.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.7 p -115.88 124.91 51.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.828 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 28.7 p90 -148.04 156.54 42.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.849 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -114.86 169.88 8.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -45.64 137.42 5.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.871 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.45 46.51 9.88 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.548 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.9 136.28 52.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.341 . . . . 0.0 111.037 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.582 HG23 ' HE3' ' A' ' 19' ' ' LYS . 21.8 mm -88.72 135.7 25.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.522 HD11 ' CD2' ' A' ' 36' ' ' PHE . 65.9 mt -141.99 143.46 26.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -110.28 109.67 20.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.96 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.486 HG13 ' HB3' ' A' ' 53' ' ' TYR . 92.8 t -69.25 110.07 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.137 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 26.2 pt -107.79 -14.12 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.193 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 46.9 tttt -144.52 138.45 27.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.886 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 6.6 mtmp? -135.05 102.99 5.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -75.97 175.51 8.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -76.38 48.36 0.53 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -163.36 -176.92 5.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.481 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -82.7 49.62 4.22 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.472 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.524 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 46.1 m95 -148.71 121.39 8.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.552 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 2.9 m-85 -119.06 149.26 41.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.65 123.13 37.91 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.8 177.02 19.6 Favored Glycine 0 N--CA 1.454 -0.157 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.449 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.467 HG22 HG23 ' A' ' 61' ' ' THR . 45.8 t -117.86 144.22 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.73 0.3 . . . . 0.0 111.196 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -157.02 129.99 7.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.816 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 58' ' ' ASN . 30.7 t30 47.55 38.47 8.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.01 -35.14 2.55 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.499 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 97.9 t -76.02 126.04 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.467 HG23 HG22 ' A' ' 56' ' ' VAL . 2.9 m -106.97 150.87 26.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.159 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA3' ' C ' ' A' ' 33' ' ' GLU . . . 173.91 162.2 25.29 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.526 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.22 163.96 22.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.511 ' CE1' HG21 ' A' ' 42' ' ' ILE . 29.8 p90 -160.68 152.47 16.52 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.525 0.679 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.524 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.78 137.27 35.03 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.679 2.253 . . . . 0.0 112.321 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 68' ' ' TYR . . . -67.27 -56.11 13.28 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.429 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.9 m-20 -40.95 -24.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.472 ' CG ' ' HG2' ' A' ' 65' ' ' PRO . 13.4 m-85 -76.77 -42.73 39.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 18.8 m -108.24 142.64 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.231 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -102.94 165.64 10.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.802 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.4 t -105.66 105.23 15.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.403 HD11 ' HD3' ' A' ' 19' ' ' LYS . 37.3 pt . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.172 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.567 ' CG ' ' CE2' ' A' ' 11' ' ' TRP . 53.8 Cg_endo . . . . . 0 C--O 1.23 0.115 0 CA-C-O 121.662 0.609 . . . . 0.0 112.329 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.8 -33.35 16.62 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.603 2.202 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.567 ' CE2' ' CG ' ' A' ' 9' ' ' PRO . 22.2 p-90 -65.56 -27.82 68.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.54 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -58.32 147.41 67.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.59 0.71 . . . . 0.0 111.126 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.6 10.72 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.668 2.245 . . . . 0.0 112.294 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.4 mtt180 -85.0 -43.94 13.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.8 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 39.0 t -136.66 152.79 50.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.812 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.53 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 7.1 p90 -159.77 157.21 28.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.904 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 44' ' ' VAL . 19.8 mt -61.35 -66.95 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -144.14 -175.65 4.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.858 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.596 ' HD2' HD11 ' A' ' 72' ' ' ILE . 20.7 ttmt -120.19 133.05 55.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.426 HG13 HG21 ' A' ' 44' ' ' VAL . 34.4 m -128.15 161.23 36.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.195 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 ' HG3' ' A' ' 70' ' ' GLU . 11.3 p -126.14 141.08 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.193 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.9 118.4 14.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.102 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.4 pt -99.04 -35.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -129.77 135.11 48.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -56.69 122.58 12.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.894 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 87.9 t80 -121.1 127.71 51.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -97.04 123.51 40.79 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.074 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.413 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -76.15 131.29 39.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.887 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -94.08 -47.9 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -105.14 146.8 28.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -45.22 -32.29 1.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.33 -44.77 96.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.922 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -65.68 165.33 12.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.958 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.625 HD23 ' N ' ' A' ' 35' ' ' SER . 3.7 tt -121.63 140.09 52.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.625 ' N ' HD23 ' A' ' 34' ' ' LEU . 52.8 p -99.2 130.99 45.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -151.6 167.91 26.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.965 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -127.6 159.74 33.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.81 109.07 0.37 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.897 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.59 43.47 0.75 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.445 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.96 131.7 47.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.788 0.328 . . . . 0.0 111.068 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.78 100.4 11.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.4 mt -104.8 137.55 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.1 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.53 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 80.7 m-85 -91.18 121.79 33.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.966 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 17' ' ' LEU . 48.0 t -80.92 104.5 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.066 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 46' ' ' LYS . 33.0 pt -95.33 -33.58 4.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.406 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.4 tptm -129.31 144.22 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.479 ' HG2' ' CG ' ' A' ' 53' ' ' TYR . 10.9 mtpt -136.45 124.46 22.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -101.4 151.25 22.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -39.34 -49.66 1.99 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.921 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.74 177.22 7.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.951 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.6 66.9 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.516 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -151.68 113.07 4.34 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.733 0.301 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.479 ' CG ' ' HG2' ' A' ' 47' ' ' LYS . 1.3 m-85 -122.95 154.23 38.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.406 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.4 tt0 -104.45 134.59 47.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.879 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.17 157.07 27.05 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.488 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.3 t -95.48 136.43 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.926 0.394 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.41 ' O ' ' N ' ' A' ' 60' ' ' VAL . 21.8 ttp -141.18 119.67 12.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.824 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 43.93 42.76 4.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.79 -26.64 4.65 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.493 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.41 ' N ' ' O ' ' A' ' 57' ' ' MET . 93.0 t -81.1 127.76 39.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.881 0.372 . . . . 0.0 111.162 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.7 m -112.19 147.86 35.27 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.503 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 178.04 162.84 28.63 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.533 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.9 mt -88.44 128.79 35.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -120.38 147.33 44.95 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.716 0.77 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 122.83 9.5 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.667 2.245 . . . . 0.0 112.35 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.458 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -58.53 -10.8 8.46 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -76.61 -32.16 57.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.732 0.301 . . . . 0.0 110.787 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 11.7 m-85 -97.83 35.32 1.72 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.906 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 68' ' ' TYR . 9.9 m -161.32 153.81 3.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.608 ' HG3' HG12 ' A' ' 21' ' ' VAL . 5.6 pt-20 -130.06 144.14 51.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 37.9 m -84.66 120.33 26.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.596 HD11 ' HD2' ' A' ' 19' ' ' LYS . 24.9 pt . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.181 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.796 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 121.624 0.593 . . . . 0.0 112.33 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.81 -33.95 15.4 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.681 2.254 . . . . 0.0 112.318 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 54.8 p-90 -73.55 -29.7 62.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.796 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -52.71 151.53 7.99 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.604 0.716 . . . . 0.0 111.089 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.63 133.25 25.33 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 56.5 mtm180 -48.68 -45.48 39.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.865 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.5 p -136.64 163.39 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.942 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -166.27 171.21 12.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.005 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.57 HD13 ' HE3' ' A' ' 47' ' ' LYS . 19.4 mt -77.03 -52.29 9.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.882 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.727 ' OE1' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -160.44 172.84 16.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.967 179.898 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.05 145.92 42.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.727 HG13 ' OE1' ' A' ' 18' ' ' GLU . 30.4 m -135.64 163.28 35.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.109 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.29 140.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.05 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.19 102.93 12.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.072 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CE2' ' A' ' 24' ' ' TYR . 8.5 pt -84.25 -7.22 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.688 ' CE2' HD12 ' A' ' 23' ' ' ILE . 46.7 m-85 -145.43 136.6 24.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.912 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -65.69 136.02 55.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.872 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -137.97 128.1 25.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.883 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.3 m -97.32 151.33 20.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.209 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 7.8 ptmt -93.03 132.58 37.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.844 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.02 -18.26 22.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.816 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -138.16 167.73 21.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.92 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -83.33 36.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.902 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -127.39 -28.94 2.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.937 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -88.98 -174.97 4.68 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.969 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.701 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.21 140.4 51.5 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.701 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.1 p -108.38 140.32 41.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -153.75 166.58 32.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.933 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -114.41 170.27 8.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -61.8 102.02 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 115.23 42.5 0.76 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.584 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.38 140.96 48.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 111.146 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.2 mm -92.85 122.44 44.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.151 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.543 HG21 ' CE2' ' A' ' 64' ' ' PHE . 70.4 mt -127.47 136.21 61.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -101.35 107.68 19.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.962 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 53' ' ' TYR . 87.5 t -69.17 113.49 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.435 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.0 pt -113.93 -2.37 10.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.164 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.475 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.0 tptm -156.2 137.08 13.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HE3' HD13 ' A' ' 17' ' ' LEU . 14.5 ptpt -136.51 116.65 13.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 58.7 m-20 -90.1 155.91 18.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -43.15 -37.33 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -85.11 -175.27 5.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.526 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -82.56 81.37 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.526 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 91.9 m95 -162.02 120.66 2.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.52 ' HB3' HG13 ' A' ' 44' ' ' VAL . 33.6 m-85 -118.52 135.36 54.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.927 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.475 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 7.8 tt0 -91.0 111.11 22.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 61' ' ' THR . . . -125.96 169.89 17.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.487 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.506 HG22 ' OG1' ' A' ' 61' ' ' THR . 77.3 t -115.52 129.83 71.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 111.097 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.8 tmm? -137.34 125.36 22.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 45.8 t30 51.02 37.98 19.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.28 -31.49 2.9 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.6 132.36 31.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.914 0.388 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.712 HG23 ' O ' ' A' ' 55' ' ' GLY . 18.9 m -114.27 145.14 42.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.76 145.12 9.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.405 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.7 mm? -67.95 123.85 21.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.543 ' CE2' HG21 ' A' ' 42' ' ' ILE . 42.3 p90 -123.82 152.67 66.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 138.91 38.88 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.646 2.231 . . . . 0.0 112.324 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.19 29.24 3.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -116.78 -35.02 4.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.848 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -78.21 2.36 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.938 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.96 178.41 2.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.082 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -142.68 124.17 14.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 72.2 m -71.7 103.69 3.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.9 pt . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.973 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HB2' ' CE2' ' A' ' 11' ' ' TRP . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.148 0 CA-C-O 121.558 0.566 . . . . 0.0 112.297 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 2.87 3.13 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.692 2.262 . . . . 0.0 112.366 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.432 ' CE2' ' HB2' ' A' ' 9' ' ' PRO . 32.0 p-90 -120.42 18.01 12.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.91 144.51 64.05 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.611 0.72 . . . . 0.0 111.057 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 155.89 64.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.386 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -50.98 -53.72 30.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.867 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.3 t -145.13 165.45 28.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -158.67 155.39 28.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.905 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -64.56 -46.94 80.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.912 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -165.97 179.35 5.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 24.2 ttmt -119.43 132.76 55.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.823 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.0 m -120.44 168.53 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.83 137.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.997 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.06 92.53 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.114 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 24' ' ' TYR . 35.7 pt -69.38 -34.71 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.192 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 23' ' ' ILE . 77.6 m-85 -128.82 151.81 49.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.869 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.81 102.02 11.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.891 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -103.49 130.55 50.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.9 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -96.04 108.97 21.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.412 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 12.7 pttm -45.24 142.18 2.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.928 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -95.34 -48.93 5.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -101.26 175.84 5.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.902 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -67.85 -38.65 83.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.68 -40.52 95.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.829 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.412 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 32.5 mt-10 -57.09 162.41 2.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 62' ' ' GLY . 2.0 tt -118.59 141.2 48.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.509 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.6 p -108.4 133.22 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -155.84 152.6 28.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.912 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -106.4 160.01 15.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.423 ' OE1' ' C ' ' A' ' 38' ' ' GLU . 1.0 OUTLIER -45.37 137.72 4.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.865 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.3 48.03 5.83 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.83 142.51 50.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 111.145 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.434 ' C ' HG13 ' A' ' 42' ' ' ILE . 28.7 mm -94.84 139.51 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.137 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.454 HG21 ' CE2' ' A' ' 64' ' ' PHE . 20.8 mt -141.88 143.19 27.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.181 179.858 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.583 ' CE1' ' HE2' ' A' ' 19' ' ' LYS . 97.9 m-85 -103.05 98.81 8.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.897 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.536 HG11 ' HE3' ' A' ' 47' ' ' LYS . 25.6 t -64.25 95.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.207 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.433 HG13 ' N ' ' A' ' 46' ' ' LYS . 48.1 pt -88.12 -34.48 7.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.433 ' N ' HG13 ' A' ' 45' ' ' ILE . 1.4 tppp? -126.04 148.04 49.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.916 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' HE2' ' CD1' ' A' ' 53' ' ' TYR . 13.9 mtpt -136.58 112.75 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -87.64 150.73 23.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -41.89 -49.38 4.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.36 175.4 6.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.907 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.17 61.65 2.21 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.53 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -151.39 110.66 3.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.715 0.293 . . . . 0.0 110.939 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.56 ' CD1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -112.8 151.71 30.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.429 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.4 tt0 -99.78 126.91 45.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.958 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.15 27.9 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.568 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.0 t -97.22 139.85 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 111.092 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.7 ttp -153.4 111.11 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.1 t30 62.24 39.3 12.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.35 -35.26 2.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.26 130.46 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 0.0 111.06 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.568 ' OG1' HG22 ' A' ' 56' ' ' VAL . 87.2 m -116.86 131.42 56.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -158.37 163.42 32.94 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.451 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.2 mt -80.09 123.38 27.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.609 ' HE1' HG21 ' A' ' 69' ' ' VAL . 21.3 p90 -115.6 151.25 45.94 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 110.906 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 118.01 5.42 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.724 2.283 . . . . 0.0 112.307 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.456 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -55.03 -13.04 4.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.416 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -75.67 -34.12 60.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.842 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 69' ' ' VAL . 13.2 m-85 -94.59 32.6 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.609 HG21 ' HE1' ' A' ' 64' ' ' PHE . 26.9 m -158.34 139.24 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.6 mm-40 -120.55 158.16 27.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.826 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.7 p -90.15 127.03 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.5 pt . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.147 179.915 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.542 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.4 Cg_endo . . . . . 0 C--O 1.231 0.134 0 CA-C-O 121.587 0.578 . . . . 0.0 112.376 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -29.32 24.18 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.619 2.212 . . . . 0.0 112.389 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.542 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 48.4 p-90 -73.47 -14.21 61.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.934 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.515 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -76.67 143.68 72.08 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.684 0.754 . . . . 0.0 111.025 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 123.24 9.89 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.2 mmt85 -41.9 -47.48 4.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.4 t -121.57 153.24 38.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.541 ' HA ' HG22 ' A' ' 45' ' ' ILE . 25.9 p90 -164.8 163.95 21.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.936 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.446 HD13 ' HG3' ' A' ' 47' ' ' LYS . 51.4 mt -65.85 -61.98 1.76 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.019 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -156.86 178.58 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.001 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -114.92 147.95 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.481 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 22.1 m -146.55 158.95 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.668 HG12 HG23 ' A' ' 72' ' ' ILE . 13.0 p -124.81 132.62 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.221 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -70.16 117.9 12.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.513 HG13 ' CD2' ' A' ' 24' ' ' TYR . 41.7 pt -98.89 -14.47 7.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.513 ' CD2' HG13 ' A' ' 23' ' ' ILE . 47.5 m-85 -136.38 151.63 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.931 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -78.33 115.07 17.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -113.88 148.61 36.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.4 m -120.16 112.03 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.179 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.403 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 15.0 pttm -57.82 136.75 57.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.931 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.32 -24.43 42.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 pttt -155.06 179.02 9.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.12 -43.01 77.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.939 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -47.23 -36.4 8.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.976 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.403 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -87.4 176.99 7.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.92 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.688 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.7 tt -128.0 152.44 47.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.932 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.665 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.0 p -108.54 139.31 43.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.843 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -165.43 153.86 11.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.936 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -112.59 166.06 11.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.949 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -51.83 106.23 0.14 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.966 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 116.83 46.43 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.425 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -141.38 117.83 10.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.809 0.338 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.489 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.7 mp -80.82 147.53 6.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.405 HG13 ' C ' ' A' ' 41' ' ' ILE . 34.9 mt -142.89 133.42 22.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -86.74 109.89 19.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.528 HG13 ' HB3' ' A' ' 53' ' ' TYR . 80.2 t -76.29 124.05 33.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 16' ' ' TYR . 10.6 pt -120.7 -23.87 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.127 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 9.5 tmtt? -128.75 145.95 51.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 19.1 mtpt -123.38 160.65 26.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.914 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -129.79 -174.89 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.869 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -104.45 -26.73 12.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.814 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.597 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 34.6 t70 -100.04 39.85 1.3 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.528 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 59.06 78.17 0.14 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.497 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.597 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 97.5 m95 -162.33 115.16 1.72 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.805 0.336 . . . . 0.0 110.853 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.528 ' HB3' HG13 ' A' ' 44' ' ' VAL . 3.3 m-85 -116.32 137.65 51.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.92 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -91.1 126.24 36.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.863 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.98 167.13 25.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.523 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 84.7 t -112.64 126.75 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.778 0.323 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.3 ttp -133.24 107.18 7.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.905 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 59.27 41.73 19.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.982 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.73 -34.15 3.19 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 92.7 t -76.21 125.02 35.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.938 0.399 . . . . 0.0 111.067 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.7 m -107.58 146.79 31.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.133 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.688 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.49 139.69 3.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 63' ' ' LEU . 5.2 mp -69.13 161.42 29.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.369 . . . . 0.0 110.877 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -163.11 154.51 14.78 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.587 0.708 . . . . 0.0 110.9 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.502 ' HG2' ' CD1' ' A' ' 68' ' ' TYR . 53.7 Cg_endo -69.68 122.74 9.44 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.391 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.523 ' O ' HG22 ' A' ' 69' ' ' VAL . . . -51.29 -52.0 34.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 68' ' ' TYR . 19.0 m120 -40.71 -65.05 0.46 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.817 0.341 . . . . 0.0 110.818 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.502 ' CD1' ' HG2' ' A' ' 65' ' ' PRO . 23.7 m-85 -36.37 -33.99 0.05 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 22' ' ' ALA . 30.9 m -108.67 164.54 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.129 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.475 ' CD ' ' N ' ' A' ' 71' ' ' SER . 2.8 tm-20 -122.03 137.49 54.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.475 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 14.9 m -80.7 77.86 7.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.834 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.668 HG23 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.563 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.0 Cg_endo . . . . . 0 C--O 1.23 0.123 0 CA-C-O 121.62 0.591 . . . . 0.0 112.321 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -25.65 28.4 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.64 2.227 . . . . 0.0 112.341 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.529 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 47.0 p-90 -79.33 -18.78 51.85 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -75.08 148.34 84.19 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.73 . . . . 0.0 111.087 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.8 Cg_endo -69.79 132.61 23.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.634 2.223 . . . . 0.0 112.399 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.449 ' C ' ' O ' ' A' ' 13' ' ' PRO . 3.6 ptt180 -34.37 -46.81 0.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.833 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 24.2 m -144.5 169.51 17.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -160.65 166.88 28.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.969 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -65.86 -56.67 10.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -152.57 -175.76 5.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -126.11 121.82 33.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.95 167.28 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.175 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 p -133.95 136.87 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.61 119.06 15.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.414 HG13 ' CD2' ' A' ' 24' ' ' TYR . 24.4 pt -97.79 -8.55 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.151 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.414 ' CD2' HG13 ' A' ' 23' ' ' ILE . 41.1 m-85 -142.58 165.79 26.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -88.35 114.28 24.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.836 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.429 ' HB3' ' CZ ' ' A' ' 36' ' ' PHE . 90.8 t80 -114.47 111.49 21.48 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.97 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 22.2 m -92.57 94.69 9.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.438 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 0.7 OUTLIER -43.67 157.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.904 179.925 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -118.53 -20.85 8.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' GLU . 12.6 mmmm -124.69 137.3 54.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -41.93 -30.53 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.19 -41.94 85.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.953 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.7 OUTLIER -64.22 169.22 4.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.606 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -121.1 138.96 53.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.962 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.606 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.7 p -101.15 153.28 19.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.902 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.429 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 24.9 p90 -174.24 165.91 4.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.973 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.426 ' O ' ' C ' ' A' ' 38' ' ' GLU . 15.0 pt20 -130.5 151.35 51.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 37' ' ' GLN . 16.6 tt0 -36.69 104.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 117.94 38.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.481 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -123.54 130.09 52.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.717 0.294 . . . . 0.0 111.108 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.4 mm -87.11 133.01 31.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.416 HG21 ' CE1' ' A' ' 64' ' ' PHE . 78.5 mt -131.18 140.93 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.118 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -105.88 97.9 7.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.449 HG11 ' HE3' ' A' ' 47' ' ' LYS . 92.4 t -60.36 114.03 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.164 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.5 pt -110.91 -20.1 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.172 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 37.4 mttp -144.46 154.92 43.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.449 ' HE3' HG11 ' A' ' 44' ' ' VAL . 69.4 mttt -136.5 159.71 40.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -129.45 149.03 51.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -38.34 -39.28 0.43 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 52' ' ' TRP . 1.5 m-20 -96.03 174.21 7.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.969 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -63.62 77.19 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.489 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.536 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 85.0 m95 -160.16 120.33 2.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.877 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -131.73 151.89 51.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -91.47 142.54 27.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.81 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -156.86 158.61 28.94 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.463 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.457 HG22 ' OG1' ' A' ' 61' ' ' THR . 50.5 t -104.65 131.04 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 111.133 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.1 tmm? -136.26 112.2 9.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.3 t30 59.35 38.1 23.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.42 -38.17 3.17 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.446 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 87.3 t -77.42 126.79 38.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 111.201 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.457 ' OG1' HG22 ' A' ' 56' ' ' VAL . 33.2 m -107.57 142.92 36.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.469 ' H ' HD12 ' A' ' 34' ' ' LEU . . . -163.09 173.52 39.29 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.483 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.4 mt -95.77 128.07 42.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.839 0.352 . . . . 0.0 110.922 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.45 ' HE2' HG21 ' A' ' 69' ' ' VAL . 23.2 p90 -130.34 148.98 72.06 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.715 0.769 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -70.03 142.75 47.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.594 2.196 . . . . 0.0 112.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.82 11.83 45.22 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.443 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -99.38 -12.91 19.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.796 0.331 . . . . 0.0 110.893 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -108.17 17.6 22.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.45 HG21 ' HE2' ' A' ' 64' ' ' PHE . 4.7 m -139.17 173.55 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 -145.74 167.05 24.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.857 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 96.7 p -102.12 112.83 25.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.0 pt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.138 179.958 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 121.639 0.6 . . . . 0.0 112.331 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.73 -31.63 20.28 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.684 2.256 . . . . 0.0 112.373 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.555 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 38.0 p-90 -68.99 -22.95 64.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.871 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.42 145.07 87.37 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.0 Cg_endo -69.77 136.93 34.2 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.753 2.302 . . . . 0.0 112.362 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.451 ' C ' ' O ' ' A' ' 13' ' ' PRO . 5.2 ptt85 -34.31 -48.2 0.33 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -148.44 174.19 12.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 23.5 p90 -169.14 151.39 4.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.936 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -49.67 -68.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -151.24 -179.67 7.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.29 144.07 44.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.0 m -127.87 170.36 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.129 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 21' ' ' VAL . 6.7 p -136.69 127.37 41.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.15 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.08 112.35 9.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.129 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 12.2 pt -92.84 -7.54 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -136.94 166.12 24.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.951 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -85.23 141.7 29.94 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.827 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.408 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 83.6 t80 -151.96 118.25 5.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.916 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 91.3 m -104.83 111.98 24.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.128 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -43.94 150.28 0.28 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.997 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -115.91 -47.01 2.8 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.877 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.47 149.64 24.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 64.6 mm-40 -48.47 -28.35 3.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.873 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -89.21 43.23 1.13 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -143.27 159.53 42.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.566 HD23 ' N ' ' A' ' 35' ' ' SER . 1.7 tt -116.87 130.74 56.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.906 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.566 ' N ' HD23 ' A' ' 34' ' ' LEU . 22.5 t -97.41 144.21 27.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.905 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -164.83 150.3 9.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 18.5 mt-30 -105.46 153.54 21.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -45.52 110.11 0.22 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.96 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.53 36.87 1.25 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.6 141.8 48.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.719 0.295 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -92.18 112.86 26.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.087 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.707 HG21 ' CE2' ' A' ' 64' ' ' PHE . 45.5 mt -115.89 125.25 72.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -89.22 106.03 18.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.9 t -68.05 120.62 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.106 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 12.8 pt -121.45 -14.97 7.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.172 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.4 ttmt -132.78 122.2 24.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 53' ' ' TYR . 18.7 mmtt -114.55 102.72 10.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -90.59 143.44 26.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -40.07 -48.2 2.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 -71.88 -178.1 2.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.27 62.71 4.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -152.28 118.97 5.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.48 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 4.4 m-85 -120.99 160.6 23.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HG3' HD22 ' A' ' 63' ' ' LEU . 7.5 tt0 -112.28 123.46 50.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.937 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 61' ' ' THR . . . -134.27 166.46 24.11 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.463 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 ' OG1' ' A' ' 61' ' ' THR . 65.1 t -107.9 124.42 64.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.9 0.381 . . . . 0.0 111.157 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.8 tmm? -129.79 106.29 8.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.798 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 4.5 t30 61.24 39.8 15.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.72 -30.01 3.96 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.482 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.9 t -82.59 115.98 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.92 0.39 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 55' ' ' GLY . 3.4 m -109.77 143.43 39.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -172.16 163.72 36.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.447 HD22 ' HG3' ' A' ' 54' ' ' GLU . 2.1 mm? -68.56 150.15 48.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.878 0.37 . . . . 0.0 110.922 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.707 ' CE2' HG21 ' A' ' 42' ' ' ILE . 5.3 p90 -162.17 151.42 13.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.676 0.75 . . . . 0.0 110.872 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 136.79 33.87 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.708 2.272 . . . . 0.0 112.308 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -75.44 -42.29 27.94 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.477 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -51.06 -29.32 12.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.895 0.378 . . . . 0.0 110.917 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.408 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 10.5 m-85 -71.62 -30.06 65.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.9 m -110.0 137.15 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.12 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 71' ' ' SER . 0.4 OUTLIER -101.52 131.39 47.7 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.404 ' N ' ' OE2' ' A' ' 70' ' ' GLU . 19.2 m -74.6 103.3 4.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.7 pt . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.578 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.139 0 CA-C-O 121.537 0.557 . . . . 0.0 112.402 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -39.32 6.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.244 . . . . 0.0 112.361 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.578 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 41.9 p-90 -58.13 -38.25 76.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.53 143.15 20.56 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.51 0.672 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 135.43 30.62 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.2 mtm180 -87.06 36.05 0.72 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.3 t -171.51 105.99 0.22 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.827 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 19.9 p90 -157.7 171.21 20.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.7 mt -85.8 -47.15 9.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.451 ' C ' ' OE2' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -168.84 174.26 6.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.9 pttm -116.98 161.21 19.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 33.9 m -148.67 160.97 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.11 139.68 40.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.184 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.19 95.59 6.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.101 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.532 HG13 ' CD2' ' A' ' 24' ' ' TYR . 38.7 pt -69.67 -23.89 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.137 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.532 ' CD2' HG13 ' A' ' 23' ' ' ILE . 64.3 m-85 -124.23 160.41 28.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.927 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.65 100.62 13.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.461 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 89.4 t80 -109.74 130.19 55.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.418 ' O ' ' CE2' ' A' ' 26' ' ' TYR . 15.4 t -93.43 -175.16 3.72 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.081 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.41 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -114.52 130.52 56.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.941 179.938 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -102.48 -52.2 3.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.884 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -96.86 145.32 25.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -49.43 -24.01 1.79 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.03 47.86 1.23 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -146.37 172.16 13.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.852 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.669 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.5 tt -129.3 133.43 47.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.857 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.6 t -100.24 141.33 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.825 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 11.3 p90 -155.32 174.81 14.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.934 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -127.36 165.32 19.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.933 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -57.97 109.55 0.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.89 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.56 45.75 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -145.13 119.25 9.44 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.652 0.263 . . . . 0.0 111.205 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.502 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -80.7 139.07 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.126 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.3 mt -129.77 117.98 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -72.21 107.17 4.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.484 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 59.6 t -73.68 105.79 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.4 pt -93.65 -15.31 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.043 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 9.8 tptt -141.72 143.8 33.72 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.834 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -134.58 116.33 14.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -97.16 152.1 19.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.841 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.01 -43.42 29.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -75.75 176.04 8.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -76.2 70.17 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.481 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.0 m95 -163.34 119.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 110.891 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.471 ' HB3' HG13 ' A' ' 44' ' ' VAL . 4.3 m-85 -120.55 155.11 34.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.432 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 19.8 tt0 -103.77 118.3 36.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.35 160.53 25.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.408 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 85.4 t -101.27 139.73 21.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.764 0.316 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.1 ttp -140.02 111.78 7.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.879 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.8 t30 49.24 38.65 13.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.03 -29.97 6.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.66 ' O ' HD11 ' A' ' 34' ' ' LEU . 94.6 t -79.81 118.92 28.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.927 0.394 . . . . 0.0 111.196 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.4 m -108.98 139.64 43.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.669 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.37 163.23 36.0 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.526 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -81.19 135.45 35.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.726 0.298 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.484 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 45.5 p90 -136.34 152.96 76.01 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.689 0.756 . . . . 0.0 110.842 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 132.4 23.26 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.627 2.218 . . . . 0.0 112.392 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.39 -1.13 41.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.554 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -86.85 -33.71 19.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.439 ' O ' HG13 ' A' ' 69' ' ' VAL . 69.7 m-85 -87.11 29.53 0.83 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.977 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 68' ' ' TYR . 20.4 m -157.38 142.28 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -118.49 164.87 14.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.965 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 p -92.89 132.63 36.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.872 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.464 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.121 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.552 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo . . . . . 0 N--CA 1.465 -0.158 0 CA-C-O 121.517 0.549 . . . . 0.0 112.343 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.26 4.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.602 2.201 . . . . 0.0 112.367 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.552 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 64.4 p-90 -60.46 -40.21 90.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.012 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.484 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -40.21 144.17 0.58 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.627 0.727 . . . . 0.0 111.018 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.4 Cg_endo -69.9 140.26 41.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.618 2.212 . . . . 0.0 112.294 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -65.39 -45.06 85.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 73.2 m -115.22 150.97 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.455 ' HA ' HG22 ' A' ' 45' ' ' ILE . 10.8 p90 -169.41 147.44 3.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.837 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -56.11 -52.94 62.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.931 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -165.0 170.83 14.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -103.6 155.9 18.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.5 m -149.06 138.98 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.159 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.4 p -110.87 127.36 68.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.17 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.83 123.38 24.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.122 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.8 pt -97.68 -34.56 4.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -108.0 178.12 4.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -95.54 126.39 40.8 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -126.0 134.48 51.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.906 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.6 m -116.75 111.96 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.135 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.08 127.07 9.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -90.17 -57.2 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -94.72 -177.36 4.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -78.26 -28.8 47.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.447 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 8.7 m-20 -85.62 23.95 1.3 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLU . . . . . 0.447 ' OE1' ' C ' ' A' ' 32' ' ' ASP . 1.5 mp0 -114.69 177.89 4.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.934 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.649 HD23 ' N ' ' A' ' 35' ' ' SER . 2.7 tt -132.16 134.2 45.11 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.915 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.649 ' N ' HD23 ' A' ' 34' ' ' LEU . 87.6 p -97.67 127.71 43.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -150.51 170.4 19.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.907 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -139.1 162.23 35.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -43.86 109.35 0.14 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 106.61 44.22 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -121.35 125.4 46.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.336 . . . . 0.0 111.115 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.9 mm -82.75 100.1 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.015 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.659 HG21 ' CZ ' ' A' ' 64' ' ' PHE . 32.6 mt -105.95 131.16 56.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.146 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.412 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 79.4 m-85 -99.34 104.11 15.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.931 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.674 HG13 ' HB3' ' A' ' 53' ' ' TYR . 75.2 t -67.54 124.43 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.179 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.455 HG22 ' HA ' ' A' ' 16' ' ' TYR . 8.9 pt -124.77 -25.37 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.131 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.38 152.99 42.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 6.0 mtmp? -128.56 151.05 49.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.855 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB2' ' A' ' 52' ' ' TRP . 2.6 m-20 -126.47 -174.69 3.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.871 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -94.22 -31.54 14.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.607 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -95.34 39.29 1.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.55 63.14 5.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.531 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.607 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 95.0 m95 -134.75 96.97 3.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.674 ' HB3' HG13 ' A' ' 44' ' ' VAL . 11.8 m-85 -91.63 137.63 32.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.455 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.4 tt0 -96.67 111.63 23.71 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.842 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -124.65 171.71 16.81 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.412 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.8 t -110.42 134.66 51.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.891 0.377 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -140.61 111.31 6.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.87 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.1 t30 59.29 39.8 22.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.847 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.62 -38.17 2.93 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.441 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 98.7 t -75.62 127.43 37.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.999 0.428 . . . . 0.0 111.086 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.403 HG22 ' N ' ' A' ' 62' ' ' GLY . 38.3 m -106.46 153.91 21.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.16 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 61' ' ' THR . . . -177.1 170.03 42.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 13.6 mt -98.89 141.25 31.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.818 0.342 . . . . 0.0 110.912 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.659 ' CZ ' HG21 ' A' ' 42' ' ' ILE . 20.7 p90 -139.58 154.39 71.29 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.744 0.783 . . . . 0.0 110.838 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.456 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 53.9 Cg_endo -69.83 140.69 43.05 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.584 2.189 . . . . 0.0 112.349 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -80.59 41.17 2.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 -126.37 -43.53 1.76 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.901 0.382 . . . . 0.0 110.898 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -69.02 -23.65 64.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.963 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.8 m -113.66 148.83 16.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.156 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -108.55 155.52 20.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.973 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 44.6 p -99.56 100.67 11.71 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.79 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.6 pt . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.102 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.672 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 52.9 Cg_endo . . . . . 0 N--CA 1.466 -0.118 0 CA-C-O 121.619 0.591 . . . . 0.0 112.25 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -47.86 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.596 2.197 . . . . 0.0 112.378 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 34.0 p-90 -57.07 -20.83 27.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.874 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.672 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -66.84 144.06 98.36 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.503 0.668 . . . . 0.0 111.124 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 14' ' ' ARG . 54.0 Cg_endo -69.77 105.8 1.55 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.622 2.215 . . . . 0.0 112.434 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.452 ' C ' ' O ' ' A' ' 13' ' ' PRO . 4.4 ptt85 -34.41 -46.54 0.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 t -120.23 149.75 41.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.464 ' CB ' HG22 ' A' ' 45' ' ' ILE . 38.4 p90 -169.01 163.12 11.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.922 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mt -60.96 -66.96 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.401 ' O ' ' CD1' ' A' ' 16' ' ' TYR . 11.2 pt-20 -146.8 -176.41 5.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.945 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.448 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 16.3 ttmt -127.91 127.34 43.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.839 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.536 HG22 HG23 ' A' ' 44' ' ' VAL . 16.5 m -122.03 158.97 25.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.166 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.77 124.12 64.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -54.72 138.36 42.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.077 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.8 pt -121.0 -13.51 8.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.154 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -132.64 147.65 52.34 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.04 105.65 3.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -113.56 141.81 46.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.954 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 50.9 m -122.73 110.98 16.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 24.7 pttt -48.68 151.05 1.24 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.953 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -97.33 -45.23 6.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.877 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.63 171.71 8.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -66.63 -7.02 17.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.892 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -87.4 -23.83 24.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.929 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -90.55 -178.35 5.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.42 150.76 50.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.802 ' N ' HD23 ' A' ' 34' ' ' LEU . 21.8 t -116.53 139.32 50.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -156.34 152.27 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.904 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -113.32 153.27 28.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.956 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -43.08 99.19 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.86 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 123.6 28.22 1.33 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.479 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.05 138.34 46.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.719 0.295 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.1 mm -95.81 127.61 47.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.169 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 64.5 mt -127.65 133.98 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.196 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 72.5 m-85 -95.44 98.54 10.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 53' ' ' TYR . 96.9 t -63.65 117.85 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.522 HD11 ' OE2' ' A' ' 54' ' ' GLU . 6.5 pt -116.58 -25.14 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.478 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 28.6 ttmt -128.42 142.8 50.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 21.3 mtpp -130.21 120.62 24.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.848 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -94.77 152.67 18.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -39.13 -47.12 1.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -81.98 -179.42 7.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.769 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.435 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -75.21 70.52 1.84 Allowed Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.472 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 58.3 m95 -149.74 122.77 8.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 111.043 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.77 ' HB3' HG13 ' A' ' 44' ' ' VAL . 7.0 m-85 -120.29 151.43 39.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.91 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.522 ' OE2' HD11 ' A' ' 45' ' ' ILE . 2.8 tt0 -104.02 113.58 27.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -131.48 154.43 20.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.553 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.538 HG22 ' OG1' ' A' ' 61' ' ' THR . 93.0 t -96.64 112.36 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.326 . . . . 0.0 111.176 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -118.11 112.0 19.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 22.5 t30 65.5 35.81 7.04 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.06 -31.57 3.1 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 76.7 t -83.69 129.98 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.826 0.345 . . . . 0.0 111.158 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.538 ' OG1' HG22 ' A' ' 56' ' ' VAL . 12.8 m -109.51 143.33 39.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.8 148.61 12.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.521 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.422 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.8 mm? -66.28 135.19 54.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -140.35 148.48 54.09 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.612 0.72 . . . . 0.0 110.91 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 132.47 23.22 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.4 -10.29 69.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -79.72 -28.35 40.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.881 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -89.21 20.9 3.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.8 m -138.06 178.43 4.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.126 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 71' ' ' SER . 6.3 tm-20 -143.69 160.07 41.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.828 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.472 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 9.7 m -104.11 113.64 27.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.886 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.5 pt . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 -179.992 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.471 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 52.7 Cg_endo . . . . . 0 C--O 1.23 0.116 0 CA-C-O 121.62 0.591 . . . . 0.0 112.293 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.73 2.287 . . . . 0.0 112.373 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.471 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 50.3 p-90 -54.85 -29.79 56.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.954 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.461 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -61.06 156.07 51.02 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.497 0.665 . . . . 0.0 111.134 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD2' ' HB1' ' A' ' 12' ' ' ALA . 53.5 Cg_endo -69.81 151.14 68.67 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.707 2.271 . . . . 0.0 112.26 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 68.2 mtt180 -72.51 -48.87 37.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.841 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.2 t -129.22 98.61 4.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.836 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -105.32 143.35 33.62 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.93 -67.31 0.27 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.933 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -143.31 178.9 7.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.888 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.618 ' HE2' HG23 ' A' ' 41' ' ' ILE . 27.9 tttt -123.12 141.98 51.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.482 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.0 m -137.54 174.05 11.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.045 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.495 HG12 HG23 ' A' ' 72' ' ' ILE . 12.6 p -134.13 150.6 31.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.12 96.92 10.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.036 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.472 HG13 ' CD2' ' A' ' 24' ' ' TYR . 32.1 pt -73.24 -12.27 15.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.472 ' CD2' HG13 ' A' ' 23' ' ' ILE . 60.5 m-85 -131.53 172.25 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.93 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.24 96.49 6.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 29.5 t80 -98.96 155.35 17.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -123.81 131.59 53.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.428 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -78.31 125.95 30.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -96.68 -53.27 3.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.807 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.438 ' NZ ' ' HA ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -96.21 164.47 12.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.959 179.934 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.08 -28.43 67.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -86.76 42.97 1.05 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.966 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -148.01 152.95 38.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.894 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.582 HD23 ' N ' ' A' ' 35' ' ' SER . 1.8 tt -112.17 130.67 55.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.792 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.582 ' N ' HD23 ' A' ' 34' ' ' LEU . 55.7 p -96.16 134.03 39.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -154.96 169.18 24.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.909 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -126.25 161.19 28.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -50.47 108.01 0.2 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.892 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.48 32.96 2.59 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.476 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.61 145.67 34.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.71 0.291 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.618 HG23 ' HE2' ' A' ' 19' ' ' LYS . 22.0 mm -102.37 126.55 56.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.129 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.489 HG21 ' CE2' ' A' ' 64' ' ' PHE . 19.5 mt -134.76 141.99 41.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.112 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -104.16 124.02 48.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.899 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.6 t -77.62 117.44 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.042 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.3 pt -116.99 -12.2 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.463 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 17.7 tttm -153.95 151.32 29.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -134.16 111.45 10.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.921 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -75.26 164.88 25.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -40.72 -46.61 2.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.34 -179.83 7.28 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.803 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.449 ' O ' ' CZ ' ' A' ' 53' ' ' TYR . . . -60.82 -7.66 8.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.476 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -69.88 128.28 35.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.852 0.358 . . . . 0.0 110.93 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.449 ' CZ ' ' O ' ' A' ' 51' ' ' GLY . 3.8 m-85 -126.68 148.72 49.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.951 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.463 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.2 tt0 -90.88 130.3 36.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -146.24 167.19 27.96 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.437 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.7 t -108.82 136.1 45.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.864 0.364 . . . . 0.0 111.146 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.6 ttp -143.48 122.62 12.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.882 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.461 ' ND2' ' O ' ' A' ' 58' ' ' ASN . 2.8 p-10 43.81 39.76 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.93 -30.74 3.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.06 117.01 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 111.084 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 10.3 m -99.38 135.18 41.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -164.5 163.15 36.0 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.459 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.7 mt -89.88 124.61 34.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.81 0.338 . . . . 0.0 110.917 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.489 ' CE2' HG21 ' A' ' 42' ' ' ILE . 35.8 p90 -119.83 144.65 37.74 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.619 0.724 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 138.63 38.17 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.667 2.244 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.08 3.69 56.85 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.521 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -89.89 -24.58 21.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.925 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -98.12 26.0 5.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.926 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.2 m -144.27 179.97 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.086 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.416 ' CG ' HD13 ' A' ' 23' ' ' ILE . 2.2 mm-40 -150.69 125.91 10.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 31.3 p -64.35 82.35 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.599 HD13 ' N ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.126 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.583 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.199 0 CA-C-O 121.617 0.59 . . . . 0.0 112.327 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -47.6 0.9 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.41 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.6 p-90 -55.24 -40.73 71.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.583 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -47.39 153.1 1.02 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.558 0.694 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.63 146.92 62.47 Favored 'Trans proline' 0 C--O 1.23 0.121 0 C-N-CA 122.744 2.296 . . . . 0.0 112.33 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.9 ptt180 -49.14 -57.89 5.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.844 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 36.1 t -133.85 149.88 51.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.1 p90 -149.2 159.72 44.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.9 mt -66.79 -61.06 2.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.873 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.11 175.72 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.439 ' HE3' HG23 ' A' ' 41' ' ' ILE . 31.1 tttt -121.46 151.72 39.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.971 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.478 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 29.1 m -145.36 177.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.177 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.622 HG12 HG23 ' A' ' 72' ' ' ILE . 8.3 p -137.1 139.18 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.29 87.99 4.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 24' ' ' TYR . 30.2 pt -64.52 -28.02 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.135 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.584 ' CE2' HD12 ' A' ' 23' ' ' ILE . 55.3 m-85 -128.97 156.31 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -81.34 120.71 25.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.918 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.56 ' CE1' ' O ' ' A' ' 27' ' ' THR . 5.4 t80 -129.28 124.09 33.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.56 ' O ' ' CE1' ' A' ' 26' ' ' TYR . 5.7 t -84.85 172.63 11.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.125 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 17.2 pttm -107.97 124.24 49.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -80.19 -29.68 38.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.1 mttp -126.66 150.29 49.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.864 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -51.72 -28.02 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.916 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.544 ' OD2' HD12 ' A' ' 63' ' ' LEU . 15.3 t70 -70.92 -38.43 72.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.892 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -66.52 171.18 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.771 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.4 tt -122.68 137.96 54.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.976 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -108.21 138.49 44.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -151.84 172.29 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -127.73 154.39 45.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -38.22 123.79 1.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.07 52.85 2.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.449 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.75 128.58 42.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.723 0.297 . . . . 0.0 111.115 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.439 HG23 ' HE3' ' A' ' 19' ' ' LYS . 31.9 mm -84.19 125.63 40.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.076 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.0 mt -134.22 131.18 55.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.172 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -96.51 114.15 25.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.5 t -72.4 123.29 26.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 16.2 pt -120.78 -28.02 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.127 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 30.5 tptt -123.1 140.36 53.1 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -130.71 105.32 7.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -86.64 154.06 21.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.915 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -44.98 -56.81 4.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.96 176.75 3.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.884 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -74.33 73.71 1.32 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' TRP . . . . . 0.533 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 95.7 m95 -158.56 112.22 2.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.797 0.332 . . . . 0.0 110.993 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -112.6 154.6 25.77 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -108.8 120.65 43.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.872 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -136.0 173.36 21.92 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -105.18 132.8 51.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.814 0.34 . . . . 0.0 111.156 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.11 109.71 7.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 t30 55.15 39.79 31.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.58 -31.23 3.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.446 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.46 ' O ' HD11 ' A' ' 34' ' ' LEU . 89.7 t -79.12 121.16 31.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 111.141 -179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.0 m -99.47 150.07 22.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.771 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -178.5 169.58 41.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.485 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.544 HD12 ' OD2' ' A' ' 32' ' ' ASP . 5.4 mt -94.47 138.32 32.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.843 0.354 . . . . 0.0 110.992 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -139.85 150.85 64.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.592 0.71 . . . . 0.0 110.959 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.533 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.5 Cg_endo -69.76 139.73 40.94 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.711 2.274 . . . . 0.0 112.355 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.73 6.28 47.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.509 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -92.58 -30.83 15.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.776 0.322 . . . . 0.0 110.79 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -90.35 25.06 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.957 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 21.0 m -148.34 142.73 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.113 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLU . . . . . 0.649 ' OE2' HG22 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -112.37 141.51 46.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.888 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.428 ' C ' ' OE1' ' A' ' 70' ' ' GLU . 74.7 m -78.25 79.69 4.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.649 HG22 ' OE2' ' A' ' 70' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.109 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.9 Cg_endo . . . . . 0 C--O 1.233 0.246 0 CA-C-O 121.597 0.582 . . . . 0.0 112.302 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.63 21.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.312 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' TRP . . . . . 0.492 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 21.9 p-90 -100.46 -31.31 11.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.878 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.47 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -72.55 149.02 90.76 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.626 0.727 . . . . 0.0 111.109 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.469 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 54.2 Cg_endo -69.66 168.19 22.14 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.66 2.24 . . . . 0.0 112.412 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 -83.97 -49.67 8.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.1 t -128.79 141.33 51.34 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.859 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -150.66 160.09 44.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.947 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.8 mt -59.83 -62.1 2.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -150.15 175.4 11.78 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.882 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.603 ' HD2' HG21 ' A' ' 41' ' ' ILE . 6.4 ttpm? -120.91 140.42 51.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.776 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.25 158.21 43.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.102 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.6 p -122.16 116.7 49.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.173 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -57.69 148.39 24.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.091 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.408 HD12 ' CE2' ' A' ' 24' ' ' TYR . 3.2 pt -124.71 -33.01 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.183 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE2' HD12 ' A' ' 23' ' ' ILE . 42.7 m-85 -117.92 165.97 13.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.967 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -86.59 139.72 30.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.868 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -140.26 128.71 22.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.917 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 35.3 m -111.11 111.22 22.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -53.63 138.32 34.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.95 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -92.38 -28.58 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 mmtp -112.77 -177.04 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.931 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -99.58 34.37 2.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -128.69 -38.82 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -68.85 -175.02 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.8 tt -126.12 146.4 49.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.927 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.497 ' N ' HD23 ' A' ' 34' ' ' LEU . 3.8 m -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.917 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -147.1 159.66 43.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.804 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -113.03 166.64 11.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.96 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -51.97 124.7 13.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 92.61 36.79 6.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.473 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.72 116.12 21.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.668 0.27 . . . . 0.0 111.134 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.603 HG21 ' HD2' ' A' ' 19' ' ' LYS . 3.6 mp -82.37 143.55 11.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.118 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.472 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 21.3 mt -135.37 132.61 52.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.076 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.469 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 76.7 m-85 -85.71 100.87 12.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.972 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.414 HG13 ' HB3' ' A' ' 53' ' ' TYR . 86.4 t -69.74 111.25 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.199 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 pt -101.73 -19.93 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.044 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -139.81 138.63 35.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.498 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 58.3 mttt -130.67 110.02 11.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 49' ' ' ASP . 65.8 m-80 -83.0 151.06 25.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 48' ' ' ASN . 34.1 m-20 -36.0 -59.64 0.59 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -72.79 179.8 3.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.37 74.94 0.68 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.532 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -156.76 110.94 2.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.935 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.498 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.5 OUTLIER -123.47 148.83 45.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.881 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -93.52 128.66 39.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.906 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.472 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -143.94 152.14 23.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.616 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.5 t -96.43 143.06 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.931 0.396 . . . . 0.0 111.093 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.401 ' O ' ' C ' ' A' ' 58' ' ' ASN . 4.8 tmm? -145.15 127.01 15.38 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 57' ' ' MET . 21.2 t-20 38.24 46.12 0.85 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.973 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.91 -40.97 3.01 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.476 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.4 t -75.84 124.12 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.0 0.429 . . . . 0.0 111.126 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.616 ' OG1' HG22 ' A' ' 56' ' ' VAL . 31.8 m -107.55 150.16 27.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.172 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . 0.679 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.47 152.97 11.16 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.477 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.1 mp -72.71 151.96 41.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.864 0.364 . . . . 0.0 110.993 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.566 ' HE2' HG11 ' A' ' 69' ' ' VAL . 34.1 p90 -151.46 147.51 20.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.595 0.712 . . . . 0.0 110.925 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.86 133.04 24.44 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.654 2.236 . . . . 0.0 112.365 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.06 49.02 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.484 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -121.55 -29.86 4.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -94.3 3.4 55.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.994 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.566 HG11 ' HE2' ' A' ' 64' ' ' PHE . 19.3 m -112.09 160.86 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.113 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -135.35 124.65 24.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 66.2 m -58.05 113.33 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG2' HG12 ' A' ' 21' ' ' VAL . 44.3 pt . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.131 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.554 -0.218 . . . . 0.0 112.554 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 m -63.69 176.93 0.79 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.839 0.352 . . . . 0.0 110.869 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.9 m -112.27 114.95 28.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.834 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 152.74 -136.28 5.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 m -85.25 124.5 31.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.835 0.35 . . . . 0.0 110.826 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 27.6 p -110.45 82.32 1.58 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.857 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -122.1 91.58 0.47 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -131.56 144.2 52.37 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.508 0.67 . . . . 0.0 110.886 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.602 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.0 Cg_endo -69.85 164.56 34.18 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.654 2.236 . . . . 0.0 112.286 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 -31.02 20.97 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.712 2.275 . . . . 0.0 112.304 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 51.2 p-90 -76.57 -11.73 59.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.602 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -89.01 144.25 32.48 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.487 0.661 . . . . 0.0 111.197 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.84 132.55 23.44 Favored 'Trans proline' 0 C--O 1.231 0.132 0 C-N-CA 122.62 2.214 . . . . 0.0 112.322 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 34.6 mtm180 -57.07 -40.17 76.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -120.55 148.86 43.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.868 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -165.46 166.24 18.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -70.05 -61.91 1.59 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -150.96 -177.62 6.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.842 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.1 ttmm -118.23 144.78 45.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.649 HG22 ' O ' ' A' ' 42' ' ' ILE . 27.9 m -142.44 152.93 17.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.198 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 21' ' ' VAL . 3.6 p -127.71 115.73 40.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.057 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -52.05 138.53 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.0 pt -113.62 -25.13 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -126.11 159.37 33.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 -75.78 127.53 33.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CE1' ' HG3' ' A' ' 65' ' ' PRO . 89.2 t80 -131.62 109.81 10.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.97 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.5 m -93.41 110.49 22.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.188 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.422 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 1.6 pptp? -58.69 157.56 9.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -101.66 -45.83 5.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 pttt -128.43 155.96 43.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -44.11 -32.37 1.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.92 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.41 -42.49 70.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -81.05 178.66 8.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.738 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -123.6 140.86 52.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.738 ' N ' HD23 ' A' ' 34' ' ' LEU . 99.5 p -110.82 128.1 55.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 4.2 p90 -149.96 168.03 24.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -121.09 158.28 28.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -51.62 96.84 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.83 34.11 0.49 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.424 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.55 124.41 45.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.796 0.332 . . . . 0.0 111.043 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.688 ' N ' HD12 ' A' ' 41' ' ' ILE . 2.0 mp -82.39 101.41 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.649 ' O ' HG22 ' A' ' 20' ' ' VAL . 23.0 mt -95.64 122.28 46.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.075 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -83.96 97.29 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.21 133.03 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.169 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.448 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.0 pt -127.25 -29.0 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -135.25 148.92 49.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.519 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 5.7 mtmp? -135.74 105.39 6.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -66.76 170.52 6.37 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -50.54 -54.58 21.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.815 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' A' ' 52' ' ' TRP . 16.2 m-20 -84.37 174.71 9.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.828 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.44 76.16 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.504 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.484 ' N ' ' O ' ' A' ' 50' ' ' ASP . 93.2 m95 -156.23 108.89 2.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.801 0.334 . . . . 0.0 110.916 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.519 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.4 OUTLIER -113.58 149.38 34.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.448 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 6.2 tt0 -100.13 128.57 46.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.912 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.41 167.68 29.1 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.448 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.6 t -104.72 133.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 0.0 111.2 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.21 125.01 22.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 50.41 30.7 4.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.908 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.09 -27.06 8.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.6 t -88.46 128.71 40.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.942 0.401 . . . . 0.0 111.143 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.72 151.48 21.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.108 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -179.95 153.05 11.46 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.446 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.96 133.68 36.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 110.869 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.536 ' CE1' HG21 ' A' ' 42' ' ' ILE . 47.5 p90 -132.85 150.53 75.94 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.651 0.738 . . . . 0.0 110.866 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.435 ' HG3' ' CE1' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.8 131.54 21.39 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.753 2.302 . . . . 0.0 112.421 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.02 51.17 3.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -130.42 -37.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.776 0.322 . . . . 0.0 110.915 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -84.25 10.52 10.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.957 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -123.1 161.55 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.201 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -136.8 126.69 25.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.5 m -69.65 127.51 33.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.841 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 3.4 pt -116.5 -10.64 12.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.9 t -134.61 116.22 14.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 163.51 -167.99 37.95 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.463 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -8.89 24.76 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 64.8 p -88.54 122.06 31.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.928 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 t -74.51 105.97 5.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.788 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.435 179.988 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.3 p -105.72 154.32 20.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.407 . . . . 0.0 110.781 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.8 m -95.53 132.91 40.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.82 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.04 117.71 0.32 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.47 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.4 t -118.02 -46.23 2.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.79 0.329 . . . . 0.0 110.85 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.9 m -90.89 103.89 16.54 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.86 159.36 49.41 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -48.27 154.22 1.12 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.551 0.691 . . . . 0.0 110.899 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.556 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.6 Cg_endo -69.85 169.55 18.76 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.641 2.227 . . . . 0.0 112.379 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 -41.63 4.21 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.36 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 54.8 p-90 -57.15 -18.79 16.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.75 61.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.544 0.687 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 133.24 25.19 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.627 2.218 . . . . 0.0 112.355 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 52.9 mtm180 -72.57 -33.55 66.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.5 t -112.94 118.1 33.93 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.815 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.474 ' HB3' HG22 ' A' ' 45' ' ' ILE . 22.3 p90 -160.98 142.43 11.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.969 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -56.8 -60.53 3.43 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -161.07 -178.12 6.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 ptpp? -114.84 168.51 9.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.923 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.44 ' HA ' HD13 ' A' ' 72' ' ' ILE . 27.4 m -146.93 156.88 10.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.178 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 70' ' ' GLU . 14.8 p -113.34 142.16 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.124 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.88 106.87 15.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.096 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.473 HD12 ' CE2' ' A' ' 24' ' ' TYR . 28.2 pt -80.84 -15.76 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.473 ' CE2' HD12 ' A' ' 23' ' ' ILE . 58.5 m-85 -138.81 158.72 43.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.84 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 98.66 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.797 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.449 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 61.3 t80 -91.93 133.98 35.2 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.998 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 38.9 m -112.29 120.21 40.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.68 135.45 52.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.915 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -103.2 -33.33 9.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -113.81 159.28 19.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -62.67 -22.15 66.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -90.94 38.54 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.931 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -140.14 174.92 10.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -124.88 135.69 53.11 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.457 ' N ' HD23 ' A' ' 34' ' ' LEU . 84.8 p -104.41 137.87 41.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.845 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 13.8 p90 -161.57 159.77 28.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.827 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -109.16 173.46 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -66.01 110.35 2.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.85 39.4 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.437 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.41 149.89 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.791 0.329 . . . . 0.0 111.097 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 45.6 mm -102.78 123.47 56.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.411 HG21 ' CE1' ' A' ' 64' ' ' PHE . 49.4 mt -126.9 125.54 66.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.103 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -84.18 120.07 25.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.4 t -82.45 114.83 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.474 HG22 ' HB3' ' A' ' 16' ' ' TYR . 31.6 pt -110.56 -14.54 10.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.172 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.44 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 32.1 tttp -146.19 144.49 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.908 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.581 ' HE2' ' CE1' ' A' ' 53' ' ' TYR . 13.2 mtpt -136.51 110.65 8.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.889 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -82.41 161.42 22.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -55.63 -36.82 67.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -84.57 175.65 9.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.892 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -72.15 67.62 1.15 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.392 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.496 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 65.5 m95 -158.8 121.35 3.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.731 0.3 . . . . 0.0 110.999 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.581 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 6.4 m-85 -118.65 154.9 31.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.936 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.44 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 16.7 tt0 -104.19 123.55 47.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 61' ' ' THR . . . -143.24 167.91 26.3 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.64 133.27 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.115 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -139.23 116.52 11.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.8 t30 55.7 39.11 30.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.31 -36.61 2.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.446 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 88.2 t -76.31 123.91 33.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.983 0.42 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.49 HG23 ' O ' ' A' ' 55' ' ' GLY . 5.3 m -107.62 146.38 32.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.114 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.59 169.0 41.41 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.544 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.459 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.2 mm? -88.52 127.16 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.881 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.411 ' CE1' HG21 ' A' ' 42' ' ' ILE . 49.1 p90 -136.63 144.75 48.39 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.666 0.746 . . . . 0.0 110.892 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 143.11 49.71 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.707 2.272 . . . . 0.0 112.337 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.484 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -83.98 7.26 71.42 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.427 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.0 m-20 -90.24 -35.24 15.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.871 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -80.1 3.25 21.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.62 172.75 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.163 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.487 ' O ' HG12 ' A' ' 21' ' ' VAL . 13.7 tt0 -142.26 137.03 30.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 49.1 m -69.42 130.59 42.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.849 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.496 HD13 ' H ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -122.48 -14.23 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.156 180.0 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 51.4 p -63.77 -52.25 61.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.28 177.24 18.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.542 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 111.08 2.72 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.5 m -102.66 156.94 17.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 96.2 p -86.81 121.23 29.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.88 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.496 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.386 0 N-CA-C 112.459 -0.256 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 75.7 p -56.02 127.07 28.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.85 0.357 . . . . 0.0 110.817 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.6 m -61.74 118.19 6.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.828 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.74 -131.56 3.79 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 m -157.19 125.67 5.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.923 0.392 . . . . 0.0 110.804 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -93.65 129.01 40.09 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.92 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.58 110.66 0.43 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.457 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -138.52 144.06 40.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.841 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.685 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.7 Cg_endo -69.81 167.21 25.15 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.716 2.277 . . . . 0.0 112.335 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -29.56 23.5 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.301 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.521 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 62.5 p-90 -77.8 -25.94 49.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.853 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.685 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -65.58 151.68 94.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.59 0.709 . . . . 0.0 111.172 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 175.92 7.44 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.666 2.244 . . . . 0.0 112.297 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 10.7 tpp180 -88.29 -51.26 5.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.87 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.2 t -123.53 155.26 37.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.895 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 13.5 p90 -164.84 161.22 20.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 82.5 mt -66.72 -59.9 3.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -156.96 167.67 29.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -102.22 128.73 48.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 44' ' ' VAL . 10.7 m -119.68 164.69 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.144 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.7 p -133.63 140.54 46.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.255 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.439 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -79.88 118.64 21.83 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.075 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.2 pt -91.39 -14.75 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.09 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -136.74 161.36 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -86.23 132.66 33.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.887 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -130.91 144.89 51.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.9 m -118.34 95.44 4.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.241 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.423 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -40.49 135.45 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.866 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -108.77 -54.64 2.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.916 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -79.91 162.47 24.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -69.84 -25.05 63.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -95.94 54.38 1.48 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -149.66 178.29 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.71 HD23 ' N ' ' A' ' 35' ' ' SER . 2.6 tt -131.32 142.43 50.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.926 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.71 ' N ' HD23 ' A' ' 34' ' ' LEU . 59.7 p -108.19 143.36 37.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -166.91 167.99 14.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.774 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -120.34 164.81 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.979 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -55.74 117.97 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 105.25 43.88 1.55 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.95 138.52 52.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.78 0.324 . . . . 0.0 111.12 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 47.9 mm -89.76 129.72 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.164 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.23 145.5 34.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.165 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -106.96 114.17 28.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.442 HG13 ' HB3' ' A' ' 53' ' ' TYR . 43.6 t -77.76 118.03 23.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.149 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.61 HD11 ' OE1' ' A' ' 54' ' ' GLU . 2.9 pt -117.06 -8.88 12.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.5 ttmm -136.36 140.85 43.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.981 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 36.9 mttp -134.89 103.02 5.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' A' ' 50' ' ' ASP . 32.7 m-20 -83.55 38.81 0.64 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.891 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 48' ' ' ASN . 2.4 m-20 36.67 32.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.932 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.463 ' O ' ' CE1' ' A' ' 53' ' ' TYR . 31.0 m-20 -151.89 -175.04 5.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.816 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -76.27 52.99 3.07 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.419 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 96.4 m95 -162.87 106.97 1.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.766 0.317 . . . . 0.0 110.927 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.463 ' CE1' ' O ' ' A' ' 50' ' ' ASP . 4.7 m-85 -120.32 154.82 34.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.94 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.61 ' OE1' HD11 ' A' ' 45' ' ' ILE . 0.1 OUTLIER -98.25 141.14 31.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.88 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' A' ' 54' ' ' GLU . . . -161.85 165.45 35.77 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.413 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.578 HG22 ' OG1' ' A' ' 61' ' ' THR . 56.1 t -107.43 146.13 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.858 0.361 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.3 ttp -155.22 108.18 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.2 t30 68.14 32.96 4.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.65 -23.77 7.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.502 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.1 t -88.29 122.75 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.91 0.386 . . . . 0.0 111.107 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.578 ' OG1' HG22 ' A' ' 56' ' ' VAL . 7.3 m -106.33 148.43 28.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -176.77 163.29 32.18 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.489 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.0 mm? -84.58 125.85 32.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.368 . . . . 0.0 110.909 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -127.19 152.11 75.49 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.683 0.754 . . . . 0.0 110.886 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 143.41 51.08 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.715 2.277 . . . . 0.0 112.289 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -86.56 24.79 7.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.494 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -111.33 -28.81 8.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -87.72 5.08 41.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.439 HG12 ' HA ' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -127.82 173.27 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.127 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.82 135.6 18.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.904 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.8 p -65.77 131.47 46.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.1 pt -113.95 -30.37 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -87.21 89.15 7.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.803 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 59.8 164.06 0.14 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.509 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 1.58 4.34 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.65 2.233 . . . . 0.0 112.34 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 77' ' ' SER . 77.7 p -168.52 162.04 11.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 76' ' ' SER . 98.9 p -37.04 116.16 0.43 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.761 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.483 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.5 m -41.4 141.19 0.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.913 0.387 . . . . 0.0 110.828 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -101.9 118.75 37.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.819 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.75 -78.21 0.53 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.449 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.8 p -54.68 138.76 40.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.882 0.372 . . . . 0.0 110.897 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.0 p -116.3 171.92 7.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.912 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.97 -71.14 1.3 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.492 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -40.45 143.83 0.63 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.633 0.73 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.653 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo -69.81 164.16 35.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.79 2.327 . . . . 0.0 112.278 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.67 -13.68 35.24 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.675 2.25 . . . . 0.0 112.398 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.576 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.9 p-90 -93.93 -34.65 13.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.653 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -51.31 145.78 13.14 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.521 0.677 . . . . 0.0 111.096 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.554 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.7 Cg_endo -69.8 133.68 26.08 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.727 2.285 . . . . 0.0 112.36 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 43.4 mtt180 -59.93 -33.43 71.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.98 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -140.42 137.92 34.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -153.74 161.54 42.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.97 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.598 HD13 ' HG3' ' A' ' 47' ' ' LYS . 5.1 mt -57.14 -71.68 0.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.912 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -151.49 165.74 33.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.634 ' HG2' HD11 ' A' ' 72' ' ' ILE . 15.5 ttpt -100.83 134.39 43.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.02 159.72 26.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.497 HG12 HG23 ' A' ' 72' ' ' ILE . 8.1 p -119.02 132.97 67.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.18 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.639 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -77.76 100.59 6.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.3 pt -75.86 -14.9 15.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -134.1 173.7 11.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -100.3 107.91 19.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.849 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.55 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 70.5 t80 -107.07 134.05 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 28' ' ' LYS . 30.1 m -110.23 111.94 23.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.101 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 27' ' ' THR . 0.0 OUTLIER -36.15 128.99 0.71 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 179.898 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -100.88 -41.07 6.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -104.3 165.01 11.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -67.37 -27.01 66.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 9.6 p-10 -94.21 16.61 14.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.826 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.486 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -106.13 166.12 10.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.943 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -118.37 141.57 48.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.623 ' N ' HD23 ' A' ' 34' ' ' LEU . 2.4 t -107.68 140.33 40.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -158.31 150.6 21.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -102.56 160.78 14.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -46.42 152.35 0.45 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 63.78 36.26 93.08 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.53 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -106.74 166.49 10.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.764 0.316 . . . . 0.0 111.087 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.7 mm -120.2 129.5 75.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.211 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.4 mt -129.54 141.14 47.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.554 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 53.6 m-85 -105.28 92.13 4.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.5 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 86.1 t -58.27 113.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.075 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.7 pt -110.84 -15.15 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.441 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.2 ttmt -140.76 147.46 39.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.598 ' HG3' HD13 ' A' ' 17' ' ' LEU . 64.0 mttt -135.85 147.76 48.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.968 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -125.53 151.09 46.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -39.15 -49.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.867 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -76.56 -176.0 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.21 64.73 4.11 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -148.75 114.79 5.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.478 ' C ' HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -121.23 146.78 46.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.895 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.441 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 4.1 tt0 -96.44 126.63 41.77 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.882 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -140.18 167.45 25.44 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.448 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 t -105.1 143.52 16.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.831 0.348 . . . . 0.0 111.082 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.574 ' HB3' HD21 ' A' ' 34' ' ' LEU . 7.5 tmm? -152.66 112.36 3.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.28 39.71 22.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.956 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.86 -34.68 2.55 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 86.8 t -75.58 126.78 36.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.95 0.405 . . . . 0.0 111.131 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.5 m -104.27 141.38 36.39 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.454 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -174.33 153.89 17.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.517 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 53' ' ' TYR . 5.3 mt -75.63 156.23 35.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.5 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 35.2 p90 -155.79 148.16 17.66 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 130.26 19.13 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.738 2.292 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -71.13 -2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.52 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -86.22 -33.73 20.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.838 0.352 . . . . 0.0 110.911 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.55 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 9.5 m-85 -69.83 -23.59 63.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 22' ' ' ALA . 12.3 m -115.33 175.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.167 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -136.36 162.72 32.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 m -88.22 113.71 24.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.791 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.634 HD11 ' HG2' ' A' ' 19' ' ' LYS . 47.7 pt -84.1 -19.69 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.179 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.2 t -112.71 121.55 45.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 95.77 -158.32 21.96 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.455 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 140.24 42.03 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.698 2.266 . . . . 0.0 112.344 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 93.6 p -64.01 -45.25 89.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.86 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 67.8 p -163.1 173.66 13.22 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.964 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.2 p -113.57 168.15 10.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.899 0.38 . . . . 0.0 110.853 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.3 p -45.67 -65.35 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.887 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.09 60.79 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.541 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.2 m -88.49 152.71 21.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.967 0.413 . . . . 0.0 110.728 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.8 p -138.62 117.56 12.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.879 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.91 -39.77 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.427 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -87.66 145.65 37.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.589 0.709 . . . . 0.0 110.88 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.615 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.3 Cg_endo -69.7 169.33 19.1 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.824 2.35 . . . . 0.0 112.377 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -19.69 35.77 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.731 2.287 . . . . 0.0 112.316 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 42.0 p-90 -90.47 -20.25 22.93 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.942 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.615 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -70.93 148.47 94.59 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.614 0.721 . . . . 0.0 111.151 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 133.45 25.67 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 67.6 mtt85 -43.06 -46.25 5.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.824 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.6 p -145.8 144.16 30.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.3 p90 -134.66 174.6 10.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -76.68 -56.36 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.95 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -154.46 168.94 25.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttt -110.12 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.798 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.7 148.28 22.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.177 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -112.86 131.79 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.32 99.68 2.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.082 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.749 HD12 ' CE2' ' A' ' 24' ' ' TYR . 16.3 pt -73.13 -14.65 16.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.749 ' CE2' HD12 ' A' ' 23' ' ' ILE . 28.9 m-85 -143.56 156.13 44.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.92 162.96 28.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 2.9 t80 -168.84 131.5 1.32 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.946 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 17.4 m -109.84 131.99 54.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.093 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.471 ' HZ3' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -63.67 164.27 10.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.954 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -129.07 -5.74 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.849 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ptpp? -146.6 143.13 28.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -47.11 -23.9 0.57 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -93.45 47.35 1.24 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.818 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -145.26 -179.74 6.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.587 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -126.48 151.16 48.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.924 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.587 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.9 p -121.22 123.99 43.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -140.95 152.59 45.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -110.26 165.02 12.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.961 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -52.64 108.29 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 104.96 39.66 2.27 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.88 21.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.74 0.305 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.8 mm -107.4 111.14 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.201 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.534 HG21 ' CE1' ' A' ' 64' ' ' PHE . 81.3 mt -117.06 141.36 35.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.164 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -105.09 108.85 20.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.971 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -67.11 115.36 4.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.181 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.1 pt -118.17 -18.44 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.14 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 4.1 tmtm? -138.94 146.45 41.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 17.1 mtpp -136.2 112.36 9.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -74.9 173.76 10.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -51.61 -17.52 0.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -112.75 -175.84 2.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.586 ' O ' ' CE2' ' A' ' 53' ' ' TYR . . . -63.31 -10.19 33.93 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.443 ' CH2' ' HD3' ' A' ' 65' ' ' PRO . 59.4 m95 -61.96 122.53 15.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.705 0.288 . . . . 0.0 110.9 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.586 ' CE2' ' O ' ' A' ' 51' ' ' GLY . 19.5 m-85 -123.84 135.55 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.454 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 9.3 tt0 -87.39 121.9 30.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.453 ' O ' ' CD1' ' A' ' 34' ' ' LEU . . . -134.57 158.23 23.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.454 HG22 ' OG1' ' A' ' 61' ' ' THR . 59.2 t -101.43 129.8 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.476 ' O ' ' ND2' ' A' ' 58' ' ' ASN . 2.2 tmm? -138.43 138.08 37.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.813 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.476 ' ND2' ' O ' ' A' ' 57' ' ' MET . 1.9 p30 39.97 38.07 0.44 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.909 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.61 -38.08 2.79 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -75.95 117.71 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.454 ' OG1' HG22 ' A' ' 56' ' ' VAL . 17.1 m -100.62 145.64 28.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.158 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.75 177.13 44.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.622 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.1 mt -94.47 155.31 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.784 0.326 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.534 ' CE1' HG21 ' A' ' 42' ' ' ILE . 51.2 p90 -158.54 151.55 18.5 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.612 0.72 . . . . 0.0 110.927 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.443 ' HD3' ' CH2' ' A' ' 52' ' ' TRP . 53.6 Cg_endo -69.74 129.91 18.44 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.755 2.304 . . . . 0.0 112.371 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -61.47 -17.66 53.86 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.463 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 69' ' ' VAL . 32.0 t30 -68.97 -65.89 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -38.52 -31.71 0.06 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.871 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.404 ' N ' ' O ' ' A' ' 67' ' ' ASN . 3.3 m -107.18 173.66 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -143.59 168.72 19.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 28.9 t -96.05 118.41 32.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 21.5 pt -104.59 -22.09 5.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.091 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.0 m -126.14 158.62 35.06 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.823 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 169.35 -167.81 40.78 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.516 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -13.29 34.48 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.652 2.235 . . . . 0.0 112.316 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 88.7 p -56.2 125.03 19.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.811 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 45.7 t -87.42 103.33 15.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.833 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.23 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.425 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.558 -0.217 . . . . 0.0 112.558 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.1 t -170.63 175.82 4.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.861 0.362 . . . . 0.0 110.844 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.4 t -66.56 172.58 4.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.874 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.38 -66.46 0.43 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.486 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 m -164.59 173.71 11.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.899 0.38 . . . . 0.0 110.841 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.2 m -130.17 -44.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.827 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.92 85.4 0.61 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.464 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 0.4 OUTLIER -152.77 149.8 23.07 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.656 0.741 . . . . 0.0 110.842 -179.99 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.5 Cg_endo -69.71 167.56 24.01 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.694 2.263 . . . . 0.0 112.282 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -44.59 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.326 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.403 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 33.8 p-90 -56.25 -16.72 5.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 144.19 89.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.656 0.741 . . . . 0.0 111.103 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.31 14.42 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -55.64 -39.92 71.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 7.3 t -117.49 129.93 56.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.789 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.455 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 9.6 p90 -156.32 140.52 16.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.936 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.59 HD22 ' HE2' ' A' ' 47' ' ' LYS . 3.9 mp -49.93 -68.12 0.2 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.93 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -146.37 175.66 10.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 43' ' ' TYR . 0.6 OUTLIER -116.46 126.82 53.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.903 179.952 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.26 159.51 23.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.086 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.44 HG23 HD13 ' A' ' 41' ' ' ILE . 9.2 p -119.68 143.46 31.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.112 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.16 114.67 18.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.088 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.549 HG13 ' CD2' ' A' ' 24' ' ' TYR . 33.6 pt -92.97 -9.34 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.549 ' CD2' HG13 ' A' ' 23' ' ' ILE . 55.1 m-85 -147.88 158.23 43.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -82.12 128.71 34.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -135.22 129.84 34.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.918 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 28' ' ' LYS . 91.0 m -107.17 104.43 14.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 27' ' ' THR . 14.8 pttm -36.84 122.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -81.59 -8.68 59.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.789 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.9 mmtm -135.27 -175.08 3.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.91 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.26 -16.74 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.943 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -88.69 -22.42 23.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.821 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.43 166.4 22.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.553 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -120.0 134.77 55.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.553 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.4 t -99.73 145.4 27.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -164.9 161.26 20.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -106.85 172.83 6.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -66.3 112.04 3.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 122.8 -17.26 8.22 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.448 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.03 146.92 52.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.752 0.311 . . . . 0.0 111.123 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.44 HD13 HG23 ' A' ' 21' ' ' VAL . 10.8 mm -104.47 141.45 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.182 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.699 HG21 ' CE2' ' A' ' 64' ' ' PHE . 16.8 mt -135.58 142.85 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.088 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.504 ' CE1' ' HE3' ' A' ' 19' ' ' LYS . 93.1 m-85 -105.67 104.76 14.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.873 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.5 t -61.24 121.92 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.105 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.2 pt -123.93 -14.91 5.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.171 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.486 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 35.3 tttm -137.29 148.79 46.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.59 ' HE2' HD22 ' A' ' 17' ' ' LEU . 38.2 mmtt -119.76 161.66 20.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.432 ' CB ' ' HB2' ' A' ' 52' ' ' TRP . 5.9 m120 -133.12 -174.95 3.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.943 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -109.72 -28.07 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.593 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 54.9 m-20 -99.45 40.39 1.22 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.837 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 60.79 79.8 0.11 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.543 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.593 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 94.1 m95 -162.67 137.37 6.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.76 0.314 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.485 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 11.9 m-85 -132.87 136.46 46.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.861 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.486 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.7 tt0 -95.86 115.37 27.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.959 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.41 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -125.68 173.26 17.61 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.472 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.3 t -113.01 139.1 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.157 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.469 ' O ' ' N ' ' A' ' 60' ' ' VAL . 5.3 tmm? -149.36 143.8 26.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.424 ' C ' ' O ' ' A' ' 57' ' ' MET . 11.6 p-10 35.78 37.79 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.0 2.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' MET . 89.1 t -76.05 138.94 19.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.0 111.165 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 15.8 m -114.64 146.72 40.53 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.402 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.86 177.9 44.38 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.376 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.0 mp -105.05 134.12 48.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.825 0.345 . . . . 0.0 110.951 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 42' ' ' ILE . 29.4 p90 -125.92 153.1 73.62 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.677 0.751 . . . . 0.0 110.846 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.42 50.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.281 . . . . 0.0 112.297 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.31 36.8 2.4 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.477 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -127.87 -29.69 2.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -91.25 16.29 10.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.6 m -146.59 162.5 9.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.098 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 33.0 mm-40 -139.76 150.97 45.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 91.7 p -85.74 109.57 18.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.8 pt -95.18 -26.21 4.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.084 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.2 t -74.1 -62.81 1.38 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.838 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -125.97 -161.42 10.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.568 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 177.95 5.06 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.629 2.22 . . . . 0.0 112.316 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.5 t -107.02 116.5 32.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 32.7 p -81.25 138.25 35.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.466 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 m -116.9 94.88 4.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.843 0.354 . . . . 0.0 110.829 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -144.73 156.17 43.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.958 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 5' ' ' SER . . . 113.27 104.25 2.64 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.449 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 4' ' ' GLY . 5.1 t -35.06 104.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.861 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.5 m -113.04 129.5 56.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.834 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 126.26 -48.8 0.95 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.449 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -51.85 153.0 4.7 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.642 0.734 . . . . 0.0 110.804 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.642 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.2 Cg_endo -69.75 169.28 19.27 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.692 2.261 . . . . 0.0 112.34 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.87 -34.84 13.42 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.404 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 52.2 p-90 -71.43 -30.48 66.11 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.642 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -55.13 148.8 28.11 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.51 0.671 . . . . 0.0 111.118 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.87 145.53 56.77 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.647 2.232 . . . . 0.0 112.35 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -51.39 -36.56 44.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.3 m -160.45 156.41 25.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.708 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 19.3 p90 -150.19 -180.0 7.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.3 mt -84.09 -64.6 1.13 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -139.99 176.24 8.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.8 130.65 54.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 44' ' ' VAL . 15.8 m -123.85 160.4 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.177 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.88 147.77 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.13 22.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.061 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.417 HG13 ' CD2' ' A' ' 24' ' ' TYR . 31.3 pt -92.74 -7.61 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.417 ' CD2' HG13 ' A' ' 23' ' ' ILE . 59.8 m-85 -146.84 163.37 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.944 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.76 121.81 28.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.872 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -135.19 114.26 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.42 ' O ' ' C ' ' A' ' 28' ' ' LYS . 24.6 m -98.21 106.01 18.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' A' ' 27' ' ' THR . 5.2 pttm -35.57 133.18 0.4 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.933 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -90.55 -27.71 18.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -128.94 163.64 24.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.828 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -53.77 -39.95 65.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.947 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -76.2 49.1 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.805 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -157.11 167.08 31.46 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.803 HD23 ' N ' ' A' ' 35' ' ' SER . 2.5 tt -122.63 146.42 47.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.937 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.803 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.5 p -109.46 145.46 36.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.85 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.3 p90 -169.88 148.04 3.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -103.76 153.15 21.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.97 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -39.62 110.57 0.15 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.19 44.88 0.97 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.487 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -126.25 130.46 50.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.772 0.32 . . . . 0.0 111.103 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.3 mm -87.97 136.19 23.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.6 148.97 22.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.118 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.708 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 77.0 m-85 -104.31 115.02 29.64 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 20' ' ' VAL . 22.9 t -74.66 121.74 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.184 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.9 pt -122.72 -7.0 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.455 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 0.1 OUTLIER -136.67 144.8 44.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -122.16 103.23 8.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.862 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -74.73 -175.01 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.942 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -99.4 -10.47 22.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.42 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -120.38 40.42 3.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.595 ' O ' ' CE1' ' A' ' 53' ' ' TYR . . . 79.84 -44.29 2.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.43 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.474 ' O ' ' CD1' ' A' ' 53' ' ' TYR . 25.9 m95 -34.46 137.96 0.11 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.808 0.337 . . . . 0.0 110.926 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.595 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 22.0 m-85 -136.84 137.9 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.926 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.455 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 23.8 tt0 -94.15 116.67 29.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.89 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.4 163.34 25.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.547 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.6 t -98.73 146.12 8.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.143 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -151.45 118.65 5.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.902 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.9 t30 49.67 43.76 24.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.931 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 80.4 -40.67 2.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 95.2 t -75.83 120.56 25.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 m -100.96 141.47 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.168 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.428 ' C ' ' HB2' ' A' ' 34' ' ' LEU . . . -165.87 154.37 24.95 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.498 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -80.54 147.87 30.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.902 0.382 . . . . 0.0 110.902 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -147.99 148.43 29.79 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.676 0.751 . . . . 0.0 110.884 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.5 40.27 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.464 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -73.22 -3.93 62.46 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.527 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -82.22 -28.45 31.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -90.48 8.36 34.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.464 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 8.6 m -135.7 169.06 21.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -140.63 150.18 43.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.4 t -85.03 113.63 21.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.877 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.3 pt -104.48 -32.62 2.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.139 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.7 t -74.95 -53.63 8.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -59.15 168.64 6.56 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.556 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.87 176.36 6.96 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.704 2.27 . . . . 0.0 112.246 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 85.2 p -150.76 148.22 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.837 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 93.5 p -111.38 -47.37 3.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.858 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.248 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.434 179.961 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.9 m -72.79 127.26 32.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.836 0.351 . . . . 0.0 110.903 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.0 t -166.33 163.41 17.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.896 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.13 -102.76 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.463 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.4 m -95.77 81.89 3.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.823 0.344 . . . . 0.0 110.883 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 70.6 m 57.79 48.49 13.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.865 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.93 127.38 8.97 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.449 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -45.31 148.81 1.06 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.657 0.741 . . . . 0.0 110.792 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.585 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.79 163.55 37.88 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.612 2.208 . . . . 0.0 112.339 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -33.36 17.04 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.585 2.19 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 22.4 p-90 -63.6 -23.18 67.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.434 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -65.23 148.26 98.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 121.493 0.663 . . . . 0.0 111.087 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 149.15 66.19 Favored 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.662 2.242 . . . . 0.0 112.37 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -54.94 -44.18 74.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.897 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.5 t -145.79 165.66 28.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -159.6 -179.14 7.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 22.9 mt -84.58 -57.31 3.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -152.96 -179.88 8.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.582 ' HE3' HG23 ' A' ' 41' ' ' ILE . 13.3 tttp -113.75 154.38 27.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.41 ' N ' ' HG2' ' A' ' 19' ' ' LYS . 29.1 m -152.18 147.15 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -117.09 139.4 44.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.206 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.27 135.42 36.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.109 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.492 HG13 ' CD2' ' A' ' 24' ' ' TYR . 16.1 pt -115.07 -15.17 10.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.179 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CD2' HG13 ' A' ' 23' ' ' ILE . 62.9 m-85 -128.53 164.51 22.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.895 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -87.22 123.98 32.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.919 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' A' ' 27' ' ' THR . 86.0 t80 -117.31 160.27 21.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.949 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.41 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 6.7 m -133.53 132.08 40.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.22 136.34 36.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.914 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -99.56 -32.02 11.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.978 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -110.12 163.42 13.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.13 4.71 13.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -108.55 -26.75 10.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.411 ' C ' ' HA3' ' A' ' 62' ' ' GLY . 0.1 OUTLIER -70.4 -177.99 1.61 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -124.41 139.57 53.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.7 p -115.88 124.91 51.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.828 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 28.7 p90 -148.04 156.54 42.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.849 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -114.86 169.88 8.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -45.64 137.42 5.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.871 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.45 46.51 9.88 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.548 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.9 136.28 52.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.341 . . . . 0.0 111.037 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.582 HG23 ' HE3' ' A' ' 19' ' ' LYS . 21.8 mm -88.72 135.7 25.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.522 HD11 ' CD2' ' A' ' 36' ' ' PHE . 65.9 mt -141.99 143.46 26.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -110.28 109.67 20.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.96 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.486 HG13 ' HB3' ' A' ' 53' ' ' TYR . 92.8 t -69.25 110.07 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.137 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 26.2 pt -107.79 -14.12 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.193 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 46.9 tttt -144.52 138.45 27.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.886 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 6.6 mtmp? -135.05 102.99 5.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -75.97 175.51 8.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -76.38 48.36 0.53 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -163.36 -176.92 5.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.481 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -82.7 49.62 4.22 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.472 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.524 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 46.1 m95 -148.71 121.39 8.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.552 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 2.9 m-85 -119.06 149.26 41.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.65 123.13 37.91 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.8 177.02 19.6 Favored Glycine 0 N--CA 1.454 -0.157 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.449 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.467 HG22 HG23 ' A' ' 61' ' ' THR . 45.8 t -117.86 144.22 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.73 0.3 . . . . 0.0 111.196 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -157.02 129.99 7.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.816 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 58' ' ' ASN . 30.7 t30 47.55 38.47 8.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.01 -35.14 2.55 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.499 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 97.9 t -76.02 126.04 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.467 HG23 HG22 ' A' ' 56' ' ' VAL . 2.9 m -106.97 150.87 26.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.159 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA3' ' C ' ' A' ' 33' ' ' GLU . . . 173.91 162.2 25.29 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.526 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.22 163.96 22.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.511 ' CE1' HG21 ' A' ' 42' ' ' ILE . 29.8 p90 -160.68 152.47 16.52 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.525 0.679 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.524 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.78 137.27 35.03 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.679 2.253 . . . . 0.0 112.321 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 68' ' ' TYR . . . -67.27 -56.11 13.28 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.429 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.9 m-20 -40.95 -24.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.472 ' CG ' ' HG2' ' A' ' 65' ' ' PRO . 13.4 m-85 -76.77 -42.73 39.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 18.8 m -108.24 142.64 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.231 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -102.94 165.64 10.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.802 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.4 t -105.66 105.23 15.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.403 HD11 ' HD3' ' A' ' 19' ' ' LYS . 37.3 pt -86.33 -16.27 9.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.172 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 11.1 t -74.59 159.29 32.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 88.33 -169.38 37.74 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.474 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 161.46 45.86 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.657 2.238 . . . . 0.0 112.309 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 84.1 p -77.8 160.27 28.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.868 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.0 m -94.29 118.34 31.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.833 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.376 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.474 -179.969 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.9 m -101.06 128.76 46.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.833 0.349 . . . . 0.0 110.843 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 86.6 p -158.32 157.47 32.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 129.38 -167.96 21.14 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.2 m -70.1 -58.01 4.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.857 0.36 . . . . 0.0 110.864 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 77.5 p -106.61 -50.39 3.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.58 -93.5 0.16 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.516 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -115.41 156.28 46.04 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.729 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.567 ' CG ' ' CE2' ' A' ' 11' ' ' TRP . 53.8 Cg_endo -69.8 166.81 26.4 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.645 2.23 . . . . 0.0 112.329 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.8 -33.35 16.62 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.603 2.202 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.567 ' CE2' ' CG ' ' A' ' 9' ' ' PRO . 22.2 p-90 -65.56 -27.82 68.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.54 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -58.32 147.41 67.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.59 0.71 . . . . 0.0 111.126 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.6 10.72 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.668 2.245 . . . . 0.0 112.294 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.4 mtt180 -85.0 -43.94 13.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.8 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 39.0 t -136.66 152.79 50.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.812 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.53 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 7.1 p90 -159.77 157.21 28.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.904 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 44' ' ' VAL . 19.8 mt -61.35 -66.95 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -144.14 -175.65 4.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.858 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.596 ' HD2' HD11 ' A' ' 72' ' ' ILE . 20.7 ttmt -120.19 133.05 55.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.426 HG13 HG21 ' A' ' 44' ' ' VAL . 34.4 m -128.15 161.23 36.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.195 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 ' HG3' ' A' ' 70' ' ' GLU . 11.3 p -126.14 141.08 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.193 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.9 118.4 14.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.102 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.4 pt -99.04 -35.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -129.77 135.11 48.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -56.69 122.58 12.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.894 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 87.9 t80 -121.1 127.71 51.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -97.04 123.51 40.79 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.074 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.413 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -76.15 131.29 39.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.887 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -94.08 -47.9 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -105.14 146.8 28.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -45.22 -32.29 1.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.33 -44.77 96.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.922 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -65.68 165.33 12.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.958 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.625 HD23 ' N ' ' A' ' 35' ' ' SER . 3.7 tt -121.63 140.09 52.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.625 ' N ' HD23 ' A' ' 34' ' ' LEU . 52.8 p -99.2 130.99 45.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -151.6 167.91 26.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.965 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -127.6 159.74 33.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.81 109.07 0.37 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.897 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.59 43.47 0.75 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.445 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.96 131.7 47.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.788 0.328 . . . . 0.0 111.068 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.78 100.4 11.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.4 mt -104.8 137.55 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.1 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.53 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 80.7 m-85 -91.18 121.79 33.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.966 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 17' ' ' LEU . 48.0 t -80.92 104.5 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.066 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 46' ' ' LYS . 33.0 pt -95.33 -33.58 4.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.406 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.4 tptm -129.31 144.22 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.479 ' HG2' ' CG ' ' A' ' 53' ' ' TYR . 10.9 mtpt -136.45 124.46 22.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -101.4 151.25 22.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -39.34 -49.66 1.99 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.921 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.74 177.22 7.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.951 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.6 66.9 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.516 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -151.68 113.07 4.34 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.733 0.301 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.479 ' CG ' ' HG2' ' A' ' 47' ' ' LYS . 1.3 m-85 -122.95 154.23 38.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.406 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.4 tt0 -104.45 134.59 47.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.879 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.17 157.07 27.05 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.488 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.3 t -95.48 136.43 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.926 0.394 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.41 ' O ' ' N ' ' A' ' 60' ' ' VAL . 21.8 ttp -141.18 119.67 12.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.824 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 43.93 42.76 4.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.79 -26.64 4.65 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.493 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.41 ' N ' ' O ' ' A' ' 57' ' ' MET . 93.0 t -81.1 127.76 39.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.881 0.372 . . . . 0.0 111.162 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.7 m -112.19 147.86 35.27 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.503 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 178.04 162.84 28.63 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.533 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.9 mt -88.44 128.79 35.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -120.38 147.33 44.95 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.716 0.77 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 122.83 9.5 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.667 2.245 . . . . 0.0 112.35 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.458 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -58.53 -10.8 8.46 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -76.61 -32.16 57.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.732 0.301 . . . . 0.0 110.787 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 11.7 m-85 -97.83 35.32 1.72 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.906 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 68' ' ' TYR . 9.9 m -161.32 153.81 3.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.608 ' HG3' HG12 ' A' ' 21' ' ' VAL . 5.6 pt-20 -130.06 144.14 51.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 37.9 m -84.66 120.33 26.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.596 HD11 ' HD2' ' A' ' 19' ' ' LYS . 24.9 pt -99.33 -32.76 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.181 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 28.0 t -62.54 155.5 25.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 161.44 164.46 16.38 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.57 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 120.53 7.32 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.735 2.29 . . . . 0.0 112.296 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.2 t 53.37 43.05 31.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.915 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 51.5 m -126.9 139.13 53.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.52 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.53 -0.228 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.4 m -89.56 -57.65 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 110.857 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.5 t -88.55 154.06 20.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.836 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.22 117.65 0.58 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.538 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.0 t -79.77 -46.75 16.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.832 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.8 t -75.33 -57.55 3.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 114.88 45.68 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -81.57 157.0 70.45 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-O 121.606 0.717 . . . . 0.0 110.821 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.796 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.6 Cg_endo -69.72 166.24 28.2 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.602 2.201 . . . . 0.0 112.33 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.81 -33.95 15.4 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.681 2.254 . . . . 0.0 112.318 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 54.8 p-90 -73.55 -29.7 62.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.796 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -52.71 151.53 7.99 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.604 0.716 . . . . 0.0 111.089 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.63 133.25 25.33 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 56.5 mtm180 -48.68 -45.48 39.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.865 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.5 p -136.64 163.39 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.942 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -166.27 171.21 12.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.005 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.57 HD13 ' HE3' ' A' ' 47' ' ' LYS . 19.4 mt -77.03 -52.29 9.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.882 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.727 ' OE1' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -160.44 172.84 16.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.967 179.898 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.05 145.92 42.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.727 HG13 ' OE1' ' A' ' 18' ' ' GLU . 30.4 m -135.64 163.28 35.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.109 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.29 140.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.05 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.19 102.93 12.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.072 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CE2' ' A' ' 24' ' ' TYR . 8.5 pt -84.25 -7.22 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.688 ' CE2' HD12 ' A' ' 23' ' ' ILE . 46.7 m-85 -145.43 136.6 24.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.912 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -65.69 136.02 55.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.872 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -137.97 128.1 25.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.883 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.3 m -97.32 151.33 20.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.209 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 7.8 ptmt -93.03 132.58 37.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.844 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.02 -18.26 22.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.816 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -138.16 167.73 21.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.92 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -83.33 36.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.902 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -127.39 -28.94 2.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.937 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -88.98 -174.97 4.68 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.969 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.701 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.21 140.4 51.5 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.701 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.1 p -108.38 140.32 41.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -153.75 166.58 32.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.933 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -114.41 170.27 8.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -61.8 102.02 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 115.23 42.5 0.76 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.584 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.38 140.96 48.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 111.146 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.2 mm -92.85 122.44 44.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.151 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.543 HG21 ' CE2' ' A' ' 64' ' ' PHE . 70.4 mt -127.47 136.21 61.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -101.35 107.68 19.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.962 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 53' ' ' TYR . 87.5 t -69.17 113.49 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.435 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.0 pt -113.93 -2.37 10.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.164 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.475 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.0 tptm -156.2 137.08 13.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HE3' HD13 ' A' ' 17' ' ' LEU . 14.5 ptpt -136.51 116.65 13.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 58.7 m-20 -90.1 155.91 18.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -43.15 -37.33 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -85.11 -175.27 5.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.526 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -82.56 81.37 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.526 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 91.9 m95 -162.02 120.66 2.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.52 ' HB3' HG13 ' A' ' 44' ' ' VAL . 33.6 m-85 -118.52 135.36 54.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.927 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.475 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 7.8 tt0 -91.0 111.11 22.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 61' ' ' THR . . . -125.96 169.89 17.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.487 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.506 HG22 ' OG1' ' A' ' 61' ' ' THR . 77.3 t -115.52 129.83 71.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 111.097 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.8 tmm? -137.34 125.36 22.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 45.8 t30 51.02 37.98 19.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.28 -31.49 2.9 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.6 132.36 31.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.914 0.388 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.712 HG23 ' O ' ' A' ' 55' ' ' GLY . 18.9 m -114.27 145.14 42.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.76 145.12 9.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.405 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.7 mm? -67.95 123.85 21.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.543 ' CE2' HG21 ' A' ' 42' ' ' ILE . 42.3 p90 -123.82 152.67 66.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 138.91 38.88 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.646 2.231 . . . . 0.0 112.324 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.19 29.24 3.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -116.78 -35.02 4.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.848 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -78.21 2.36 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.938 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.96 178.41 2.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.082 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -142.68 124.17 14.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 72.2 m -71.7 103.69 3.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.9 pt -91.29 -29.32 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 28.9 t -48.41 130.65 16.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -55.12 164.23 3.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.467 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 172.74 12.04 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.731 2.287 . . . . 0.0 112.387 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 68.7 m -108.25 -54.65 2.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 33.9 p -55.18 100.68 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.405 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.519 -179.965 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.3 t -89.55 42.43 1.09 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.887 0.375 . . . . 0.0 110.844 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.2 m -88.83 155.68 19.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.73 -133.48 0.24 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.528 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.8 p -51.84 177.2 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.906 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -129.81 97.74 4.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.44 88.4 0.18 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -154.41 152.4 26.09 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.637 0.732 . . . . 0.0 110.832 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HB2' ' CE2' ' A' ' 11' ' ' TRP . 53.5 Cg_endo -69.8 158.11 58.01 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.653 2.235 . . . . 0.0 112.297 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 2.87 3.13 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.692 2.262 . . . . 0.0 112.366 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.432 ' CE2' ' HB2' ' A' ' 9' ' ' PRO . 32.0 p-90 -120.42 18.01 12.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.91 144.51 64.05 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.611 0.72 . . . . 0.0 111.057 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 155.89 64.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.386 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -50.98 -53.72 30.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.867 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.3 t -145.13 165.45 28.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -158.67 155.39 28.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.905 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -64.56 -46.94 80.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.912 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -165.97 179.35 5.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 24.2 ttmt -119.43 132.76 55.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.823 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.0 m -120.44 168.53 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.83 137.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.997 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.06 92.53 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.114 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 24' ' ' TYR . 35.7 pt -69.38 -34.71 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.192 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 23' ' ' ILE . 77.6 m-85 -128.82 151.81 49.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.869 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.81 102.02 11.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.891 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -103.49 130.55 50.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.9 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -96.04 108.97 21.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.412 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 12.7 pttm -45.24 142.18 2.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.928 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -95.34 -48.93 5.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -101.26 175.84 5.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.902 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -67.85 -38.65 83.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.68 -40.52 95.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.829 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.412 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 32.5 mt-10 -57.09 162.41 2.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 62' ' ' GLY . 2.0 tt -118.59 141.2 48.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.509 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.6 p -108.4 133.22 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -155.84 152.6 28.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.912 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -106.4 160.01 15.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.423 ' OE1' ' C ' ' A' ' 38' ' ' GLU . 1.0 OUTLIER -45.37 137.72 4.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.865 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.3 48.03 5.83 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.83 142.51 50.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 111.145 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.434 ' C ' HG13 ' A' ' 42' ' ' ILE . 28.7 mm -94.84 139.51 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.137 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.454 HG21 ' CE2' ' A' ' 64' ' ' PHE . 20.8 mt -141.88 143.19 27.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.181 179.858 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.583 ' CE1' ' HE2' ' A' ' 19' ' ' LYS . 97.9 m-85 -103.05 98.81 8.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.897 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.536 HG11 ' HE3' ' A' ' 47' ' ' LYS . 25.6 t -64.25 95.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.207 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.433 HG13 ' N ' ' A' ' 46' ' ' LYS . 48.1 pt -88.12 -34.48 7.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.433 ' N ' HG13 ' A' ' 45' ' ' ILE . 1.4 tppp? -126.04 148.04 49.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.916 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' HE2' ' CD1' ' A' ' 53' ' ' TYR . 13.9 mtpt -136.58 112.75 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -87.64 150.73 23.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -41.89 -49.38 4.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.36 175.4 6.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.907 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.17 61.65 2.21 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.53 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -151.39 110.66 3.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.715 0.293 . . . . 0.0 110.939 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.56 ' CD1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -112.8 151.71 30.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.429 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.4 tt0 -99.78 126.91 45.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.958 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.15 27.9 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.568 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.0 t -97.22 139.85 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 111.092 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.7 ttp -153.4 111.11 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.1 t30 62.24 39.3 12.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.35 -35.26 2.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.26 130.46 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 0.0 111.06 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.568 ' OG1' HG22 ' A' ' 56' ' ' VAL . 87.2 m -116.86 131.42 56.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -158.37 163.42 32.94 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.451 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.2 mt -80.09 123.38 27.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.609 ' HE1' HG21 ' A' ' 69' ' ' VAL . 21.3 p90 -115.6 151.25 45.94 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 110.906 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 118.01 5.42 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.724 2.283 . . . . 0.0 112.307 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.456 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -55.03 -13.04 4.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.416 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -75.67 -34.12 60.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.842 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 69' ' ' VAL . 13.2 m-85 -94.59 32.6 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.609 HG21 ' HE1' ' A' ' 64' ' ' PHE . 26.9 m -158.34 139.24 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.6 mm-40 -120.55 158.16 27.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.826 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.7 p -90.15 127.03 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.473 HG13 ' N ' ' A' ' 73' ' ' SER . 43.5 pt -111.98 -37.2 2.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.147 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.473 ' N ' HG13 ' A' ' 72' ' ' ILE . 58.7 m -106.19 101.0 10.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.94 -175.05 47.28 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.467 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 1.21 4.57 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.77 2.313 . . . . 0.0 112.344 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.1 t -113.06 82.25 1.63 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.893 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.7 t -69.22 87.5 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.83 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.456 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.0 p -132.75 153.89 50.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.838 0.352 . . . . 0.0 110.879 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.6 m -58.72 128.14 35.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.819 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.06 78.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.447 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.7 m -104.29 168.72 8.91 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.868 0.366 . . . . 0.0 110.907 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.1 m -47.66 165.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.854 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.01 -44.55 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.442 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -90.43 151.59 44.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.64 0.733 . . . . 0.0 110.865 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.542 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.4 Cg_endo -69.73 160.67 48.84 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.651 2.234 . . . . 0.0 112.376 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -29.32 24.18 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.619 2.212 . . . . 0.0 112.389 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.542 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 48.4 p-90 -73.47 -14.21 61.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.934 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.515 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -76.67 143.68 72.08 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.684 0.754 . . . . 0.0 111.025 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 123.24 9.89 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.2 mmt85 -41.9 -47.48 4.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.4 t -121.57 153.24 38.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.541 ' HA ' HG22 ' A' ' 45' ' ' ILE . 25.9 p90 -164.8 163.95 21.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.936 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.446 HD13 ' HG3' ' A' ' 47' ' ' LYS . 51.4 mt -65.85 -61.98 1.76 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.019 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -156.86 178.58 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.001 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -114.92 147.95 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.481 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 22.1 m -146.55 158.95 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.668 HG12 HG23 ' A' ' 72' ' ' ILE . 13.0 p -124.81 132.62 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.221 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -70.16 117.9 12.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.513 HG13 ' CD2' ' A' ' 24' ' ' TYR . 41.7 pt -98.89 -14.47 7.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.513 ' CD2' HG13 ' A' ' 23' ' ' ILE . 47.5 m-85 -136.38 151.63 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.931 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -78.33 115.07 17.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -113.88 148.61 36.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.4 m -120.16 112.03 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.179 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.403 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 15.0 pttm -57.82 136.75 57.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.931 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.32 -24.43 42.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 pttt -155.06 179.02 9.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.12 -43.01 77.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.939 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -47.23 -36.4 8.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.976 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.403 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -87.4 176.99 7.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.92 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.688 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.7 tt -128.0 152.44 47.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.932 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.665 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.0 p -108.54 139.31 43.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.843 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -165.43 153.86 11.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.936 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -112.59 166.06 11.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.949 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -51.83 106.23 0.14 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.966 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 116.83 46.43 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.425 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -141.38 117.83 10.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.809 0.338 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.489 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.7 mp -80.82 147.53 6.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.405 HG13 ' C ' ' A' ' 41' ' ' ILE . 34.9 mt -142.89 133.42 22.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -86.74 109.89 19.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.528 HG13 ' HB3' ' A' ' 53' ' ' TYR . 80.2 t -76.29 124.05 33.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 16' ' ' TYR . 10.6 pt -120.7 -23.87 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.127 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 9.5 tmtt? -128.75 145.95 51.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 19.1 mtpt -123.38 160.65 26.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.914 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -129.79 -174.89 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.869 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -104.45 -26.73 12.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.814 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.597 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 34.6 t70 -100.04 39.85 1.3 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.528 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 59.06 78.17 0.14 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.497 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.597 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 97.5 m95 -162.33 115.16 1.72 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.805 0.336 . . . . 0.0 110.853 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.528 ' HB3' HG13 ' A' ' 44' ' ' VAL . 3.3 m-85 -116.32 137.65 51.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.92 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -91.1 126.24 36.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.863 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.98 167.13 25.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.523 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 84.7 t -112.64 126.75 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.778 0.323 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.3 ttp -133.24 107.18 7.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.905 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 59.27 41.73 19.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.982 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.73 -34.15 3.19 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 92.7 t -76.21 125.02 35.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.938 0.399 . . . . 0.0 111.067 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.7 m -107.58 146.79 31.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.133 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.688 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.49 139.69 3.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 63' ' ' LEU . 5.2 mp -69.13 161.42 29.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.369 . . . . 0.0 110.877 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -163.11 154.51 14.78 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.587 0.708 . . . . 0.0 110.9 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.502 ' HG2' ' CD1' ' A' ' 68' ' ' TYR . 53.7 Cg_endo -69.68 122.74 9.44 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.391 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.523 ' O ' HG22 ' A' ' 69' ' ' VAL . . . -51.29 -52.0 34.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 68' ' ' TYR . 19.0 m120 -40.71 -65.05 0.46 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.817 0.341 . . . . 0.0 110.818 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.502 ' CD1' ' HG2' ' A' ' 65' ' ' PRO . 23.7 m-85 -36.37 -33.99 0.05 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 22' ' ' ALA . 30.9 m -108.67 164.54 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.129 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.475 ' CD ' ' N ' ' A' ' 71' ' ' SER . 2.8 tm-20 -122.03 137.49 54.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.475 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 14.9 m -80.7 77.86 7.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.834 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.668 HG23 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -42.32 -26.87 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.7 t -73.35 159.51 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -173.96 -173.13 39.85 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.386 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 147.4 62.86 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.409 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.2 m -99.51 117.21 33.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.847 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.1 t 46.53 43.82 12.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.863 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.227 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.433 -179.921 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.567 -0.213 . . . . 0.0 112.567 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 84.1 p -117.01 162.23 18.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.862 0.363 . . . . 0.0 110.886 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.1 m -130.61 157.16 43.5 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.817 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -162.15 -77.23 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.551 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.9 m -131.72 -51.9 0.99 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.901 0.381 . . . . 0.0 110.868 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 p -129.33 166.08 20.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.818 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 131.46 -147.4 18.56 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.429 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 0.2 OUTLIER -127.83 150.06 72.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.582 0.706 . . . . 0.0 110.942 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.563 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.0 Cg_endo -69.73 163.56 37.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.718 2.279 . . . . 0.0 112.321 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -25.65 28.4 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.64 2.227 . . . . 0.0 112.341 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.529 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 47.0 p-90 -79.33 -18.78 51.85 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -75.08 148.34 84.19 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.73 . . . . 0.0 111.087 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.8 Cg_endo -69.79 132.61 23.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.634 2.223 . . . . 0.0 112.399 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.449 ' C ' ' O ' ' A' ' 13' ' ' PRO . 3.6 ptt180 -34.37 -46.81 0.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.833 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 24.2 m -144.5 169.51 17.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -160.65 166.88 28.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.969 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -65.86 -56.67 10.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -152.57 -175.76 5.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -126.11 121.82 33.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.95 167.28 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.175 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 p -133.95 136.87 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.61 119.06 15.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.414 HG13 ' CD2' ' A' ' 24' ' ' TYR . 24.4 pt -97.79 -8.55 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.151 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.414 ' CD2' HG13 ' A' ' 23' ' ' ILE . 41.1 m-85 -142.58 165.79 26.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -88.35 114.28 24.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.836 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.429 ' HB3' ' CZ ' ' A' ' 36' ' ' PHE . 90.8 t80 -114.47 111.49 21.48 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.97 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 22.2 m -92.57 94.69 9.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.438 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 0.7 OUTLIER -43.67 157.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.904 179.925 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -118.53 -20.85 8.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' GLU . 12.6 mmmm -124.69 137.3 54.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -41.93 -30.53 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.19 -41.94 85.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.953 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.7 OUTLIER -64.22 169.22 4.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.606 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -121.1 138.96 53.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.962 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.606 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.7 p -101.15 153.28 19.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.902 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.429 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 24.9 p90 -174.24 165.91 4.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.973 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.426 ' O ' ' C ' ' A' ' 38' ' ' GLU . 15.0 pt20 -130.5 151.35 51.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 37' ' ' GLN . 16.6 tt0 -36.69 104.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 117.94 38.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.481 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -123.54 130.09 52.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.717 0.294 . . . . 0.0 111.108 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.4 mm -87.11 133.01 31.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.416 HG21 ' CE1' ' A' ' 64' ' ' PHE . 78.5 mt -131.18 140.93 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.118 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -105.88 97.9 7.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.449 HG11 ' HE3' ' A' ' 47' ' ' LYS . 92.4 t -60.36 114.03 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.164 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.5 pt -110.91 -20.1 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.172 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 37.4 mttp -144.46 154.92 43.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.449 ' HE3' HG11 ' A' ' 44' ' ' VAL . 69.4 mttt -136.5 159.71 40.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -129.45 149.03 51.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -38.34 -39.28 0.43 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 52' ' ' TRP . 1.5 m-20 -96.03 174.21 7.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.969 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -63.62 77.19 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.489 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.536 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 85.0 m95 -160.16 120.33 2.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.877 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -131.73 151.89 51.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -91.47 142.54 27.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.81 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -156.86 158.61 28.94 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.463 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.457 HG22 ' OG1' ' A' ' 61' ' ' THR . 50.5 t -104.65 131.04 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 111.133 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.1 tmm? -136.26 112.2 9.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.3 t30 59.35 38.1 23.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.42 -38.17 3.17 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.446 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 87.3 t -77.42 126.79 38.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 111.201 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.457 ' OG1' HG22 ' A' ' 56' ' ' VAL . 33.2 m -107.57 142.92 36.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.469 ' H ' HD12 ' A' ' 34' ' ' LEU . . . -163.09 173.52 39.29 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.483 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.4 mt -95.77 128.07 42.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.839 0.352 . . . . 0.0 110.922 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.45 ' HE2' HG21 ' A' ' 69' ' ' VAL . 23.2 p90 -130.34 148.98 72.06 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.715 0.769 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -70.03 142.75 47.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.594 2.196 . . . . 0.0 112.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.82 11.83 45.22 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.443 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -99.38 -12.91 19.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.796 0.331 . . . . 0.0 110.893 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -108.17 17.6 22.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.45 HG21 ' HE2' ' A' ' 64' ' ' PHE . 4.7 m -139.17 173.55 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 -145.74 167.05 24.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.857 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 96.7 p -102.12 112.83 25.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.418 HG13 ' N ' ' A' ' 73' ' ' SER . 32.0 pt -104.22 -33.84 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.138 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.418 ' N ' HG13 ' A' ' 72' ' ' ILE . 29.5 t -124.32 106.77 10.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.815 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 153.23 -158.24 27.84 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.475 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 129.87 18.39 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.303 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 58.8 m -103.94 155.4 18.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 39.1 t -77.53 -57.26 3.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.483 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.9 t 53.8 41.84 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.0 110.8 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.2 m -63.81 176.12 1.0 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.805 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -130.88 -131.3 3.28 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.51 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m -104.6 85.2 2.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.838 0.351 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.0 m -129.48 167.93 17.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.802 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -143.35 51.36 0.66 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.477 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -54.14 145.88 32.85 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.599 0.714 . . . . 0.0 110.839 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.5 Cg_endo -69.74 165.47 30.85 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.657 2.238 . . . . 0.0 112.331 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.73 -31.63 20.28 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.684 2.256 . . . . 0.0 112.373 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.555 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 38.0 p-90 -68.99 -22.95 64.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.871 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.42 145.07 87.37 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.0 Cg_endo -69.77 136.93 34.2 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.753 2.302 . . . . 0.0 112.362 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.451 ' C ' ' O ' ' A' ' 13' ' ' PRO . 5.2 ptt85 -34.31 -48.2 0.33 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -148.44 174.19 12.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 23.5 p90 -169.14 151.39 4.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.936 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -49.67 -68.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -151.24 -179.67 7.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.29 144.07 44.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.0 m -127.87 170.36 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.129 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 21' ' ' VAL . 6.7 p -136.69 127.37 41.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.15 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.08 112.35 9.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.129 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 12.2 pt -92.84 -7.54 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -136.94 166.12 24.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.951 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -85.23 141.7 29.94 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.827 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.408 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 83.6 t80 -151.96 118.25 5.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.916 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 91.3 m -104.83 111.98 24.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.128 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -43.94 150.28 0.28 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.997 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -115.91 -47.01 2.8 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.877 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.47 149.64 24.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 64.6 mm-40 -48.47 -28.35 3.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.873 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -89.21 43.23 1.13 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -143.27 159.53 42.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.566 HD23 ' N ' ' A' ' 35' ' ' SER . 1.7 tt -116.87 130.74 56.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.906 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.566 ' N ' HD23 ' A' ' 34' ' ' LEU . 22.5 t -97.41 144.21 27.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.905 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -164.83 150.3 9.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 18.5 mt-30 -105.46 153.54 21.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -45.52 110.11 0.22 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.96 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.53 36.87 1.25 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.6 141.8 48.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.719 0.295 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -92.18 112.86 26.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.087 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.707 HG21 ' CE2' ' A' ' 64' ' ' PHE . 45.5 mt -115.89 125.25 72.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -89.22 106.03 18.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.9 t -68.05 120.62 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.106 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 12.8 pt -121.45 -14.97 7.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.172 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.4 ttmt -132.78 122.2 24.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 53' ' ' TYR . 18.7 mmtt -114.55 102.72 10.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -90.59 143.44 26.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -40.07 -48.2 2.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 -71.88 -178.1 2.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.27 62.71 4.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -152.28 118.97 5.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.48 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 4.4 m-85 -120.99 160.6 23.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HG3' HD22 ' A' ' 63' ' ' LEU . 7.5 tt0 -112.28 123.46 50.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.937 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 61' ' ' THR . . . -134.27 166.46 24.11 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.463 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 ' OG1' ' A' ' 61' ' ' THR . 65.1 t -107.9 124.42 64.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.9 0.381 . . . . 0.0 111.157 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.8 tmm? -129.79 106.29 8.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.798 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 4.5 t30 61.24 39.8 15.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.72 -30.01 3.96 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.482 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.9 t -82.59 115.98 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.92 0.39 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 55' ' ' GLY . 3.4 m -109.77 143.43 39.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -172.16 163.72 36.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.447 HD22 ' HG3' ' A' ' 54' ' ' GLU . 2.1 mm? -68.56 150.15 48.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.878 0.37 . . . . 0.0 110.922 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.707 ' CE2' HG21 ' A' ' 42' ' ' ILE . 5.3 p90 -162.17 151.42 13.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.676 0.75 . . . . 0.0 110.872 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 136.79 33.87 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.708 2.272 . . . . 0.0 112.308 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -75.44 -42.29 27.94 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.477 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -51.06 -29.32 12.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.895 0.378 . . . . 0.0 110.917 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.408 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 10.5 m-85 -71.62 -30.06 65.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.9 m -110.0 137.15 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.12 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 71' ' ' SER . 0.4 OUTLIER -101.52 131.39 47.7 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.404 ' N ' ' OE2' ' A' ' 70' ' ' GLU . 19.2 m -74.6 103.3 4.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.7 pt -92.12 -11.69 9.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 m -99.64 143.52 29.78 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.924 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 87.14 -162.77 33.99 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.54 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 99.14 0.72 Allowed 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.703 2.268 . . . . 0.0 112.34 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.3 t -102.28 129.76 48.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 97.8 p -71.65 153.54 42.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.816 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.505 179.92 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.237 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.1 t -154.56 111.44 3.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.349 . . . . 0.0 110.945 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 52.6 p -58.0 169.42 0.78 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 114.51 -165.68 12.09 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.483 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.5 m -138.79 170.53 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.377 . . . . 0.0 110.87 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.1 m -57.85 155.45 10.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.836 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.5 -50.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.71 150.78 88.86 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.605 0.717 . . . . 0.0 110.839 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.578 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.69 167.6 23.88 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -39.32 6.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.244 . . . . 0.0 112.361 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.578 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 41.9 p-90 -58.13 -38.25 76.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.53 143.15 20.56 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.51 0.672 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 135.43 30.62 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.2 mtm180 -87.06 36.05 0.72 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.3 t -171.51 105.99 0.22 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.827 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 19.9 p90 -157.7 171.21 20.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.7 mt -85.8 -47.15 9.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.451 ' C ' ' OE2' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -168.84 174.26 6.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.9 pttm -116.98 161.21 19.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 33.9 m -148.67 160.97 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.11 139.68 40.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.184 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.19 95.59 6.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.101 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.532 HG13 ' CD2' ' A' ' 24' ' ' TYR . 38.7 pt -69.67 -23.89 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.137 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.532 ' CD2' HG13 ' A' ' 23' ' ' ILE . 64.3 m-85 -124.23 160.41 28.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.927 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.65 100.62 13.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.461 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 89.4 t80 -109.74 130.19 55.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.418 ' O ' ' CE2' ' A' ' 26' ' ' TYR . 15.4 t -93.43 -175.16 3.72 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.081 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.41 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -114.52 130.52 56.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.941 179.938 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -102.48 -52.2 3.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.884 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -96.86 145.32 25.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -49.43 -24.01 1.79 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.03 47.86 1.23 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -146.37 172.16 13.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.852 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.669 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.5 tt -129.3 133.43 47.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.857 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.6 t -100.24 141.33 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.825 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 11.3 p90 -155.32 174.81 14.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.934 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -127.36 165.32 19.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.933 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -57.97 109.55 0.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.89 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.56 45.75 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -145.13 119.25 9.44 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.652 0.263 . . . . 0.0 111.205 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.502 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -80.7 139.07 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.126 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.3 mt -129.77 117.98 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -72.21 107.17 4.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.484 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 59.6 t -73.68 105.79 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.4 pt -93.65 -15.31 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.043 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 9.8 tptt -141.72 143.8 33.72 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.834 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -134.58 116.33 14.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -97.16 152.1 19.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.841 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.01 -43.42 29.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -75.75 176.04 8.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -76.2 70.17 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.481 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.0 m95 -163.34 119.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 110.891 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.471 ' HB3' HG13 ' A' ' 44' ' ' VAL . 4.3 m-85 -120.55 155.11 34.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.432 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 19.8 tt0 -103.77 118.3 36.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.35 160.53 25.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.408 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 85.4 t -101.27 139.73 21.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.764 0.316 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.1 ttp -140.02 111.78 7.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.879 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.8 t30 49.24 38.65 13.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.03 -29.97 6.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.66 ' O ' HD11 ' A' ' 34' ' ' LEU . 94.6 t -79.81 118.92 28.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.927 0.394 . . . . 0.0 111.196 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.4 m -108.98 139.64 43.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.669 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.37 163.23 36.0 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.526 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -81.19 135.45 35.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.726 0.298 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.484 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 45.5 p90 -136.34 152.96 76.01 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.689 0.756 . . . . 0.0 110.842 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 132.4 23.26 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.627 2.218 . . . . 0.0 112.392 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.39 -1.13 41.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.554 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -86.85 -33.71 19.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.439 ' O ' HG13 ' A' ' 69' ' ' VAL . 69.7 m-85 -87.11 29.53 0.83 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.977 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 68' ' ' TYR . 20.4 m -157.38 142.28 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -118.49 164.87 14.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.965 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 p -92.89 132.63 36.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.872 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.464 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -121.4 -28.37 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.121 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.402 ' N ' HG12 ' A' ' 72' ' ' ILE . 36.4 t -85.0 156.13 21.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.868 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 170.94 -168.14 41.29 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.66 -20.91 34.67 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.691 2.261 . . . . 0.0 112.325 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 62.3 m -69.83 -48.59 58.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.933 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.8 m 57.11 42.36 25.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.829 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.528 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.0 p -165.59 110.57 0.87 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.848 0.356 . . . . 0.0 110.804 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.8 t -71.27 89.92 0.9 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.823 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 50.51 -148.41 7.25 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.523 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.5 m 48.5 47.22 20.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.914 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.2 m -137.64 141.37 41.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.961 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -121.08 65.69 0.46 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.459 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.44 144.0 29.28 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.573 0.702 . . . . 0.0 110.94 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.552 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo -69.69 168.28 21.93 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.26 4.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.602 2.201 . . . . 0.0 112.367 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.552 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 64.4 p-90 -60.46 -40.21 90.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.012 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.484 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -40.21 144.17 0.58 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.627 0.727 . . . . 0.0 111.018 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.4 Cg_endo -69.9 140.26 41.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.618 2.212 . . . . 0.0 112.294 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -65.39 -45.06 85.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 73.2 m -115.22 150.97 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.455 ' HA ' HG22 ' A' ' 45' ' ' ILE . 10.8 p90 -169.41 147.44 3.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.837 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -56.11 -52.94 62.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.931 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -165.0 170.83 14.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -103.6 155.9 18.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.5 m -149.06 138.98 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.159 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.4 p -110.87 127.36 68.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.17 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.83 123.38 24.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.122 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.8 pt -97.68 -34.56 4.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -108.0 178.12 4.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -95.54 126.39 40.8 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -126.0 134.48 51.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.906 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.6 m -116.75 111.96 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.135 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.08 127.07 9.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -90.17 -57.2 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -94.72 -177.36 4.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -78.26 -28.8 47.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.447 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 8.7 m-20 -85.62 23.95 1.3 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLU . . . . . 0.447 ' OE1' ' C ' ' A' ' 32' ' ' ASP . 1.5 mp0 -114.69 177.89 4.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.934 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.649 HD23 ' N ' ' A' ' 35' ' ' SER . 2.7 tt -132.16 134.2 45.11 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.915 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.649 ' N ' HD23 ' A' ' 34' ' ' LEU . 87.6 p -97.67 127.71 43.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -150.51 170.4 19.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.907 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -139.1 162.23 35.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -43.86 109.35 0.14 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 106.61 44.22 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -121.35 125.4 46.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.336 . . . . 0.0 111.115 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.9 mm -82.75 100.1 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.015 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.659 HG21 ' CZ ' ' A' ' 64' ' ' PHE . 32.6 mt -105.95 131.16 56.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.146 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.412 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 79.4 m-85 -99.34 104.11 15.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.931 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.674 HG13 ' HB3' ' A' ' 53' ' ' TYR . 75.2 t -67.54 124.43 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.179 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.455 HG22 ' HA ' ' A' ' 16' ' ' TYR . 8.9 pt -124.77 -25.37 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.131 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.38 152.99 42.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 6.0 mtmp? -128.56 151.05 49.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.855 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB2' ' A' ' 52' ' ' TRP . 2.6 m-20 -126.47 -174.69 3.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.871 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -94.22 -31.54 14.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.607 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -95.34 39.29 1.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.55 63.14 5.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.531 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.607 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 95.0 m95 -134.75 96.97 3.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.674 ' HB3' HG13 ' A' ' 44' ' ' VAL . 11.8 m-85 -91.63 137.63 32.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.455 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.4 tt0 -96.67 111.63 23.71 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.842 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -124.65 171.71 16.81 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.412 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.8 t -110.42 134.66 51.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.891 0.377 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -140.61 111.31 6.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.87 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.1 t30 59.29 39.8 22.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.847 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.62 -38.17 2.93 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.441 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 98.7 t -75.62 127.43 37.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.999 0.428 . . . . 0.0 111.086 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.403 HG22 ' N ' ' A' ' 62' ' ' GLY . 38.3 m -106.46 153.91 21.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.16 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 61' ' ' THR . . . -177.1 170.03 42.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 13.6 mt -98.89 141.25 31.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.818 0.342 . . . . 0.0 110.912 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.659 ' CZ ' HG21 ' A' ' 42' ' ' ILE . 20.7 p90 -139.58 154.39 71.29 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.744 0.783 . . . . 0.0 110.838 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.456 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 53.9 Cg_endo -69.83 140.69 43.05 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.584 2.189 . . . . 0.0 112.349 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -80.59 41.17 2.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 -126.37 -43.53 1.76 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.901 0.382 . . . . 0.0 110.898 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -69.02 -23.65 64.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.963 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.8 m -113.66 148.83 16.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.156 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -108.55 155.52 20.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.973 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 44.6 p -99.56 100.67 11.71 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.79 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.6 pt -80.07 -29.79 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.102 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 18.2 t -46.38 131.79 10.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -64.07 -158.34 0.25 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.69 -42.22 3.67 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.687 2.258 . . . . 0.0 112.363 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 47.1 m 60.33 40.15 17.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.823 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 17.0 t -96.39 -55.41 2.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.798 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.459 -179.996 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.385 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.7 t -105.83 116.35 31.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m -151.82 134.24 15.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.08 -69.82 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.517 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.9 t -135.39 144.84 46.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 0.0 110.879 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.3 m -85.74 96.86 9.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.39 -125.15 0.75 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.522 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.421 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 1.2 m-20 -40.91 149.04 0.35 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.609 0.719 . . . . 0.0 110.832 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.672 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 52.9 Cg_endo -69.82 163.88 36.68 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.705 2.27 . . . . 0.0 112.25 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -47.86 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.596 2.197 . . . . 0.0 112.378 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 34.0 p-90 -57.07 -20.83 27.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.874 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.672 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -66.84 144.06 98.36 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.503 0.668 . . . . 0.0 111.124 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 14' ' ' ARG . 54.0 Cg_endo -69.77 105.8 1.55 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.622 2.215 . . . . 0.0 112.434 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.452 ' C ' ' O ' ' A' ' 13' ' ' PRO . 4.4 ptt85 -34.41 -46.54 0.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 t -120.23 149.75 41.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.464 ' CB ' HG22 ' A' ' 45' ' ' ILE . 38.4 p90 -169.01 163.12 11.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.922 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mt -60.96 -66.96 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.401 ' O ' ' CD1' ' A' ' 16' ' ' TYR . 11.2 pt-20 -146.8 -176.41 5.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.945 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.448 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 16.3 ttmt -127.91 127.34 43.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.839 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG22 HG23 ' A' ' 44' ' ' VAL . 16.5 m -122.03 158.97 25.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.166 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.77 124.12 64.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -54.72 138.36 42.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.077 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.8 pt -121.0 -13.51 8.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.154 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -132.64 147.65 52.34 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.04 105.65 3.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -113.56 141.81 46.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.954 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 50.9 m -122.73 110.98 16.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 24.7 pttt -48.68 151.05 1.24 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.953 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -97.33 -45.23 6.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.877 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.63 171.71 8.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -66.63 -7.02 17.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.892 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -87.4 -23.83 24.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.929 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -90.55 -178.35 5.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.42 150.76 50.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.802 ' N ' HD23 ' A' ' 34' ' ' LEU . 21.8 t -116.53 139.32 50.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -156.34 152.27 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.904 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -113.32 153.27 28.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.956 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -43.08 99.19 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.86 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 123.6 28.22 1.33 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.479 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.05 138.34 46.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.719 0.295 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.1 mm -95.81 127.61 47.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.169 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 64.5 mt -127.65 133.98 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.196 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 72.5 m-85 -95.44 98.54 10.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 53' ' ' TYR . 96.9 t -63.65 117.85 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.522 HD11 ' OE2' ' A' ' 54' ' ' GLU . 6.5 pt -116.58 -25.14 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.478 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 28.6 ttmt -128.42 142.8 50.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 21.3 mtpp -130.21 120.62 24.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.848 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -94.77 152.67 18.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -39.13 -47.12 1.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -81.98 -179.42 7.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.769 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.435 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -75.21 70.52 1.84 Allowed Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.472 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 58.3 m95 -149.74 122.77 8.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 111.043 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.77 ' HB3' HG13 ' A' ' 44' ' ' VAL . 7.0 m-85 -120.29 151.43 39.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.91 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.522 ' OE2' HD11 ' A' ' 45' ' ' ILE . 2.8 tt0 -104.02 113.58 27.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -131.48 154.43 20.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.553 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.538 HG22 ' OG1' ' A' ' 61' ' ' THR . 93.0 t -96.64 112.36 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.326 . . . . 0.0 111.176 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -118.11 112.0 19.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 22.5 t30 65.5 35.81 7.04 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.06 -31.57 3.1 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 76.7 t -83.69 129.98 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.826 0.345 . . . . 0.0 111.158 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.538 ' OG1' HG22 ' A' ' 56' ' ' VAL . 12.8 m -109.51 143.33 39.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.8 148.61 12.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.521 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.422 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.8 mm? -66.28 135.19 54.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -140.35 148.48 54.09 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.612 0.72 . . . . 0.0 110.91 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 132.47 23.22 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.4 -10.29 69.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -79.72 -28.35 40.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.881 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -89.21 20.9 3.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.8 m -138.06 178.43 4.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.126 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 71' ' ' SER . 6.3 tm-20 -143.69 160.07 41.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.828 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.472 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 9.7 m -104.11 113.64 27.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.886 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.5 pt -109.5 -30.87 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.1 t -100.27 105.98 17.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.8 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 145.06 -164.72 27.87 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.508 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.67 -3.48 12.04 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.668 2.245 . . . . 0.0 112.386 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.1 t -43.76 113.45 0.51 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.843 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.1 t -40.03 -43.37 1.56 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.843 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.479 179.969 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.369 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.1 p 41.72 42.89 2.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.837 0.351 . . . . 0.0 110.862 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.3 m -106.08 149.33 26.83 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.844 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 173.26 -110.88 0.35 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.43 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.7 p -70.6 156.86 38.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.87 0.367 . . . . 0.0 110.868 -179.653 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.2 t -55.46 -48.45 74.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.6 125.83 1.42 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.46 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -88.81 148.3 41.16 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.623 0.725 . . . . 0.0 110.822 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.471 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 52.7 Cg_endo -69.77 163.67 37.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.706 2.271 . . . . 0.0 112.293 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.73 2.287 . . . . 0.0 112.373 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.471 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 50.3 p-90 -54.85 -29.79 56.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.954 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.461 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -61.06 156.07 51.02 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.497 0.665 . . . . 0.0 111.134 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD2' ' HB1' ' A' ' 12' ' ' ALA . 53.5 Cg_endo -69.81 151.14 68.67 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.707 2.271 . . . . 0.0 112.26 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 68.2 mtt180 -72.51 -48.87 37.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.841 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.2 t -129.22 98.61 4.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.836 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -105.32 143.35 33.62 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.93 -67.31 0.27 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.933 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -143.31 178.9 7.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.888 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.618 ' HE2' HG23 ' A' ' 41' ' ' ILE . 27.9 tttt -123.12 141.98 51.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.482 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.0 m -137.54 174.05 11.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.045 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.495 HG12 HG23 ' A' ' 72' ' ' ILE . 12.6 p -134.13 150.6 31.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.12 96.92 10.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.036 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.472 HG13 ' CD2' ' A' ' 24' ' ' TYR . 32.1 pt -73.24 -12.27 15.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.472 ' CD2' HG13 ' A' ' 23' ' ' ILE . 60.5 m-85 -131.53 172.25 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.93 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.24 96.49 6.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 29.5 t80 -98.96 155.35 17.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -123.81 131.59 53.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.428 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -78.31 125.95 30.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -96.68 -53.27 3.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.807 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.438 ' NZ ' ' HA ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -96.21 164.47 12.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.959 179.934 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.08 -28.43 67.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -86.76 42.97 1.05 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.966 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -148.01 152.95 38.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.894 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.582 HD23 ' N ' ' A' ' 35' ' ' SER . 1.8 tt -112.17 130.67 55.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.792 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.582 ' N ' HD23 ' A' ' 34' ' ' LEU . 55.7 p -96.16 134.03 39.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -154.96 169.18 24.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.909 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -126.25 161.19 28.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -50.47 108.01 0.2 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.892 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.48 32.96 2.59 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.476 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.61 145.67 34.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.71 0.291 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.618 HG23 ' HE2' ' A' ' 19' ' ' LYS . 22.0 mm -102.37 126.55 56.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.129 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.489 HG21 ' CE2' ' A' ' 64' ' ' PHE . 19.5 mt -134.76 141.99 41.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.112 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -104.16 124.02 48.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.899 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.6 t -77.62 117.44 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.042 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.3 pt -116.99 -12.2 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.463 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 17.7 tttm -153.95 151.32 29.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -134.16 111.45 10.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.921 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -75.26 164.88 25.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -40.72 -46.61 2.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.34 -179.83 7.28 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.803 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.449 ' O ' ' CZ ' ' A' ' 53' ' ' TYR . . . -60.82 -7.66 8.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.476 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -69.88 128.28 35.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.852 0.358 . . . . 0.0 110.93 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.449 ' CZ ' ' O ' ' A' ' 51' ' ' GLY . 3.8 m-85 -126.68 148.72 49.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.951 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.463 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.2 tt0 -90.88 130.3 36.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -146.24 167.19 27.96 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.437 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.7 t -108.82 136.1 45.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.864 0.364 . . . . 0.0 111.146 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.6 ttp -143.48 122.62 12.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.882 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.461 ' ND2' ' O ' ' A' ' 58' ' ' ASN . 2.8 p-10 43.81 39.76 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.93 -30.74 3.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.06 117.01 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 111.084 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 10.3 m -99.38 135.18 41.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -164.5 163.15 36.0 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.459 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.7 mt -89.88 124.61 34.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.81 0.338 . . . . 0.0 110.917 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.489 ' CE2' HG21 ' A' ' 42' ' ' ILE . 35.8 p90 -119.83 144.65 37.74 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.619 0.724 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 138.63 38.17 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.667 2.244 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.08 3.69 56.85 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.521 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -89.89 -24.58 21.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.925 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -98.12 26.0 5.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.926 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.2 m -144.27 179.97 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.086 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.416 ' CG ' HD13 ' A' ' 23' ' ' ILE . 2.2 mm-40 -150.69 125.91 10.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 31.3 p -64.35 82.35 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.599 HD13 ' N ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -51.56 -32.36 13.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.126 179.935 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 45.0 m -107.25 152.59 23.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 105.85 -167.03 14.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.443 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 85.4 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.661 2.241 . . . . 0.0 112.351 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.7 p -115.76 151.45 35.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 60.4 p -152.23 137.38 17.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.917 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.481 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.418 -0.273 . . . . 0.0 112.418 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.4 p -174.99 171.23 3.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.5 p -169.06 155.15 6.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.821 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -134.85 92.22 0.24 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.555 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.7 m -79.61 144.12 34.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.899 0.38 . . . . 0.0 110.858 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.8 m -115.73 105.3 12.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.828 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.96 41.23 1.47 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.462 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -127.61 152.19 76.35 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.602 0.715 . . . . 0.0 110.869 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.583 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo -69.73 167.77 23.44 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.754 2.302 . . . . 0.0 112.327 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -47.6 0.9 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.41 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.6 p-90 -55.24 -40.73 71.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.583 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -47.39 153.1 1.02 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.558 0.694 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.63 146.92 62.47 Favored 'Trans proline' 0 C--O 1.23 0.121 0 C-N-CA 122.744 2.296 . . . . 0.0 112.33 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.9 ptt180 -49.14 -57.89 5.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.844 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 36.1 t -133.85 149.88 51.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.1 p90 -149.2 159.72 44.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.9 mt -66.79 -61.06 2.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.873 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.11 175.72 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.439 ' HE3' HG23 ' A' ' 41' ' ' ILE . 31.1 tttt -121.46 151.72 39.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.971 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.478 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 29.1 m -145.36 177.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.177 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.622 HG12 HG23 ' A' ' 72' ' ' ILE . 8.3 p -137.1 139.18 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.29 87.99 4.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 24' ' ' TYR . 30.2 pt -64.52 -28.02 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.135 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.584 ' CE2' HD12 ' A' ' 23' ' ' ILE . 55.3 m-85 -128.97 156.31 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -81.34 120.71 25.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.918 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.56 ' CE1' ' O ' ' A' ' 27' ' ' THR . 5.4 t80 -129.28 124.09 33.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.56 ' O ' ' CE1' ' A' ' 26' ' ' TYR . 5.7 t -84.85 172.63 11.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.125 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 17.2 pttm -107.97 124.24 49.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -80.19 -29.68 38.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.1 mttp -126.66 150.29 49.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.864 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -51.72 -28.02 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.916 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.544 ' OD2' HD12 ' A' ' 63' ' ' LEU . 15.3 t70 -70.92 -38.43 72.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.892 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -66.52 171.18 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.771 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.4 tt -122.68 137.96 54.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.976 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -108.21 138.49 44.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -151.84 172.29 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -127.73 154.39 45.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -38.22 123.79 1.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.07 52.85 2.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.449 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.75 128.58 42.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.723 0.297 . . . . 0.0 111.115 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.439 HG23 ' HE3' ' A' ' 19' ' ' LYS . 31.9 mm -84.19 125.63 40.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.076 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.0 mt -134.22 131.18 55.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.172 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -96.51 114.15 25.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.5 t -72.4 123.29 26.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 16.2 pt -120.78 -28.02 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.127 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 30.5 tptt -123.1 140.36 53.1 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -130.71 105.32 7.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -86.64 154.06 21.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.915 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -44.98 -56.81 4.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.96 176.75 3.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.884 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -74.33 73.71 1.32 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' TRP . . . . . 0.533 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 95.7 m95 -158.56 112.22 2.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.797 0.332 . . . . 0.0 110.993 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -112.6 154.6 25.77 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -108.8 120.65 43.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.872 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -136.0 173.36 21.92 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -105.18 132.8 51.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.814 0.34 . . . . 0.0 111.156 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.11 109.71 7.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 t30 55.15 39.79 31.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.58 -31.23 3.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.446 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.46 ' O ' HD11 ' A' ' 34' ' ' LEU . 89.7 t -79.12 121.16 31.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 111.141 -179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.0 m -99.47 150.07 22.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.771 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -178.5 169.58 41.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.485 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.544 HD12 ' OD2' ' A' ' 32' ' ' ASP . 5.4 mt -94.47 138.32 32.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.843 0.354 . . . . 0.0 110.992 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -139.85 150.85 64.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.592 0.71 . . . . 0.0 110.959 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.533 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.5 Cg_endo -69.76 139.73 40.94 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.711 2.274 . . . . 0.0 112.355 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.73 6.28 47.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.509 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -92.58 -30.83 15.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.776 0.322 . . . . 0.0 110.79 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -90.35 25.06 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.957 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 21.0 m -148.34 142.73 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.113 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.649 ' OE2' HG22 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -112.37 141.51 46.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.888 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.428 ' C ' ' OE1' ' A' ' 70' ' ' GLU . 74.7 m -78.25 79.69 4.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.649 HG22 ' OE2' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -46.91 -33.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.109 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -105.73 149.45 26.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.844 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -169.25 -158.43 13.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.453 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 -24.7 28.98 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.662 2.241 . . . . 0.0 112.264 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.0 m 37.91 43.09 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.791 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 89.6 p -82.17 165.5 20.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.796 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.46 -179.93 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.559 -0.216 . . . . 0.0 112.559 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m 63.76 42.83 5.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.864 0.364 . . . . 0.0 110.787 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.3 t -52.75 124.78 14.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.839 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.48 -100.75 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.1 m -87.26 109.51 19.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.821 0.343 . . . . 0.0 110.868 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 p -136.48 127.05 26.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.3 92.39 0.39 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.526 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -122.75 144.01 41.61 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.669 0.747 . . . . 0.0 110.834 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.9 Cg_endo -69.75 163.74 37.15 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.709 2.273 . . . . 0.0 112.302 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.63 21.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.312 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' TRP . . . . . 0.492 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 21.9 p-90 -100.46 -31.31 11.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.878 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.47 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -72.55 149.02 90.76 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.626 0.727 . . . . 0.0 111.109 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.469 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 54.2 Cg_endo -69.66 168.19 22.14 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.66 2.24 . . . . 0.0 112.412 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 -83.97 -49.67 8.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.1 t -128.79 141.33 51.34 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.859 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -150.66 160.09 44.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.947 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.8 mt -59.83 -62.1 2.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -150.15 175.4 11.78 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.882 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.603 ' HD2' HG21 ' A' ' 41' ' ' ILE . 6.4 ttpm? -120.91 140.42 51.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.776 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.25 158.21 43.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.102 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.6 p -122.16 116.7 49.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.173 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -57.69 148.39 24.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.091 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.408 HD12 ' CE2' ' A' ' 24' ' ' TYR . 3.2 pt -124.71 -33.01 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.183 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE2' HD12 ' A' ' 23' ' ' ILE . 42.7 m-85 -117.92 165.97 13.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.967 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -86.59 139.72 30.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.868 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -140.26 128.71 22.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.917 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 35.3 m -111.11 111.22 22.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -53.63 138.32 34.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.95 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -92.38 -28.58 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 mmtp -112.77 -177.04 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.931 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -99.58 34.37 2.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -128.69 -38.82 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -68.85 -175.02 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.8 tt -126.12 146.4 49.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.927 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.497 ' N ' HD23 ' A' ' 34' ' ' LEU . 3.8 m -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.917 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -147.1 159.66 43.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.804 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -113.03 166.64 11.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.96 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -51.97 124.7 13.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 92.61 36.79 6.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.473 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.72 116.12 21.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.668 0.27 . . . . 0.0 111.134 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.603 HG21 ' HD2' ' A' ' 19' ' ' LYS . 3.6 mp -82.37 143.55 11.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.118 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.472 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 21.3 mt -135.37 132.61 52.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.076 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.469 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 76.7 m-85 -85.71 100.87 12.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.972 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.414 HG13 ' HB3' ' A' ' 53' ' ' TYR . 86.4 t -69.74 111.25 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.199 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 pt -101.73 -19.93 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.044 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -139.81 138.63 35.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.498 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 58.3 mttt -130.67 110.02 11.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 49' ' ' ASP . 65.8 m-80 -83.0 151.06 25.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 48' ' ' ASN . 34.1 m-20 -36.0 -59.64 0.59 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -72.79 179.8 3.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.37 74.94 0.68 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.532 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -156.76 110.94 2.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.935 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.498 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.5 OUTLIER -123.47 148.83 45.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.881 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -93.52 128.66 39.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.906 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.472 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -143.94 152.14 23.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.616 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.5 t -96.43 143.06 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.931 0.396 . . . . 0.0 111.093 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.401 ' O ' ' C ' ' A' ' 58' ' ' ASN . 4.8 tmm? -145.15 127.01 15.38 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 57' ' ' MET . 21.2 t-20 38.24 46.12 0.85 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.973 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.91 -40.97 3.01 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.476 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.4 t -75.84 124.12 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.0 0.429 . . . . 0.0 111.126 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.616 ' OG1' HG22 ' A' ' 56' ' ' VAL . 31.8 m -107.55 150.16 27.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.172 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . 0.679 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.47 152.97 11.16 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.477 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.1 mp -72.71 151.96 41.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.864 0.364 . . . . 0.0 110.993 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.566 ' HE2' HG11 ' A' ' 69' ' ' VAL . 34.1 p90 -151.46 147.51 20.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.595 0.712 . . . . 0.0 110.925 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.86 133.04 24.44 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.654 2.236 . . . . 0.0 112.365 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.06 49.02 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.484 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -121.55 -29.86 4.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -94.3 3.4 55.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.994 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.566 HG11 ' HE2' ' A' ' 64' ' ' PHE . 19.3 m -112.09 160.86 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.113 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -135.35 124.65 24.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 66.2 m -58.05 113.33 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG2' HG12 ' A' ' 21' ' ' VAL . 44.3 pt -80.52 -38.36 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.481 ' N ' HG13 ' A' ' 72' ' ' ILE . 30.8 t -73.09 147.41 44.97 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 92.79 162.41 36.88 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.511 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 138.0 36.75 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.672 2.248 . . . . 0.0 112.334 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -107.38 -46.37 3.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.837 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.7 m -94.42 119.38 33.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.884 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 -179.961 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.602 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.0 Cg_endo . . . . . 0 C--O 1.232 0.21 0 CA-C-O 121.59 0.579 . . . . 0.0 112.286 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 -31.02 20.97 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.712 2.275 . . . . 0.0 112.304 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 51.2 p-90 -76.57 -11.73 59.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.602 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -89.01 144.25 32.48 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.487 0.661 . . . . 0.0 111.197 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.84 132.55 23.44 Favored 'Trans proline' 0 C--O 1.231 0.132 0 C-N-CA 122.62 2.214 . . . . 0.0 112.322 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 34.6 mtm180 -57.07 -40.17 76.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -120.55 148.86 43.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.868 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -165.46 166.24 18.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -70.05 -61.91 1.59 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -150.96 -177.62 6.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.842 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.1 ttmm -118.23 144.78 45.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.649 HG22 ' O ' ' A' ' 42' ' ' ILE . 27.9 m -142.44 152.93 17.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.198 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 21' ' ' VAL . 3.6 p -127.71 115.73 40.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.057 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -52.05 138.53 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.0 pt -113.62 -25.13 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -126.11 159.37 33.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 -75.78 127.53 33.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CE1' ' HG3' ' A' ' 65' ' ' PRO . 89.2 t80 -131.62 109.81 10.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.97 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.5 m -93.41 110.49 22.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.188 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.422 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 1.6 pptp? -58.69 157.56 9.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -101.66 -45.83 5.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 pttt -128.43 155.96 43.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -44.11 -32.37 1.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.92 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.41 -42.49 70.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -81.05 178.66 8.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.738 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -123.6 140.86 52.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.738 ' N ' HD23 ' A' ' 34' ' ' LEU . 99.5 p -110.82 128.1 55.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 4.2 p90 -149.96 168.03 24.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -121.09 158.28 28.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -51.62 96.84 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.83 34.11 0.49 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.424 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.55 124.41 45.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.796 0.332 . . . . 0.0 111.043 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.688 ' N ' HD12 ' A' ' 41' ' ' ILE . 2.0 mp -82.39 101.41 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.649 ' O ' HG22 ' A' ' 20' ' ' VAL . 23.0 mt -95.64 122.28 46.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.075 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -83.96 97.29 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.21 133.03 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.169 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.448 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.0 pt -127.25 -29.0 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -135.25 148.92 49.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.519 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 5.7 mtmp? -135.74 105.39 6.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -66.76 170.52 6.37 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -50.54 -54.58 21.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.815 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' A' ' 52' ' ' TRP . 16.2 m-20 -84.37 174.71 9.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.828 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.44 76.16 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.504 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.484 ' N ' ' O ' ' A' ' 50' ' ' ASP . 93.2 m95 -156.23 108.89 2.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.801 0.334 . . . . 0.0 110.916 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.519 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.4 OUTLIER -113.58 149.38 34.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.448 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 6.2 tt0 -100.13 128.57 46.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.912 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.41 167.68 29.1 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.448 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.6 t -104.72 133.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 0.0 111.2 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.21 125.01 22.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 58' ' ' ASN . 12.5 t30 50.41 30.7 4.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.09 -27.06 8.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.6 t -88.46 128.71 40.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.942 0.401 . . . . 0.0 111.143 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.72 151.48 21.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.108 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -179.95 153.05 11.46 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.446 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.96 133.68 36.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 110.869 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.536 ' CE1' HG21 ' A' ' 42' ' ' ILE . 47.5 p90 -132.85 150.53 75.94 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.651 0.738 . . . . 0.0 110.866 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.435 ' HG3' ' CE1' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.8 131.54 21.39 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.753 2.302 . . . . 0.0 112.421 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.02 51.17 3.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -130.42 -37.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.776 0.322 . . . . 0.0 110.915 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -84.25 10.52 10.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.957 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -123.1 161.55 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.201 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -136.8 126.69 25.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.5 m -69.65 127.51 33.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.841 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 3.4 pt . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.207 179.929 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.556 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.163 0 CA-C-O 121.566 0.569 . . . . 0.0 112.379 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 -41.63 4.21 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.36 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 54.8 p-90 -57.15 -18.79 16.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.75 61.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.544 0.687 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 133.24 25.19 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.627 2.218 . . . . 0.0 112.355 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 52.9 mtm180 -72.57 -33.55 66.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.5 t -112.94 118.1 33.93 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.815 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.474 ' HB3' HG22 ' A' ' 45' ' ' ILE . 22.3 p90 -160.98 142.43 11.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.969 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -56.8 -60.53 3.43 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -161.07 -178.12 6.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 ptpp? -114.84 168.51 9.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.923 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.44 ' HA ' HD13 ' A' ' 72' ' ' ILE . 27.4 m -146.93 156.88 10.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.178 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 70' ' ' GLU . 14.8 p -113.34 142.16 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.124 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.88 106.87 15.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.096 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.473 HD12 ' CE2' ' A' ' 24' ' ' TYR . 28.2 pt -80.84 -15.76 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.473 ' CE2' HD12 ' A' ' 23' ' ' ILE . 58.5 m-85 -138.81 158.72 43.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.84 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 98.66 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.797 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.449 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 61.3 t80 -91.93 133.98 35.2 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.998 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 38.9 m -112.29 120.21 40.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.68 135.45 52.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.915 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -103.2 -33.33 9.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -113.81 159.28 19.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -62.67 -22.15 66.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -90.94 38.54 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.931 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -140.14 174.92 10.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -124.88 135.69 53.11 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.457 ' N ' HD23 ' A' ' 34' ' ' LEU . 84.8 p -104.41 137.87 41.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.845 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 13.8 p90 -161.57 159.77 28.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.827 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -109.16 173.46 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -66.01 110.35 2.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.85 39.4 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.437 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.41 149.89 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.791 0.329 . . . . 0.0 111.097 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 45.6 mm -102.78 123.47 56.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.411 HG21 ' CE1' ' A' ' 64' ' ' PHE . 49.4 mt -126.9 125.54 66.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.103 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -84.18 120.07 25.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.4 t -82.45 114.83 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.474 HG22 ' HB3' ' A' ' 16' ' ' TYR . 31.6 pt -110.56 -14.54 10.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.172 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.44 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 32.1 tttp -146.19 144.49 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.908 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.581 ' HE2' ' CE1' ' A' ' 53' ' ' TYR . 13.2 mtpt -136.51 110.65 8.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.889 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -82.41 161.42 22.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -55.63 -36.82 67.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -84.57 175.65 9.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.892 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -72.15 67.62 1.15 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.392 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.496 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 65.5 m95 -158.8 121.35 3.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.731 0.3 . . . . 0.0 110.999 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.581 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 6.4 m-85 -118.65 154.9 31.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.936 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.44 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 16.7 tt0 -104.19 123.55 47.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 61' ' ' THR . . . -143.24 167.91 26.3 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.64 133.27 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.115 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -139.23 116.52 11.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.8 t30 55.7 39.11 30.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.31 -36.61 2.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.446 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 88.2 t -76.31 123.91 33.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.983 0.42 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.49 HG23 ' O ' ' A' ' 55' ' ' GLY . 5.3 m -107.62 146.38 32.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.114 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.59 169.0 41.41 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.544 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.459 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.2 mm? -88.52 127.16 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.881 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.411 ' CE1' HG21 ' A' ' 42' ' ' ILE . 49.1 p90 -136.63 144.75 48.39 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.666 0.746 . . . . 0.0 110.892 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 143.11 49.71 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.707 2.272 . . . . 0.0 112.337 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.484 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -83.98 7.26 71.42 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.427 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.0 m-20 -90.24 -35.24 15.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.871 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -80.1 3.25 21.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.62 172.75 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.163 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.487 ' O ' HG12 ' A' ' 21' ' ' VAL . 13.7 tt0 -142.26 137.03 30.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 49.1 m -69.42 130.59 42.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.849 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.496 HD13 ' H ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.156 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.685 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.7 Cg_endo . . . . . 0 N--CA 1.465 -0.187 0 CA-C-O 121.599 0.583 . . . . 0.0 112.335 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -29.56 23.5 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.301 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.521 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 62.5 p-90 -77.8 -25.94 49.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.853 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.685 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -65.58 151.68 94.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.59 0.709 . . . . 0.0 111.172 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 175.92 7.44 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.666 2.244 . . . . 0.0 112.297 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 10.7 tpp180 -88.29 -51.26 5.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.87 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.2 t -123.53 155.26 37.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.895 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 13.5 p90 -164.84 161.22 20.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 82.5 mt -66.72 -59.9 3.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -156.96 167.67 29.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -102.22 128.73 48.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 44' ' ' VAL . 10.7 m -119.68 164.69 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.144 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.7 p -133.63 140.54 46.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.255 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.439 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -79.88 118.64 21.83 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.075 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.2 pt -91.39 -14.75 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.09 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -136.74 161.36 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -86.23 132.66 33.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.887 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -130.91 144.89 51.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.9 m -118.34 95.44 4.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.241 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.423 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -40.49 135.45 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.866 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -108.77 -54.64 2.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.916 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -79.91 162.47 24.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -69.84 -25.05 63.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -95.94 54.38 1.48 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -149.66 178.29 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.71 HD23 ' N ' ' A' ' 35' ' ' SER . 2.6 tt -131.32 142.43 50.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.926 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.71 ' N ' HD23 ' A' ' 34' ' ' LEU . 59.7 p -108.19 143.36 37.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -166.91 167.99 14.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.774 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -120.34 164.81 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.979 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -55.74 117.97 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 105.25 43.88 1.55 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.95 138.52 52.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.78 0.324 . . . . 0.0 111.12 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 47.9 mm -89.76 129.72 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.164 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.23 145.5 34.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.165 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -106.96 114.17 28.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.442 HG13 ' HB3' ' A' ' 53' ' ' TYR . 43.6 t -77.76 118.03 23.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.149 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.61 HD11 ' OE1' ' A' ' 54' ' ' GLU . 2.9 pt -117.06 -8.88 12.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.5 ttmm -136.36 140.85 43.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.981 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 36.9 mttp -134.89 103.02 5.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' A' ' 50' ' ' ASP . 32.7 m-20 -83.55 38.81 0.64 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.891 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 48' ' ' ASN . 2.4 m-20 36.67 32.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.932 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.463 ' O ' ' CE1' ' A' ' 53' ' ' TYR . 31.0 m-20 -151.89 -175.04 5.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.816 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -76.27 52.99 3.07 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.419 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 96.4 m95 -162.87 106.97 1.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.766 0.317 . . . . 0.0 110.927 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.463 ' CE1' ' O ' ' A' ' 50' ' ' ASP . 4.7 m-85 -120.32 154.82 34.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.94 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.61 ' OE1' HD11 ' A' ' 45' ' ' ILE . 0.1 OUTLIER -98.25 141.14 31.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.88 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' A' ' 54' ' ' GLU . . . -161.85 165.45 35.77 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.413 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.578 HG22 ' OG1' ' A' ' 61' ' ' THR . 56.1 t -107.43 146.13 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.858 0.361 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.3 ttp -155.22 108.18 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.2 t30 68.14 32.96 4.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.65 -23.77 7.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.502 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.1 t -88.29 122.75 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.91 0.386 . . . . 0.0 111.107 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.578 ' OG1' HG22 ' A' ' 56' ' ' VAL . 7.3 m -106.33 148.43 28.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -176.77 163.29 32.18 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.489 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.451 HD22 ' N ' ' A' ' 63' ' ' LEU . 3.0 mm? -84.58 125.85 32.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.368 . . . . 0.0 110.909 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -127.19 152.11 75.49 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.683 0.754 . . . . 0.0 110.886 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 143.41 51.08 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.715 2.277 . . . . 0.0 112.289 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -86.56 24.79 7.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.494 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -111.33 -28.81 8.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -87.72 5.08 41.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.439 HG12 ' HA ' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -127.82 173.27 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.127 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.82 135.6 18.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.904 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.8 p -65.77 131.47 46.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.1 pt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.976 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.653 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.185 0 CA-C-O 121.662 0.609 . . . . 0.0 112.278 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.67 -13.68 35.24 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.675 2.25 . . . . 0.0 112.398 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.576 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.9 p-90 -93.93 -34.65 13.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.653 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -51.31 145.78 13.14 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.521 0.677 . . . . 0.0 111.096 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.554 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.7 Cg_endo -69.8 133.68 26.08 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.727 2.285 . . . . 0.0 112.36 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 43.4 mtt180 -59.93 -33.43 71.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.98 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -140.42 137.92 34.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -153.74 161.54 42.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.97 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.598 HD13 ' HG3' ' A' ' 47' ' ' LYS . 5.1 mt -57.14 -71.68 0.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.912 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -151.49 165.74 33.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.634 ' HG2' HD11 ' A' ' 72' ' ' ILE . 15.5 ttpt -100.83 134.39 43.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.02 159.72 26.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.497 HG12 HG23 ' A' ' 72' ' ' ILE . 8.1 p -119.02 132.97 67.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.18 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.639 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -77.76 100.59 6.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.3 pt -75.86 -14.9 15.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -134.1 173.7 11.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -100.3 107.91 19.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.849 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.55 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 70.5 t80 -107.07 134.05 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 28' ' ' LYS . 30.1 m -110.23 111.94 23.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.101 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 27' ' ' THR . 0.0 OUTLIER -36.15 128.99 0.71 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 179.898 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -100.88 -41.07 6.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -104.3 165.01 11.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -67.37 -27.01 66.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.448 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 9.6 p-10 -94.21 16.61 14.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.826 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.486 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -106.13 166.12 10.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.943 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -118.37 141.57 48.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.623 ' N ' HD23 ' A' ' 34' ' ' LEU . 2.4 t -107.68 140.33 40.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -158.31 150.6 21.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -102.56 160.78 14.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -46.42 152.35 0.45 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 63.78 36.26 93.08 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.53 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -106.74 166.49 10.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.764 0.316 . . . . 0.0 111.087 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.7 mm -120.2 129.5 75.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.211 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.4 mt -129.54 141.14 47.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.554 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 53.6 m-85 -105.28 92.13 4.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.5 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 86.1 t -58.27 113.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.075 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.7 pt -110.84 -15.15 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.441 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.2 ttmt -140.76 147.46 39.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.598 ' HG3' HD13 ' A' ' 17' ' ' LEU . 64.0 mttt -135.85 147.76 48.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.968 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -125.53 151.09 46.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -39.15 -49.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.867 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -76.56 -176.0 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.21 64.73 4.11 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -148.75 114.79 5.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.478 ' C ' HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -121.23 146.78 46.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.895 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.441 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 4.1 tt0 -96.44 126.63 41.77 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.882 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -140.18 167.45 25.44 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.448 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 t -105.1 143.52 16.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.831 0.348 . . . . 0.0 111.082 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.574 ' HB3' HD21 ' A' ' 34' ' ' LEU . 7.5 tmm? -152.66 112.36 3.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.28 39.71 22.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.956 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.86 -34.68 2.55 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 86.8 t -75.58 126.78 36.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.95 0.405 . . . . 0.0 111.131 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.5 m -104.27 141.38 36.39 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.454 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -174.33 153.89 17.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.517 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 53' ' ' TYR . 5.3 mt -75.63 156.23 35.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.5 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 35.2 p90 -155.79 148.16 17.66 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 130.26 19.13 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.738 2.292 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -71.13 -2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.52 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -86.22 -33.73 20.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.838 0.352 . . . . 0.0 110.911 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.55 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 9.5 m-85 -69.83 -23.59 63.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 22' ' ' ALA . 12.3 m -115.33 175.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.167 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -136.36 162.72 32.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 m -88.22 113.71 24.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.791 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.634 HD11 ' HG2' ' A' ' 19' ' ' LYS . 47.7 pt . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.179 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.615 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.3 Cg_endo . . . . . 0 N--CA 1.464 -0.228 0 CA-C-O 121.614 0.589 . . . . 0.0 112.377 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -19.69 35.77 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.731 2.287 . . . . 0.0 112.316 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 42.0 p-90 -90.47 -20.25 22.93 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.942 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.615 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -70.93 148.47 94.59 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.614 0.721 . . . . 0.0 111.151 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 133.45 25.67 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 67.6 mtt85 -43.06 -46.25 5.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.824 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.6 p -145.8 144.16 30.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.3 p90 -134.66 174.6 10.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -76.68 -56.36 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.95 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -154.46 168.94 25.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttt -110.12 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.798 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.7 148.28 22.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.177 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -112.86 131.79 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.32 99.68 2.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.082 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.749 HD12 ' CE2' ' A' ' 24' ' ' TYR . 16.3 pt -73.13 -14.65 16.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.749 ' CE2' HD12 ' A' ' 23' ' ' ILE . 28.9 m-85 -143.56 156.13 44.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.92 162.96 28.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 2.9 t80 -168.84 131.5 1.32 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.946 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 17.4 m -109.84 131.99 54.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.093 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' HZ3' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -63.67 164.27 10.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.954 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -129.07 -5.74 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.849 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ptpp? -146.6 143.13 28.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -47.11 -23.9 0.57 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -93.45 47.35 1.24 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.818 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -145.26 -179.74 6.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.587 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -126.48 151.16 48.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.924 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.587 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.9 p -121.22 123.99 43.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -140.95 152.59 45.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -110.26 165.02 12.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.961 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -52.64 108.29 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 104.96 39.66 2.27 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.88 21.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.74 0.305 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.8 mm -107.4 111.14 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.201 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.534 HG21 ' CE1' ' A' ' 64' ' ' PHE . 81.3 mt -117.06 141.36 35.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.164 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -105.09 108.85 20.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.971 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -67.11 115.36 4.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.181 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.1 pt -118.17 -18.44 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.14 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 4.1 tmtm? -138.94 146.45 41.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 17.1 mtpp -136.2 112.36 9.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -74.9 173.76 10.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -51.61 -17.52 0.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -112.75 -175.84 2.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.586 ' O ' ' CE2' ' A' ' 53' ' ' TYR . . . -63.31 -10.19 33.93 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.443 ' CH2' ' HD3' ' A' ' 65' ' ' PRO . 59.4 m95 -61.96 122.53 15.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.705 0.288 . . . . 0.0 110.9 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.586 ' CE2' ' O ' ' A' ' 51' ' ' GLY . 19.5 m-85 -123.84 135.55 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.454 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 9.3 tt0 -87.39 121.9 30.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.453 ' O ' ' CD1' ' A' ' 34' ' ' LEU . . . -134.57 158.23 23.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.454 HG22 ' OG1' ' A' ' 61' ' ' THR . 59.2 t -101.43 129.8 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.476 ' O ' ' ND2' ' A' ' 58' ' ' ASN . 2.2 tmm? -138.43 138.08 37.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.813 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.476 ' ND2' ' O ' ' A' ' 57' ' ' MET . 1.9 p30 39.97 38.07 0.44 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.909 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.61 -38.08 2.79 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -75.95 117.71 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.454 ' OG1' HG22 ' A' ' 56' ' ' VAL . 17.1 m -100.62 145.64 28.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.158 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.75 177.13 44.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.622 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.1 mt -94.47 155.31 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.784 0.326 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.534 ' CE1' HG21 ' A' ' 42' ' ' ILE . 51.2 p90 -158.54 151.55 18.5 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.612 0.72 . . . . 0.0 110.927 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.443 ' HD3' ' CH2' ' A' ' 52' ' ' TRP . 53.6 Cg_endo -69.74 129.91 18.44 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.755 2.304 . . . . 0.0 112.371 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -61.47 -17.66 53.86 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.463 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 69' ' ' VAL . 32.0 t30 -68.97 -65.89 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -38.52 -31.71 0.06 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.871 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.404 ' N ' ' O ' ' A' ' 67' ' ' ASN . 3.3 m -107.18 173.66 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -143.59 168.72 19.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 28.9 t -96.05 118.41 32.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 21.5 pt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.091 180.0 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.5 Cg_endo . . . . . 0 C--O 1.23 0.116 0 CA-C-O 121.661 0.609 . . . . 0.0 112.282 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -44.59 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.326 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.403 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 33.8 p-90 -56.25 -16.72 5.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 144.19 89.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.656 0.741 . . . . 0.0 111.103 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.31 14.42 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -55.64 -39.92 71.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 7.3 t -117.49 129.93 56.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.789 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.455 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 9.6 p90 -156.32 140.52 16.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.936 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.59 HD22 ' HE2' ' A' ' 47' ' ' LYS . 3.9 mp -49.93 -68.12 0.2 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.93 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -146.37 175.66 10.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 43' ' ' TYR . 0.6 OUTLIER -116.46 126.82 53.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.903 179.952 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.26 159.51 23.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.086 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.44 HG23 HD13 ' A' ' 41' ' ' ILE . 9.2 p -119.68 143.46 31.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.112 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.16 114.67 18.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.088 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.549 HG13 ' CD2' ' A' ' 24' ' ' TYR . 33.6 pt -92.97 -9.34 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.549 ' CD2' HG13 ' A' ' 23' ' ' ILE . 55.1 m-85 -147.88 158.23 43.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -82.12 128.71 34.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -135.22 129.84 34.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.918 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 28' ' ' LYS . 91.0 m -107.17 104.43 14.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 27' ' ' THR . 14.8 pttm -36.84 122.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -81.59 -8.68 59.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.789 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.9 mmtm -135.27 -175.08 3.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.91 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.26 -16.74 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.943 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -88.69 -22.42 23.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.821 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.43 166.4 22.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.553 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -120.0 134.77 55.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.553 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.4 t -99.73 145.4 27.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -164.9 161.26 20.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -106.85 172.83 6.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -66.3 112.04 3.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 122.8 -17.26 8.22 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.448 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.03 146.92 52.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.752 0.311 . . . . 0.0 111.123 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.44 HD13 HG23 ' A' ' 21' ' ' VAL . 10.8 mm -104.47 141.45 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.182 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.699 HG21 ' CE2' ' A' ' 64' ' ' PHE . 16.8 mt -135.58 142.85 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.088 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.504 ' CE1' ' HE3' ' A' ' 19' ' ' LYS . 93.1 m-85 -105.67 104.76 14.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.873 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.5 t -61.24 121.92 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.105 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.2 pt -123.93 -14.91 5.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.171 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.486 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 35.3 tttm -137.29 148.79 46.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.59 ' HE2' HD22 ' A' ' 17' ' ' LEU . 38.2 mmtt -119.76 161.66 20.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.432 ' CB ' ' HB2' ' A' ' 52' ' ' TRP . 2.4 m-80 -133.12 -174.95 3.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.943 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -109.72 -28.07 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.593 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 54.9 m-20 -99.45 40.39 1.22 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.837 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 60.79 79.8 0.11 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.543 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.593 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 94.1 m95 -162.67 137.37 6.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.76 0.314 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.485 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 11.9 m-85 -132.87 136.46 46.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.861 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.486 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.7 tt0 -95.86 115.37 27.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.959 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.41 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -125.68 173.26 17.61 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.472 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.3 t -113.01 139.1 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.157 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.469 ' O ' ' N ' ' A' ' 60' ' ' VAL . 5.3 tmm? -149.36 143.8 26.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.424 ' C ' ' O ' ' A' ' 57' ' ' MET . 11.6 p-10 35.78 37.79 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.0 2.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' MET . 89.1 t -76.05 138.94 19.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.0 111.165 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 15.8 m -114.64 146.72 40.53 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.402 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.86 177.9 44.38 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.376 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.0 mp -105.05 134.12 48.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.825 0.345 . . . . 0.0 110.951 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 42' ' ' ILE . 29.4 p90 -125.92 153.1 73.62 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.677 0.751 . . . . 0.0 110.846 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.42 50.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.281 . . . . 0.0 112.297 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.31 36.8 2.4 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.477 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -127.87 -29.69 2.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -91.25 16.29 10.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.6 m -146.59 162.5 9.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.098 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 33.0 mm-40 -139.76 150.97 45.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 91.7 p -85.74 109.57 18.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.8 pt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.084 -179.995 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.642 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.2 Cg_endo . . . . . 0 C--O 1.232 0.196 0 CA-C-O 121.65 0.604 . . . . 0.0 112.34 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.87 -34.84 13.42 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.404 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 52.2 p-90 -71.43 -30.48 66.11 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.642 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -55.13 148.8 28.11 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.51 0.671 . . . . 0.0 111.118 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.87 145.53 56.77 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.647 2.232 . . . . 0.0 112.35 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -51.39 -36.56 44.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.3 m -160.45 156.41 25.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.708 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 19.3 p90 -150.19 -180.0 7.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.3 mt -84.09 -64.6 1.13 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -139.99 176.24 8.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.8 130.65 54.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 44' ' ' VAL . 15.8 m -123.85 160.4 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.177 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.88 147.77 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.13 22.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.061 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.417 HG13 ' CD2' ' A' ' 24' ' ' TYR . 31.3 pt -92.74 -7.61 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.417 ' CD2' HG13 ' A' ' 23' ' ' ILE . 59.8 m-85 -146.84 163.37 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.944 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.76 121.81 28.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.872 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -135.19 114.26 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.42 ' O ' ' C ' ' A' ' 28' ' ' LYS . 24.6 m -98.21 106.01 18.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' A' ' 27' ' ' THR . 5.2 pttm -35.57 133.18 0.4 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.933 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -90.55 -27.71 18.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -128.94 163.64 24.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.828 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -53.77 -39.95 65.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.947 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -76.2 49.1 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.805 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -157.11 167.08 31.46 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.803 HD23 ' N ' ' A' ' 35' ' ' SER . 2.5 tt -122.63 146.42 47.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.937 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.803 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.5 p -109.46 145.46 36.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.85 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.3 p90 -169.88 148.04 3.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -103.76 153.15 21.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.97 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -39.62 110.57 0.15 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.19 44.88 0.97 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.487 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -126.25 130.46 50.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.772 0.32 . . . . 0.0 111.103 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.3 mm -87.97 136.19 23.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.6 148.97 22.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.118 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.708 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 77.0 m-85 -104.31 115.02 29.64 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 20' ' ' VAL . 22.9 t -74.66 121.74 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.184 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.9 pt -122.72 -7.0 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.455 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 0.1 OUTLIER -136.67 144.8 44.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -122.16 103.23 8.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.862 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -74.73 -175.01 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.942 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -99.4 -10.47 22.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.42 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -120.38 40.42 3.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.595 ' O ' ' CE1' ' A' ' 53' ' ' TYR . . . 79.84 -44.29 2.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.43 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.474 ' O ' ' CD1' ' A' ' 53' ' ' TYR . 25.9 m95 -34.46 137.96 0.11 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.808 0.337 . . . . 0.0 110.926 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.595 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 22.0 m-85 -136.84 137.9 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.926 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.455 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 23.8 tt0 -94.15 116.67 29.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.89 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.4 163.34 25.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.547 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.6 t -98.73 146.12 8.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.143 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -151.45 118.65 5.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.902 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.9 t30 49.67 43.76 24.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.931 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 80.4 -40.67 2.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 95.2 t -75.83 120.56 25.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 m -100.96 141.47 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.168 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.428 ' C ' ' HB2' ' A' ' 34' ' ' LEU . . . -165.87 154.37 24.95 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.498 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -80.54 147.87 30.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.902 0.382 . . . . 0.0 110.902 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -147.99 148.43 29.79 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.676 0.751 . . . . 0.0 110.884 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.5 40.27 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.464 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -73.22 -3.93 62.46 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.527 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -82.22 -28.45 31.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -90.48 8.36 34.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.464 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 8.6 m -135.7 169.06 21.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -140.63 150.18 43.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.4 t -85.03 113.63 21.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.877 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.3 pt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.139 179.895 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.585 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 N--CA 1.467 -0.086 0 CA-C-O 121.585 0.577 . . . . 0.0 112.339 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -33.36 17.04 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.585 2.19 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 22.4 p-90 -63.6 -23.18 67.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.434 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -65.23 148.26 98.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 121.493 0.663 . . . . 0.0 111.087 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 149.15 66.19 Favored 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.662 2.242 . . . . 0.0 112.37 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -54.94 -44.18 74.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.897 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.5 t -145.79 165.66 28.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -159.6 -179.14 7.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 22.9 mt -84.58 -57.31 3.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -152.96 -179.88 8.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.582 ' HE3' HG23 ' A' ' 41' ' ' ILE . 13.3 tttp -113.75 154.38 27.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.41 ' N ' ' HG2' ' A' ' 19' ' ' LYS . 29.1 m -152.18 147.15 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -117.09 139.4 44.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.206 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.27 135.42 36.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.109 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.492 HG13 ' CD2' ' A' ' 24' ' ' TYR . 16.1 pt -115.07 -15.17 10.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.179 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CD2' HG13 ' A' ' 23' ' ' ILE . 62.9 m-85 -128.53 164.51 22.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.895 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -87.22 123.98 32.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.919 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' A' ' 27' ' ' THR . 86.0 t80 -117.31 160.27 21.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.949 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.41 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 6.7 m -133.53 132.08 40.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.22 136.34 36.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.914 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -99.56 -32.02 11.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.978 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -110.12 163.42 13.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.13 4.71 13.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -108.55 -26.75 10.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.411 ' C ' ' HA3' ' A' ' 62' ' ' GLY . 0.1 OUTLIER -70.4 -177.99 1.61 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -124.41 139.57 53.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.7 p -115.88 124.91 51.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.828 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 28.7 p90 -148.04 156.54 42.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.849 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -114.86 169.88 8.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -45.64 137.42 5.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.871 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.45 46.51 9.88 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.548 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.9 136.28 52.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.341 . . . . 0.0 111.037 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.582 HG23 ' HE3' ' A' ' 19' ' ' LYS . 21.8 mm -88.72 135.7 25.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.522 HD11 ' CD2' ' A' ' 36' ' ' PHE . 65.9 mt -141.99 143.46 26.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -110.28 109.67 20.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.96 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.486 HG13 ' HB3' ' A' ' 53' ' ' TYR . 92.8 t -69.25 110.07 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.137 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 26.2 pt -107.79 -14.12 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.193 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 46.9 tttt -144.52 138.45 27.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.886 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 6.6 mtmp? -135.05 102.99 5.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -75.97 175.51 8.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -76.38 48.36 0.53 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -163.36 -176.92 5.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.481 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -82.7 49.62 4.22 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.472 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.524 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 46.1 m95 -148.71 121.39 8.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.552 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 2.9 m-85 -119.06 149.26 41.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.65 123.13 37.91 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.8 177.02 19.6 Favored Glycine 0 N--CA 1.454 -0.157 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.449 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.467 HG22 HG23 ' A' ' 61' ' ' THR . 45.8 t -117.86 144.22 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.73 0.3 . . . . 0.0 111.196 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -157.02 129.99 7.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.816 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 58' ' ' ASN . 30.7 t30 47.55 38.47 8.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.01 -35.14 2.55 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.499 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 97.9 t -76.02 126.04 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.467 HG23 HG22 ' A' ' 56' ' ' VAL . 2.9 m -106.97 150.87 26.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.159 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA3' ' C ' ' A' ' 33' ' ' GLU . . . 173.91 162.2 25.29 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.526 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.22 163.96 22.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.511 ' CE1' HG21 ' A' ' 42' ' ' ILE . 29.8 p90 -160.68 152.47 16.52 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.525 0.679 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.524 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.78 137.27 35.03 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.679 2.253 . . . . 0.0 112.321 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 68' ' ' TYR . . . -67.27 -56.11 13.28 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.429 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.9 m-20 -40.95 -24.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.472 ' CG ' ' HG2' ' A' ' 65' ' ' PRO . 13.4 m-85 -76.77 -42.73 39.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 18.8 m -108.24 142.64 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.231 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -102.94 165.64 10.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.802 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.4 t -105.66 105.23 15.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.403 HD11 ' HD3' ' A' ' 19' ' ' LYS . 37.3 pt . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.172 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.567 ' CG ' ' CE2' ' A' ' 11' ' ' TRP . 53.8 Cg_endo . . . . . 0 C--O 1.23 0.115 0 CA-C-O 121.662 0.609 . . . . 0.0 112.329 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.8 -33.35 16.62 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.603 2.202 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.567 ' CE2' ' CG ' ' A' ' 9' ' ' PRO . 22.2 p-90 -65.56 -27.82 68.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.54 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -58.32 147.41 67.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.59 0.71 . . . . 0.0 111.126 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.6 10.72 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.668 2.245 . . . . 0.0 112.294 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.4 mtt180 -85.0 -43.94 13.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.8 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 39.0 t -136.66 152.79 50.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.812 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.53 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 7.1 p90 -159.77 157.21 28.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.904 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 44' ' ' VAL . 19.8 mt -61.35 -66.95 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -144.14 -175.65 4.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.858 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.596 ' HD2' HD11 ' A' ' 72' ' ' ILE . 20.7 ttmt -120.19 133.05 55.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.426 HG13 HG21 ' A' ' 44' ' ' VAL . 34.4 m -128.15 161.23 36.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.195 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 ' HG3' ' A' ' 70' ' ' GLU . 11.3 p -126.14 141.08 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.193 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.9 118.4 14.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.102 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.4 pt -99.04 -35.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -129.77 135.11 48.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -56.69 122.58 12.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.894 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 87.9 t80 -121.1 127.71 51.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -97.04 123.51 40.79 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.074 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.413 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -76.15 131.29 39.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.887 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -94.08 -47.9 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -105.14 146.8 28.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -45.22 -32.29 1.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.33 -44.77 96.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.922 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -65.68 165.33 12.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.958 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.625 HD23 ' N ' ' A' ' 35' ' ' SER . 3.7 tt -121.63 140.09 52.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.625 ' N ' HD23 ' A' ' 34' ' ' LEU . 52.8 p -99.2 130.99 45.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -151.6 167.91 26.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.965 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -127.6 159.74 33.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.81 109.07 0.37 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.897 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.59 43.47 0.75 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.445 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.96 131.7 47.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.788 0.328 . . . . 0.0 111.068 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.78 100.4 11.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.4 mt -104.8 137.55 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.1 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.53 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 80.7 m-85 -91.18 121.79 33.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.966 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 17' ' ' LEU . 48.0 t -80.92 104.5 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.066 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 46' ' ' LYS . 33.0 pt -95.33 -33.58 4.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.406 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.4 tptm -129.31 144.22 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.479 ' HG2' ' CG ' ' A' ' 53' ' ' TYR . 10.9 mtpt -136.45 124.46 22.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -101.4 151.25 22.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -39.34 -49.66 1.99 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.921 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.74 177.22 7.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.951 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.6 66.9 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.516 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -151.68 113.07 4.34 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.733 0.301 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.479 ' CG ' ' HG2' ' A' ' 47' ' ' LYS . 1.3 m-85 -122.95 154.23 38.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.406 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.4 tt0 -104.45 134.59 47.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.879 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.17 157.07 27.05 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.488 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.3 t -95.48 136.43 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.926 0.394 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.41 ' O ' ' N ' ' A' ' 60' ' ' VAL . 21.8 ttp -141.18 119.67 12.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.824 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 43.93 42.76 4.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.79 -26.64 4.65 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.493 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.41 ' N ' ' O ' ' A' ' 57' ' ' MET . 93.0 t -81.1 127.76 39.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.881 0.372 . . . . 0.0 111.162 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.7 m -112.19 147.86 35.27 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.503 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 178.04 162.84 28.63 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.533 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.9 mt -88.44 128.79 35.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -120.38 147.33 44.95 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.716 0.77 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 122.83 9.5 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.667 2.245 . . . . 0.0 112.35 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.458 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -58.53 -10.8 8.46 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -76.61 -32.16 57.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.732 0.301 . . . . 0.0 110.787 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 11.7 m-85 -97.83 35.32 1.72 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.906 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 68' ' ' TYR . 9.9 m -161.32 153.81 3.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.608 ' HG3' HG12 ' A' ' 21' ' ' VAL . 5.6 pt-20 -130.06 144.14 51.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 37.9 m -84.66 120.33 26.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.596 HD11 ' HD2' ' A' ' 19' ' ' LYS . 24.9 pt . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.181 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.796 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 121.624 0.593 . . . . 0.0 112.33 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.81 -33.95 15.4 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.681 2.254 . . . . 0.0 112.318 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 54.8 p-90 -73.55 -29.7 62.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.796 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -52.71 151.53 7.99 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.604 0.716 . . . . 0.0 111.089 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.63 133.25 25.33 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 56.5 mtm180 -48.68 -45.48 39.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.865 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.5 p -136.64 163.39 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.942 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -166.27 171.21 12.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.005 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.57 HD13 ' HE3' ' A' ' 47' ' ' LYS . 19.4 mt -77.03 -52.29 9.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.882 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.727 ' OE1' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -160.44 172.84 16.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.967 179.898 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.05 145.92 42.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.727 HG13 ' OE1' ' A' ' 18' ' ' GLU . 30.4 m -135.64 163.28 35.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.109 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.29 140.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.05 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.19 102.93 12.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.072 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CE2' ' A' ' 24' ' ' TYR . 8.5 pt -84.25 -7.22 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.688 ' CE2' HD12 ' A' ' 23' ' ' ILE . 46.7 m-85 -145.43 136.6 24.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.912 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -65.69 136.02 55.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.872 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -137.97 128.1 25.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.883 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.3 m -97.32 151.33 20.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.209 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 7.8 ptmt -93.03 132.58 37.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.844 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.02 -18.26 22.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.816 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -138.16 167.73 21.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.92 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -83.33 36.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.902 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -127.39 -28.94 2.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.937 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -88.98 -174.97 4.68 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.969 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.701 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.21 140.4 51.5 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.701 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.1 p -108.38 140.32 41.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -153.75 166.58 32.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.933 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -114.41 170.27 8.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -61.8 102.02 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 115.23 42.5 0.76 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.584 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.38 140.96 48.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 111.146 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.2 mm -92.85 122.44 44.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.151 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.543 HG21 ' CE2' ' A' ' 64' ' ' PHE . 70.4 mt -127.47 136.21 61.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -101.35 107.68 19.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.962 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 53' ' ' TYR . 87.5 t -69.17 113.49 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.435 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.0 pt -113.93 -2.37 10.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.164 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.475 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.0 tptm -156.2 137.08 13.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HE3' HD13 ' A' ' 17' ' ' LEU . 14.5 ptpt -136.51 116.65 13.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 58.7 m-20 -90.1 155.91 18.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -43.15 -37.33 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -85.11 -175.27 5.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.526 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -82.56 81.37 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.526 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 91.9 m95 -162.02 120.66 2.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.52 ' HB3' HG13 ' A' ' 44' ' ' VAL . 33.6 m-85 -118.52 135.36 54.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.927 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.475 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 7.8 tt0 -91.0 111.11 22.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 61' ' ' THR . . . -125.96 169.89 17.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.487 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.506 HG22 ' OG1' ' A' ' 61' ' ' THR . 77.3 t -115.52 129.83 71.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 111.097 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.8 tmm? -137.34 125.36 22.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 45.8 t30 51.02 37.98 19.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.28 -31.49 2.9 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.6 132.36 31.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.914 0.388 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.712 HG23 ' O ' ' A' ' 55' ' ' GLY . 18.9 m -114.27 145.14 42.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.76 145.12 9.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.405 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.7 mm? -67.95 123.85 21.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.543 ' CE2' HG21 ' A' ' 42' ' ' ILE . 42.3 p90 -123.82 152.67 66.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 138.91 38.88 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.646 2.231 . . . . 0.0 112.324 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.19 29.24 3.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -116.78 -35.02 4.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.848 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -78.21 2.36 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.938 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.96 178.41 2.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.082 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -142.68 124.17 14.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 72.2 m -71.7 103.69 3.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.9 pt . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.973 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HB2' ' CE2' ' A' ' 11' ' ' TRP . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.148 0 CA-C-O 121.558 0.566 . . . . 0.0 112.297 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 2.87 3.13 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.692 2.262 . . . . 0.0 112.366 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.432 ' CE2' ' HB2' ' A' ' 9' ' ' PRO . 32.0 p-90 -120.42 18.01 12.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.91 144.51 64.05 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.611 0.72 . . . . 0.0 111.057 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 155.89 64.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.386 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -50.98 -53.72 30.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.867 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.3 t -145.13 165.45 28.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -158.67 155.39 28.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.905 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -64.56 -46.94 80.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.912 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -165.97 179.35 5.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 24.2 ttmt -119.43 132.76 55.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.823 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.0 m -120.44 168.53 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.83 137.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.997 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.06 92.53 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.114 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 24' ' ' TYR . 35.7 pt -69.38 -34.71 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.192 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 23' ' ' ILE . 77.6 m-85 -128.82 151.81 49.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.869 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.81 102.02 11.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.891 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -103.49 130.55 50.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.9 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -96.04 108.97 21.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.412 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 12.7 pttm -45.24 142.18 2.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.928 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -95.34 -48.93 5.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -101.26 175.84 5.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.902 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -67.85 -38.65 83.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.68 -40.52 95.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.829 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.412 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 32.5 mt-10 -57.09 162.41 2.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 62' ' ' GLY . 2.0 tt -118.59 141.2 48.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.509 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.6 p -108.4 133.22 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -155.84 152.6 28.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.912 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -106.4 160.01 15.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.423 ' OE1' ' C ' ' A' ' 38' ' ' GLU . 1.0 OUTLIER -45.37 137.72 4.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.865 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.3 48.03 5.83 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.83 142.51 50.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 111.145 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.434 ' C ' HG13 ' A' ' 42' ' ' ILE . 28.7 mm -94.84 139.51 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.137 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.454 HG21 ' CE2' ' A' ' 64' ' ' PHE . 20.8 mt -141.88 143.19 27.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.181 179.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.583 ' CE1' ' HE2' ' A' ' 19' ' ' LYS . 97.9 m-85 -103.05 98.81 8.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.897 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.536 HG11 ' HE3' ' A' ' 47' ' ' LYS . 25.6 t -64.25 95.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.207 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.433 HG13 ' N ' ' A' ' 46' ' ' LYS . 48.1 pt -88.12 -34.48 7.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.433 ' N ' HG13 ' A' ' 45' ' ' ILE . 1.4 tppp? -126.04 148.04 49.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.916 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' HE2' ' CD1' ' A' ' 53' ' ' TYR . 13.9 mtpt -136.58 112.75 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -87.64 150.73 23.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -41.89 -49.38 4.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.36 175.4 6.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.907 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.17 61.65 2.21 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.53 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -151.39 110.66 3.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.715 0.293 . . . . 0.0 110.939 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.56 ' CD1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -112.8 151.71 30.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.429 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.4 tt0 -99.78 126.91 45.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.958 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.15 27.9 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.568 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.0 t -97.22 139.85 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 111.092 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.7 ttp -153.4 111.11 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.1 t30 62.24 39.3 12.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.35 -35.26 2.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.26 130.46 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 0.0 111.06 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.568 ' OG1' HG22 ' A' ' 56' ' ' VAL . 87.2 m -116.86 131.42 56.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -158.37 163.42 32.94 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.451 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.2 mt -80.09 123.38 27.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.609 ' HE1' HG21 ' A' ' 69' ' ' VAL . 21.3 p90 -115.6 151.25 45.94 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 110.906 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 118.01 5.42 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.724 2.283 . . . . 0.0 112.307 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.456 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -55.03 -13.04 4.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.416 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -75.67 -34.12 60.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.842 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 69' ' ' VAL . 13.2 m-85 -94.59 32.6 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.609 HG21 ' HE1' ' A' ' 64' ' ' PHE . 26.9 m -158.34 139.24 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.6 mm-40 -120.55 158.16 27.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.826 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.7 p -90.15 127.03 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.5 pt . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.147 179.915 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.542 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.4 Cg_endo . . . . . 0 C--O 1.231 0.134 0 CA-C-O 121.587 0.578 . . . . 0.0 112.376 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -29.32 24.18 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.619 2.212 . . . . 0.0 112.389 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.542 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 48.4 p-90 -73.47 -14.21 61.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.934 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.515 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -76.67 143.68 72.08 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.684 0.754 . . . . 0.0 111.025 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 123.24 9.89 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.2 mmt85 -41.9 -47.48 4.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.4 t -121.57 153.24 38.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.541 ' HA ' HG22 ' A' ' 45' ' ' ILE . 25.9 p90 -164.8 163.95 21.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.936 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.446 HD13 ' HG3' ' A' ' 47' ' ' LYS . 51.4 mt -65.85 -61.98 1.76 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.019 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -156.86 178.58 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.001 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -114.92 147.95 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.481 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 22.1 m -146.55 158.95 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.668 HG12 HG23 ' A' ' 72' ' ' ILE . 13.0 p -124.81 132.62 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.221 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -70.16 117.9 12.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.513 HG13 ' CD2' ' A' ' 24' ' ' TYR . 41.7 pt -98.89 -14.47 7.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.513 ' CD2' HG13 ' A' ' 23' ' ' ILE . 47.5 m-85 -136.38 151.63 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.931 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -78.33 115.07 17.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -113.88 148.61 36.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.4 m -120.16 112.03 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.179 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.403 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 15.0 pttm -57.82 136.75 57.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.931 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.32 -24.43 42.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 pttt -155.06 179.02 9.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.12 -43.01 77.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.939 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -47.23 -36.4 8.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.976 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.403 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -87.4 176.99 7.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.92 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.688 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.7 tt -128.0 152.44 47.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.932 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.665 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.0 p -108.54 139.31 43.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.843 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -165.43 153.86 11.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.936 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -112.59 166.06 11.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.949 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -51.83 106.23 0.14 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.966 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 116.83 46.43 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.425 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -141.38 117.83 10.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.809 0.338 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.489 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.7 mp -80.82 147.53 6.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.405 HG13 ' C ' ' A' ' 41' ' ' ILE . 34.9 mt -142.89 133.42 22.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -86.74 109.89 19.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.528 HG13 ' HB3' ' A' ' 53' ' ' TYR . 80.2 t -76.29 124.05 33.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 16' ' ' TYR . 10.6 pt -120.7 -23.87 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.127 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 9.5 tmtt? -128.75 145.95 51.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 19.1 mtpt -123.38 160.65 26.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.914 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 52' ' ' TRP . 2.7 m-80 -129.79 -174.89 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -104.45 -26.73 12.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.814 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.597 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 34.6 t70 -100.04 39.85 1.3 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.528 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 59.06 78.17 0.14 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.497 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.597 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 97.5 m95 -162.33 115.16 1.72 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.805 0.336 . . . . 0.0 110.853 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.528 ' HB3' HG13 ' A' ' 44' ' ' VAL . 3.3 m-85 -116.32 137.65 51.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.92 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -91.1 126.24 36.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.863 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.98 167.13 25.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.523 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 84.7 t -112.64 126.75 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.778 0.323 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.3 ttp -133.24 107.18 7.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.905 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 59.27 41.73 19.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.982 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.73 -34.15 3.19 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 92.7 t -76.21 125.02 35.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.938 0.399 . . . . 0.0 111.067 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.7 m -107.58 146.79 31.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.133 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.688 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.49 139.69 3.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 63' ' ' LEU . 5.2 mp -69.13 161.42 29.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.369 . . . . 0.0 110.877 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -163.11 154.51 14.78 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.587 0.708 . . . . 0.0 110.9 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.502 ' HG2' ' CD1' ' A' ' 68' ' ' TYR . 53.7 Cg_endo -69.68 122.74 9.44 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.391 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.523 ' O ' HG22 ' A' ' 69' ' ' VAL . . . -51.29 -52.0 34.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 68' ' ' TYR . 19.0 m120 -40.71 -65.05 0.46 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.817 0.341 . . . . 0.0 110.818 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.502 ' CD1' ' HG2' ' A' ' 65' ' ' PRO . 23.7 m-85 -36.37 -33.99 0.05 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 22' ' ' ALA . 30.9 m -108.67 164.54 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.129 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.475 ' CD ' ' N ' ' A' ' 71' ' ' SER . 2.8 tm-20 -122.03 137.49 54.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.475 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 14.9 m -80.7 77.86 7.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.834 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.668 HG23 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.563 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.0 Cg_endo . . . . . 0 C--O 1.23 0.123 0 CA-C-O 121.62 0.591 . . . . 0.0 112.321 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -25.65 28.4 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.64 2.227 . . . . 0.0 112.341 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.529 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 47.0 p-90 -79.33 -18.78 51.85 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -75.08 148.34 84.19 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.73 . . . . 0.0 111.087 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.8 Cg_endo -69.79 132.61 23.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.634 2.223 . . . . 0.0 112.399 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.449 ' C ' ' O ' ' A' ' 13' ' ' PRO . 3.6 ptt180 -34.37 -46.81 0.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.833 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 24.2 m -144.5 169.51 17.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -160.65 166.88 28.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.969 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -65.86 -56.67 10.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -152.57 -175.76 5.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -126.11 121.82 33.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.95 167.28 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.175 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 p -133.95 136.87 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.61 119.06 15.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.414 HG13 ' CD2' ' A' ' 24' ' ' TYR . 24.4 pt -97.79 -8.55 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.151 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.414 ' CD2' HG13 ' A' ' 23' ' ' ILE . 41.1 m-85 -142.58 165.79 26.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -88.35 114.28 24.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.836 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.429 ' HB3' ' CZ ' ' A' ' 36' ' ' PHE . 90.8 t80 -114.47 111.49 21.48 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.97 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 22.2 m -92.57 94.69 9.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.438 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 0.7 OUTLIER -43.67 157.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.904 179.925 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -118.53 -20.85 8.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' GLU . 12.6 mmmm -124.69 137.3 54.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -41.93 -30.53 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.19 -41.94 85.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.953 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.7 OUTLIER -64.22 169.22 4.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.606 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -121.1 138.96 53.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.962 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.606 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.7 p -101.15 153.28 19.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.902 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.429 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 24.9 p90 -174.24 165.91 4.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.973 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.426 ' O ' ' C ' ' A' ' 38' ' ' GLU . 15.0 pt20 -130.5 151.35 51.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 37' ' ' GLN . 16.6 tt0 -36.69 104.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 117.94 38.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.481 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -123.54 130.09 52.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.717 0.294 . . . . 0.0 111.108 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.4 mm -87.11 133.01 31.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.416 HG21 ' CE1' ' A' ' 64' ' ' PHE . 78.5 mt -131.18 140.93 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.118 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -105.88 97.9 7.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.449 HG11 ' HE3' ' A' ' 47' ' ' LYS . 92.4 t -60.36 114.03 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.164 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.5 pt -110.91 -20.1 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.172 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 37.4 mttp -144.46 154.92 43.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.449 ' HE3' HG11 ' A' ' 44' ' ' VAL . 69.4 mttt -136.5 159.71 40.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -129.45 149.03 51.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -38.34 -39.28 0.43 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 52' ' ' TRP . 1.5 m-20 -96.03 174.21 7.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.969 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -63.62 77.19 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.489 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.536 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 85.0 m95 -160.16 120.33 2.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.877 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -131.73 151.89 51.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -91.47 142.54 27.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.81 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -156.86 158.61 28.94 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.463 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.457 HG22 ' OG1' ' A' ' 61' ' ' THR . 50.5 t -104.65 131.04 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 111.133 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.1 tmm? -136.26 112.2 9.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.3 t30 59.35 38.1 23.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.42 -38.17 3.17 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.446 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 87.3 t -77.42 126.79 38.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 111.201 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.457 ' OG1' HG22 ' A' ' 56' ' ' VAL . 33.2 m -107.57 142.92 36.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.469 ' H ' HD12 ' A' ' 34' ' ' LEU . . . -163.09 173.52 39.29 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.483 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.4 mt -95.77 128.07 42.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.839 0.352 . . . . 0.0 110.922 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.45 ' HE2' HG21 ' A' ' 69' ' ' VAL . 23.2 p90 -130.34 148.98 72.06 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.715 0.769 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -70.03 142.75 47.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.594 2.196 . . . . 0.0 112.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.82 11.83 45.22 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.443 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -99.38 -12.91 19.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.796 0.331 . . . . 0.0 110.893 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -108.17 17.6 22.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.45 HG21 ' HE2' ' A' ' 64' ' ' PHE . 4.7 m -139.17 173.55 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 -145.74 167.05 24.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.857 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 96.7 p -102.12 112.83 25.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.0 pt . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.138 179.958 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.5 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 121.639 0.6 . . . . 0.0 112.331 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.73 -31.63 20.28 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.684 2.256 . . . . 0.0 112.373 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.555 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 38.0 p-90 -68.99 -22.95 64.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.871 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.42 145.07 87.37 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.0 Cg_endo -69.77 136.93 34.2 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.753 2.302 . . . . 0.0 112.362 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.451 ' C ' ' O ' ' A' ' 13' ' ' PRO . 5.2 ptt85 -34.31 -48.2 0.33 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -148.44 174.19 12.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 23.5 p90 -169.14 151.39 4.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.936 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -49.67 -68.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -151.24 -179.67 7.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.29 144.07 44.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.0 m -127.87 170.36 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.129 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 21' ' ' VAL . 6.7 p -136.69 127.37 41.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.15 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.08 112.35 9.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.129 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 12.2 pt -92.84 -7.54 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -136.94 166.12 24.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.951 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -85.23 141.7 29.94 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.827 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.408 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 83.6 t80 -151.96 118.25 5.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.916 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 91.3 m -104.83 111.98 24.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.128 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -43.94 150.28 0.28 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.997 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -115.91 -47.01 2.8 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.877 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.47 149.64 24.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 64.6 mm-40 -48.47 -28.35 3.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.873 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -89.21 43.23 1.13 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -143.27 159.53 42.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.566 HD23 ' N ' ' A' ' 35' ' ' SER . 1.7 tt -116.87 130.74 56.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.906 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.566 ' N ' HD23 ' A' ' 34' ' ' LEU . 22.5 t -97.41 144.21 27.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.905 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -164.83 150.3 9.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 18.5 mt-30 -105.46 153.54 21.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -45.52 110.11 0.22 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.96 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.53 36.87 1.25 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.6 141.8 48.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.719 0.295 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -92.18 112.86 26.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.087 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.707 HG21 ' CE2' ' A' ' 64' ' ' PHE . 45.5 mt -115.89 125.25 72.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -89.22 106.03 18.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.9 t -68.05 120.62 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.106 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 12.8 pt -121.45 -14.97 7.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.172 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.4 ttmt -132.78 122.2 24.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 53' ' ' TYR . 18.7 mmtt -114.55 102.72 10.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -90.59 143.44 26.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -40.07 -48.2 2.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 -71.88 -178.1 2.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.27 62.71 4.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -152.28 118.97 5.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.48 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 4.4 m-85 -120.99 160.6 23.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HG3' HD22 ' A' ' 63' ' ' LEU . 7.5 tt0 -112.28 123.46 50.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.937 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 61' ' ' THR . . . -134.27 166.46 24.11 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.463 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 ' OG1' ' A' ' 61' ' ' THR . 65.1 t -107.9 124.42 64.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.9 0.381 . . . . 0.0 111.157 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.8 tmm? -129.79 106.29 8.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.798 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 4.5 t30 61.24 39.8 15.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.72 -30.01 3.96 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.482 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.9 t -82.59 115.98 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.92 0.39 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 55' ' ' GLY . 3.4 m -109.77 143.43 39.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -172.16 163.72 36.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.447 HD22 ' HG3' ' A' ' 54' ' ' GLU . 2.1 mm? -68.56 150.15 48.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.878 0.37 . . . . 0.0 110.922 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.707 ' CE2' HG21 ' A' ' 42' ' ' ILE . 5.3 p90 -162.17 151.42 13.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.676 0.75 . . . . 0.0 110.872 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 136.79 33.87 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.708 2.272 . . . . 0.0 112.308 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -75.44 -42.29 27.94 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.477 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -51.06 -29.32 12.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.895 0.378 . . . . 0.0 110.917 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.408 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 10.5 m-85 -71.62 -30.06 65.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.9 m -110.0 137.15 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.12 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 71' ' ' SER . 0.4 OUTLIER -101.52 131.39 47.7 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.404 ' N ' ' OE2' ' A' ' 70' ' ' GLU . 19.2 m -74.6 103.3 4.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.7 pt . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.578 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo . . . . . 0 C--O 1.231 0.139 0 CA-C-O 121.537 0.557 . . . . 0.0 112.402 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -39.32 6.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.244 . . . . 0.0 112.361 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.578 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 41.9 p-90 -58.13 -38.25 76.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.53 143.15 20.56 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.51 0.672 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 135.43 30.62 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.2 mtm180 -87.06 36.05 0.72 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.3 t -171.51 105.99 0.22 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.827 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 19.9 p90 -157.7 171.21 20.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.7 mt -85.8 -47.15 9.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.451 ' C ' ' OE2' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -168.84 174.26 6.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.9 pttm -116.98 161.21 19.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 33.9 m -148.67 160.97 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.11 139.68 40.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.184 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.19 95.59 6.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.101 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.532 HG13 ' CD2' ' A' ' 24' ' ' TYR . 38.7 pt -69.67 -23.89 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.137 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.532 ' CD2' HG13 ' A' ' 23' ' ' ILE . 64.3 m-85 -124.23 160.41 28.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.927 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.65 100.62 13.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.461 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 89.4 t80 -109.74 130.19 55.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.418 ' O ' ' CE2' ' A' ' 26' ' ' TYR . 15.4 t -93.43 -175.16 3.72 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.081 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.41 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -114.52 130.52 56.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.941 179.938 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -102.48 -52.2 3.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.884 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -96.86 145.32 25.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -49.43 -24.01 1.79 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.03 47.86 1.23 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -146.37 172.16 13.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.852 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.669 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.5 tt -129.3 133.43 47.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.857 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.6 t -100.24 141.33 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.825 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 11.3 p90 -155.32 174.81 14.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.934 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -127.36 165.32 19.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.933 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -57.97 109.55 0.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.89 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.56 45.75 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -145.13 119.25 9.44 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.652 0.263 . . . . 0.0 111.205 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.502 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -80.7 139.07 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.126 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.3 mt -129.77 117.98 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -72.21 107.17 4.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.484 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 59.6 t -73.68 105.79 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.4 pt -93.65 -15.31 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.043 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 9.8 tptt -141.72 143.8 33.72 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.834 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -134.58 116.33 14.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -97.16 152.1 19.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.841 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.01 -43.42 29.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -75.75 176.04 8.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -76.2 70.17 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.481 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.0 m95 -163.34 119.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 110.891 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.471 ' HB3' HG13 ' A' ' 44' ' ' VAL . 4.3 m-85 -120.55 155.11 34.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.432 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 19.8 tt0 -103.77 118.3 36.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.35 160.53 25.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.408 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 85.4 t -101.27 139.73 21.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.764 0.316 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.1 ttp -140.02 111.78 7.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.879 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.8 t30 49.24 38.65 13.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.03 -29.97 6.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.66 ' O ' HD11 ' A' ' 34' ' ' LEU . 94.6 t -79.81 118.92 28.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.927 0.394 . . . . 0.0 111.196 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.4 m -108.98 139.64 43.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.669 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.37 163.23 36.0 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.526 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -81.19 135.45 35.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.726 0.298 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.484 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 45.5 p90 -136.34 152.96 76.01 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.689 0.756 . . . . 0.0 110.842 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 132.4 23.26 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.627 2.218 . . . . 0.0 112.392 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.39 -1.13 41.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.554 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -86.85 -33.71 19.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.439 ' O ' HG13 ' A' ' 69' ' ' VAL . 69.7 m-85 -87.11 29.53 0.83 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.977 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 68' ' ' TYR . 20.4 m -157.38 142.28 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -118.49 164.87 14.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.965 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 p -92.89 132.63 36.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.872 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.464 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.121 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.552 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo . . . . . 0 N--CA 1.465 -0.158 0 CA-C-O 121.517 0.549 . . . . 0.0 112.343 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.26 4.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.602 2.201 . . . . 0.0 112.367 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.552 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 64.4 p-90 -60.46 -40.21 90.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.012 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.484 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -40.21 144.17 0.58 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.627 0.727 . . . . 0.0 111.018 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.4 Cg_endo -69.9 140.26 41.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.618 2.212 . . . . 0.0 112.294 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -65.39 -45.06 85.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 73.2 m -115.22 150.97 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.455 ' HA ' HG22 ' A' ' 45' ' ' ILE . 10.8 p90 -169.41 147.44 3.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.837 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -56.11 -52.94 62.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.931 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -165.0 170.83 14.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -103.6 155.9 18.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.5 m -149.06 138.98 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.159 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.4 p -110.87 127.36 68.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.17 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.83 123.38 24.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.122 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.8 pt -97.68 -34.56 4.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -108.0 178.12 4.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -95.54 126.39 40.8 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -126.0 134.48 51.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.906 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.6 m -116.75 111.96 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.135 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.08 127.07 9.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -90.17 -57.2 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -94.72 -177.36 4.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -78.26 -28.8 47.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.447 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 8.7 m-20 -85.62 23.95 1.3 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . 0.447 ' OE1' ' C ' ' A' ' 32' ' ' ASP . 1.5 mp0 -114.69 177.89 4.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.934 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.649 HD23 ' N ' ' A' ' 35' ' ' SER . 2.7 tt -132.16 134.2 45.11 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.915 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.649 ' N ' HD23 ' A' ' 34' ' ' LEU . 87.6 p -97.67 127.71 43.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -150.51 170.4 19.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.907 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -139.1 162.23 35.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -43.86 109.35 0.14 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 106.61 44.22 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -121.35 125.4 46.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.336 . . . . 0.0 111.115 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.9 mm -82.75 100.1 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.015 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.659 HG21 ' CZ ' ' A' ' 64' ' ' PHE . 32.6 mt -105.95 131.16 56.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.146 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.412 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 79.4 m-85 -99.34 104.11 15.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.931 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.674 HG13 ' HB3' ' A' ' 53' ' ' TYR . 75.2 t -67.54 124.43 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.179 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.455 HG22 ' HA ' ' A' ' 16' ' ' TYR . 8.9 pt -124.77 -25.37 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.131 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.38 152.99 42.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 6.0 mtmp? -128.56 151.05 49.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.855 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB2' ' A' ' 52' ' ' TRP . 2.6 m-20 -126.47 -174.69 3.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.871 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -94.22 -31.54 14.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.607 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -95.34 39.29 1.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.55 63.14 5.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.531 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.607 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 95.0 m95 -134.75 96.97 3.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.674 ' HB3' HG13 ' A' ' 44' ' ' VAL . 11.8 m-85 -91.63 137.63 32.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.455 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.4 tt0 -96.67 111.63 23.71 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.842 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -124.65 171.71 16.81 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.412 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.8 t -110.42 134.66 51.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.891 0.377 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -140.61 111.31 6.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.87 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.1 t30 59.29 39.8 22.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.847 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.62 -38.17 2.93 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.441 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 98.7 t -75.62 127.43 37.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.999 0.428 . . . . 0.0 111.086 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.403 HG22 ' N ' ' A' ' 62' ' ' GLY . 38.3 m -106.46 153.91 21.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.16 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 61' ' ' THR . . . -177.1 170.03 42.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 13.6 mt -98.89 141.25 31.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.818 0.342 . . . . 0.0 110.912 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.659 ' CZ ' HG21 ' A' ' 42' ' ' ILE . 20.7 p90 -139.58 154.39 71.29 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.744 0.783 . . . . 0.0 110.838 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.456 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 53.9 Cg_endo -69.83 140.69 43.05 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.584 2.189 . . . . 0.0 112.349 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -80.59 41.17 2.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 -126.37 -43.53 1.76 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.901 0.382 . . . . 0.0 110.898 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -69.02 -23.65 64.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.963 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.8 m -113.66 148.83 16.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.156 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -108.55 155.52 20.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.973 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 44.6 p -99.56 100.67 11.71 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.79 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.6 pt . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.102 179.974 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.672 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 52.9 Cg_endo . . . . . 0 N--CA 1.466 -0.118 0 CA-C-O 121.619 0.591 . . . . 0.0 112.25 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -47.86 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.596 2.197 . . . . 0.0 112.378 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 34.0 p-90 -57.07 -20.83 27.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.874 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.672 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -66.84 144.06 98.36 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.503 0.668 . . . . 0.0 111.124 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 14' ' ' ARG . 54.0 Cg_endo -69.77 105.8 1.55 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.622 2.215 . . . . 0.0 112.434 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.452 ' C ' ' O ' ' A' ' 13' ' ' PRO . 4.4 ptt85 -34.41 -46.54 0.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 t -120.23 149.75 41.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.464 ' CB ' HG22 ' A' ' 45' ' ' ILE . 38.4 p90 -169.01 163.12 11.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.922 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mt -60.96 -66.96 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.401 ' O ' ' CD1' ' A' ' 16' ' ' TYR . 11.2 pt-20 -146.8 -176.41 5.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.945 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.448 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 16.3 ttmt -127.91 127.34 43.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.839 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.536 HG22 HG23 ' A' ' 44' ' ' VAL . 16.5 m -122.03 158.97 25.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.166 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.77 124.12 64.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -54.72 138.36 42.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.077 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.8 pt -121.0 -13.51 8.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.154 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -132.64 147.65 52.34 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.04 105.65 3.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -113.56 141.81 46.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.954 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 50.9 m -122.73 110.98 16.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 24.7 pttt -48.68 151.05 1.24 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.953 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -97.33 -45.23 6.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.877 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.63 171.71 8.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -66.63 -7.02 17.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.892 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -87.4 -23.83 24.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.929 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -90.55 -178.35 5.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.42 150.76 50.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.802 ' N ' HD23 ' A' ' 34' ' ' LEU . 21.8 t -116.53 139.32 50.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -156.34 152.27 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.904 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -113.32 153.27 28.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.956 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -43.08 99.19 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.86 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 123.6 28.22 1.33 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.479 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.05 138.34 46.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.719 0.295 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.1 mm -95.81 127.61 47.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.169 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 64.5 mt -127.65 133.98 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.196 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 72.5 m-85 -95.44 98.54 10.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 53' ' ' TYR . 96.9 t -63.65 117.85 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.522 HD11 ' OE2' ' A' ' 54' ' ' GLU . 6.5 pt -116.58 -25.14 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.478 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 28.6 ttmt -128.42 142.8 50.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 21.3 mtpp -130.21 120.62 24.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.848 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -94.77 152.67 18.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -39.13 -47.12 1.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -81.98 -179.42 7.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.769 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.435 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -75.21 70.52 1.84 Allowed Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.472 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 58.3 m95 -149.74 122.77 8.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 111.043 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.77 ' HB3' HG13 ' A' ' 44' ' ' VAL . 7.0 m-85 -120.29 151.43 39.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.91 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.522 ' OE2' HD11 ' A' ' 45' ' ' ILE . 2.8 tt0 -104.02 113.58 27.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -131.48 154.43 20.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.553 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.538 HG22 ' OG1' ' A' ' 61' ' ' THR . 93.0 t -96.64 112.36 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.326 . . . . 0.0 111.176 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -118.11 112.0 19.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 22.5 t30 65.5 35.81 7.04 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.06 -31.57 3.1 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 76.7 t -83.69 129.98 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.826 0.345 . . . . 0.0 111.158 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.538 ' OG1' HG22 ' A' ' 56' ' ' VAL . 12.8 m -109.51 143.33 39.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.8 148.61 12.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.521 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.422 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.8 mm? -66.28 135.19 54.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -140.35 148.48 54.09 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.612 0.72 . . . . 0.0 110.91 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 132.47 23.22 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.4 -10.29 69.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -79.72 -28.35 40.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.881 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -89.21 20.9 3.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.8 m -138.06 178.43 4.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.126 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 71' ' ' SER . 6.3 tm-20 -143.69 160.07 41.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.828 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.472 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 9.7 m -104.11 113.64 27.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.886 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.5 pt . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 -179.992 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.471 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 52.7 Cg_endo . . . . . 0 C--O 1.23 0.116 0 CA-C-O 121.62 0.591 . . . . 0.0 112.293 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.73 2.287 . . . . 0.0 112.373 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.471 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 50.3 p-90 -54.85 -29.79 56.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.954 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.461 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -61.06 156.07 51.02 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.497 0.665 . . . . 0.0 111.134 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD2' ' HB1' ' A' ' 12' ' ' ALA . 53.5 Cg_endo -69.81 151.14 68.67 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.707 2.271 . . . . 0.0 112.26 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 68.2 mtt180 -72.51 -48.87 37.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.841 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.2 t -129.22 98.61 4.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.836 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -105.32 143.35 33.62 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.93 -67.31 0.27 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.933 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -143.31 178.9 7.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.888 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.618 ' HE2' HG23 ' A' ' 41' ' ' ILE . 27.9 tttt -123.12 141.98 51.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.482 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.0 m -137.54 174.05 11.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.045 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.495 HG12 HG23 ' A' ' 72' ' ' ILE . 12.6 p -134.13 150.6 31.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.12 96.92 10.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.036 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.472 HG13 ' CD2' ' A' ' 24' ' ' TYR . 32.1 pt -73.24 -12.27 15.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.472 ' CD2' HG13 ' A' ' 23' ' ' ILE . 60.5 m-85 -131.53 172.25 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.93 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.24 96.49 6.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 29.5 t80 -98.96 155.35 17.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -123.81 131.59 53.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.428 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -78.31 125.95 30.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -96.68 -53.27 3.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.807 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.438 ' NZ ' ' HA ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -96.21 164.47 12.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.959 179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.08 -28.43 67.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -86.76 42.97 1.05 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.966 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -148.01 152.95 38.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.894 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.582 HD23 ' N ' ' A' ' 35' ' ' SER . 1.8 tt -112.17 130.67 55.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.792 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.582 ' N ' HD23 ' A' ' 34' ' ' LEU . 55.7 p -96.16 134.03 39.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -154.96 169.18 24.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.909 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -126.25 161.19 28.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -50.47 108.01 0.2 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.892 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.48 32.96 2.59 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.476 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.61 145.67 34.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.71 0.291 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.618 HG23 ' HE2' ' A' ' 19' ' ' LYS . 22.0 mm -102.37 126.55 56.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.129 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.489 HG21 ' CE2' ' A' ' 64' ' ' PHE . 19.5 mt -134.76 141.99 41.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.112 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -104.16 124.02 48.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.899 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.6 t -77.62 117.44 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.042 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.3 pt -116.99 -12.2 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.463 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 17.7 tttm -153.95 151.32 29.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -134.16 111.45 10.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.921 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -75.26 164.88 25.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -40.72 -46.61 2.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.34 -179.83 7.28 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.803 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.449 ' O ' ' CZ ' ' A' ' 53' ' ' TYR . . . -60.82 -7.66 8.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.476 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -69.88 128.28 35.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.852 0.358 . . . . 0.0 110.93 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.449 ' CZ ' ' O ' ' A' ' 51' ' ' GLY . 3.8 m-85 -126.68 148.72 49.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.951 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.463 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.2 tt0 -90.88 130.3 36.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -146.24 167.19 27.96 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.437 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.7 t -108.82 136.1 45.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.864 0.364 . . . . 0.0 111.146 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.6 ttp -143.48 122.62 12.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.882 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.6 p30 43.81 39.76 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.93 -30.74 3.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.06 117.01 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 111.084 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 10.3 m -99.38 135.18 41.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -164.5 163.15 36.0 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.459 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.7 mt -89.88 124.61 34.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.81 0.338 . . . . 0.0 110.917 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.489 ' CE2' HG21 ' A' ' 42' ' ' ILE . 35.8 p90 -119.83 144.65 37.74 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.619 0.724 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 138.63 38.17 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.667 2.244 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.08 3.69 56.85 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.521 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -89.89 -24.58 21.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.925 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -98.12 26.0 5.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.926 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.2 m -144.27 179.97 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.086 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.416 ' CG ' HD13 ' A' ' 23' ' ' ILE . 2.2 mm-40 -150.69 125.91 10.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 31.3 p -64.35 82.35 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.599 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.126 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.583 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo . . . . . 0 C--O 1.232 0.199 0 CA-C-O 121.617 0.59 . . . . 0.0 112.327 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -47.6 0.9 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.41 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.6 p-90 -55.24 -40.73 71.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.583 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -47.39 153.1 1.02 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.558 0.694 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.63 146.92 62.47 Favored 'Trans proline' 0 C--O 1.23 0.121 0 C-N-CA 122.744 2.296 . . . . 0.0 112.33 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.9 ptt180 -49.14 -57.89 5.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.844 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 36.1 t -133.85 149.88 51.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.1 p90 -149.2 159.72 44.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.9 mt -66.79 -61.06 2.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.873 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.11 175.72 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.439 ' HE3' HG23 ' A' ' 41' ' ' ILE . 31.1 tttt -121.46 151.72 39.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.971 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.478 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 29.1 m -145.36 177.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.177 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.622 HG12 HG23 ' A' ' 72' ' ' ILE . 8.3 p -137.1 139.18 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.29 87.99 4.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 24' ' ' TYR . 30.2 pt -64.52 -28.02 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.135 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.584 ' CE2' HD12 ' A' ' 23' ' ' ILE . 55.3 m-85 -128.97 156.31 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -81.34 120.71 25.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.918 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.56 ' CE1' ' O ' ' A' ' 27' ' ' THR . 5.4 t80 -129.28 124.09 33.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.56 ' O ' ' CE1' ' A' ' 26' ' ' TYR . 5.7 t -84.85 172.63 11.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.125 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 17.2 pttm -107.97 124.24 49.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -80.19 -29.68 38.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.1 mttp -126.66 150.29 49.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.864 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -51.72 -28.02 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.916 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.544 ' OD2' HD12 ' A' ' 63' ' ' LEU . 15.3 t70 -70.92 -38.43 72.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.892 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -66.52 171.18 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.771 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.4 tt -122.68 137.96 54.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.976 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -108.21 138.49 44.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -151.84 172.29 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -127.73 154.39 45.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -38.22 123.79 1.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.07 52.85 2.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.449 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.75 128.58 42.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.723 0.297 . . . . 0.0 111.115 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.439 HG23 ' HE3' ' A' ' 19' ' ' LYS . 31.9 mm -84.19 125.63 40.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.076 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.0 mt -134.22 131.18 55.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.172 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -96.51 114.15 25.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.5 t -72.4 123.29 26.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 16.2 pt -120.78 -28.02 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.127 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 30.5 tptt -123.1 140.36 53.1 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -130.71 105.32 7.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -86.64 154.06 21.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.915 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -44.98 -56.81 4.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.96 176.75 3.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.884 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -74.33 73.71 1.32 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . 0.533 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 95.7 m95 -158.56 112.22 2.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.797 0.332 . . . . 0.0 110.993 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -112.6 154.6 25.77 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -108.8 120.65 43.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.872 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -136.0 173.36 21.92 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -105.18 132.8 51.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.814 0.34 . . . . 0.0 111.156 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.11 109.71 7.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 t30 55.15 39.79 31.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.58 -31.23 3.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.446 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.46 ' O ' HD11 ' A' ' 34' ' ' LEU . 89.7 t -79.12 121.16 31.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 111.141 -179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.0 m -99.47 150.07 22.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.771 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -178.5 169.58 41.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.485 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.544 HD12 ' OD2' ' A' ' 32' ' ' ASP . 5.4 mt -94.47 138.32 32.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.843 0.354 . . . . 0.0 110.992 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -139.85 150.85 64.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.592 0.71 . . . . 0.0 110.959 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.533 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.5 Cg_endo -69.76 139.73 40.94 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.711 2.274 . . . . 0.0 112.355 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.73 6.28 47.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.509 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -92.58 -30.83 15.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.776 0.322 . . . . 0.0 110.79 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -90.35 25.06 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.957 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 21.0 m -148.34 142.73 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.113 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . 0.649 ' OE2' HG22 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -112.37 141.51 46.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.888 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.428 ' C ' ' OE1' ' A' ' 70' ' ' GLU . 74.7 m -78.25 79.69 4.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.649 HG22 ' OE2' ' A' ' 70' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.109 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.9 Cg_endo . . . . . 0 C--O 1.233 0.246 0 CA-C-O 121.597 0.582 . . . . 0.0 112.302 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.63 21.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.312 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' TRP . . . . . 0.492 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 21.9 p-90 -100.46 -31.31 11.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.878 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.47 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -72.55 149.02 90.76 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.626 0.727 . . . . 0.0 111.109 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.469 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 54.2 Cg_endo -69.66 168.19 22.14 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.66 2.24 . . . . 0.0 112.412 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 -83.97 -49.67 8.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.1 t -128.79 141.33 51.34 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.859 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -150.66 160.09 44.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.947 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.8 mt -59.83 -62.1 2.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -150.15 175.4 11.78 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.882 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.603 ' HD2' HG21 ' A' ' 41' ' ' ILE . 6.4 ttpm? -120.91 140.42 51.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.776 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.25 158.21 43.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.102 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.6 p -122.16 116.7 49.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.173 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -57.69 148.39 24.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.091 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.408 HD12 ' CE2' ' A' ' 24' ' ' TYR . 3.2 pt -124.71 -33.01 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.183 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE2' HD12 ' A' ' 23' ' ' ILE . 42.7 m-85 -117.92 165.97 13.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.967 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -86.59 139.72 30.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.868 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -140.26 128.71 22.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.917 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 35.3 m -111.11 111.22 22.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -53.63 138.32 34.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.95 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -92.38 -28.58 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 mmtp -112.77 -177.04 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.931 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -99.58 34.37 2.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -128.69 -38.82 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -68.85 -175.02 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.8 tt -126.12 146.4 49.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.927 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.497 ' N ' HD23 ' A' ' 34' ' ' LEU . 3.8 m -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.917 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -147.1 159.66 43.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.804 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -113.03 166.64 11.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.96 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -51.97 124.7 13.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 92.61 36.79 6.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.473 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.72 116.12 21.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.668 0.27 . . . . 0.0 111.134 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.603 HG21 ' HD2' ' A' ' 19' ' ' LYS . 3.6 mp -82.37 143.55 11.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.118 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.472 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 21.3 mt -135.37 132.61 52.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.076 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.469 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 76.7 m-85 -85.71 100.87 12.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.972 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.414 HG13 ' HB3' ' A' ' 53' ' ' TYR . 86.4 t -69.74 111.25 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.199 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 pt -101.73 -19.93 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.044 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -139.81 138.63 35.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.498 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 58.3 mttt -130.67 110.02 11.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 49' ' ' ASP . 65.8 m-80 -83.0 151.06 25.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 48' ' ' ASN . 34.1 m-20 -36.0 -59.64 0.59 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -72.79 179.8 3.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.37 74.94 0.68 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.532 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -156.76 110.94 2.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.935 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.498 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.5 OUTLIER -123.47 148.83 45.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.881 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -93.52 128.66 39.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.906 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.472 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -143.94 152.14 23.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.616 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.5 t -96.43 143.06 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.931 0.396 . . . . 0.0 111.093 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.401 ' O ' ' C ' ' A' ' 58' ' ' ASN . 4.8 tmm? -145.15 127.01 15.38 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 57' ' ' MET . 22.0 t30 38.24 46.12 0.85 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.973 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.91 -40.97 3.01 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.476 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.4 t -75.84 124.12 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.0 0.429 . . . . 0.0 111.126 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.616 ' OG1' HG22 ' A' ' 56' ' ' VAL . 31.8 m -107.55 150.16 27.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.172 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . 0.679 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.47 152.97 11.16 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.477 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.1 mp -72.71 151.96 41.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.864 0.364 . . . . 0.0 110.993 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.566 ' HE2' HG11 ' A' ' 69' ' ' VAL . 34.1 p90 -151.46 147.51 20.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.595 0.712 . . . . 0.0 110.925 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.86 133.04 24.44 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.654 2.236 . . . . 0.0 112.365 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.06 49.02 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.484 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -121.55 -29.86 4.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -94.3 3.4 55.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.994 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.566 HG11 ' HE2' ' A' ' 64' ' ' PHE . 19.3 m -112.09 160.86 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.113 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -135.35 124.65 24.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 66.2 m -58.05 113.33 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG2' HG12 ' A' ' 21' ' ' VAL . 44.3 pt . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.131 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 N-CA-C 112.554 -0.218 . . . . 0.0 112.554 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 m -63.69 176.93 0.79 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.839 0.352 . . . . 0.0 110.869 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.9 m -112.27 114.95 28.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.834 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 152.74 -136.28 5.3 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.458 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.6 m -85.25 124.5 31.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.835 0.35 . . . . 0.0 110.826 -179.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 27.6 p -110.45 82.32 1.58 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.857 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -122.1 91.58 0.47 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -131.56 144.2 52.37 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.508 0.67 . . . . 0.0 110.886 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.602 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.0 Cg_endo -69.85 164.56 34.18 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.654 2.236 . . . . 0.0 112.286 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.84 -31.02 20.97 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.712 2.275 . . . . 0.0 112.304 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 51.2 p-90 -76.57 -11.73 59.91 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.602 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -89.01 144.25 32.48 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 121.487 0.661 . . . . 0.0 111.197 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.84 132.55 23.44 Favored 'Trans proline' 0 C--O 1.231 0.132 0 C-N-CA 122.62 2.214 . . . . 0.0 112.322 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 34.6 mtm180 -57.07 -40.17 76.34 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.892 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 26.1 t -120.55 148.86 43.31 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.868 -179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -165.46 166.24 18.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.4 mt -70.05 -61.91 1.59 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -150.96 -177.62 6.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.842 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.1 ttmm -118.23 144.78 45.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.943 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.649 HG22 ' O ' ' A' ' 42' ' ' ILE . 27.9 m -142.44 152.93 17.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.198 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 21' ' ' VAL . 3.6 p -127.71 115.73 40.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.057 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -52.05 138.53 25.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.099 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.0 pt -113.62 -25.13 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.117 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -126.11 159.37 33.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.932 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 49.0 m-20 -75.78 127.53 33.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CE1' ' HG3' ' A' ' 65' ' ' PRO . 89.2 t80 -131.62 109.81 10.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.97 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.5 m -93.41 110.49 22.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.188 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.422 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 1.6 pptp? -58.69 157.56 9.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.819 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -101.66 -45.83 5.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.862 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 30.3 pttt -128.43 155.96 43.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.9 pt-20 -44.11 -32.37 1.19 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.92 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.41 -42.49 70.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.801 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -81.05 178.66 8.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.87 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.738 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -123.6 140.86 52.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.738 ' N ' HD23 ' A' ' 34' ' ' LEU . 99.5 p -110.82 128.1 55.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 4.2 p90 -149.96 168.03 24.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.6 pt20 -121.09 158.28 28.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -51.62 96.84 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.927 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 129.83 34.11 0.49 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.424 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -120.55 124.41 45.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.796 0.332 . . . . 0.0 111.043 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.688 ' N ' HD12 ' A' ' 41' ' ' ILE . 2.0 mp -82.39 101.41 7.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.075 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.649 ' O ' HG22 ' A' ' 20' ' ' VAL . 23.0 mt -95.64 122.28 46.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.075 179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -83.96 97.29 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.95 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.21 133.03 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.169 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.448 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 6.0 pt -127.25 -29.0 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -135.25 148.92 49.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.519 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 5.7 mtmp? -135.74 105.39 6.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -66.76 170.52 6.37 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.899 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -50.54 -54.58 21.39 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.815 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.484 ' O ' ' N ' ' A' ' 52' ' ' TRP . 16.2 m-20 -84.37 174.71 9.89 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.828 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.44 76.16 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.504 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.484 ' N ' ' O ' ' A' ' 50' ' ' ASP . 93.2 m95 -156.23 108.89 2.6 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.801 0.334 . . . . 0.0 110.916 -179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.519 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.4 OUTLIER -113.58 149.38 34.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.852 -179.835 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.448 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 6.2 tt0 -100.13 128.57 46.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.912 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -148.41 167.68 29.1 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.448 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.6 t -104.72 133.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.824 0.345 . . . . 0.0 111.2 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.21 125.01 22.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 58' ' ' ASN . 12.5 t30 50.41 30.7 4.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.908 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.09 -27.06 8.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.503 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 71.6 t -88.46 128.71 40.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.942 0.401 . . . . 0.0 111.143 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.72 151.48 21.99 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.108 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -179.95 153.05 11.46 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.446 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.6 mt -79.96 133.68 36.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 110.869 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.536 ' CE1' HG21 ' A' ' 42' ' ' ILE . 47.5 p90 -132.85 150.53 75.94 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.651 0.738 . . . . 0.0 110.866 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.435 ' HG3' ' CE1' ' A' ' 26' ' ' TYR . 54.1 Cg_endo -69.8 131.54 21.39 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.753 2.302 . . . . 0.0 112.421 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.02 51.17 3.48 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.544 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -130.42 -37.97 1.38 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.776 0.322 . . . . 0.0 110.915 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -84.25 10.52 10.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.957 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 12.3 m -123.1 161.55 24.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.201 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -136.8 126.69 25.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.903 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 27.5 m -69.65 127.51 33.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.841 -179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 3.4 pt -116.5 -10.64 12.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 10.9 t -134.61 116.22 14.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 163.51 -167.99 37.95 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.463 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -8.89 24.76 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 64.8 p -88.54 122.06 31.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.928 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 t -74.51 105.97 5.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.788 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.435 179.988 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 80.3 p -105.72 154.32 20.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.956 0.407 . . . . 0.0 110.781 -179.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 51.8 m -95.53 132.91 40.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.82 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 80.04 117.71 0.32 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.47 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.4 t -118.02 -46.23 2.63 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.79 0.329 . . . . 0.0 110.85 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.9 m -90.89 103.89 16.54 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.86 159.36 49.41 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -48.27 154.22 1.12 Allowed Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.551 0.691 . . . . 0.0 110.899 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.556 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.6 Cg_endo -69.85 169.55 18.76 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.641 2.227 . . . . 0.0 112.379 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 -41.63 4.21 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.36 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.556 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 54.8 p-90 -57.15 -18.79 16.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -81.36 147.75 61.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.544 0.687 . . . . 0.0 111.13 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 133.24 25.19 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.627 2.218 . . . . 0.0 112.355 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 52.9 mtm180 -72.57 -33.55 66.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 27.5 t -112.94 118.1 33.93 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.815 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.474 ' HB3' HG22 ' A' ' 45' ' ' ILE . 22.3 p90 -160.98 142.43 11.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.969 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mt -56.8 -60.53 3.43 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -161.07 -178.12 6.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.863 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 ptpp? -114.84 168.51 9.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.923 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.44 ' HA ' HD13 ' A' ' 72' ' ' ILE . 27.4 m -146.93 156.88 10.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.178 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 70' ' ' GLU . 14.8 p -113.34 142.16 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.124 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.88 106.87 15.89 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.096 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.473 HD12 ' CE2' ' A' ' 24' ' ' TYR . 28.2 pt -80.84 -15.76 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.473 ' CE2' HD12 ' A' ' 23' ' ' ILE . 58.5 m-85 -138.81 158.72 43.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.84 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.0 98.66 9.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.797 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.449 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 61.3 t80 -91.93 133.98 35.2 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.998 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 38.9 m -112.29 120.21 40.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.68 135.45 52.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.915 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -103.2 -33.33 9.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.863 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -113.81 159.28 19.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -62.67 -22.15 66.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -90.94 38.54 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.931 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -140.14 174.92 10.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.457 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -124.88 135.69 53.11 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.942 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.457 ' N ' HD23 ' A' ' 34' ' ' LEU . 84.8 p -104.41 137.87 41.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.845 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 13.8 p90 -161.57 159.77 28.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.827 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -109.16 173.46 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -66.01 110.35 2.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.85 39.4 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.437 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.41 149.89 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.791 0.329 . . . . 0.0 111.097 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 45.6 mm -102.78 123.47 56.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.161 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.411 HG21 ' CE1' ' A' ' 64' ' ' PHE . 49.4 mt -126.9 125.54 66.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.103 179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -84.18 120.07 25.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.4 t -82.45 114.83 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.474 HG22 ' HB3' ' A' ' 16' ' ' TYR . 31.6 pt -110.56 -14.54 10.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.172 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.44 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 32.1 tttp -146.19 144.49 29.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.908 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.581 ' HE2' ' CE1' ' A' ' 53' ' ' TYR . 13.2 mtpt -136.51 110.65 8.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.889 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 75.1 m-20 -82.41 161.42 22.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -55.63 -36.82 67.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -84.57 175.65 9.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.892 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -72.15 67.62 1.15 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.392 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.496 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 65.5 m95 -158.8 121.35 3.63 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.731 0.3 . . . . 0.0 110.999 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.581 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 6.4 m-85 -118.65 154.9 31.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.936 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.44 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 16.7 tt0 -104.19 123.55 47.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 61' ' ' THR . . . -143.24 167.91 26.3 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.64 133.27 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.801 0.334 . . . . 0.0 111.115 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -139.23 116.52 11.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.8 t30 55.7 39.11 30.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.914 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.31 -36.61 2.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.446 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 88.2 t -76.31 123.91 33.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.983 0.42 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.49 HG23 ' O ' ' A' ' 55' ' ' GLY . 5.3 m -107.62 146.38 32.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.114 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.59 169.0 41.41 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.544 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.459 ' N ' HD22 ' A' ' 63' ' ' LEU . 2.2 mm? -88.52 127.16 35.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.942 0.401 . . . . 0.0 110.881 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.411 ' CE1' HG21 ' A' ' 42' ' ' ILE . 49.1 p90 -136.63 144.75 48.39 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.666 0.746 . . . . 0.0 110.892 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 143.11 49.71 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.707 2.272 . . . . 0.0 112.337 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.484 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -83.98 7.26 71.42 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.427 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.0 m-20 -90.24 -35.24 15.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.871 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -80.1 3.25 21.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.934 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.62 172.75 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.163 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.487 ' O ' HG12 ' A' ' 21' ' ' VAL . 13.7 tt0 -142.26 137.03 30.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 49.1 m -69.42 130.59 42.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.849 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.496 HD13 ' H ' ' A' ' 72' ' ' ILE . 0.2 OUTLIER -122.48 -14.23 6.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.156 180.0 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 51.4 p -63.77 -52.25 61.2 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.86 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -112.28 177.24 18.46 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.542 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 111.08 2.72 Favored 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.687 2.258 . . . . 0.0 112.35 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.5 m -102.66 156.94 17.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 96.2 p -86.81 121.23 29.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.88 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.496 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.386 0 N-CA-C 112.459 -0.256 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 75.7 p -56.02 127.07 28.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.85 0.357 . . . . 0.0 110.817 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.6 m -61.74 118.19 6.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.828 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 148.74 -131.56 3.79 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 m -157.19 125.67 5.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.923 0.392 . . . . 0.0 110.804 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.3 t -93.65 129.01 40.09 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.92 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.58 110.66 0.43 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.457 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -138.52 144.06 40.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.629 0.728 . . . . 0.0 110.841 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.685 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.7 Cg_endo -69.81 167.21 25.15 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.716 2.277 . . . . 0.0 112.335 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -29.56 23.5 Favored 'Trans proline' 0 C--O 1.233 0.227 0 C-N-CA 122.644 2.23 . . . . 0.0 112.301 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.521 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 62.5 p-90 -77.8 -25.94 49.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.853 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.685 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -65.58 151.68 94.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.59 0.709 . . . . 0.0 111.172 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 175.92 7.44 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.666 2.244 . . . . 0.0 112.297 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 10.7 tpp180 -88.29 -51.26 5.85 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.87 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.2 t -123.53 155.26 37.91 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.895 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 13.5 p90 -164.84 161.22 20.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 82.5 mt -66.72 -59.9 3.16 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.903 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -156.96 167.67 29.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -102.22 128.73 48.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 44' ' ' VAL . 10.7 m -119.68 164.69 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.144 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.7 p -133.63 140.54 46.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.255 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.439 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -79.88 118.64 21.83 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.075 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.2 pt -91.39 -14.75 8.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.09 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -136.74 161.36 36.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -86.23 132.66 33.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.887 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 15.8 t80 -130.91 144.89 51.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.9 m -118.34 95.44 4.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.241 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.423 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -40.49 135.45 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.866 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -108.77 -54.64 2.49 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.916 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -79.91 162.47 24.97 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.921 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -69.84 -25.05 63.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.894 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -95.94 54.38 1.48 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -149.66 178.29 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.71 HD23 ' N ' ' A' ' 35' ' ' SER . 2.6 tt -131.32 142.43 50.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.926 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.71 ' N ' HD23 ' A' ' 34' ' ' LEU . 59.7 p -108.19 143.36 37.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.874 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 p90 -166.91 167.99 14.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.774 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -120.34 164.81 15.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.979 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -55.74 117.97 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 105.25 43.88 1.55 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.572 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.95 138.52 52.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.78 0.324 . . . . 0.0 111.12 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 47.9 mm -89.76 129.72 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.164 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.23 145.5 34.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.165 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -106.96 114.17 28.1 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.002 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.442 HG13 ' HB3' ' A' ' 53' ' ' TYR . 43.6 t -77.76 118.03 23.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.149 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.61 HD11 ' OE1' ' A' ' 54' ' ' GLU . 2.9 pt -117.06 -8.88 12.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.5 ttmm -136.36 140.85 43.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.981 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 36.9 mttp -134.89 103.02 5.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.889 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.448 ' O ' ' N ' ' A' ' 50' ' ' ASP . 32.7 m-20 -83.55 38.81 0.64 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.891 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 48' ' ' ASN . 2.4 m-20 36.67 32.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.932 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.463 ' O ' ' CE1' ' A' ' 53' ' ' TYR . 31.0 m-20 -151.89 -175.04 5.06 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.816 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.537 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -76.27 52.99 3.07 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.419 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.537 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 96.4 m95 -162.87 106.97 1.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.766 0.317 . . . . 0.0 110.927 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.463 ' CE1' ' O ' ' A' ' 50' ' ' ASP . 4.7 m-85 -120.32 154.82 34.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.94 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.61 ' OE1' HD11 ' A' ' 45' ' ' ILE . 0.1 OUTLIER -98.25 141.14 31.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.88 -179.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' A' ' 54' ' ' GLU . . . -161.85 165.45 35.77 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.413 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.578 HG22 ' OG1' ' A' ' 61' ' ' THR . 56.1 t -107.43 146.13 13.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.858 0.361 . . . . 0.0 111.081 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.3 ttp -155.22 108.18 2.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.2 t30 68.14 32.96 4.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.65 -23.77 7.22 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.502 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.1 t -88.29 122.75 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.91 0.386 . . . . 0.0 111.107 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.578 ' OG1' HG22 ' A' ' 56' ' ' VAL . 7.3 m -106.33 148.43 28.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.135 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -176.77 163.29 32.18 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.489 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.0 mm? -84.58 125.85 32.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.368 . . . . 0.0 110.909 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -127.19 152.11 75.49 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.683 0.754 . . . . 0.0 110.886 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 143.41 51.08 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.715 2.277 . . . . 0.0 112.289 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -86.56 24.79 7.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.494 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -111.33 -28.81 8.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -87.72 5.08 41.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.887 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.439 HG12 ' HA ' ' A' ' 22' ' ' ALA . 0.7 OUTLIER -127.82 173.27 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.127 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -149.82 135.6 18.56 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.904 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 36.8 p -65.77 131.47 46.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.925 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.1 pt -113.95 -30.37 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -87.21 89.15 7.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.803 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 59.8 164.06 0.14 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.509 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 1.58 4.34 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.65 2.233 . . . . 0.0 112.34 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 77' ' ' SER . 77.7 p -168.52 162.04 11.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . 0.416 ' C ' ' O ' ' A' ' 76' ' ' SER . 98.9 p -37.04 116.16 0.43 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.761 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.483 179.999 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.5 m -41.4 141.19 0.75 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.913 0.387 . . . . 0.0 110.828 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -101.9 118.75 37.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.819 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.75 -78.21 0.53 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.449 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.8 p -54.68 138.76 40.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.882 0.372 . . . . 0.0 110.897 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.0 p -116.3 171.92 7.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.912 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.97 -71.14 1.3 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.492 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -40.45 143.83 0.63 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.633 0.73 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.653 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo -69.81 164.16 35.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.79 2.327 . . . . 0.0 112.278 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.67 -13.68 35.24 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.675 2.25 . . . . 0.0 112.398 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.576 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.9 p-90 -93.93 -34.65 13.01 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.975 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.653 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -51.31 145.78 13.14 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.521 0.677 . . . . 0.0 111.096 179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.554 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.7 Cg_endo -69.8 133.68 26.08 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.727 2.285 . . . . 0.0 112.36 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 43.4 mtt180 -59.93 -33.43 71.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.98 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.9 t -140.42 137.92 34.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -153.74 161.54 42.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.97 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.598 HD13 ' HG3' ' A' ' 47' ' ' LYS . 5.1 mt -57.14 -71.68 0.09 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.912 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -151.49 165.74 33.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.634 ' HG2' HD11 ' A' ' 72' ' ' ILE . 15.5 ttpt -100.83 134.39 43.87 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.871 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.1 m -123.02 159.72 26.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.08 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.497 HG12 HG23 ' A' ' 72' ' ' ILE . 8.1 p -119.02 132.97 67.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.18 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.639 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -77.76 100.59 6.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.3 pt -75.86 -14.9 15.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.098 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -134.1 173.7 11.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -100.3 107.91 19.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.849 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.55 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 70.5 t80 -107.07 134.05 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.935 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 28' ' ' LYS . 30.1 m -110.23 111.94 23.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.101 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.427 ' C ' ' O ' ' A' ' 27' ' ' THR . 0.0 OUTLIER -36.15 128.99 0.71 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.906 179.898 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -100.88 -41.07 6.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 mtpp -104.3 165.01 11.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.891 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.6 mm-40 -67.37 -27.01 66.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.923 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.448 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 9.6 p-10 -94.21 16.61 14.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.826 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.486 ' N ' ' OE1' ' A' ' 33' ' ' GLU . 0.1 OUTLIER -106.13 166.12 10.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.943 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.623 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -118.37 141.57 48.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.623 ' N ' HD23 ' A' ' 34' ' ' LEU . 2.4 t -107.68 140.33 40.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -158.31 150.6 21.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -102.56 160.78 14.26 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -46.42 152.35 0.45 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.895 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 63.78 36.26 93.08 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.53 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -106.74 166.49 10.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.764 0.316 . . . . 0.0 111.087 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.7 mm -120.2 129.5 75.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.211 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.4 mt -129.54 141.14 47.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.554 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 53.6 m-85 -105.28 92.13 4.08 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.5 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 86.1 t -58.27 113.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.075 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.7 pt -110.84 -15.15 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.441 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.2 ttmt -140.76 147.46 39.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.913 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.598 ' HG3' HD13 ' A' ' 17' ' ' LEU . 64.0 mttt -135.85 147.76 48.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.968 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 -125.53 151.09 46.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.889 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -39.15 -49.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.867 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -76.56 -176.0 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.21 64.73 4.11 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.479 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -148.75 114.79 5.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.839 0.352 . . . . 0.0 110.84 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.478 ' C ' HD23 ' A' ' 63' ' ' LEU . 0.7 OUTLIER -121.23 146.78 46.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.895 -179.976 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.441 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 4.1 tt0 -96.44 126.63 41.77 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.882 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -140.18 167.45 25.44 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.448 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 t -105.1 143.52 16.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.831 0.348 . . . . 0.0 111.082 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.574 ' HB3' HD21 ' A' ' 34' ' ' LEU . 7.5 tmm? -152.66 112.36 3.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.28 39.71 22.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.956 -179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 81.86 -34.68 2.55 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.447 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 86.8 t -75.58 126.78 36.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.95 0.405 . . . . 0.0 111.131 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 5.5 m -104.27 141.38 36.39 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.167 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.454 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -174.33 153.89 17.7 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.517 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 53' ' ' TYR . 5.3 mt -75.63 156.23 35.08 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.758 0.313 . . . . 0.0 110.955 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.5 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 35.2 p90 -155.79 148.16 17.66 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.671 0.748 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.68 130.26 19.13 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.738 2.292 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.415 ' HA3' ' CE2' ' A' ' 53' ' ' TYR . . . -71.13 -2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.52 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -86.22 -33.73 20.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.838 0.352 . . . . 0.0 110.911 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.55 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 9.5 m-85 -69.83 -23.59 63.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.869 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 22' ' ' ALA . 12.3 m -115.33 175.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.167 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -136.36 162.72 32.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 m -88.22 113.71 24.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.791 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.634 HD11 ' HG2' ' A' ' 19' ' ' LYS . 47.7 pt -84.1 -19.69 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.179 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 3.2 t -112.71 121.55 45.06 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 95.77 -158.32 21.96 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.455 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 140.24 42.03 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.698 2.266 . . . . 0.0 112.344 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 93.6 p -64.01 -45.25 89.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.86 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 67.8 p -163.1 173.66 13.22 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.506 -179.964 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.2 p -113.57 168.15 10.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.899 0.38 . . . . 0.0 110.853 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.3 p -45.67 -65.35 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.887 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 134.09 60.79 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.541 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.2 m -88.49 152.71 21.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.967 0.413 . . . . 0.0 110.728 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.8 p -138.62 117.56 12.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.879 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -152.91 -39.77 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.427 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -87.66 145.65 37.54 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.589 0.709 . . . . 0.0 110.88 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.615 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.3 Cg_endo -69.7 169.33 19.1 Favored 'Trans proline' 0 N--CA 1.464 -0.228 0 C-N-CA 122.824 2.35 . . . . 0.0 112.377 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -19.69 35.77 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.731 2.287 . . . . 0.0 112.316 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . . . . . . . . . 42.0 p-90 -90.47 -20.25 22.93 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.942 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.615 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -70.93 148.47 94.59 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.614 0.721 . . . . 0.0 111.151 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 133.45 25.67 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.727 2.285 . . . . 0.0 112.374 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 67.6 mtt85 -43.06 -46.25 5.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.824 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.6 p -145.8 144.16 30.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 15.3 p90 -134.66 174.6 10.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.84 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -76.68 -56.36 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.95 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -154.46 168.94 25.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.863 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttt -110.12 142.17 41.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.798 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.7 148.28 22.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.177 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.1 p -112.86 131.79 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.145 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.32 99.68 2.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.082 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.749 HD12 ' CE2' ' A' ' 24' ' ' TYR . 16.3 pt -73.13 -14.65 16.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.181 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.749 ' CE2' HD12 ' A' ' 23' ' ' ILE . 28.9 m-85 -143.56 156.13 44.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.868 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -72.92 162.96 28.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.405 ' CD1' ' C ' ' A' ' 26' ' ' TYR . 2.9 t80 -168.84 131.5 1.32 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.946 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 17.4 m -109.84 131.99 54.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.093 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.471 ' HZ3' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -63.67 164.27 10.05 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.954 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -129.07 -5.74 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.849 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.2 ptpp? -146.6 143.13 28.62 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -47.11 -23.9 0.57 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -93.45 47.35 1.24 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.818 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -145.26 -179.74 6.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.867 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.587 HD23 ' N ' ' A' ' 35' ' ' SER . 2.2 tt -126.48 151.16 48.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.924 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.587 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.9 p -121.22 123.99 43.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -140.95 152.59 45.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -110.26 165.02 12.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.961 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -52.64 108.29 0.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.895 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 104.96 39.66 2.27 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.88 21.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.74 0.305 . . . . 0.0 111.102 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.8 mm -107.4 111.14 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.201 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.534 HG21 ' CE1' ' A' ' 64' ' ' PHE . 81.3 mt -117.06 141.36 35.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.164 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -105.09 108.85 20.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.971 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -67.11 115.36 4.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.181 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 7.1 pt -118.17 -18.44 6.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.14 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 4.1 tmtm? -138.94 146.45 41.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.872 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.429 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 17.1 mtpp -136.2 112.36 9.74 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -74.9 173.76 10.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -51.61 -17.52 0.88 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -112.75 -175.84 2.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.889 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.586 ' O ' ' CE2' ' A' ' 53' ' ' TYR . . . -63.31 -10.19 33.93 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.485 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.443 ' CH2' ' HD3' ' A' ' 65' ' ' PRO . 59.4 m95 -61.96 122.53 15.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.705 0.288 . . . . 0.0 110.9 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.586 ' CE2' ' O ' ' A' ' 51' ' ' GLY . 19.5 m-85 -123.84 135.55 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.889 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.454 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 9.3 tt0 -87.39 121.9 30.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.453 ' O ' ' CD1' ' A' ' 34' ' ' LEU . . . -134.57 158.23 23.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.477 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.454 HG22 ' OG1' ' A' ' 61' ' ' THR . 59.2 t -101.43 129.8 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.476 ' O ' ' ND2' ' A' ' 58' ' ' ASN . 2.2 tmm? -138.43 138.08 37.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.813 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.476 ' ND2' ' O ' ' A' ' 57' ' ' MET . 1.9 p30 39.97 38.07 0.44 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.909 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.61 -38.08 2.79 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 41.0 t -75.95 117.71 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.907 0.384 . . . . 0.0 111.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.454 ' OG1' HG22 ' A' ' 56' ' ' VAL . 17.1 m -100.62 145.64 28.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.158 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.75 177.13 44.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.622 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.1 mt -94.47 155.31 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.784 0.326 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.534 ' CE1' HG21 ' A' ' 42' ' ' ILE . 51.2 p90 -158.54 151.55 18.5 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.612 0.72 . . . . 0.0 110.927 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.443 ' HD3' ' CH2' ' A' ' 52' ' ' TRP . 53.6 Cg_endo -69.74 129.91 18.44 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.755 2.304 . . . . 0.0 112.371 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -61.47 -17.66 53.86 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.463 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 69' ' ' VAL . 32.0 t30 -68.97 -65.89 0.65 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.8 0.333 . . . . 0.0 110.874 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.8 m-85 -38.52 -31.71 0.06 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.871 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.404 ' N ' ' O ' ' A' ' 67' ' ' ASN . 3.3 m -107.18 173.66 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -143.59 168.72 19.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.881 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 28.9 t -96.05 118.41 32.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 21.5 pt -104.59 -22.09 5.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.091 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.0 m -126.14 158.62 35.06 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.823 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 169.35 -167.81 40.78 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.516 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -13.29 34.48 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.652 2.235 . . . . 0.0 112.316 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 88.7 p -56.2 125.03 19.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.811 -179.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 45.7 t -87.42 103.33 15.4 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.833 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.23 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.425 179.962 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.558 -0.217 . . . . 0.0 112.558 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.1 t -170.63 175.82 4.51 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.861 0.362 . . . . 0.0 110.844 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.4 t -66.56 172.58 4.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.874 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.38 -66.46 0.43 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.486 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 m -164.59 173.71 11.67 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.899 0.38 . . . . 0.0 110.841 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.2 m -130.17 -44.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.827 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.92 85.4 0.61 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.511 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.464 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 0.4 OUTLIER -152.77 149.8 23.07 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.656 0.741 . . . . 0.0 110.842 -179.99 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.5 Cg_endo -69.71 167.56 24.01 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.694 2.263 . . . . 0.0 112.282 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -44.59 1.98 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.736 2.291 . . . . 0.0 112.326 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.403 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 33.8 p-90 -56.25 -16.72 5.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.974 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -71.29 144.19 89.15 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.656 0.741 . . . . 0.0 111.103 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 127.31 14.42 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.738 2.292 . . . . 0.0 112.309 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.5 ttm180 -55.64 -39.92 71.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 7.3 t -117.49 129.93 56.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.789 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.455 ' CD1' ' O ' ' A' ' 16' ' ' TYR . 9.6 p90 -156.32 140.52 16.52 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.936 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.59 HD22 ' HE2' ' A' ' 47' ' ' LYS . 3.9 mp -49.93 -68.12 0.2 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.93 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -146.37 175.66 10.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.92 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.504 ' HE3' ' CE1' ' A' ' 43' ' ' TYR . 0.6 OUTLIER -116.46 126.82 53.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.903 179.952 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 28.7 m -121.26 159.51 23.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.086 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.44 HG23 HD13 ' A' ' 41' ' ' ILE . 9.2 p -119.68 143.46 31.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.112 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.16 114.67 18.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.088 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.549 HG13 ' CD2' ' A' ' 24' ' ' TYR . 33.6 pt -92.97 -9.34 9.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.096 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.549 ' CD2' HG13 ' A' ' 23' ' ' ILE . 55.1 m-85 -147.88 158.23 43.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -82.12 128.71 34.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.892 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -135.22 129.84 34.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.918 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.414 ' O ' ' C ' ' A' ' 28' ' ' LYS . 91.0 m -107.17 104.43 14.07 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.143 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' A' ' 27' ' ' THR . 14.8 pttm -36.84 122.27 0.8 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -81.59 -8.68 59.74 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.789 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 21.9 mmtm -135.27 -175.08 3.81 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.91 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -87.26 -16.74 34.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.943 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 46.2 m-20 -88.69 -22.42 23.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.821 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -78.43 166.4 22.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.553 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -120.0 134.77 55.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.91 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.553 ' N ' HD23 ' A' ' 34' ' ' LEU . 1.4 t -99.73 145.4 27.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -164.9 161.26 20.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -106.85 172.83 6.61 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -66.3 112.04 3.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 122.8 -17.26 8.22 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.448 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.03 146.92 52.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.752 0.311 . . . . 0.0 111.123 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.44 HD13 HG23 ' A' ' 21' ' ' VAL . 10.8 mm -104.47 141.45 19.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.182 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.699 HG21 ' CE2' ' A' ' 64' ' ' PHE . 16.8 mt -135.58 142.85 38.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.088 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.504 ' CE1' ' HE3' ' A' ' 19' ' ' LYS . 93.1 m-85 -105.67 104.76 14.54 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.873 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.5 t -61.24 121.92 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.105 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.458 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.2 pt -123.93 -14.91 5.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.171 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.486 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 35.3 tttm -137.29 148.79 46.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.59 ' HE2' HD22 ' A' ' 17' ' ' LEU . 38.2 mmtt -119.76 161.66 20.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.432 ' CB ' ' HB2' ' A' ' 52' ' ' TRP . 2.4 m-80 -133.12 -174.95 3.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.943 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -109.72 -28.07 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.593 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 54.9 m-20 -99.45 40.39 1.22 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.837 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.529 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 60.79 79.8 0.11 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.543 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.593 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 94.1 m95 -162.67 137.37 6.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.76 0.314 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.485 ' CD1' ' HD3' ' A' ' 47' ' ' LYS . 11.9 m-85 -132.87 136.46 46.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.861 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.486 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.7 tt0 -95.86 115.37 27.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.959 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.41 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -125.68 173.26 17.61 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.472 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.3 t -113.01 139.1 39.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.869 0.366 . . . . 0.0 111.157 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.469 ' O ' ' N ' ' A' ' 60' ' ' VAL . 5.3 tmm? -149.36 143.8 26.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.861 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.424 ' C ' ' O ' ' A' ' 57' ' ' MET . 11.6 p-10 35.78 37.79 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.0 2.98 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.482 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' MET . 89.1 t -76.05 138.94 19.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.979 0.419 . . . . 0.0 111.165 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 15.8 m -114.64 146.72 40.53 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.402 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.86 177.9 44.38 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.376 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.0 mp -105.05 134.12 48.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.825 0.345 . . . . 0.0 110.951 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 42' ' ' ILE . 29.4 p90 -125.92 153.1 73.62 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.677 0.751 . . . . 0.0 110.846 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 143.42 50.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.281 . . . . 0.0 112.297 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.31 36.8 2.4 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.477 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 -127.87 -29.69 2.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.825 0.345 . . . . 0.0 110.878 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -91.25 16.29 10.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.6 m -146.59 162.5 9.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.098 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 33.0 mm-40 -139.76 150.97 45.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 91.7 p -85.74 109.57 18.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 26.8 pt -95.18 -26.21 4.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.084 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.2 t -74.1 -62.81 1.38 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.838 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -125.97 -161.42 10.96 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.568 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 177.95 5.06 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.629 2.22 . . . . 0.0 112.316 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 28.5 t -107.02 116.5 32.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.917 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 32.7 p -81.25 138.25 35.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.85 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.466 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.0 m -116.9 94.88 4.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.843 0.354 . . . . 0.0 110.829 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -144.73 156.17 43.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.958 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 5' ' ' SER . . . 113.27 104.25 2.64 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.449 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 4' ' ' GLY . 5.1 t -35.06 104.48 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.841 0.353 . . . . 0.0 110.861 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.5 m -113.04 129.5 56.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.834 -179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 126.26 -48.8 0.95 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.449 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -51.85 153.0 4.7 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.642 0.734 . . . . 0.0 110.804 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.642 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.2 Cg_endo -69.75 169.28 19.27 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.692 2.261 . . . . 0.0 112.34 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.87 -34.84 13.42 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.404 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 52.2 p-90 -71.43 -30.48 66.11 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.642 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -55.13 148.8 28.11 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.51 0.671 . . . . 0.0 111.118 179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.87 145.53 56.77 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.647 2.232 . . . . 0.0 112.35 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -51.39 -36.56 44.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.3 m -160.45 156.41 25.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.88 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.708 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 19.3 p90 -150.19 -180.0 7.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.3 mt -84.09 -64.6 1.13 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -139.99 176.24 8.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.8 130.65 54.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 44' ' ' VAL . 15.8 m -123.85 160.4 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.177 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.8 p -124.88 147.77 29.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.86 115.13 22.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.061 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.417 HG13 ' CD2' ' A' ' 24' ' ' TYR . 31.3 pt -92.74 -7.61 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.108 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.417 ' CD2' HG13 ' A' ' 23' ' ' ILE . 59.8 m-85 -146.84 163.37 36.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.944 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -85.76 121.81 28.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.872 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 71.9 t80 -135.19 114.26 12.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.994 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.42 ' O ' ' C ' ' A' ' 28' ' ' LYS . 24.6 m -98.21 106.01 18.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.181 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' A' ' 27' ' ' THR . 5.2 pttm -35.57 133.18 0.4 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.933 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -90.55 -27.71 18.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.835 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 2.8 pttp -128.94 163.64 24.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.828 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -53.77 -39.95 65.82 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.947 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -76.2 49.1 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.805 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -157.11 167.08 31.46 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.803 HD23 ' N ' ' A' ' 35' ' ' SER . 2.5 tt -122.63 146.42 47.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.937 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.803 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.5 p -109.46 145.46 36.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.85 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.3 p90 -169.88 148.04 3.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -103.76 153.15 21.02 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.97 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -39.62 110.57 0.15 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.938 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.19 44.88 0.97 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.487 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -126.25 130.46 50.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.772 0.32 . . . . 0.0 111.103 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.3 mm -87.97 136.19 23.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.1 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.6 148.97 22.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.118 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.708 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 77.0 m-85 -104.31 115.02 29.64 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 20' ' ' VAL . 22.9 t -74.66 121.74 26.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.184 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.447 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.9 pt -122.72 -7.0 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.168 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.455 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 0.1 OUTLIER -136.67 144.8 44.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.0 mmmp? -122.16 103.23 8.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.862 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -74.73 -175.01 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.942 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -99.4 -10.47 22.19 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.42 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -120.38 40.42 3.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.817 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.595 ' O ' ' CE1' ' A' ' 53' ' ' TYR . . . 79.84 -44.29 2.75 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.43 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.474 ' O ' ' CD1' ' A' ' 53' ' ' TYR . 25.9 m95 -34.46 137.96 0.11 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.808 0.337 . . . . 0.0 110.926 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.595 ' CE1' ' O ' ' A' ' 51' ' ' GLY . 22.0 m-85 -136.84 137.9 40.23 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.926 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.455 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 23.8 tt0 -94.15 116.67 29.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.89 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -137.4 163.34 25.44 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.547 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 96.6 t -98.73 146.12 8.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.818 0.342 . . . . 0.0 111.143 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -151.45 118.65 5.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.902 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.9 t30 49.67 43.76 24.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.931 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 80.4 -40.67 2.41 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.508 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 95.2 t -75.83 120.56 25.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.97 0.414 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 m -100.96 141.47 33.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.168 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.428 ' C ' ' HB2' ' A' ' 34' ' ' LEU . . . -165.87 154.37 24.95 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.498 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 3.4 mp -80.54 147.87 30.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.902 0.382 . . . . 0.0 110.902 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 47.2 p90 -147.99 148.43 29.79 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.676 0.751 . . . . 0.0 110.884 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 139.5 40.27 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.699 2.266 . . . . 0.0 112.361 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.464 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -73.22 -3.93 62.46 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.527 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -82.22 -28.45 31.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 10.2 m-85 -90.48 8.36 34.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.878 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.464 ' CG2' ' HA2' ' A' ' 66' ' ' GLY . 8.6 m -135.7 169.06 21.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 28.9 mm-40 -140.63 150.18 43.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 3.4 t -85.03 113.63 21.59 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.877 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.3 pt -104.48 -32.62 2.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.139 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.7 t -74.95 -53.63 8.64 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.905 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -59.15 168.64 6.56 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.556 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.87 176.36 6.96 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.704 2.27 . . . . 0.0 112.246 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 85.2 p -150.76 148.22 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.837 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 93.5 p -111.38 -47.37 3.19 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.858 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.248 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.434 179.961 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.9 m -72.79 127.26 32.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.836 0.351 . . . . 0.0 110.903 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.0 t -166.33 163.41 17.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.896 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.13 -102.76 0.18 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.463 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.4 m -95.77 81.89 3.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.823 0.344 . . . . 0.0 110.883 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 70.6 m 57.79 48.49 13.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.865 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.93 127.38 8.97 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.449 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -45.31 148.81 1.06 Allowed Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.657 0.741 . . . . 0.0 110.792 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.585 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.79 163.55 37.88 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.612 2.208 . . . . 0.0 112.339 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 -33.36 17.04 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.585 2.19 . . . . 0.0 112.397 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 22.4 p-90 -63.6 -23.18 67.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.988 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.434 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -65.23 148.26 98.04 Favored Pre-proline 0 C--N 1.331 -0.219 0 CA-C-O 121.493 0.663 . . . . 0.0 111.087 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 149.15 66.19 Favored 'Trans proline' 0 N--CA 1.465 -0.151 0 C-N-CA 122.662 2.242 . . . . 0.0 112.37 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -54.94 -44.18 74.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.897 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.5 t -145.79 165.66 28.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 17.0 p90 -159.6 -179.14 7.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 22.9 mt -84.58 -57.31 3.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.909 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -152.96 -179.88 8.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.582 ' HE3' HG23 ' A' ' 41' ' ' ILE . 13.3 tttp -113.75 154.38 27.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.873 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.41 ' N ' ' HG2' ' A' ' 19' ' ' LYS . 29.1 m -152.18 147.15 15.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.093 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.2 p -117.09 139.4 44.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.206 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.27 135.42 36.23 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.109 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.492 HG13 ' CD2' ' A' ' 24' ' ' TYR . 16.1 pt -115.07 -15.17 10.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.179 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CD2' HG13 ' A' ' 23' ' ' ILE . 62.9 m-85 -128.53 164.51 22.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.895 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -87.22 123.98 32.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.919 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.41 ' CG ' ' N ' ' A' ' 27' ' ' THR . 86.0 t80 -117.31 160.27 21.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.949 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.41 ' N ' ' CG ' ' A' ' 26' ' ' TYR . 6.7 m -133.53 132.08 40.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.22 136.34 36.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.914 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -99.56 -32.02 11.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.978 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 42.7 mttp -110.12 163.42 13.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.13 4.71 13.92 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.864 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -108.55 -26.75 10.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.411 ' C ' ' HA3' ' A' ' 62' ' ' GLY . 0.1 OUTLIER -70.4 -177.99 1.61 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.858 -179.883 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -124.41 139.57 53.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.974 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 57.7 p -115.88 124.91 51.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.828 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.522 ' CD2' HD11 ' A' ' 42' ' ' ILE . 28.7 p90 -148.04 156.54 42.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.849 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -114.86 169.88 8.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.915 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -45.64 137.42 5.25 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.871 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.45 46.51 9.88 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.548 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.9 136.28 52.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.341 . . . . 0.0 111.037 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.582 HG23 ' HE3' ' A' ' 19' ' ' LYS . 21.8 mm -88.72 135.7 25.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.522 HD11 ' CD2' ' A' ' 36' ' ' PHE . 65.9 mt -141.99 143.46 26.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -110.28 109.67 20.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.96 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.486 HG13 ' HB3' ' A' ' 53' ' ' TYR . 92.8 t -69.25 110.07 2.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.137 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 26.2 pt -107.79 -14.12 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.193 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 46.9 tttt -144.52 138.45 27.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.886 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.552 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 6.6 mtmp? -135.05 102.99 5.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -75.97 175.51 8.77 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -76.38 48.36 0.53 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.878 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -163.36 -176.92 5.01 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.481 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -82.7 49.62 4.22 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.472 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.524 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 46.1 m95 -148.71 121.39 8.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.552 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 2.9 m-85 -119.06 149.26 41.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.877 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.65 123.13 37.91 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.921 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -134.8 177.02 19.6 Favored Glycine 0 N--CA 1.454 -0.157 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.449 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.467 HG22 HG23 ' A' ' 61' ' ' THR . 45.8 t -117.86 144.22 26.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.73 0.3 . . . . 0.0 111.196 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -157.02 129.99 7.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.816 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 58' ' ' ASN . 30.7 t30 47.55 38.47 8.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.85 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.01 -35.14 2.55 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.499 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 97.9 t -76.02 126.04 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 111.112 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.467 HG23 HG22 ' A' ' 56' ' ' VAL . 2.9 m -106.97 150.87 26.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.159 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.411 ' HA3' ' C ' ' A' ' 33' ' ' GLU . . . 173.91 162.2 25.29 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.526 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.8 mp -81.22 163.96 22.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.874 0.369 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.511 ' CE1' HG21 ' A' ' 42' ' ' ILE . 29.8 p90 -160.68 152.47 16.52 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.525 0.679 . . . . 0.0 110.871 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.524 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.1 Cg_endo -69.78 137.27 35.03 Favored 'Trans proline' 0 N--CA 1.465 -0.166 0 C-N-CA 122.679 2.253 . . . . 0.0 112.321 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 68' ' ' TYR . . . -67.27 -56.11 13.28 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.429 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.9 m-20 -40.95 -24.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.892 0.377 . . . . 0.0 110.937 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.472 ' CG ' ' HG2' ' A' ' 65' ' ' PRO . 13.4 m-85 -76.77 -42.73 39.72 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.455 ' N ' ' O ' ' A' ' 66' ' ' GLY . 18.8 m -108.24 142.64 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.231 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -102.94 165.64 10.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.802 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 8.4 t -105.66 105.23 15.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.84 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.403 HD11 ' HD3' ' A' ' 19' ' ' LYS . 37.3 pt -86.33 -16.27 9.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.172 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 11.1 t -74.59 159.29 32.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 88.33 -169.38 37.74 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.474 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 161.46 45.86 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.657 2.238 . . . . 0.0 112.309 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 84.1 p -77.8 160.27 28.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.868 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.0 m -94.29 118.34 31.45 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.833 -179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.376 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.474 -179.969 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.9 m -101.06 128.76 46.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.833 0.349 . . . . 0.0 110.843 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 86.6 p -158.32 157.47 32.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 129.38 -167.96 21.14 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.492 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.2 m -70.1 -58.01 4.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.857 0.36 . . . . 0.0 110.864 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 77.5 p -106.61 -50.39 3.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.948 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.58 -93.5 0.16 Allowed Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.516 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -115.41 156.28 46.04 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.729 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.567 ' CG ' ' CE2' ' A' ' 11' ' ' TRP . 53.8 Cg_endo -69.8 166.81 26.4 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.645 2.23 . . . . 0.0 112.329 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.8 -33.35 16.62 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.603 2.202 . . . . 0.0 112.393 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.567 ' CE2' ' CG ' ' A' ' 9' ' ' PRO . 22.2 p-90 -65.56 -27.82 68.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.54 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -58.32 147.41 67.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.59 0.71 . . . . 0.0 111.126 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.6 10.72 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.668 2.245 . . . . 0.0 112.294 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 79.4 mtt180 -85.0 -43.94 13.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.8 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 39.0 t -136.66 152.79 50.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.812 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.53 ' CE2' ' CD1' ' A' ' 43' ' ' TYR . 7.1 p90 -159.77 157.21 28.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.904 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 44' ' ' VAL . 19.8 mt -61.35 -66.95 0.46 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.821 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -144.14 -175.65 4.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.858 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.596 ' HD2' HD11 ' A' ' 72' ' ' ILE . 20.7 ttmt -120.19 133.05 55.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.87 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.426 HG13 HG21 ' A' ' 44' ' ' VAL . 34.4 m -128.15 161.23 36.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.195 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.608 HG12 ' HG3' ' A' ' 70' ' ' GLU . 11.3 p -126.14 141.08 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.193 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.9 118.4 14.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.102 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 40.4 pt -99.04 -35.09 4.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.206 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -129.77 135.11 48.05 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -56.69 122.58 12.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.894 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 87.9 t80 -121.1 127.71 51.89 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -97.04 123.51 40.79 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.074 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.413 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -76.15 131.29 39.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.919 179.887 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -94.08 -47.9 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -105.14 146.8 28.69 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -45.22 -32.29 1.84 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.92 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.33 -44.77 96.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.922 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -65.68 165.33 12.73 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.958 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.625 HD23 ' N ' ' A' ' 35' ' ' SER . 3.7 tt -121.63 140.09 52.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.625 ' N ' HD23 ' A' ' 34' ' ' LEU . 52.8 p -99.2 130.99 45.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 29.3 p90 -151.6 167.91 26.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.965 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -127.6 159.74 33.73 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.81 109.07 0.37 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.897 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.59 43.47 0.75 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.445 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -128.96 131.7 47.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.788 0.328 . . . . 0.0 111.068 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.78 100.4 11.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.156 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.4 mt -104.8 137.55 33.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.1 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.53 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 80.7 m-85 -91.18 121.79 33.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.966 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 17' ' ' LEU . 48.0 t -80.92 104.5 9.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.066 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 46' ' ' LYS . 33.0 pt -95.33 -33.58 4.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.406 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 20.4 tptm -129.31 144.22 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.889 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.479 ' HG2' ' CG ' ' A' ' 53' ' ' TYR . 10.9 mtpt -136.45 124.46 22.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.979 179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -101.4 151.25 22.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -39.34 -49.66 1.99 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.921 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -75.74 177.22 7.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.951 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.6 66.9 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.516 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -151.68 113.07 4.34 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.733 0.301 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.479 ' CG ' ' HG2' ' A' ' 47' ' ' LYS . 1.3 m-85 -122.95 154.23 38.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.406 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 14.4 tt0 -104.45 134.59 47.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.879 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -150.17 157.07 27.05 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.488 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.3 t -95.48 136.43 26.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.926 0.394 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.41 ' O ' ' N ' ' A' ' 60' ' ' VAL . 21.8 ttp -141.18 119.67 12.35 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.824 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 7.5 p-10 43.93 42.76 4.86 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.79 -26.64 4.65 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.493 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.41 ' N ' ' O ' ' A' ' 57' ' ' MET . 93.0 t -81.1 127.76 39.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.881 0.372 . . . . 0.0 111.162 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.7 m -112.19 147.86 35.27 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.141 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.503 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 178.04 162.84 28.63 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.533 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 9.9 mt -88.44 128.79 35.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.881 0.372 . . . . 0.0 110.902 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -120.38 147.33 44.95 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.716 0.77 . . . . 0.0 110.869 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 122.83 9.5 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 122.667 2.245 . . . . 0.0 112.35 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.458 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -58.53 -10.8 8.46 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.479 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -76.61 -32.16 57.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.732 0.301 . . . . 0.0 110.787 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 11.7 m-85 -97.83 35.32 1.72 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.906 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 68' ' ' TYR . 9.9 m -161.32 153.81 3.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.608 ' HG3' HG12 ' A' ' 21' ' ' VAL . 5.6 pt-20 -130.06 144.14 51.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 37.9 m -84.66 120.33 26.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.823 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.596 HD11 ' HD2' ' A' ' 19' ' ' LYS . 24.9 pt -99.33 -32.76 3.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.181 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 28.0 t -62.54 155.5 25.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.912 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 161.44 164.46 16.38 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.57 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 120.53 7.32 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.735 2.29 . . . . 0.0 112.296 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.2 t 53.37 43.05 31.91 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.915 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 51.5 m -126.9 139.13 53.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.81 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.52 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.53 -0.228 . . . . 0.0 112.53 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.4 m -89.56 -57.65 2.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.832 0.349 . . . . 0.0 110.857 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 45.5 t -88.55 154.06 20.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.836 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.22 117.65 0.58 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.538 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.0 t -79.77 -46.75 16.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.832 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.8 t -75.33 -57.55 3.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 114.88 45.68 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -81.57 157.0 70.45 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-O 121.606 0.717 . . . . 0.0 110.821 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.796 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.6 Cg_endo -69.72 166.24 28.2 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.602 2.201 . . . . 0.0 112.33 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.81 -33.95 15.4 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.681 2.254 . . . . 0.0 112.318 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 54.8 p-90 -73.55 -29.7 62.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.796 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -52.71 151.53 7.99 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.604 0.716 . . . . 0.0 111.089 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.63 133.25 25.33 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.654 2.236 . . . . 0.0 112.349 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 56.5 mtm180 -48.68 -45.48 39.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.865 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.5 p -136.64 163.39 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.942 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.5 p90 -166.27 171.21 12.39 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.005 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.57 HD13 ' HE3' ' A' ' 47' ' ' LYS . 19.4 mt -77.03 -52.29 9.59 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.882 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.727 ' OE1' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -160.44 172.84 16.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.967 179.898 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.05 145.92 42.61 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.727 HG13 ' OE1' ' A' ' 18' ' ' GLU . 30.4 m -135.64 163.28 35.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.109 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.29 140.53 47.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.05 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.19 102.93 12.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.072 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.688 HD12 ' CE2' ' A' ' 24' ' ' TYR . 8.5 pt -84.25 -7.22 10.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.177 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.688 ' CE2' HD12 ' A' ' 23' ' ' ILE . 46.7 m-85 -145.43 136.6 24.85 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.912 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -65.69 136.02 55.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.872 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -137.97 128.1 25.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.883 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.3 m -97.32 151.33 20.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.209 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 7.8 ptmt -93.03 132.58 37.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.844 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.02 -18.26 22.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.816 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -138.16 167.73 21.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.92 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -83.33 36.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.902 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -127.39 -28.94 2.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.937 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -88.98 -174.97 4.68 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.969 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.701 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.21 140.4 51.5 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.893 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.701 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.1 p -108.38 140.32 41.84 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.829 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -153.75 166.58 32.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.933 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -114.41 170.27 8.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.928 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -61.8 102.02 0.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 115.23 42.5 0.76 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.584 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -116.38 140.96 48.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 111.146 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.2 mm -92.85 122.44 44.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.151 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.543 HG21 ' CE2' ' A' ' 64' ' ' PHE . 70.4 mt -127.47 136.21 61.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.094 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -101.35 107.68 19.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.962 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.52 HG13 ' HB3' ' A' ' 53' ' ' TYR . 87.5 t -69.17 113.49 4.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.435 ' CG1' ' O ' ' A' ' 54' ' ' GLU . 15.0 pt -113.93 -2.37 10.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.164 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.475 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 11.0 tptm -156.2 137.08 13.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.57 ' HE3' HD13 ' A' ' 17' ' ' LEU . 14.5 ptpt -136.51 116.65 13.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 58.7 m-20 -90.1 155.91 18.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.936 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -43.15 -37.33 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -85.11 -175.27 5.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.864 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.526 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -82.56 81.37 1.72 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.526 ' CG ' ' O ' ' A' ' 51' ' ' GLY . 91.9 m95 -162.02 120.66 2.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.796 0.331 . . . . 0.0 110.933 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.52 ' HB3' HG13 ' A' ' 44' ' ' VAL . 33.6 m-85 -118.52 135.36 54.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.927 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.475 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 7.8 tt0 -91.0 111.11 22.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.901 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 61' ' ' THR . . . -125.96 169.89 17.86 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.487 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.506 HG22 ' OG1' ' A' ' 61' ' ' THR . 77.3 t -115.52 129.83 71.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.862 0.363 . . . . 0.0 111.097 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.8 tmm? -137.34 125.36 22.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.79 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 45.8 t30 51.02 37.98 19.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.28 -31.49 2.9 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.469 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.6 132.36 31.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.914 0.388 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.712 HG23 ' O ' ' A' ' 55' ' ' GLY . 18.9 m -114.27 145.14 42.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.76 145.12 9.25 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.461 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.405 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.7 mm? -67.95 123.85 21.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.883 -179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.543 ' CE2' HG21 ' A' ' 42' ' ' ILE . 42.3 p90 -123.82 152.67 66.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 138.91 38.88 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.646 2.231 . . . . 0.0 112.324 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.19 29.24 3.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -116.78 -35.02 4.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.848 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -78.21 2.36 18.48 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.938 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.5 m -119.96 178.41 2.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.082 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -142.68 124.17 14.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 72.2 m -71.7 103.69 3.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.9 pt -91.29 -29.32 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.143 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 28.9 t -48.41 130.65 16.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -55.12 164.23 3.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.467 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 172.74 12.04 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.731 2.287 . . . . 0.0 112.387 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 68.7 m -108.25 -54.65 2.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.853 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 33.9 p -55.18 100.68 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.883 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.405 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.519 -179.965 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.3 t -89.55 42.43 1.09 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.887 0.375 . . . . 0.0 110.844 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.2 m -88.83 155.68 19.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.73 -133.48 0.24 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.528 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.8 p -51.84 177.2 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.906 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -129.81 97.74 4.59 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.44 88.4 0.18 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -154.41 152.4 26.09 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.637 0.732 . . . . 0.0 110.832 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HB2' ' CE2' ' A' ' 11' ' ' TRP . 53.5 Cg_endo -69.8 158.11 58.01 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.653 2.235 . . . . 0.0 112.297 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 2.87 3.13 Favored 'Trans proline' 0 N--CA 1.465 -0.19 0 C-N-CA 122.692 2.262 . . . . 0.0 112.366 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.432 ' CE2' ' HB2' ' A' ' 9' ' ' PRO . 32.0 p-90 -120.42 18.01 12.15 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.919 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -78.91 144.51 64.05 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.611 0.72 . . . . 0.0 111.057 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.7 155.89 64.96 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.386 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.3 tmm_? -50.98 -53.72 30.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.867 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 48.3 t -145.13 165.45 28.25 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.849 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -158.67 155.39 28.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.905 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -64.56 -46.94 80.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.912 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -165.97 179.35 5.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 24.2 ttmt -119.43 132.76 55.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.823 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.0 m -120.44 168.53 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.115 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.83 137.93 55.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.997 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.06 92.53 0.74 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.114 179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.405 HG13 ' N ' ' A' ' 24' ' ' TYR . 35.7 pt -69.38 -34.71 63.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.192 179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.405 ' N ' HG13 ' A' ' 23' ' ' ILE . 77.6 m-85 -128.82 151.81 49.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.869 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -82.81 102.02 11.32 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.891 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 52.3 t80 -103.49 130.55 50.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.9 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 61.5 m -96.04 108.97 21.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.412 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 12.7 pttm -45.24 142.18 2.16 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.928 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -95.34 -48.93 5.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -101.26 175.84 5.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.902 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -67.85 -38.65 83.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -64.68 -40.52 95.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.829 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.412 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 32.5 mt-10 -57.09 162.41 2.57 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 62' ' ' GLY . 2.0 tt -118.59 141.2 48.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.902 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.509 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.6 p -108.4 133.22 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -155.84 152.6 28.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.912 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 44.4 mt-30 -106.4 160.01 15.71 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.896 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.423 ' OE1' ' C ' ' A' ' 38' ' ' GLU . 1.0 OUTLIER -45.37 137.72 4.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.854 -179.865 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.3 48.03 5.83 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.83 142.51 50.67 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.749 0.309 . . . . 0.0 111.145 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.434 ' C ' HG13 ' A' ' 42' ' ' ILE . 28.7 mm -94.84 139.51 18.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.137 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.454 HG21 ' CE2' ' A' ' 64' ' ' PHE . 20.8 mt -141.88 143.19 27.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.181 179.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.583 ' CE1' ' HE2' ' A' ' 19' ' ' LYS . 97.9 m-85 -103.05 98.81 8.7 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.897 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.536 HG11 ' HE3' ' A' ' 47' ' ' LYS . 25.6 t -64.25 95.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.207 179.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.433 HG13 ' N ' ' A' ' 46' ' ' LYS . 48.1 pt -88.12 -34.48 7.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.433 ' N ' HG13 ' A' ' 45' ' ' ILE . 1.4 tppp? -126.04 148.04 49.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.916 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' HE2' ' CD1' ' A' ' 53' ' ' TYR . 13.9 mtpt -136.58 112.75 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.882 179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 56.7 m-20 -87.64 150.73 23.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -41.89 -49.38 4.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.36 175.4 6.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.907 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -74.17 61.65 2.21 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.53 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -151.39 110.66 3.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.715 0.293 . . . . 0.0 110.939 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.56 ' CD1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -112.8 151.71 30.03 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.936 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.429 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.4 tt0 -99.78 126.91 45.94 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.958 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.15 27.9 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.519 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.568 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.0 t -97.22 139.85 18.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 111.092 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 5.7 ttp -153.4 111.11 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.1 t30 62.24 39.3 12.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.858 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 82.35 -35.26 2.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.453 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.26 130.46 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 0.0 111.06 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.568 ' OG1' HG22 ' A' ' 56' ' ' VAL . 87.2 m -116.86 131.42 56.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.14 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -158.37 163.42 32.94 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.451 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 4.2 mt -80.09 123.38 27.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.777 0.322 . . . . 0.0 110.878 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.609 ' HE1' HG21 ' A' ' 69' ' ' VAL . 21.3 p90 -115.6 151.25 45.94 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.632 0.73 . . . . 0.0 110.906 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 118.01 5.42 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.724 2.283 . . . . 0.0 112.307 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.456 ' HA2' ' CG2' ' A' ' 69' ' ' VAL . . . -55.03 -13.04 4.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.416 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -75.67 -34.12 60.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.849 0.357 . . . . 0.0 110.842 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.423 ' O ' HG13 ' A' ' 69' ' ' VAL . 13.2 m-85 -94.59 32.6 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.609 HG21 ' HE1' ' A' ' 64' ' ' PHE . 26.9 m -158.34 139.24 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 22.6 mm-40 -120.55 158.16 27.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.826 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.7 p -90.15 127.03 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.819 -179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.473 HG13 ' N ' ' A' ' 73' ' ' SER . 43.5 pt -111.98 -37.2 2.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.147 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.473 ' N ' HG13 ' A' ' 72' ' ' ILE . 58.7 m -106.19 101.0 10.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.862 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 175.94 -175.05 47.28 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.467 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 1.21 4.57 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.77 2.313 . . . . 0.0 112.344 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 21.1 t -113.06 82.25 1.63 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.893 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.7 t -69.22 87.5 0.42 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.83 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.456 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.498 -0.241 . . . . 0.0 112.498 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.0 p -132.75 153.89 50.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.838 0.352 . . . . 0.0 110.879 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.6 m -58.72 128.14 35.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.819 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.06 78.28 0.15 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.447 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.7 m -104.29 168.72 8.91 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.868 0.366 . . . . 0.0 110.907 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.1 m -47.66 165.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.854 -179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.01 -44.55 0.43 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.442 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -90.43 151.59 44.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.64 0.733 . . . . 0.0 110.865 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.542 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.4 Cg_endo -69.73 160.67 48.84 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.651 2.234 . . . . 0.0 112.376 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -29.32 24.18 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.619 2.212 . . . . 0.0 112.389 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.542 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 48.4 p-90 -73.47 -14.21 61.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.934 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.515 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -76.67 143.68 72.08 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.684 0.754 . . . . 0.0 111.025 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 123.24 9.89 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.601 2.201 . . . . 0.0 112.355 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.2 mmt85 -41.9 -47.48 4.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.845 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.4 t -121.57 153.24 38.3 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.541 ' HA ' HG22 ' A' ' 45' ' ' ILE . 25.9 p90 -164.8 163.95 21.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.936 -179.862 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.446 HD13 ' HG3' ' A' ' 47' ' ' LYS . 51.4 mt -65.85 -61.98 1.76 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.019 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -156.86 178.58 10.18 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.001 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -114.92 147.95 39.3 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.836 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.481 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 22.1 m -146.55 158.95 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.163 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.668 HG12 HG23 ' A' ' 72' ' ' ILE . 13.0 p -124.81 132.62 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.221 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 69' ' ' VAL . . . -70.16 117.9 12.31 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.091 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.513 HG13 ' CD2' ' A' ' 24' ' ' TYR . 41.7 pt -98.89 -14.47 7.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.154 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.513 ' CD2' HG13 ' A' ' 23' ' ' ILE . 47.5 m-85 -136.38 151.63 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.931 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -78.33 115.07 17.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -113.88 148.61 36.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.4 m -120.16 112.03 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.179 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.403 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 15.0 pttm -57.82 136.75 57.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.931 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.32 -24.43 42.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.862 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.3 pttt -155.06 179.02 9.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.909 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -56.12 -43.01 77.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.939 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -47.23 -36.4 8.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.976 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.403 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -87.4 176.99 7.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.864 -179.92 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.688 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.7 tt -128.0 152.44 47.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.932 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.665 ' N ' HD23 ' A' ' 34' ' ' LEU . 6.0 p -108.54 139.31 43.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.843 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -165.43 153.86 11.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.936 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -112.59 166.06 11.68 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.949 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.1 tt0 -51.83 106.23 0.14 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.966 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 116.83 46.43 0.52 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.425 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -141.38 117.83 10.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.809 0.338 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.489 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.7 mp -80.82 147.53 6.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.092 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.405 HG13 ' C ' ' A' ' 41' ' ' ILE . 34.9 mt -142.89 133.42 22.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.162 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -86.74 109.89 19.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.884 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.528 HG13 ' HB3' ' A' ' 53' ' ' TYR . 80.2 t -76.29 124.05 33.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.541 HG22 ' HA ' ' A' ' 16' ' ' TYR . 10.6 pt -120.7 -23.87 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.127 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.46 ' HD3' ' N ' ' A' ' 47' ' ' LYS . 9.5 tmtt? -128.75 145.95 51.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.909 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.46 ' N ' ' HD3' ' A' ' 46' ' ' LYS . 19.1 mtpt -123.38 160.65 26.34 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.914 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 52' ' ' TRP . 2.7 m-80 -129.79 -174.89 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.869 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -104.45 -26.73 12.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.814 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.597 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 34.6 t70 -100.04 39.85 1.3 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.528 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . 59.06 78.17 0.14 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.497 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.597 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 97.5 m95 -162.33 115.16 1.72 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.805 0.336 . . . . 0.0 110.853 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.528 ' HB3' HG13 ' A' ' 44' ' ' VAL . 3.3 m-85 -116.32 137.65 51.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.92 -179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.2 tp10 -91.1 126.24 36.12 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.863 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.98 167.13 25.23 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.523 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 84.7 t -112.64 126.75 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.778 0.323 . . . . 0.0 111.136 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.3 ttp -133.24 107.18 7.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.905 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 59.27 41.73 19.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.982 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.73 -34.15 3.19 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.812 -0.708 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 92.7 t -76.21 125.02 35.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.938 0.399 . . . . 0.0 111.067 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.7 m -107.58 146.79 31.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.133 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.688 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.49 139.69 3.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.531 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 63' ' ' LEU . 5.2 mp -69.13 161.42 29.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.874 0.369 . . . . 0.0 110.877 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 13.9 p90 -163.11 154.51 14.78 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.587 0.708 . . . . 0.0 110.9 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.502 ' HG2' ' CD1' ' A' ' 68' ' ' TYR . 53.7 Cg_endo -69.68 122.74 9.44 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.391 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.523 ' O ' HG22 ' A' ' 69' ' ' VAL . . . -51.29 -52.0 34.06 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.484 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 68' ' ' TYR . 19.0 m120 -40.71 -65.05 0.46 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.817 0.341 . . . . 0.0 110.818 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.502 ' CD1' ' HG2' ' A' ' 65' ' ' PRO . 23.7 m-85 -36.37 -33.99 0.05 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 22' ' ' ALA . 30.9 m -108.67 164.54 5.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.129 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.475 ' CD ' ' N ' ' A' ' 71' ' ' SER . 2.8 tm-20 -122.03 137.49 54.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.475 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 14.9 m -80.7 77.86 7.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.834 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.668 HG23 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -42.32 -26.87 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.112 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 9.7 t -73.35 159.51 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.909 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -173.96 -173.13 39.85 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.386 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 147.4 62.86 Favored 'Trans proline' 0 C--O 1.232 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.409 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.2 m -99.51 117.21 33.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.847 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.1 t 46.53 43.82 12.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.863 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.227 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.433 -179.921 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.37 0 N-CA-C 112.567 -0.213 . . . . 0.0 112.567 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 84.1 p -117.01 162.23 18.11 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.862 0.363 . . . . 0.0 110.886 -179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.1 m -130.61 157.16 43.5 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.817 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -162.15 -77.23 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.551 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.9 m -131.72 -51.9 0.99 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.901 0.381 . . . . 0.0 110.868 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 49.9 p -129.33 166.08 20.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.818 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 131.46 -147.4 18.56 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.429 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.406 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 0.2 OUTLIER -127.83 150.06 72.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.582 0.706 . . . . 0.0 110.942 179.936 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.563 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 54.0 Cg_endo -69.73 163.56 37.8 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.718 2.279 . . . . 0.0 112.321 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -25.65 28.4 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.64 2.227 . . . . 0.0 112.341 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.529 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 47.0 p-90 -79.33 -18.78 51.85 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.898 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -75.08 148.34 84.19 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.632 0.73 . . . . 0.0 111.087 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.8 Cg_endo -69.79 132.61 23.64 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.634 2.223 . . . . 0.0 112.399 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.449 ' C ' ' O ' ' A' ' 13' ' ' PRO . 3.6 ptt180 -34.37 -46.81 0.28 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.833 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 24.2 m -144.5 169.51 17.83 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 10.5 p90 -160.65 166.88 28.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.969 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -65.86 -56.67 10.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -152.57 -175.76 5.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -126.11 121.82 33.96 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.7 m -120.95 167.28 14.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.175 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 p -133.95 136.87 53.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.61 119.06 15.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.061 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.414 HG13 ' CD2' ' A' ' 24' ' ' TYR . 24.4 pt -97.79 -8.55 9.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.151 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.414 ' CD2' HG13 ' A' ' 23' ' ' ILE . 41.1 m-85 -142.58 165.79 26.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -88.35 114.28 24.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.836 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.429 ' HB3' ' CZ ' ' A' ' 36' ' ' PHE . 90.8 t80 -114.47 111.49 21.48 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.97 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 22.2 m -92.57 94.69 9.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.206 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.438 ' HB2' ' CB ' ' A' ' 33' ' ' GLU . 0.7 OUTLIER -43.67 157.7 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.904 179.925 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -118.53 -20.85 8.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.424 ' O ' ' N ' ' A' ' 33' ' ' GLU . 12.6 mmmm -124.69 137.3 54.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.858 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -41.93 -30.53 0.27 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.19 -41.94 85.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.953 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.7 OUTLIER -64.22 169.22 4.71 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.87 -179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.606 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -121.1 138.96 53.95 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.962 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.606 ' N ' HD23 ' A' ' 34' ' ' LEU . 4.7 p -101.15 153.28 19.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.902 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.429 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 24.9 p90 -174.24 165.91 4.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.973 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.426 ' O ' ' C ' ' A' ' 38' ' ' GLU . 15.0 pt20 -130.5 151.35 51.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.426 ' C ' ' O ' ' A' ' 37' ' ' GLN . 16.6 tt0 -36.69 104.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.855 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 117.94 38.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.481 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -123.54 130.09 52.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.717 0.294 . . . . 0.0 111.108 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.4 mm -87.11 133.01 31.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.119 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.416 HG21 ' CE1' ' A' ' 64' ' ' PHE . 78.5 mt -131.18 140.93 47.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.118 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -105.88 97.9 7.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.449 HG11 ' HE3' ' A' ' 47' ' ' LYS . 92.4 t -60.36 114.03 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.164 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.5 pt -110.91 -20.1 6.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.172 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 37.4 mttp -144.46 154.92 43.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.915 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.449 ' HE3' HG11 ' A' ' 44' ' ' VAL . 69.4 mttt -136.5 159.71 40.96 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -129.45 149.03 51.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.905 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -38.34 -39.28 0.43 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 52' ' ' TRP . 1.5 m-20 -96.03 174.21 7.04 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.969 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.536 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -63.62 77.19 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.489 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.536 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 85.0 m95 -160.16 120.33 2.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.692 0.282 . . . . 0.0 110.877 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -131.73 151.89 51.31 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.869 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -91.47 142.54 27.55 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.81 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -156.86 158.61 28.94 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.463 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.457 HG22 ' OG1' ' A' ' 61' ' ' THR . 50.5 t -104.65 131.04 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.859 0.362 . . . . 0.0 111.133 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 7.1 tmm? -136.26 112.2 9.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.883 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 46.3 t30 59.35 38.1 23.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 87.42 -38.17 3.17 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.446 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 87.3 t -77.42 126.79 38.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.893 0.378 . . . . 0.0 111.201 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.457 ' OG1' HG22 ' A' ' 56' ' ' VAL . 33.2 m -107.57 142.92 36.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.469 ' H ' HD12 ' A' ' 34' ' ' LEU . . . -163.09 173.52 39.29 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.483 179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.4 mt -95.77 128.07 42.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.839 0.352 . . . . 0.0 110.922 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.45 ' HE2' HG21 ' A' ' 69' ' ' VAL . 23.2 p90 -130.34 148.98 72.06 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.715 0.769 . . . . 0.0 110.897 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -70.03 142.75 47.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.594 2.196 . . . . 0.0 112.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.82 11.83 45.22 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.443 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -99.38 -12.91 19.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.796 0.331 . . . . 0.0 110.893 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -108.17 17.6 22.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.894 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.45 HG21 ' HE2' ' A' ' 64' ' ' PHE . 4.7 m -139.17 173.55 11.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.1 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 -145.74 167.05 24.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.857 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 96.7 p -102.12 112.83 25.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.907 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.418 HG13 ' N ' ' A' ' 73' ' ' SER . 32.0 pt -104.22 -33.84 3.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.138 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.418 ' N ' HG13 ' A' ' 72' ' ' ILE . 29.5 t -124.32 106.77 10.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.815 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 153.23 -158.24 27.84 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.475 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 129.87 18.39 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.687 2.258 . . . . 0.0 112.303 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 58.8 m -103.94 155.4 18.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.845 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 39.1 t -77.53 -57.26 3.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.483 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.514 -0.234 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.9 t 53.8 41.84 31.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.931 0.396 . . . . 0.0 110.8 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.2 m -63.81 176.12 1.0 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.805 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -130.88 -131.3 3.28 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.51 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m -104.6 85.2 2.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.838 0.351 . . . . 0.0 110.879 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.0 m -129.48 167.93 17.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.802 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -143.35 51.36 0.66 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.477 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -54.14 145.88 32.85 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.599 0.714 . . . . 0.0 110.839 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.555 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.5 Cg_endo -69.74 165.47 30.85 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.657 2.238 . . . . 0.0 112.331 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.73 -31.63 20.28 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.684 2.256 . . . . 0.0 112.373 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.555 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 38.0 p-90 -68.99 -22.95 64.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.871 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -60.42 145.07 87.37 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.477 0.656 . . . . 0.0 111.165 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 14' ' ' ARG . 53.0 Cg_endo -69.77 136.93 34.2 Favored 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.753 2.302 . . . . 0.0 112.362 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.451 ' C ' ' O ' ' A' ' 13' ' ' PRO . 5.2 ptt85 -34.31 -48.2 0.33 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 2.4 t -148.44 174.19 12.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 23.5 p90 -169.14 151.39 4.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.936 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -49.67 -68.45 0.17 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.893 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -151.24 -179.67 7.54 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.5 ttmt -116.29 144.07 44.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.861 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.0 m -127.87 170.36 17.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.129 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 21' ' ' VAL . 6.7 p -136.69 127.37 41.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.15 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.08 112.35 9.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.129 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 12.2 pt -92.84 -7.54 10.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.173 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -136.94 166.12 24.39 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.951 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -85.23 141.7 29.94 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.827 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.408 ' HB2' ' CD2' ' A' ' 68' ' ' TYR . 83.6 t80 -151.96 118.25 5.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.916 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 91.3 m -104.83 111.98 24.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.128 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -43.94 150.28 0.28 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.997 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -115.91 -47.01 2.8 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.877 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -103.47 149.64 24.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 64.6 mm-40 -48.47 -28.35 3.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.873 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -89.21 43.23 1.13 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -143.27 159.53 42.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.835 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.566 HD23 ' N ' ' A' ' 35' ' ' SER . 1.7 tt -116.87 130.74 56.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.906 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.566 ' N ' HD23 ' A' ' 34' ' ' LEU . 22.5 t -97.41 144.21 27.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.905 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -164.83 150.3 9.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.917 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 18.5 mt-30 -105.46 153.54 21.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.875 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -45.52 110.11 0.22 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.96 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.53 36.87 1.25 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.47 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -118.6 141.8 48.24 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.719 0.295 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 16.7 mm -92.18 112.86 26.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.087 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.707 HG21 ' CE2' ' A' ' 64' ' ' PHE . 45.5 mt -115.89 125.25 72.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -89.22 106.03 18.17 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.9 t -68.05 120.62 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.106 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 12.8 pt -121.45 -14.97 7.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.172 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.4 ttmt -132.78 122.2 24.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.941 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.48 ' HD3' ' CE1' ' A' ' 53' ' ' TYR . 18.7 mmtt -114.55 102.72 10.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 -90.59 143.44 26.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.888 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -40.07 -48.2 2.42 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 -71.88 -178.1 2.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.27 62.71 4.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.489 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 93.2 m95 -152.28 118.97 5.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.48 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 4.4 m-85 -120.99 160.6 23.2 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HG3' HD22 ' A' ' 63' ' ' LEU . 7.5 tt0 -112.28 123.46 50.32 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.937 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 61' ' ' THR . . . -134.27 166.46 24.11 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.463 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.463 HG22 ' OG1' ' A' ' 61' ' ' THR . 65.1 t -107.9 124.42 64.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 120.9 0.381 . . . . 0.0 111.157 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 6.8 tmm? -129.79 106.29 8.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.798 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 4.5 t30 61.24 39.8 15.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.824 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.72 -30.01 3.96 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.482 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 89.9 t -82.59 115.98 26.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.92 0.39 . . . . 0.0 111.142 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 55' ' ' GLY . 3.4 m -109.77 143.43 39.6 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.165 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -172.16 163.72 36.05 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.447 HD22 ' HG3' ' A' ' 54' ' ' GLU . 2.1 mm? -68.56 150.15 48.36 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.878 0.37 . . . . 0.0 110.922 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.707 ' CE2' HG21 ' A' ' 42' ' ' ILE . 5.3 p90 -162.17 151.42 13.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.676 0.75 . . . . 0.0 110.872 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 136.79 33.87 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.708 2.272 . . . . 0.0 112.308 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -75.44 -42.29 27.94 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.477 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -51.06 -29.32 12.53 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.895 0.378 . . . . 0.0 110.917 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.408 ' CD2' ' HB2' ' A' ' 26' ' ' TYR . 10.5 m-85 -71.62 -30.06 65.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.926 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.9 m -110.0 137.15 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.12 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 71' ' ' SER . 0.4 OUTLIER -101.52 131.39 47.7 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.404 ' N ' ' OE2' ' A' ' 70' ' ' GLU . 19.2 m -74.6 103.3 4.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.7 pt -92.12 -11.69 9.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.13 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 59.5 m -99.64 143.52 29.78 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.924 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 87.14 -162.77 33.99 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.54 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 99.14 0.72 Allowed 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.703 2.268 . . . . 0.0 112.34 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 34.3 t -102.28 129.76 48.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 97.8 p -71.65 153.54 42.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.816 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.505 179.92 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.237 0 N-CA-C 112.434 -0.266 . . . . 0.0 112.434 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.1 t -154.56 111.44 3.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.349 . . . . 0.0 110.945 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 52.6 p -58.0 169.42 0.78 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.879 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 114.51 -165.68 12.09 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.483 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.5 m -138.79 170.53 15.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.893 0.377 . . . . 0.0 110.87 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.1 m -57.85 155.45 10.42 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.836 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.5 -50.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.477 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.71 150.78 88.86 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.605 0.717 . . . . 0.0 110.839 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.578 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 54.0 Cg_endo -69.69 167.6 23.88 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -39.32 6.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.244 . . . . 0.0 112.361 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.578 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 41.9 p-90 -58.13 -38.25 76.17 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.893 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.563 ' HA ' ' CE3' ' A' ' 11' ' ' TRP . . . -51.53 143.15 20.56 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.51 0.672 . . . . 0.0 111.093 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 135.43 30.62 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.669 2.246 . . . . 0.0 112.373 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 69.2 mtm180 -87.06 36.05 0.72 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.3 t -171.51 105.99 0.22 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.827 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 19.9 p90 -157.7 171.21 20.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.899 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 25.7 mt -85.8 -47.15 9.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.955 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.451 ' C ' ' OE2' ' A' ' 18' ' ' GLU . 0.0 OUTLIER -168.84 174.26 6.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.936 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.9 pttm -116.98 161.21 19.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 33.9 m -148.67 160.97 5.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.19 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.2 p -115.11 139.68 40.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.184 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -80.19 95.59 6.32 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.101 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.532 HG13 ' CD2' ' A' ' 24' ' ' TYR . 38.7 pt -69.67 -23.89 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.137 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.532 ' CD2' HG13 ' A' ' 23' ' ' ILE . 64.3 m-85 -124.23 160.41 28.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.927 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -90.65 100.62 13.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.828 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.461 ' HB3' ' CE1' ' A' ' 36' ' ' PHE . 89.4 t80 -109.74 130.19 55.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 -179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.418 ' O ' ' CE2' ' A' ' 26' ' ' TYR . 15.4 t -93.43 -175.16 3.72 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.081 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.41 ' HD3' ' C ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -114.52 130.52 56.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.941 179.938 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -102.48 -52.2 3.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.884 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 43.9 mttm -96.86 145.32 25.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -49.43 -24.01 1.79 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.839 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.03 47.86 1.23 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -146.37 172.16 13.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.852 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.669 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.5 tt -129.3 133.43 47.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.857 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.6 t -100.24 141.33 33.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.825 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . 0.461 ' CE1' ' HB3' ' A' ' 26' ' ' TYR . 11.3 p90 -155.32 174.81 14.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.934 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.7 pt20 -127.36 165.32 19.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.933 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tt0 -57.97 109.55 0.76 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.89 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 114.56 45.75 0.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -145.13 119.25 9.44 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.652 0.263 . . . . 0.0 111.205 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.502 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -80.7 139.07 18.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.126 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.3 mt -129.77 117.98 43.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 16.4 m-85 -72.21 107.17 4.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.484 HG22 ' HZ ' ' A' ' 64' ' ' PHE . 59.6 t -73.68 105.79 3.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.114 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.4 pt -93.65 -15.31 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.043 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 9.8 tptt -141.72 143.8 33.72 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.834 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -134.58 116.33 14.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -97.16 152.1 19.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.841 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.01 -43.42 29.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.894 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -75.75 176.04 8.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.915 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 52' ' ' TRP . . . -76.2 70.17 2.15 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.481 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.575 ' CD1' ' O ' ' A' ' 51' ' ' GLY . 96.0 m95 -163.34 119.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.819 0.342 . . . . 0.0 110.891 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.471 ' HB3' HG13 ' A' ' 44' ' ' VAL . 4.3 m-85 -120.55 155.11 34.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.908 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.432 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 19.8 tt0 -103.77 118.3 36.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -138.35 160.53 25.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.408 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 85.4 t -101.27 139.73 21.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.764 0.316 . . . . 0.0 111.175 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.1 ttp -140.02 111.78 7.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.879 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 38.8 t30 49.24 38.65 13.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 90.03 -29.97 6.16 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.66 ' O ' HD11 ' A' ' 34' ' ' LEU . 94.6 t -79.81 118.92 28.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.927 0.394 . . . . 0.0 111.196 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.4 m -108.98 139.64 43.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.669 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -171.37 163.23 36.0 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.526 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -81.19 135.45 35.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.726 0.298 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.484 ' HZ ' HG22 ' A' ' 44' ' ' VAL . 45.5 p90 -136.34 152.96 76.01 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.689 0.756 . . . . 0.0 110.842 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 132.4 23.26 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.627 2.218 . . . . 0.0 112.392 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.39 -1.13 41.85 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.554 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -86.85 -33.71 19.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 0.0 110.853 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.439 ' O ' HG13 ' A' ' 69' ' ' VAL . 69.7 m-85 -87.11 29.53 0.83 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.977 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 68' ' ' TYR . 20.4 m -157.38 142.28 8.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.105 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -118.49 164.87 14.63 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.965 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 24.6 p -92.89 132.63 36.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.872 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.464 ' CD1' ' HA ' ' A' ' 20' ' ' VAL . 0.2 OUTLIER -121.4 -28.37 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.121 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.402 ' N ' HG12 ' A' ' 72' ' ' ILE . 36.4 t -85.0 156.13 21.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.868 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 170.94 -168.14 41.29 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.463 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.66 -20.91 34.67 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.691 2.261 . . . . 0.0 112.325 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 62.3 m -69.83 -48.59 58.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.933 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.8 m 57.11 42.36 25.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.829 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.528 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.0 p -165.59 110.57 0.87 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.848 0.356 . . . . 0.0 110.804 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.8 t -71.27 89.92 0.9 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.823 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 50.51 -148.41 7.25 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.523 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.5 m 48.5 47.22 20.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.914 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.2 m -137.64 141.37 41.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.961 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -121.08 65.69 0.46 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.459 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.44 144.0 29.28 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.573 0.702 . . . . 0.0 110.94 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.552 ' HG3' ' CZ2' ' A' ' 11' ' ' TRP . 52.9 Cg_endo -69.69 168.28 21.93 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.679 2.253 . . . . 0.0 112.343 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.26 4.47 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.602 2.201 . . . . 0.0 112.367 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.552 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 64.4 p-90 -60.46 -40.21 90.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.012 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.484 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -40.21 144.17 0.58 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.627 0.727 . . . . 0.0 111.018 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 53.4 Cg_endo -69.9 140.26 41.72 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.618 2.212 . . . . 0.0 112.294 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -65.39 -45.06 85.54 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 73.2 m -115.22 150.97 35.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.455 ' HA ' HG22 ' A' ' 45' ' ' ILE . 10.8 p90 -169.41 147.44 3.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.837 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -56.11 -52.94 62.53 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.931 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -165.0 170.83 14.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -103.6 155.9 18.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.5 m -149.06 138.98 16.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.159 179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.437 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.4 p -110.87 127.36 68.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.17 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.83 123.38 24.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.122 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 36.8 pt -97.68 -34.56 4.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -108.0 178.12 4.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.0 p-10 -95.54 126.39 40.8 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.859 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -126.0 134.48 51.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.906 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 24.6 m -116.75 111.96 20.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.135 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.08 127.07 9.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -90.17 -57.2 2.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.929 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -94.72 -177.36 4.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.885 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -78.26 -28.8 47.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.447 ' C ' ' OE1' ' A' ' 33' ' ' GLU . 8.7 m-20 -85.62 23.95 1.3 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.848 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . 0.447 ' OE1' ' C ' ' A' ' 32' ' ' ASP . 1.5 mp0 -114.69 177.89 4.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.934 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.649 HD23 ' N ' ' A' ' 35' ' ' SER . 2.7 tt -132.16 134.2 45.11 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.915 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.649 ' N ' HD23 ' A' ' 34' ' ' LEU . 87.6 p -97.67 127.71 43.82 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.809 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 4.8 p90 -150.51 170.4 19.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.907 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -139.1 162.23 35.46 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -43.86 109.35 0.14 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.895 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 106.61 44.22 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -121.35 125.4 46.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.336 . . . . 0.0 111.115 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.9 mm -82.75 100.1 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.015 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.659 HG21 ' CZ ' ' A' ' 64' ' ' PHE . 32.6 mt -105.95 131.16 56.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.146 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.412 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 79.4 m-85 -99.34 104.11 15.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.931 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.674 HG13 ' HB3' ' A' ' 53' ' ' TYR . 75.2 t -67.54 124.43 22.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.179 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.455 HG22 ' HA ' ' A' ' 16' ' ' TYR . 8.9 pt -124.77 -25.37 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.131 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.38 152.99 42.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 6.0 mtmp? -128.56 151.05 49.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.855 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB2' ' A' ' 52' ' ' TRP . 2.6 m-20 -126.47 -174.69 3.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.871 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -94.22 -31.54 14.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.897 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.607 ' O ' ' CD1' ' A' ' 52' ' ' TRP . 2.1 m-20 -95.34 39.29 1.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.906 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 52.55 63.14 5.18 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.531 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.607 ' CD1' ' O ' ' A' ' 50' ' ' ASP . 95.0 m95 -134.75 96.97 3.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 110.903 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.674 ' HB3' HG13 ' A' ' 44' ' ' VAL . 11.8 m-85 -91.63 137.63 32.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.938 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.455 ' O ' ' CG1' ' A' ' 45' ' ' ILE . 23.4 tt0 -96.67 111.63 23.71 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.842 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -124.65 171.71 16.81 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.412 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 91.8 t -110.42 134.66 51.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.891 0.377 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.1 tmm? -140.61 111.31 6.89 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.87 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 33.1 t30 59.29 39.8 22.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.847 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.62 -38.17 2.93 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.441 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 98.7 t -75.62 127.43 37.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.999 0.428 . . . . 0.0 111.086 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.403 HG22 ' N ' ' A' ' 62' ' ' GLY . 38.3 m -106.46 153.91 21.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.16 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 61' ' ' THR . . . -177.1 170.03 42.54 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 13.6 mt -98.89 141.25 31.9 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.818 0.342 . . . . 0.0 110.912 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.659 ' CZ ' HG21 ' A' ' 42' ' ' ILE . 20.7 p90 -139.58 154.39 71.29 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.744 0.783 . . . . 0.0 110.838 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.456 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 53.9 Cg_endo -69.83 140.69 43.05 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.584 2.189 . . . . 0.0 112.349 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -80.59 41.17 2.49 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.492 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 -126.37 -43.53 1.76 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.901 0.382 . . . . 0.0 110.898 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.7 m-85 -69.02 -23.65 64.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.963 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.8 m -113.66 148.83 16.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.156 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -108.55 155.52 20.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.973 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 44.6 p -99.56 100.67 11.71 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.79 -179.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 43.6 pt -80.07 -29.79 12.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.102 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 18.2 t -46.38 131.79 10.57 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -64.07 -158.34 0.25 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.69 -42.22 3.67 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.687 2.258 . . . . 0.0 112.363 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 47.1 m 60.33 40.15 17.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.823 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 17.0 t -96.39 -55.41 2.94 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.798 -179.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.459 -179.996 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.385 0 N-CA-C 112.511 -0.236 . . . . 0.0 112.511 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.7 t -105.83 116.35 31.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.823 0.344 . . . . 0.0 110.9 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m -151.82 134.24 15.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.08 -69.82 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.517 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 32.9 t -135.39 144.84 46.78 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 0.0 110.879 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.3 m -85.74 96.86 9.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.848 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.39 -125.15 0.75 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.522 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.421 ' OD1' ' N ' ' A' ' 8' ' ' ASP . 1.2 m-20 -40.91 149.04 0.35 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.609 0.719 . . . . 0.0 110.832 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.672 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 52.9 Cg_endo -69.82 163.88 36.68 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.705 2.27 . . . . 0.0 112.25 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -47.86 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.596 2.197 . . . . 0.0 112.378 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.585 ' CZ2' ' HG3' ' A' ' 9' ' ' PRO . 34.0 p-90 -57.07 -20.83 27.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.874 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.672 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -66.84 144.06 98.36 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.503 0.668 . . . . 0.0 111.124 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 14' ' ' ARG . 54.0 Cg_endo -69.77 105.8 1.55 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.622 2.215 . . . . 0.0 112.434 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.452 ' C ' ' O ' ' A' ' 13' ' ' PRO . 4.4 ptt85 -34.41 -46.54 0.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 12.0 t -120.23 149.75 41.78 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.464 ' CB ' HG22 ' A' ' 45' ' ' ILE . 38.4 p90 -169.01 163.12 11.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.922 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mt -60.96 -66.96 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.858 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.401 ' O ' ' CD1' ' A' ' 16' ' ' TYR . 11.2 pt-20 -146.8 -176.41 5.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.945 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.448 ' HE2' ' CE1' ' A' ' 43' ' ' TYR . 16.3 ttmt -127.91 127.34 43.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.839 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG22 HG23 ' A' ' 44' ' ' VAL . 16.5 m -122.03 158.97 25.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.166 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.1 p -126.77 124.12 64.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.083 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -54.72 138.36 42.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.077 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.8 pt -121.0 -13.51 8.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.154 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -132.64 147.65 52.34 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -72.04 105.65 3.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.869 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -113.56 141.81 46.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.954 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 50.9 m -122.73 110.98 16.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.109 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 24.7 pttt -48.68 151.05 1.24 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.953 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -97.33 -45.23 6.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.877 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.63 171.71 8.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.81 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -66.63 -7.02 17.65 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.892 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' N ' ' OD1' ' A' ' 32' ' ' ASP . 0.2 OUTLIER -87.4 -23.83 24.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.929 179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -90.55 -178.35 5.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.884 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 35' ' ' SER . 2.4 tt -129.42 150.76 50.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.802 ' N ' HD23 ' A' ' 34' ' ' LEU . 21.8 t -116.53 139.32 50.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.887 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 6.6 p90 -156.34 152.27 27.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.904 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -113.32 153.27 28.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.956 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -43.08 99.19 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.86 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 123.6 28.22 1.33 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.479 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -110.05 138.34 46.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.719 0.295 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 20.1 mm -95.81 127.61 47.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.169 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 64.5 mt -127.65 133.98 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.196 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.451 ' CD1' ' CE2' ' A' ' 16' ' ' TYR . 72.5 m-85 -95.44 98.54 10.62 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 53' ' ' TYR . 96.9 t -63.65 117.85 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.145 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.522 HD11 ' OE2' ' A' ' 54' ' ' GLU . 6.5 pt -116.58 -25.14 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.478 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 28.6 ttmt -128.42 142.8 50.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 21.3 mtpp -130.21 120.62 24.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.848 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 80.3 m-20 -94.77 152.67 18.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -39.13 -47.12 1.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -81.98 -179.42 7.39 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.769 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.435 ' C ' ' CD1' ' A' ' 52' ' ' TRP . . . -75.21 70.52 1.84 Allowed Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.472 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' A' ' 51' ' ' GLY . 58.3 m95 -149.74 122.77 8.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 111.043 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.77 ' HB3' HG13 ' A' ' 44' ' ' VAL . 7.0 m-85 -120.29 151.43 39.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.91 -179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.522 ' OE2' HD11 ' A' ' 45' ' ' ILE . 2.8 tt0 -104.02 113.58 27.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.911 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -131.48 154.43 20.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.553 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.538 HG22 ' OG1' ' A' ' 61' ' ' THR . 93.0 t -96.64 112.36 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.326 . . . . 0.0 111.176 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -118.11 112.0 19.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.909 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 22.5 t30 65.5 35.81 7.04 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.857 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.06 -31.57 3.1 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 76.7 t -83.69 129.98 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 120.826 0.345 . . . . 0.0 111.158 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.538 ' OG1' HG22 ' A' ' 56' ' ' VAL . 12.8 m -109.51 143.33 39.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -168.8 148.61 12.55 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.521 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.422 ' N ' HD22 ' A' ' 63' ' ' LEU . 3.8 mm? -66.28 135.19 54.07 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -140.35 148.48 54.09 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.612 0.72 . . . . 0.0 110.91 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 132.47 23.22 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.4 -10.29 69.97 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.462 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -79.72 -28.35 40.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.881 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -89.21 20.9 3.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.038 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.8 m -138.06 178.43 4.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.126 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' A' ' 71' ' ' SER . 6.3 tm-20 -143.69 160.07 41.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.828 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.472 ' N ' ' CD ' ' A' ' 70' ' ' GLU . 9.7 m -104.11 113.64 27.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.886 -179.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 32.5 pt -109.5 -30.87 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.113 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 35.1 t -100.27 105.98 17.58 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.8 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 145.06 -164.72 27.87 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.508 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.67 -3.48 12.04 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.668 2.245 . . . . 0.0 112.386 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.1 t -43.76 113.45 0.51 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.843 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 1.1 t -40.03 -43.37 1.56 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.843 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.479 179.969 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.369 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.1 p 41.72 42.89 2.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.837 0.351 . . . . 0.0 110.862 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.3 m -106.08 149.33 26.83 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.844 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 173.26 -110.88 0.35 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.43 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.7 p -70.6 156.86 38.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.87 0.367 . . . . 0.0 110.868 -179.653 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.2 t -55.46 -48.45 74.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.868 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.6 125.83 1.42 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.46 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -88.81 148.3 41.16 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.623 0.725 . . . . 0.0 110.822 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.471 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 52.7 Cg_endo -69.77 163.67 37.42 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.706 2.271 . . . . 0.0 112.293 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.73 2.287 . . . . 0.0 112.373 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.471 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 50.3 p-90 -54.85 -29.79 56.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.954 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.461 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -61.06 156.07 51.02 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.497 0.665 . . . . 0.0 111.134 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.432 ' HD2' ' HB1' ' A' ' 12' ' ' ALA . 53.5 Cg_endo -69.81 151.14 68.67 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.707 2.271 . . . . 0.0 112.26 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 68.2 mtt180 -72.51 -48.87 37.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.841 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 22.2 t -129.22 98.61 4.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.836 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -105.32 143.35 33.62 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.933 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.93 -67.31 0.27 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.933 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -143.31 178.9 7.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.888 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.618 ' HE2' HG23 ' A' ' 41' ' ' ILE . 27.9 tttt -123.12 141.98 51.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.482 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 27.0 m -137.54 174.05 11.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.045 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.495 HG12 HG23 ' A' ' 72' ' ' ILE . 12.6 p -134.13 150.6 31.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.111 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.12 96.92 10.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.036 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.472 HG13 ' CD2' ' A' ' 24' ' ' TYR . 32.1 pt -73.24 -12.27 15.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.472 ' CD2' HG13 ' A' ' 23' ' ' ILE . 60.5 m-85 -131.53 172.25 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.93 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.24 96.49 6.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 29.5 t80 -98.96 155.35 17.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.918 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.7 m -123.81 131.59 53.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.13 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.428 ' CG ' ' HB3' ' A' ' 35' ' ' SER . 0.0 OUTLIER -78.31 125.95 30.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.901 179.875 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -96.68 -53.27 3.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.807 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.438 ' NZ ' ' HA ' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -96.21 164.47 12.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.959 179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -60.08 -28.43 67.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 -86.76 42.97 1.05 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.966 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -148.01 152.95 38.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.894 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.582 HD23 ' N ' ' A' ' 35' ' ' SER . 1.8 tt -112.17 130.67 55.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.792 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.582 ' N ' HD23 ' A' ' 34' ' ' LEU . 55.7 p -96.16 134.03 39.74 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.1 p90 -154.96 169.18 24.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.909 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.0 pt20 -126.25 161.19 28.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -50.47 108.01 0.2 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.892 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 110.48 32.96 2.59 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.476 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -108.61 145.67 34.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.71 0.291 . . . . 0.0 111.1 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.618 HG23 ' HE2' ' A' ' 19' ' ' LYS . 22.0 mm -102.37 126.55 56.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.129 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.489 HG21 ' CE2' ' A' ' 64' ' ' PHE . 19.5 mt -134.76 141.99 41.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.112 179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -104.16 124.02 48.34 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.899 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.6 t -77.62 117.44 22.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.042 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.3 pt -116.99 -12.2 11.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.463 ' HB3' ' CB ' ' A' ' 54' ' ' GLU . 17.7 tttm -153.95 151.32 29.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -134.16 111.45 10.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.921 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -75.26 164.88 25.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.877 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -40.72 -46.61 2.67 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.839 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.34 -179.83 7.28 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.803 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.449 ' O ' ' CZ ' ' A' ' 53' ' ' TYR . . . -60.82 -7.66 8.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.476 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -69.88 128.28 35.84 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.852 0.358 . . . . 0.0 110.93 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.449 ' CZ ' ' O ' ' A' ' 51' ' ' GLY . 3.8 m-85 -126.68 148.72 49.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.951 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.463 ' CB ' ' HB3' ' A' ' 46' ' ' LYS . 10.2 tt0 -90.88 130.3 36.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.869 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -146.24 167.19 27.96 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.437 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 66.7 t -108.82 136.1 45.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.864 0.364 . . . . 0.0 111.146 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 8.6 ttp -143.48 122.62 12.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.882 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.6 p30 43.81 39.76 2.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.874 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 83.93 -30.74 3.5 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.493 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 51.4 t -78.06 117.01 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.911 0.386 . . . . 0.0 111.084 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 10.3 m -99.38 135.18 41.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.178 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . -164.5 163.15 36.0 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.459 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 7.7 mt -89.88 124.61 34.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.81 0.338 . . . . 0.0 110.917 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.489 ' CE2' HG21 ' A' ' 42' ' ' ILE . 35.8 p90 -119.83 144.65 37.74 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.619 0.724 . . . . 0.0 110.918 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 138.63 38.17 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.667 2.244 . . . . 0.0 112.339 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.08 3.69 56.85 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.521 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 83.7 m-20 -89.89 -24.58 21.32 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.904 0.383 . . . . 0.0 110.925 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -98.12 26.0 5.66 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.926 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 14.2 m -144.27 179.97 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.086 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.416 ' CG ' HD13 ' A' ' 23' ' ' ILE . 2.2 mm-40 -150.69 125.91 10.0 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 31.3 p -64.35 82.35 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.599 ' N ' HD13 ' A' ' 72' ' ' ILE . 0.2 OUTLIER -51.56 -32.36 13.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.07 -0.513 . . . . 0.0 111.126 179.935 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 45.0 m -107.25 152.59 23.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.844 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 105.85 -167.03 14.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.443 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 85.4 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.661 2.241 . . . . 0.0 112.351 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.7 p -115.76 151.45 35.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.871 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 60.4 p -152.23 137.38 17.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.917 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.481 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.418 -0.273 . . . . 0.0 112.418 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.4 p -174.99 171.23 3.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.5 p -169.06 155.15 6.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.821 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -134.85 92.22 0.24 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.555 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 38.7 m -79.61 144.12 34.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.899 0.38 . . . . 0.0 110.858 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.8 m -115.73 105.3 12.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.828 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.96 41.23 1.47 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.462 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -127.61 152.19 76.35 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.602 0.715 . . . . 0.0 110.869 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.583 ' HG2' ' HB2' ' A' ' 12' ' ' ALA . 53.8 Cg_endo -69.73 167.77 23.44 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.754 2.302 . . . . 0.0 112.327 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -47.6 0.9 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.41 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 49.6 p-90 -55.24 -40.73 71.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.844 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.583 ' HB2' ' HG2' ' A' ' 9' ' ' PRO . . . -47.39 153.1 1.02 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.558 0.694 . . . . 0.0 111.147 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.63 146.92 62.47 Favored 'Trans proline' 0 C--O 1.23 0.121 0 C-N-CA 122.744 2.296 . . . . 0.0 112.33 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.9 ptt180 -49.14 -57.89 5.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.844 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 36.1 t -133.85 149.88 51.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.817 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.1 p90 -149.2 159.72 44.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.945 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.9 mt -66.79 -61.06 2.15 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.873 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.11 175.72 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.439 ' HE3' HG23 ' A' ' 41' ' ' ILE . 31.1 tttt -121.46 151.72 39.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.971 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.478 ' HA ' ' CD1' ' A' ' 72' ' ' ILE . 29.1 m -145.36 177.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.177 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.622 HG12 HG23 ' A' ' 72' ' ' ILE . 8.3 p -137.1 139.18 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.29 87.99 4.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.114 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 24' ' ' TYR . 30.2 pt -64.52 -28.02 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.135 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.584 ' CE2' HD12 ' A' ' 23' ' ' ILE . 55.3 m-85 -128.97 156.31 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -81.34 120.71 25.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.918 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.56 ' CE1' ' O ' ' A' ' 27' ' ' THR . 5.4 t80 -129.28 124.09 33.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.875 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.56 ' O ' ' CE1' ' A' ' 26' ' ' TYR . 5.7 t -84.85 172.63 11.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.125 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 17.2 pttm -107.97 124.24 49.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -80.19 -29.68 38.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.1 mttp -126.66 150.29 49.05 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.864 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -51.72 -28.02 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.916 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.544 ' OD2' HD12 ' A' ' 63' ' ' LEU . 15.3 t70 -70.92 -38.43 72.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.892 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -66.52 171.18 5.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.848 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.771 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.4 tt -122.68 137.96 54.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.976 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 t -108.21 138.49 44.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -151.84 172.29 16.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.919 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -127.73 154.39 45.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -38.22 123.79 1.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.941 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 90.07 52.85 2.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.449 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -129.75 128.58 42.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.723 0.297 . . . . 0.0 111.115 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.439 HG23 ' HE3' ' A' ' 19' ' ' LYS . 31.9 mm -84.19 125.63 40.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.076 -179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.0 mt -134.22 131.18 55.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.172 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -96.51 114.15 25.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.5 t -72.4 123.29 26.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.165 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 16.2 pt -120.78 -28.02 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.127 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 30.5 tptt -123.1 140.36 53.1 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -130.71 105.32 7.73 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.884 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 -86.64 154.06 21.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.915 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -44.98 -56.81 4.27 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.96 176.75 3.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.884 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' A' ' 52' ' ' TRP . . . -74.33 73.71 1.32 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.474 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . 0.533 ' CZ3' ' HD3' ' A' ' 65' ' ' PRO . 95.7 m95 -158.56 112.22 2.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.797 0.332 . . . . 0.0 110.993 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -112.6 154.6 25.77 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.939 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -108.8 120.65 43.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.872 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -136.0 173.36 21.92 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.464 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 57.5 t -105.18 132.8 51.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.814 0.34 . . . . 0.0 111.156 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -137.11 109.71 7.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.933 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.1 t30 55.15 39.79 31.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.58 -31.23 3.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.446 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.46 ' O ' HD11 ' A' ' 34' ' ' LEU . 89.7 t -79.12 121.16 31.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.894 0.378 . . . . 0.0 111.141 -179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.0 m -99.47 150.07 22.56 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.135 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.771 ' N ' HD12 ' A' ' 34' ' ' LEU . . . -178.5 169.58 41.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.485 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.544 HD12 ' OD2' ' A' ' 32' ' ' ASP . 5.4 mt -94.47 138.32 32.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.843 0.354 . . . . 0.0 110.992 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -139.85 150.85 64.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.592 0.71 . . . . 0.0 110.959 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.533 ' HD3' ' CZ3' ' A' ' 52' ' ' TRP . 54.5 Cg_endo -69.76 139.73 40.94 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.711 2.274 . . . . 0.0 112.355 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.73 6.28 47.97 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.509 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 -92.58 -30.83 15.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.776 0.322 . . . . 0.0 110.79 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -90.35 25.06 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.957 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 21.0 m -148.34 142.73 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.113 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.649 ' OE2' HG22 ' A' ' 72' ' ' ILE . 0.3 OUTLIER -112.37 141.51 46.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.888 179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.428 ' C ' ' OE1' ' A' ' 70' ' ' GLU . 74.7 m -78.25 79.69 4.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.869 -179.795 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.649 HG22 ' OE2' ' A' ' 70' ' ' GLU . 0.2 OUTLIER -46.91 -33.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.109 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -105.73 149.45 26.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.844 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -169.25 -158.43 13.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.453 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 -24.7 28.98 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.662 2.241 . . . . 0.0 112.264 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 43.0 m 37.91 43.09 0.49 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.791 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 89.6 p -82.17 165.5 20.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.796 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.46 -179.93 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 N-CA-C 112.559 -0.216 . . . . 0.0 112.559 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m 63.76 42.83 5.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.864 0.364 . . . . 0.0 110.787 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.3 t -52.75 124.78 14.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.839 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -53.48 -100.75 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.511 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.1 m -87.26 109.51 19.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.821 0.343 . . . . 0.0 110.868 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 p -136.48 127.05 26.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.905 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.3 92.39 0.39 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.526 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -122.75 144.01 41.61 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.669 0.747 . . . . 0.0 110.834 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HB2' ' CD1' ' A' ' 11' ' ' TRP . 53.9 Cg_endo -69.75 163.74 37.15 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.709 2.273 . . . . 0.0 112.302 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.63 21.53 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.69 2.26 . . . . 0.0 112.312 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' TRP . . . . . 0.492 ' CD1' ' HB2' ' A' ' 9' ' ' PRO . 21.9 p-90 -100.46 -31.31 11.35 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.878 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.47 ' CB ' ' HG2' ' A' ' 9' ' ' PRO . . . -72.55 149.02 90.76 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.626 0.727 . . . . 0.0 111.109 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.469 ' HD2' ' CD2' ' A' ' 43' ' ' TYR . 54.2 Cg_endo -69.66 168.19 22.14 Favored 'Trans proline' 0 C--O 1.233 0.238 0 C-N-CA 122.66 2.24 . . . . 0.0 112.412 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 19.5 mtp180 -83.97 -49.67 8.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.1 t -128.79 141.33 51.34 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.859 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 34.0 p90 -150.66 160.09 44.06 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.947 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 59.8 mt -59.83 -62.1 2.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -150.15 175.4 11.78 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.882 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.603 ' HD2' HG21 ' A' ' 41' ' ' ILE . 6.4 ttpm? -120.91 140.42 51.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.776 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.5 m -132.25 158.21 43.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.102 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.597 ' O ' HG13 ' A' ' 21' ' ' VAL . 11.6 p -122.16 116.7 49.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.173 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -57.69 148.39 24.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.091 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.408 HD12 ' CE2' ' A' ' 24' ' ' TYR . 3.2 pt -124.71 -33.01 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.183 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE2' HD12 ' A' ' 23' ' ' ILE . 42.7 m-85 -117.92 165.97 13.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.967 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -86.59 139.72 30.55 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.868 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -140.26 128.71 22.72 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.917 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 35.3 m -111.11 111.22 22.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 14.2 pttt -53.63 138.32 34.97 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.95 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -92.38 -28.58 16.81 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.81 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 mmtp -112.77 -177.04 3.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.931 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -99.58 34.37 2.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.89 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 -128.69 -38.82 1.67 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -68.85 -175.02 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 62' ' ' GLY . 1.8 tt -126.12 146.4 49.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.927 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.497 ' N ' HD23 ' A' ' 34' ' ' LEU . 3.8 m -113.32 132.09 55.7 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.917 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.2 p90 -147.1 159.66 43.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.804 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -113.03 166.64 11.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.96 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -51.97 124.7 13.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.857 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 92.61 36.79 6.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.473 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -125.72 116.12 21.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.668 0.27 . . . . 0.0 111.134 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.603 HG21 ' HD2' ' A' ' 19' ' ' LYS . 3.6 mp -82.37 143.55 11.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.118 -179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.472 ' CG2' ' HA3' ' A' ' 55' ' ' GLY . 21.3 mt -135.37 132.61 52.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.076 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.469 ' CD2' ' HD2' ' A' ' 13' ' ' PRO . 76.7 m-85 -85.71 100.87 12.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.972 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.414 HG13 ' HB3' ' A' ' 53' ' ' TYR . 86.4 t -69.74 111.25 3.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.042 -0.527 . . . . 0.0 111.199 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 pt -101.73 -19.93 5.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.044 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -139.81 138.63 35.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.858 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.498 ' HG2' ' CD1' ' A' ' 53' ' ' TYR . 58.3 mttt -130.67 110.02 11.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 49' ' ' ASP . 65.8 m-80 -83.0 151.06 25.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 48' ' ' ASN . 34.1 m-20 -36.0 -59.64 0.59 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.913 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -72.79 179.8 3.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -71.37 74.94 0.68 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.532 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' TRP . . . . . . . . . . . . . 87.5 m95 -156.76 110.94 2.72 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.935 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.498 ' CD1' ' HG2' ' A' ' 47' ' ' LYS . 0.5 OUTLIER -123.47 148.83 45.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.881 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 14.6 tt0 -93.52 128.66 39.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.906 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.472 ' HA3' ' CG2' ' A' ' 42' ' ' ILE . . . -143.94 152.14 23.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.509 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.616 HG22 ' OG1' ' A' ' 61' ' ' THR . 98.5 t -96.43 143.06 12.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.931 0.396 . . . . 0.0 111.093 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.401 ' O ' ' C ' ' A' ' 58' ' ' ASN . 4.8 tmm? -145.15 127.01 15.38 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.854 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' A' ' 57' ' ' MET . 22.0 t30 38.24 46.12 0.85 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.973 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 84.91 -40.97 3.01 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.476 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 75.4 t -75.84 124.12 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.0 0.429 . . . . 0.0 111.126 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.616 ' OG1' HG22 ' A' ' 56' ' ' VAL . 31.8 m -107.55 150.16 27.17 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.172 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . 0.679 ' N ' HD12 ' A' ' 34' ' ' LEU . . . 179.47 152.97 11.16 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.477 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . . . . . . . . . 5.1 mp -72.71 151.96 41.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.864 0.364 . . . . 0.0 110.993 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.566 ' HE2' HG11 ' A' ' 69' ' ' VAL . 34.1 p90 -151.46 147.51 20.45 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.595 0.712 . . . . 0.0 110.925 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.86 133.04 24.44 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.654 2.236 . . . . 0.0 112.365 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.06 49.02 2.84 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.484 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -121.55 -29.86 4.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.782 0.325 . . . . 0.0 110.891 -179.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -94.3 3.4 55.27 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.994 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.566 HG11 ' HE2' ' A' ' 64' ' ' PHE . 19.3 m -112.09 160.86 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.113 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -135.35 124.65 24.67 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 66.2 m -58.05 113.33 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.814 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' CG2' HG12 ' A' ' 21' ' ' VAL . 44.3 pt -80.52 -38.36 17.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.131 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.481 ' N ' HG13 ' A' ' 72' ' ' ILE . 30.8 t -73.09 147.41 44.97 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.84 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 92.79 162.41 36.88 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.511 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 138.0 36.75 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.672 2.248 . . . . 0.0 112.334 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.8 m -107.38 -46.37 3.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.837 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.7 m -94.42 119.38 33.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.884 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.525 -179.961 . . . . . . . . 0 0 . 1 stop_ save_